0001437749-24-03497010-Q AYTU BIOPHARMA, INC 20241113202411131720281720291720290 0001437749-24-034970 10-Q 98 20240930 20241113 20241113 AYTU BIOPHARMA, INC 0001385818 2834 470883144 DE 0630 10-Q 34 001-38247 241455734 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237 (720) 437-6580 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237 AYTU BIOSCIENCE, INC 20150609 AYTU BIOSCIENCE, INC. 20150609 Rosewind CORP 20070110 10-Q 1 aytu20240930_10q.htm FORM 10-Q aytu20240930_10q.htm 0001385818 AYTU BIOPHARMA, INC false --06-30 Q1 2025 0.0001 0.0001 50,000,000 50,000,000 0 0 0 0 0.0001 0.0001 200,000,000 200,000,000 6,149,202 6,149,202 5,972,638 5,972,638 0.0 0.1 http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent 0 0.1 4 7 4 http://fasb.org/us-gaap/2024#DerivativeGainLossOnDerivativeNet 2.35 2.35 1 5 1 5 0 1 5 1 5 false false false false Includes August 2022 Warrants, March 2022 Warrants and Avenue Capital Warrants. Relates to the exercise of 176,000 of the Tranche B Pre-Funded Warrants, which were liability classified and exercised at a price of $0.0001 per share. The number of warrants outstanding as of September 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,630,424 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. The number of warrants outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,806,434 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. As pre-funded warrants do not have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years. The warrants exercised during the three months ended September 30, 2024, were 176,000 of the Tranche B Warrants, which were exercised at a price of $0.0001 per share. 00013858182024-07-012024-09-30 xbrli:shares 00013858182024-11-01 thunderdome:item iso4217:USD 00013858182024-09-30 00013858182024-06-30 iso4217:USDxbrli:shares 00013858182023-07-012023-09-30 0001385818us-gaap:CommonStockMember2024-06-30 0001385818us-gaap:AdditionalPaidInCapitalMember2024-06-30 0001385818us-gaap:RetainedEarningsMember2024-06-30 0001385818us-gaap:CommonStockMember2024-07-012024-09-30 0001385818us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-30 0001385818us-gaap:RetainedEarningsMember2024-07-012024-09-30 0001385818us-gaap:CommonStockMember2024-09-30 0001385818us-gaap:AdditionalPaidInCapitalMember2024-09-30 0001385818us-gaap:RetainedEarningsMember2024-09-30 0001385818us-gaap:CommonStockMember2023-06-30 0001385818us-gaap:AdditionalPaidInCapitalMember2023-06-30 0001385818us-gaap:RetainedEarningsMember2023-06-30 00013858182023-06-30 0001385818us-gaap:CommonStockMember2023-07-012023-09-30 0001385818us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-30 0001385818us-gaap:RetainedEarningsMember2023-07-012023-09-30 0001385818us-gaap:CommonStockMember2023-09-30 0001385818us-gaap:AdditionalPaidInCapitalMember2023-09-30 0001385818us-gaap:RetainedEarningsMember2023-09-30 00013858182023-09-30 00013858182024-01-012024-09-30 00013858182023-01-012023-09-30 00013858182023-12-31 00013858182022-12-31 xbrli:pure 0001385818us-gaap:OtherNoncurrentLiabilitiesMember2024-03-31 00013858182024-01-012024-03-31 0001385818aytu:AdhdPortfolioMemberaytu:RxSegmentMember2024-07-012024-09-30 0001385818aytu:AdhdPortfolioMemberaytu:RxSegmentMember2023-07-012023-09-30 0001385818aytu:ThePediatricPortfolioMemberaytu:RxSegmentMember2024-07-012024-09-30 0001385818aytu:ThePediatricPortfolioMemberaytu:RxSegmentMember2023-07-012023-09-30 0001385818us-gaap:ProductAndServiceOtherMemberaytu:RxSegmentMember2024-07-012024-09-30 0001385818us-gaap:ProductAndServiceOtherMemberaytu:RxSegmentMember2023-07-012023-09-30 0001385818aytu:RxSegmentMember2024-07-012024-09-30 0001385818aytu:RxSegmentMember2023-07-012023-09-30 0001385818aytu:ManufacturingEquipmentMember2024-09-30 0001385818aytu:ManufacturingEquipmentMember2024-06-30 0001385818aytu:OfficeEquipmentFurnitureAndOtherMember2024-09-30 0001385818aytu:OfficeEquipmentFurnitureAndOtherMember2024-06-30 0001385818us-gaap:LeaseholdImprovementsMember2024-09-30 0001385818us-gaap:LeaseholdImprovementsMember2024-06-30 0001385818aytu:OfficeSpaceInBerwynPennsylvaniaMember2024-09-30 0001385818us-gaap:OperatingExpenseMember2024-07-012024-09-30 0001385818us-gaap:OperatingExpenseMember2023-07-012023-09-30 0001385818us-gaap:CostOfSalesMember2024-07-012024-09-30 0001385818us-gaap:CostOfSalesMember2023-07-012023-09-30 0001385818us-gaap:OtherExpenseMember2024-07-012024-09-30 0001385818us-gaap:OtherExpenseMember2023-07-012023-09-30 utr:Y 0001385818us-gaap:TechnologyBasedIntangibleAssetsMember2024-09-30 0001385818us-gaap:DevelopedTechnologyRightsMember2024-09-30 0001385818us-gaap:TechnologyBasedIntangibleAssetsMember2024-06-30 0001385818us-gaap:DevelopedTechnologyRightsMember2024-06-30 0001385818srt:MinimumMember2024-07-012024-09-30 0001385818srt:MaximumMember2024-07-012024-09-30 0001385818aytu:TrisKarbinalAgreementMember2023-07-012024-09-30 0001385818us-gaap:OtherCurrentLiabilitiesMemberaytu:TrisKarbinalAgreementMember2024-09-30 0001385818aytu:TrisKarbinalAgreementMember2024-07-012024-09-30 0001385818aytu:TrisKarbinalAgreementMember2024-09-30 0001385818us-gaap:OtherNoncurrentLiabilitiesMember2024-09-30 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember2024-06-12 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember2024-06-12 0001385818us-gaap:SecuredDebtMember2024-09-30 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMemberaytu:OnOrBeforeJanuary262023Member2024-03-24 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMemberaytu:AfterJanuary262023ButBeforeJanuary262024Member2024-03-24 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMemberaytu:AfterJanuary262024ButBeforeJanuary262025Member2024-03-24 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember2024-07-012024-09-30 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember2023-07-012023-09-30 0001385818aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember2024-06-30 0001385818aytu:AvenueCapitalLoanMember2022-01-26 0001385818aytu:AvenueCapitalLoanMemberus-gaap:PrimeRateMember2022-01-262022-01-26 0001385818aytu:AvenueCapitalWarrantsMember2022-01-26 0001385818aytu:AvenueCapitalIssuanceMember2022-03-07 0001385818aytu:AvenueCapitalWarrantsMember2022-03-07 0001385818aytu:AvenueCapitalWarrantsMember2022-10-25 0001385818aytu:AvenueCapitalLoanMember2022-01-262022-01-26 0001385818aytu:AvenueCapitalLoanMember2024-09-30 0001385818aytu:AvenueCapitalLoanMember2023-07-012023-09-30 0001385818aytu:AvenueCapitalLoanMemberaytu:AfterJanuary262024ButBeforeJanuary262025Member2024-09-30 0001385818aytu:AvenueCapitalLoanMember2024-04-012024-06-30 0001385818aytu:EclipseTermLoanMember2024-06-12 0001385818aytu:EclipseTermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-06-122024-06-12 0001385818aytu:EclipseTermLoanMember2024-06-122024-06-12 0001385818aytu:EclipseTermLoanMember2024-09-30 0001385818aytu:EclipseTermLoanMemberaytu:OnOrBeforeJune122025Member2024-06-12 0001385818aytu:EclipseTermLoanMemberaytu:AfterJune122025ButOnOrBeforeJune122026Member2024-06-12 0001385818aytu:EclipseTermLoanMemberaytu:AfterJune122026ButOnOrBeforeJune122027Member2024-06-12 0001385818aytu:EclipseTermLoanMemberaytu:AfterJune122026ButOnOrBeforeJune122028Member2024-06-12 0001385818aytu:EclipseTermLoanMember2024-07-012024-09-30 0001385818us-gaap:FairValueInputsLevel1Member2024-09-30 0001385818us-gaap:FairValueInputsLevel2Member2024-09-30 0001385818us-gaap:FairValueInputsLevel3Member2024-09-30 0001385818us-gaap:FairValueInputsLevel1Member2024-06-30 0001385818us-gaap:FairValueInputsLevel2Member2024-06-30 0001385818us-gaap:FairValueInputsLevel3Member2024-06-30 0001385818us-gaap:FairValueInputsLevel3Member2024-07-012024-09-30 0001385818aytu:TrancheBPrefundedWarrantsMember2024-09-30 0001385818aytu:June2023WarrantsTrancheAMemberus-gaap:MeasurementInputSharePriceMember2024-09-30 0001385818aytu:OtherWarrantsMemberus-gaap:MeasurementInputSharePriceMember2024-09-30 0001385818aytu:June2023WarrantsTrancheAMemberus-gaap:MeasurementInputExpectedTermMember2024-09-30 0001385818aytu:OtherWarrantsMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2024-09-30 0001385818aytu:OtherWarrantsMemberus-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2024-09-30 0001385818aytu:June2023WarrantsTrancheAMemberus-gaap:MeasurementInputPriceVolatilityMember2024-09-30 0001385818aytu:OtherWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2024-09-30 0001385818aytu:OtherWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2024-09-30 0001385818aytu:June2023WarrantsTrancheAMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2024-09-30 0001385818aytu:June2023WarrantsTrancheAMemberus-gaap:MeasurementInputExpectedDividendRateMember2024-09-30 0001385818aytu:OtherWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2024-09-30 0001385818srt:MaximumMemberaytu:TrisKarbinalAgreementMember2024-09-30 0001385818us-gaap:RestrictedStockMember2024-09-30 0001385818aytu:The2020ShelfMember2020-06-17 0001385818aytu:TheAugust2022OfferingMember2022-08-112022-08-11 0001385818aytu:August2022PrefundedWarrantsMember2022-08-11 0001385818aytu:August2022CommonWarrantsMember2022-08-11 0001385818aytu:August2022CommonAndPrefundedWarrantsMember2022-08-11 0001385818aytu:TheAugust2022OfferingMember2022-08-11 0001385818aytu:PrefundedWarrantsMember2022-08-11 0001385818aytu:SecuritiesPurchaseAgreementMember2023-06-082023-06-08 0001385818aytu:PrefundedWarrantsMember2023-06-08 0001385818aytu:TrancheACommonWarrantsMember2023-06-08 0001385818aytu:TrancheBCommonWarrantsMember2023-06-08 0001385818aytu:CommonWarrantsMember2023-06-08 0001385818aytu:CommonWarrantsExchangedForPrefundedWarrantsMember2023-06-08 0001385818aytu:SecuritiesPurchaseAgreementWarrantsMember2023-06-08 0001385818aytu:SecuritiesPurchaseAgreementWarrantsMember2023-06-082023-06-08 0001385818aytu:TrancheBCommonWarrantsMember2024-06-142024-06-14 0001385818aytu:TrancheBPrefundedWarrantsMember2024-06-142024-06-14 0001385818aytu:TrancheBPrefundedWarrantsMember2024-06-14 0001385818aytu:The2024ShelfMember2024-09-26 0001385818aytu:The2023EquityIncentivePlanMember2023-05-182023-05-18 0001385818aytu:The2023EquityIncentivePlanMember2023-05-18 0001385818us-gaap:EmployeeStockOptionMemberaytu:The2023EquityIncentivePlanMember2023-05-182023-05-18 0001385818us-gaap:EmployeeStockOptionMemberaytu:The2023EquityIncentivePlanMembersrt:MinimumMember2023-05-182023-05-18 0001385818us-gaap:EmployeeStockOptionMemberaytu:The2023EquityIncentivePlanMembersrt:MaximumMember2023-05-182023-05-18 0001385818aytu:RestrictedStockAndRestrictedStockUnitsRsusMemberaytu:The2023EquityIncentivePlanMembersrt:MinimumMember2023-05-182023-05-18 0001385818aytu:RestrictedStockAndRestrictedStockUnitsRsusMemberaytu:The2023EquityIncentivePlanMembersrt:MaximumMember2023-05-182023-05-18 0001385818aytu:The2023EquityIncentivePlanMember2024-09-30 0001385818aytu:The2015PlanMember2020-02-13 0001385818us-gaap:EmployeeStockOptionMemberaytu:The2015PlanMember2015-06-012015-06-01 0001385818us-gaap:EmployeeStockOptionMemberaytu:The2015PlanMembersrt:MinimumMember2015-06-012015-06-01 0001385818us-gaap:EmployeeStockOptionMemberaytu:The2015PlanMembersrt:MaximumMember2015-06-012015-06-01 0001385818us-gaap:RestrictedStockMemberaytu:The2015PlanMembersrt:MinimumMember2015-06-012015-06-01 0001385818us-gaap:RestrictedStockMemberaytu:The2015PlanMembersrt:MaximumMember2015-06-012015-06-01 0001385818us-gaap:RestrictedStockUnitsRSUMemberaytu:The2015PlanMember2015-06-012015-06-01 0001385818aytu:Neos2015PlanMember2021-04-19 0001385818us-gaap:RestrictedStockUnitsRSUMemberaytu:Neos2015PlanMember2021-04-19 0001385818us-gaap:EmployeeStockOptionMemberaytu:Neos2015PlanMember2021-04-192021-04-19 0001385818us-gaap:EmployeeStockOptionMemberaytu:Neos2015PlanMembersrt:MinimumMember2021-04-192021-04-19 0001385818us-gaap:EmployeeStockOptionMemberaytu:Neos2015PlanMembersrt:MaximumMember2021-04-192021-04-19 0001385818202 3-07-012024-06-30 0001385818us-gaap:EmployeeStockOptionMember2024-09-30 0001385818us-gaap:EmployeeStockOptionMember2024-07-012024-09-30 0001385818us-gaap:RestrictedStockMember2024-06-30 0001385818us-gaap:RestrictedStockMember2024-07-012024-09-30 0001385818us-gaap:RestrictedStockMemberaytu:The2015PlanMember2024-07-012024-09-30 0001385818us-gaap:RestrictedStockMemberaytu:The2015PlanMember2024-09-30 0001385818us-gaap:RestrictedStockMemberaytu:OutsideEquityIncentivePlanMember2024-07-012024-09-30 0001385818us-gaap:RestrictedStockMemberaytu:OutsideEquityIncentivePlanMember2024-09-30 0001385818us-gaap:RestrictedStockUnitsRSUMember2024-06-30 0001385818us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-30 0001385818us-gaap:RestrictedStockUnitsRSUMember2024-09-30 0001385818us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-30 0001385818us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-30 0001385818us-gaap:SellingAndMarketingExpenseMember2024-07-012024-09-30 0001385818us-gaap:SellingAndMarketingExpenseMember2023-07-012023-09-30 0001385818us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-30 0001385818us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-30 0001385818aytu:NetLossFromDiscontinuedOperationsMember2024-07-012024-09-30 0001385818aytu:NetLossFromDiscontinuedOperationsMember2023-07-012023-09-30 0001385818aytu:SecuritiesPurchaseAgreementWarrantsMember2023-06-08 0001385818aytu:SecuritiesPurchaseAgreementWarrantsMember2023-06-082023-06-08 0001385818aytu:August2022CommonWarrantsMembersrt:MinimumMember2022-08-11 0001385818aytu:August2022CommonWarrantsMembersrt:MaximumMember2022-08-11 0001385818aytu:August2022CommonWarrantsMember2022-12-31 0001385818aytu:ReverseStockSplitMember2023-01-062023-01-06 0001385818aytu:August2022CommonWarrantsMember2023-06-30 0001385818srt:WeightedAverageMember2024-06-30 0001385818srt:WeightedAverageMember2024-07-012024-09-30 0001385818srt:WeightedAverageMember2024-09-30 0001385818aytu:LiabilityWarrantsMember2024-06-30 0001385818aytu:LiabilityPrefundedWarrantsMember2024-06-30 0001385818aytu:TrancheBCommonWarrantsMember2024-06-30 0001385818aytu:EquityWarrantsMember2024-06-30 0001385818aytu:EquityWarrantsMember2024-07-012024-09-30 0001385818aytu:TrancheBCommonWarrantsMember2024-07-012024-09-30 0001385818aytu:LiabilityWarrantsMember2024-09-30 0001385818aytu:LiabilityPrefundedWarrantsMember2024-09-30 0001385818aytu:TrancheBCommonWarrantsMember2024-09-30 0001385818aytu:EquityWarrantsMember2024-09-30 0001385818aytu:LiabilityWarrantsMember2024-07-012024-09-30 0001385818aytu:LiabilityWarrantsMember2023-07-012023-09-30 0001385818aytu:EquityBasedWarrantsMember2024-07-012024-09-30 0001385818aytu:EquityBasedWarrantsMember2023-07-012023-09-30 0001385818us-gaap:RestrictedStockMember2024-07-012024-09-30 0001385818us-gaap:RestrictedStockMember2023-07-012023-09-30 0001385818us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-30 0001385818us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-30 0001385818us-gaap:EmployeeStockOptionMember2024-07-012024-09-30 0001385818us-gaap:EmployeeStockOptionMember2023-07-012023-09-30 0001385818aytu:ConsumerHealthDivestureMember2024-07-012024-09-30 0001385818aytu:ConsumerHealthDivestureMember2023-07-012023-09-30 0001385818aytu:ConsumerHealthDivestureMember2024-06-30 Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Â FORMÂ 10-Q Â â˜’ QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended September 30, 2024 Â or Â â˜ TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period fromÂ _____Â to _____ Â Commission File Number:Â 001-38247 Â Â AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Â Delaware Â 47-0883144 (State or other jurisdiction of incorporation or organization) Â (I.R.S. Employer Identification No.) Â 7900 East Union Avenue, SuiteÂ 920, Denver, Colorado 80237 Â (720) 437-6580 (Address of principal executive offices and zip code)Â (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â Trading Symbol(s) Â Name of each exchange on which registered Common Stock, par value $0.0001 per share Â AYTU Â The NasdaqÂ Capital Market Â Indicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days. Yes â˜’ No â˜ Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in RuleÂ 12bâ€’2 of the Exchange Act. Â Large accelerated filer Â â˜ Accelerated filer Â â˜ Non-accelerated filer Â â˜’ Smaller reporting company Â â˜’ Â Â Emerging growth

company Â â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to SectionÂ 13(a)Â of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12bâ€‘2 of the Exchange Act). YesÂ â˜ No â˜’ Â As of November 1, 2024, the registrant had 6,149,369 shares of common stock outstanding. Â Â Table of Contents Â Â Â AYTU BIOPHARMA, INC. FORM 10-Q Â TABLE OF CONTENTS Â Â Â Page Cautionary Information Regarding Forward-Looking Statements 3 Â Â Â PARTÂ IÂ -Â FINANCIAL INFORMATION 4 Item 1. Financial Statements 4 Â Unaudited Consolidated Balance Sheets 4 Â UnauditedÂ Consolidated Statements of Operations 5 Â Unaudited Consolidated Statements of Stockholdersâ€™Â Equity 6 Â UnauditedÂ Consolidated Statements of Cash Flows 7 Â NotesÂ to the Unaudited Consolidated Financial Statements 8 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 33 Item 3. Quantitative andÂ Qualitative Disclosures About Market Risk 38 Item 4. Controls and Procedures 39 Â Â Â PARTÂ IIÂ -Â OTHER INFORMATION 40 Item 1. Legal Proceedings 40 Item 1A. Risk Factors 40 Item 5. Other Information 40 Item 6. Exhibits 40 Â Â Â SIGNATURES 41 Â 2 Table of Contents Â Â CAUTIONARY INFORMATION REGARDING FORWARD-LOOKING STATEMENTS Â This Report on FormÂ 10â€‘Q (â€œForm 10-Qâ€Â or â€œthis reportâ€)Â includes forward-looking statements within the meaning of SectionÂ 27A of the Securities Act of 1933, as amended (â€œSecurities Actâ€), and SectionÂ 21E of the Securities Exchange Act of 1934, as amended (â€œExchange Actâ€). All statements other than statements of historical facts contained in this report, including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words such as â€œmay,â€ â€œwill,â€ â€œshould,â€ â€œforecast,â€ â€œcould,â€ â€œexpect,â€ â€œsuggest,â€ â€œbelieve,â€ â€œestimate,â€ â€œcontinue,â€ â€œanticipate,â€ â€œintend,â€ â€œpotential,â€ â€œplan,â€ or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, without limitation: our anticipated future cash position; the planned expanded commercialization of our products and the potential future commercialization of our product candidates; our anticipated future growth rates; anticipated sales increases; anticipated net revenue increases; amounts of certain future expenses and cost of sales; our plans to acquire additional assets or dispose of assets, anticipated increases or decreases to operating expenses, and selling, general, and administrative expenses; and future events under our current and potential future collaborations. Â These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including without limitation the risks described in â€œRisk Factorsâ€ in PartÂ I,Â ItemÂ 1A of our Annual Report on FormÂ 10â€‘K for the year ended June 30, 2024Â (â€œ2024Â Form 10-Kâ€), and in the reports we file with the United States Securities and Exchange Commission (â€œSECâ€). These risks are not exhaustive. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. We can provide no assurance that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. We assume no obligation to update or supplement forward-looking statements, except as may be required under applicable law. Â This Form 10-Q may referÂ to registered trademarks that we currently own or license, such as Aytu, Aytu BioPharma, Aytu RxConnect, Neos Therapeutics, Adzenys, Adzenys ER, Adzenys XR-ODT, Cotempla, Cotempla XR-ODT, Karbinal, Poly-Vi-Flor and Tri-Vi-Flor, which are protected under applicable intellectual property laws and are our property or the property of our subsidiaries. This Form 10-QÂ also contains trademarks, service marks, copyrights and trade names of other companies, which are the property of their respective owners. Solely for convenience, our trademarks and tradenames referred to in this Form 10-QÂ may appear without the Â® or â„¢ symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and tradename. Â 3 Table of Contents Â PART 1 - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS AYTU BIOPHARMA,Â INC. UNAUDITED CONSOLIDATED BALANCE SHEETS (in thousands, except shareÂ data) Â Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â ASSETS Â Â Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Â Â Cash and cash equivalents Â $20,108Â Â Â $20,006Â Accounts receivable, net Â Â 23,159Â Â Â 23,526Â Inventories Â Â 11,739Â Â Â 12,141Â Prepaid expenses and other current assets Â Â 5,732Â Â Â 5,097Â Current assets of discontinued operations Â Â â€”Â Â Â 1,121Â Total current assets Â Â 60,738Â Â Â 61,891Â Non-current assets: Â Â Â Â Â Â Â Â Property and equipment, net Â Â 692Â Â Â 693Â Operating lease right-of-use assets Â Â 1,225Â Â Â 829Â Intangible assets, net Â Â 51,205Â Â Â 52,453Â Other non-current assets Â Â 1,971Â Â Â 2,185Â Non-current assets of discontinued operations Â Â â€”Â Â Â 44Â Total non-current assets Â Â 55,093Â Â Â 56,204Â Total assets Â $115,831Â Â $118,095Â Â Â Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Â Â Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Â Â Accounts payable Â $13,513Â Â $10,314Â Accrued liabilities Â Â 33,723Â Â Â 38,143Â Revolving credit facility Â Â 4,270Â Â Â 2,395Â Current portion of debt Â Â 1,857Â Â Â 1,857Â Other current liabilities Â Â 7,889Â Â Â 8,962Â Current liabilities of discontinued operations Â Â â€”Â Â Â 557Â Total current liabilities Â Â 61,252Â Â Â 62,228Â Non-current liabilities: Â Â Â Â Â Â Â Â Debt, net of current portion Â Â 10,430Â Â Â 10,877Â Derivative warrant liabilities Â Â 9,402Â Â Â 12,745Â Other non-current liabilities Â Â 4,921Â Â Â 4,529Â Total non-current liabilities Â Â 24,753Â Â Â 28,151Â Â Â Â Â Â Â Â Â Â Commitments and contingencies (note 13) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholdersâ€™ equity: Â Â Â Â Â Â Â Â Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding Â Â â€”Â Â Â â€”Â Common stock, par value $.0001; 200,000,000 shares authorized; 6,149,202, and 5,972,638 shares issued and outstanding, respectively Â Â 1Â Â Â 1Â Additional paid-in capital Â Â 348,324Â Â Â 347,688Â Accumulated deficit Â Â (318,499)Â Â (319,973) Total stockholdersâ€™ equity Â Â 29,826Â Â Â 27,716Â Total liabilities and stockholdersâ€™ equity Â $115,831Â Â $118,095Â Â The accompanying notes to the unaudited consolidated financial statements are an integral part of this statement. Â 4 Table of Contents Â AYTU BIOPHARMA,Â INC. UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Net revenue Â $16,574Â Â $17,817Â Cost of sales Â Â 4,589Â Â Â 4,779Â Gross profit Â Â 11,985Â Â Â 13,038Â Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Selling and marketing Â Â 5,659Â Â Â 6,091Â General and administrative Â Â 5,125Â Â Â 6,295Â Research and development Â Â 426Â Â Â 595Â Amortization of intangible assets Â Â 921Â Â Â 924Â Restructuring costs Â Â 784Â Â Â Â â€”Â Total operating expenses Â Â 12,915Â Â Â 13,905Â Loss from operations Â Â (930)Â Â (867) Other income, net Â Â 542Â Â Â Â 584Â Interest expense Â Â (994)Â Â (1,283) Derivative warrant liabilities gain (loss) Â Â 2,880Â Â Â Â (5,907) Income (loss) from continuing operations before income tax expense Â Â 1,498Â Â Â Â (7,473) Income tax expense Â Â (405)Â Â Â â€”Â Net income (loss) from continuing operations Â Â 1,093Â Â Â Â (7,473) Net income (loss) from discontinued operations, net of tax Â Â 381Â Â Â Â (647) Net income (loss) Â $1,474Â Â $(8,120) Â Â Â Â Â Â Â Â Â Basic weighted-average common shares outstanding (note 17) Â Â 6,068,019Â Â Â 5,482,037Â Diluted weighted-average common shares outstanding (note 17) Â Â 9,099,601Â Â Â 5,482,037Â Â Â Â Â Â Â Â Â Â Net income (loss) per share (note 17): Â Â Â Â Â Â Â Â Basic - continuing operations Â $0.18Â Â $(1.36) Diluted - continuing operations Â $(0.20)Â $(1.36) Basic - discontinued operations, net of tax Â $0.06Â Â $(0.12) Diluted - discontinued operations, net of tax Â $0.04Â Â $(0.12) Basic - net income (loss) Â $0.24Â Â $(1.48) Diluted - net loss Â $(0.15)Â $(1.48) Â TheÂ accompanying notes to the unaudited consolidated financial statements are an integral part of this statement. Â 5 Table of Contents Â AYTU BIOPHARMA,Â INC. UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (in thousands, except share data) Â Â Â Â Â Â Â Â Â Â Additional Â Â Â Â Â Â Total Â Â Â Common Stock Â Â Paid-in Â Â Accumulated Â Â Stockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Equity Â Balances, June 30, 2024 Â Â 5,972,638Â Â Â $1Â Â $347,688Â Â Â $(319,973)Â $27,716Â Stock-based compensation expense Â Â 564Â Â Â Â â€”Â Â Â 173Â Â Â Â â€”Â Â Â 173Â Issuance of common stock from exercise of warrants Â Â 176,000Â Â Â Â â€”Â Â Â 463Â Â Â Â â€”Â Â Â 463Â Net income Â Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â 1,474Â Â Â 1,474Â Balances, September 30, 2024 Â Â 6,149,202Â Â Â $1Â Â $348,324Â Â Â $(318,499)Â $29,826Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Additional Â Â Â Â Â Â Total Â Â Â Common Stock Â Â Paid-in Â Â Accumulated Â Â Stockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Equity Â Balances, June 30, 2023 Â Â 5,517,174Â Â Â $1Â Â $343,485Â Â $(304,129)Â $39,357Â Stock-based compensation expense Â Â 13,061Â Â Â Â â€”Â Â Â 930Â Â Â Â â€”Â Â Â 930Â Net loss Â Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â (8,120)Â Â (8,120) Balances, September 30, 2023 Â Â 5,530,235Â Â Â $1Â Â $344,415Â Â $(312,249)Â $32,167Â Â The accompanying notes to the unaudited consolidated financial statements are an integral part of this statement. Â 6 Table of Contents Â AYTU BIOPHARMA,Â INC. UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities: Â Â Â Â Â Â Â Â Net income (loss) Â $1,474Â Â $(8,120) Adjustments to reconcile net income (loss) to cash used in operating activities: Â Â Â Â Â Â Â Â Depreciation, amortization and accretion Â Â 1,427Â Â Â 1,843Â Stock-based compensation expense Â Â 173Â Â Â 725Â Derivative warrant liabilities (gain) loss Â Â (2,880)Â Â 5,907Â Amortization of debt discount and issuance costs Â Â 27Â Â Â 148Â Inventory write-down Â Â 68Â Â Â 51Â Other non-cash adjustments Â Â (468)Â Â (6) Non-cash adjustments from discontinued operations Â Â (157)Â Â 592Â Changes in operating assets and liabilities: Â Â Â Â Â Â Â Â Accounts receivable, net Â Â 478Â Â Â (1,684) Inventories Â Â 334Â Â Â (1,121) Prepaid expenses and other current assets Â Â 119Â Â Â 467Â Accounts payable Â Â 3,143Â Â Â 946Â Accrued liabilities Â Â (4,969)Â Â (4,827) Other operating assets and liabilities, net Â Â 101Â Â Â 3,744Â Changes in operating assets and liabilities from discontinued operations Â Â (60)Â Â 1,124Â Net cash used in operating activities Â Â (1,190)Â Â (211) Â Â Â Â Â Â Â Â Â Cash flows from investing activities: Â Â Â Â Â Â Â Â Cash received from sales of fixed assets Â Â 517Â Â Â Â â€”Â Cash payments for fixed asset purchases Â Â (136)Â Â â€”Â Other investing activities Â Â â€”Â Â Â (76) Net cash provided by (used in) investing activities Â Â 381Â Â Â (76) Â Â Â Â Â Â Â Â Â Cash flows from financing activities: Â Â Â Â Â Â Â Â Net proceeds received from (payments made on) revolving credit facility Â Â 1,875Â Â Â (348) Payment made to fixed payment arrangements Â Â (500)Â Â (2,204) Payment of stock issuance costs Â Â â€”Â Â Â (160) Payments made to borrowings Â Â (464)Â Â (22) Net cash provided by (used in) financing activities Â Â 911Â Â Â (2,734) Â Â Â Â Â Â Â Â Â Net change in cash and cash equivalents Â Â 102Â Â Â (3,021) Cash and cash equivalents at beginning of period Â Â 20,006Â Â Â 22,985Â Cash and cash equivalents at end of period Â $20,108Â Â $19,964Â Â Â Â Â Â Â Â Â Â Supplemental disclosure of cash flow information: Â Â Â Â Â Â Â Â Cash paid for interest Â $366Â Â $1,359Â Cash paid for income taxes Â $446Â Â $246Â Non-cash investing and financing activities: Â Â Â Â Â Â Â Â Other non-cash investing and financing activities Â $483Â Â $â€”Â Â The accompanying notes to the unaudited consolidated financial statements are an integral part of this statement. Â 7 Table of Contents Â AYTU BIOPHARMA,Â INC. NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS Â Note 1 - Nature of Business Â AytuÂ BioPharma, Inc. (â€œAytu,â€ the â€œCompany,â€ â€œwe,â€ â€œus,â€ or â€œourâ€), is a pharmaceutical company focused on commercializing novel therapeutics. The Company was originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and was re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (â€œNeosâ€) in March 2021 (the â€œNeos Acquisitionâ€), the Company changed its name to Aytu BioPharma, Inc. Â The Companyâ€™s strategy is to become a leading pharmaceutical company that improves the lives of patients. The Company uses a focused approach of in-licensing, acquiring, developing, and commercializing novel prescription therapeutics in order to continue building its portfolio of revenue-generating products and leveraging its commercial teamâ€™s expertise to build leading brands within large therapeutic markets. The Companyâ€™s primary focus is on commercializing innovative prescription products that address conditions frequently developed or diagnosed in childhood. Â The Companyâ€™s business from continuing operations is focused on itsÂ prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment ofÂ attention deficit hyperactivity disorder (â€œADHDâ€):Â Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (â€œAdzenysâ€) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets (â€œCotemplaâ€ and Adzenys together with Cotempla the â€œADHD Portfolioâ€). The second consists primarily of KarbinalÂ® ER (carbinoxamine maleate extended-release oral suspension) (â€œKarbinalâ€), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency (the â€œPediatric Portfolioâ€). Â Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (â€œCODMâ€). After the previously announced successful wind down and divestiture of the Consumer Health business that occurred during the first quarter of fiscal 2025, the CompanyÂ determined that its continuing operations now operateÂ in a single operating and reportable segment. The Companyâ€™s CODM is its Chief Executive Officer who manages operations and regularly reviews the financial information of the Companyâ€™s continuing operations as a single operating segment for the purposes of allocating resources and evaluating its financial performance, and for which discrete financial information is available. The results of the Consumer Health business have been reported as discontinued operations (see Note 20Â â€” Discontinued Operations). Â In July 2023, the CompanyÂ entered into an exclusive collaboration, distribution and supply agreement with Medomie Pharma Ltd (â€œMedomieâ€), a privately owned pharmaceutical company, for Medomie to sell Adzenys and Cotempla in Israel and the Palestinian Authority. In September 2024, the Company entered into an exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada Ltd (â€œLupinâ€), a subsidiary of global pharmaceutical company Lupin Limited, for Lupin to sell Adzenys and Cotempla inÂ Canada. The Company will supplyÂ Adzenys and Cotempla to Medomie and Lupin based on forecasts and provide product training.Â Medomie and Lupin areÂ responsible for seeking local regulatory approvals and marketing authorizations for both Adzenys and Cotempla, which is expected to occur over the next 18 to 24 months. The agreement with Medomie and the agreement with Lupin represent the Companyâ€™s first and second international commercial agreements for Adzenys and Cotempla, respectively. Â Note 2Â - Summary of Significant Accounting Policies Â Principals of Consolidation Â The Companyâ€™s unaudited consolidated financial statementsÂ and notes thereto include the accounts of its wholly owned subsidiaries Aytu Therapeutics, LLC and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries, as well as Innovus Pharmaceuticals, Inc. and its wholly ownedÂ subsidiaries prior to the divestiture of Innovus Pharmaceuticals, Inc. on July 31, 2024. All significant inter-company balances and transactions have been eliminated in consolidation. Â 8 Table of Contents Â Basis of Presentation Â The unaudited consolidated financial statements and notes thereto contained in this Form 10-Q represent the financial statements of the Company and its wholly owned subsidiaries and have been prepared pursuant to the rules and regulations of the SEC regarding interim financial reporting.Â Accordingly, certain information and disclosures normally included in the complete financial statements prepared in accordance with accounting principles generally accepted in the United States (â€œU.S. GAAPâ€) have been omitted pursuant to such rules and regulations.Â The unaudited consolidated financial statements and notes thereto should be read in conjunction with the Companyâ€™sÂ 2024Â Form 10-K, which included all disclosures required by U.S. GAAP. In the opinion of management, these unaudited consolidated financial statements and notes thereto contain all adjustments necessary for the fair statement of the financial position of the Company and the results of operations and cash flows for the interim periods presented. The consolidated balance sheet as ofÂ June 30, 2024, was derived from the audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements.Â The results of operations for the period ended September 30, 2024, are not necessarily indicative of expected operating results for the full year or any future period. Â Use of Estimates Â The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results may differ from estimates. In the accompanying unaudited consolidated financial statements and notes thereto, estimates are used for, but not limited to, stock-based compensation; revenue recognition,Â determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for credit losses; inventory impairment; determination of right-of-use (â€œROUâ€) assets and lease liabilities; valuation of financial instruments, warrants and derivative warrant liabilities, intangible assets, and long-lived assets; purchase price allocations and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance.Â Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. The CompanyÂ periodically evaluates estimates used in the preparation of the financial statements for reasonableness. Â Prior Period Reclassification Â Certain prior year amounts in the Companyâ€™s unaudited consolidated financial statements and the notes thereto have been reclassified to conform to the current year presentation. These reclassifications did not impact operating results or cash flows for theÂ three months ended September 30, 2024, and 2023, or the Companyâ€™s financial position as of September 30, 2024, or June 30, 2024. Â Warrants Â The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrantâ€™s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) Topic 480, Distinguishing Liabilities from Equity (â€œASC 480â€) and ASC Topic 815, Derivatives and Hedging (â€œASC 815â€). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability

pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Companyâ€™s own common shares and whether the warrant holders could potentially require â€œnet cash settlementâ€ in a circumstance outside of the Companyâ€™s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option pricing model or Monte Carlo simulation model at issuance and for each reporting period when applicable. Â 9 Table of Contents Â Income Taxes Â The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three months ended September 30, 2024. The effective tax rate was 27.0% and zero percent for the three months ended September 30, 2024, and 2023, respectively, primarily driven by the limitations on losses as a result of Section 382 of the Internal Revenue CodeÂ changes in ownership coupled with existing valuation allowances. Â An ownership change has limited the Companyâ€™s ability to offset, post-change, United StatesÂ federal taxable income. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past five years have caused a significant limitation on the Companyâ€™s ability to use the change in controlÂ net operating loss carryovers. The ownership changes result in increased future tax liability and are a driver of the change from a zero percent effective tax rate. Â The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of theÂ balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized. Â The Company recognizes the effect of income tax positions only if those positions are more likely than notÂ to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense in the unaudited consolidated statements of operations. Â Employee Retention Credit Â On March 27, 2020, the United StatesÂ government enacted the Coronavirus Aid, Relief, and Economic Security Act (theÂ â€œCARES Actâ€) to provide certain relief as a result of the COVID-19 pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (â€œERCâ€), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to 70% of the qualified wages paid to employees after December 31, 2020, through September 30, 2021. The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-19 pandemic. Â As there is no authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company accounted for the ERC by analogy to International Accounting Standard (â€œIASâ€) 20, Accounting for Government Grants and Disclosure of Government Assistance (â€œIAS 20â€). In accordance with IAS 20, the Company recorded a $3.8 million ERC accrual in other non-current liabilities, which represents the proceeds the Company received from the ERC program during the first quarter of fiscal 2024. Further in accordance with IAS 20, when management determines it has reasonable assurance that the Company has substantially met all eligibility requirements of the ERC and following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Code of 1986, as amended (the â€œIRCâ€), the ERC accrual shall be recognized as a benefit in other income in the unaudited consolidated statement of operations. The associated vendor fee of $0.4 million was expensed as incurred in the first quarter of fiscal 2024. Â RecentlyÂ Adopted Accounting Pronouncements Â Debt - DebtÂ with Conversion and Other Option Â In August 2020, the FASB issued Accounting Standards Update (â€œASUâ€) No. 2020-06, Debtâ€”Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedgingâ€”Contracts in Entityâ€™s Own Equity (Subtopic 815-40)â€”Accounting for Convertible Instruments and Contracts in an Entityâ€™s Own Equity, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The CompanyÂ adopted the guidance on July 1, 2024, and the adoption of the standard did not have a material impact on the Companyâ€™sÂ consolidated financial statements. Â 10 Table of Contents Â Recent Accounting Pronouncements Not Yet Adopted Â Segment Reporting - Improvements to Reportable Segment Disclosures Â InÂ November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€). ASU 2023-07 was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Companyâ€™s consolidated financial statements and disclosures. Â Disaggregation of Income Statement Expenses Â In November 2024, the FASB issuedÂ ASU No. 2024-03,Â Income Statement â€“ Reporting Comprehensive Income â€“ Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement ExpensesÂ (â€œASU 2024-03â€). The amendments inÂ ASU 2024-03Â require public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory;Â employee compensation; andÂ depreciation, amortizationÂ and depletion expenses for each caption on the income statement where such expenses are included.Â ASU 2024-03Â is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Companyâ€™s consolidated financial statements and disclosures. Â For a complete set of the Companyâ€™s significant accounting policies, refer to the Companyâ€™s 2024Â Form 10-K. There have been no significant changes to the Companyâ€™s significant accounting policies and thereÂ is no other accounting guidance has been issued and not yet adopted that is applicable to the Company and that would have a material effect on the Companyâ€™s unaudited consolidated financial statements and related disclosuresÂ as of September 30, 2024, and through the filing of this Form 10-Q. Â Note 3Â - Revenue Â NetÂ revenueÂ from continuing operations consists of sales of prescription pharmaceutical products from the Companyâ€™s ADHD Portfolio and Pediatric Portfolio, principally to a limited number of wholesale distributors and pharmacies in the United States. NetÂ revenue is recognized at the point in time that control of the product transfers to the customer, which typically aligns with shipping terms (i.e., upon delivery), generally â€œfree-on-boardâ€ destination when shipped domestically within the United States, consistent with contractual terms. Â Savings offers, rebates, and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. The Companyâ€™s periodic adjustments of its estimates are subject to time delays between the initial product sale, and the ultimate reporting and settlement of deductions. The Company entered into negotiations with a vendor related to certain variable interest accruals that reduce revenue for the Companyâ€™sÂ ADHD Portfolio. As a result of these negotiations, the Company and the vendor agreed to a reduction to the liability purportedly owed by the Company ofÂ $3.3 million, which resulted in a decrease in the estimated variable consideration accrualÂ as of September 30, 2024, and a related increase in net revenue of $3.3 million for the three months ended September 30, 2024. Â 11 Table of Contents Â RevenueÂ by Product Portfolio Â Net revenue disaggregated by significant product portfolio for theÂ three months ended September 30, 2024, and 2023, were as follows: Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â ADHD Portfolio Â $15,264Â Â $15,128Â Pediatric Portfolio Â Â 1,293Â Â Â 2,565Â Other Â Â 17Â Â Â 124Â Total net revenue Â $16,574Â Â $17,817Â Â Other includes net revenue from various discontinued deprioritized products. The Consumer Health business was divested in the first quarter of fiscal 2025 and is reported within discontinued operationsÂ (see Note 20Â â€“ Discontinued Operations). Â RevenueÂ by Geographic Location Â The Companyâ€™s net revenue isÂ predominately within the United States, with insignificant international sales. Â Note 4Â - Inventories Â Inventories consist of raw materials, work in processÂ and finished goods, and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of its inventories to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identifiedÂ and there are no alternate uses for the inventory, the Company will record a charge to reduce the value of the inventory to net realizable value in the period first recognized. The Company incurred inventory write-downs ofÂ $0.1 millionÂ for both the three months ended September 30, 2024, and 2023, primarily as a result of unsalable and slow-moving products. Â InventoriesÂ consist of the following: Â Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Â Â (in thousands) Â Raw materials Â $720Â Â $266Â Work in process Â Â 3,363Â Â Â 5,725Â Finished goods Â Â 7,656Â Â Â 6,150Â Inventories Â $11,739Â Â $12,141Â Â 12 Table of Contents Â Â Note 5Â - Property and Equipment Â Properties and equipment are recorded at cost and depreciated on a straight-line basis over the assetsâ€™ estimated economic life. Leasehold improvements are amortized over the shorter of the estimated economic life or remaining lease term. Â Property and equipment, net, consist of the following: Â Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Â Â (in thousands) Â Manufacturing and lab equipment Â $1,443Â Â $1,838Â Office equipment, furniture and other Â Â 956Â Â Â 945Â Leasehold improvements Â Â 158Â Â Â 35Â Property and equipment, gross Â Â 2,557Â Â Â 2,818Â Less: accumulated depreciation and amortization Â Â (1,865)Â Â (2,125) Property and equipment, net Â $692Â Â $693Â Â Depreciation and amortization expense from property and equipment was $0.1Â million and $0.3Â million forÂ the three months ended September 30, 2024, and 2023, respectively. Â Note 6Â - Leases Â The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment, and finance lease agreements for certain equipment. These leases have original lease periods expiring between calendar year 2024 and calendarÂ year 2030. Most leases include one or more options to renew, and the exercise of a lease renewal option typically occurs at the discretion of both parties. Certain non-real estate leases also include options to purchase the leased property. The Companyâ€™s lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.Â The Company had no remaining finance leases recorded as of June 30, 2024. Â In June 2024, the Company entered into a forward-starting operating lease agreement to lease office space in Berwyn, Pennsylvania from the owner of the office space that the Company is currently renting under a sublease arrangement. The Company determined that it is an operating lease, and that lease commencement occurred in July 2024. The initial lease termination date is July 31, 2030, and under the lease agreement the Company has one five-year renewal option to extend the lease through July 2035. Undiscounted minimum monthly rent payments average approximately $13,000 over the initial term of the lease. The Company has elected to utilize the practical expedient to not separate lease and non-lease components upon recognition and variable lease payments will be expensed as incurred. The Company recorded anÂ operating lease ROU asset of $0.5 million and a lease liability of $0.5 million at lease commencement in July 2024. The ROU asset and lease liability will be recorded at present value using an incremental borrowing rate of 12.3%. Â The components of lease costs areÂ as follows: Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Statement of Operations Classification Â Â (in thousands) Â Â Lease cost: Â Â Â Â Â Â Â Â Â Operating lease cost Â $122Â Â $360Â Operating expenses Short-term lease cost Â Â 91Â Â Â 23Â Operating expenses Finance lease cost: Â Â Â Â Â Â Â Â Â Amortization of leased assets Â Â â€”Â Â Â 14Â Cost of sales Interest on lease liabilities Â Â â€”Â Â Â 1Â Interest expense Total lease cost Â $213Â Â $398Â Â Â 13 Table of Contents Â Supplemental balance sheet information related to leases is as follows: Â Â Â September 30, Â Â June 30, Â Â Â 2024Â Â 2024Â Balance Sheet Classification Â Â (in thousands) Â Â Assets: Â Â Â Â Â Â Â Â Â Operating lease assets Â $1,225Â Â $829Â Operating lease right-of-use assets Â Â Â Â Â Â Â Â Â Â Liabilities: Â Â Â Â Â Â Â Â Â Current: operating leases Â $484Â Â $712Â Other current liabilities Non-current: operating leases Â Â 1,144Â Â Â 577Â Other non-current liabilities Total lease liabilities Â $1,628Â Â $1,289Â Â Â The remaining weighted-average lease term and discount rate used are as follows: Â Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Weighted-average remaining lease term (years): Â Â Â Â Â Â Â Â Operating lease assets Â Â 4.2Â Â Â 2.7Â Weighted-average discount rate: Â Â Â Â Â Â Â Â Operating lease assets Â Â 11.1%Â Â 10.0% Â Supplemental cash flow information related to leases is as follows: Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Cash flow classification of lease payments: Â Â Â Â Â Â Â Â Â Operating cash flows from operating leases Â $168Â Â $360Â Operating cash flows from finance leases Â $â€”Â Â $1Â Financing cash flows from finance leases Â $â€”Â Â $23Â Â As of June 30, 2024, theÂ Company did not have any remaining finance leases. As of September 30, 2024, theÂ Companyâ€™s future minimum lease payments were as follows: Â Â Â Operating Â Â Â (in thousands) Â 2025 (remaining 9 months) Â $792Â 2026 Â Â 399Â 2027 Â Â 377Â 2028 Â Â 386Â 2029 Â Â 358Â 2030 Â Â 230Â Thereafter Â Â 19Â Total lease payments Â Â 2,561Â Less: imputed interest Â Â (520) Less: tenant improvement allowance Â Â (413) Lease liabilities Â $1,628Â Â 14 Table of Contents Â Â Note 7Â - Intangible Assets Â A summary of the Companyâ€™s definite-lived intangible assets as of September 30, 2024, and June 30, 2024, respectively, isÂ as follows: Â Â Â September 30, 2024 Â Â Â Gross Carrying Amount Â Â Accumulated Amortization Â Â Net Carrying Amount Â Â Weighted-Average Remaining Life Â Â Â (in thousands) Â Â (in years) Â Acquired product technology rights Â $41,268Â Â $(13,988)Â $27,280Â Â Â 10.5Â Acquired technology rights Â Â 30,200Â Â Â (6,275)Â Â 23,925Â Â Â 13.5Â Total intangible assets Â $71,468Â Â $(20,263)Â $51,205Â Â Â 11.9Â Â Â Â June 30, 2024 Â Â Â Gross Carrying Amount Â Â Accumulated Amortization Â Â Net Carrying Amount Â Â Weighted-Average Remaining Life Â Â Â (in thousands) Â Â (in years) Â Acquired product technology rights Â $41,268Â Â $(13,184)Â $28,084Â Â Â 10.7Â Acquired technology rights Â Â 30,200Â Â Â (5,831)Â Â 24,369Â Â Â 13.8Â Total intangible assets Â $71,468Â Â $(19,015)Â $52,453Â Â Â 12.0Â Â Carrying amounts are net of any impairment charges from prior periods. An intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period. Certain of the Companyâ€™s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximatelyÂ 1Â toÂ 20 yearsÂ depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $1.2Â millionÂ and $1.5 million for the three months ended September 30, 2024, and 2023, respectively. Â The following table summarizes the estimated future amortization expense to be recognized over the next five fiscalÂ years and periods thereafter: Â Â Â Estimated Future Amortization Expense Â Â Â (in thousands) Â 2025 (remaining 9 months) Â $3,742Â Â 2026 Â Â 4,989Â Â 2027 Â Â 4,989Â Â 2028 Â Â 4,989Â Â 2029 Â Â 4,989Â Â 2030 Â Â 2,847Â Â Thereafter Â Â 24,660Â Total future amortization expense Â $51,205Â Â Acquired Product Technology Rights Â The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of the Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021. Â 15 Table of Contents Â ADHD Portfolio Â As part of the Neos Acquisition, the Company acquired developed product technology for the production and sale of AdzenysÂ and Cotempla. The formulations for the ADHD products are protected by patented technology. The estimated remaining economic life of these proprietary technologies is 14Â years. Â Karbinal Â The Company acquired and assumed all rights and obligations pursuant to the supply and distribution agreement, as amended, with Tris Pharma, Inc. (â€œTrisâ€) for the exclusive rights to commercialize KarbinalÂ in the United States (the â€œTris Karbinal Agreementâ€). The Tris Karbinal Agreementâ€™s initial term terminates in AugustÂ of 2033, with an optional initial 20-year extension. Â Poly-Vi-FlorÂ and Tri-Vi-Flor Â The Company acquired and assumed all rights and obligations pursuant to a supply and license agreement and various assignment and release agreements, including a previously agreed to settlement and license agreements (the â€œPoly-Tri Agreementsâ€) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States. Â Acquired Technology Rights Â TRRP Technology Â As part of the Neos Acquisition, the Company acquired time release resin particle (â€œTRRPâ€) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlines each of the ADHD Portfolio core products and can potentially be used in future product development initiatives as well. Â Note 8Â - Accrued Liabilities Â Accrued liabilities consist of the following: Â Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Â Â (in thousands) Â Accrued savings offers Â $9,929Â Â $11,054Â Accrued program liabilities Â Â 5,990Â Â Â 9,964Â Accrued customer and product related fees Â Â 5,540Â Â Â 5,395Â Accrued employee compensation Â Â 5,212Â Â Â 4,603Â Return reserve Â Â 4,218Â Â Â 4,832Â Other accrued liabilities Â Â 2,834Â Â Â 2,295Â Total accrued liabilities Â $33,723Â Â $38,143Â Â AccruedÂ savings offers represent programs for the Companyâ€™s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Accrued program liabilities include government and commercial rebates. Accrued customer and product related fees include

accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. The return reserve represents the Companyâ€™s accrual for estimated product returns. Accrued employee compensation includes sales commissions, paid time off earned, accrued payroll and accrued bonus. Other accrued liabilities consist of various other accruals, none of which individually or in the aggregate represent greater than five percent of total liabilities. Â 16 Table of Contents Â Â Note 9Â - Other Liabilities Â Other liabilities consist of the following: Â Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Â Â (in thousands) Â Fixed payment arrangements Â $7,405Â Â $8,337Â Employee retention credit Â Â 3,759Â Â Â 3,759Â Operating lease liabilities Â Â 1,628Â Â Â 1,289Â Other Â Â 18Â Â Â 106Â Total other liabilities Â Â 12,810Â Â Â 13,491Â Less: current portion of other liabilities Â Â (7,889)Â Â (8,962) Total non-current portion of other liabilities Â $4,921Â Â $4,529Â Â Fixed Payment Arrangements Â Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in 2019, including fixed and variable payments. Â In May 2022, the Company entered into an agreement with Tris to terminate the license, development, manufacturing and supply agreement dated November 2, 2018, related to Tuzistra XR (the â€œTuzistra License Agreementâ€). Pursuant to such termination, as of September 30, 2024, the Company has accrued a settlement liability of $5.8Â million in other current liabilities on the consolidated balance sheet payable to Tris, with a provision that allows the CompanyÂ to pay interest on any principal amounts due but remaining unpaid past July 2024. Â The Tris Karbinal Agreement grants the Company the exclusive right to distribute and sell Karbinal in the United States. The initial term of the agreement was 20 years. The Company pays Tris a royalty equal to 23.5% of net revenue from the product. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make-whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net revenue from the product, the first of which is triggered at $40.0 million. As of September 30, 2024, the Tris Karbinal Agreement accrued fixed payment arrangement balance was $1.7Â millionÂ recorded in other current liabilities on the consolidated balance sheet. Â Employee Retention CreditÂ Â The $3.8 millionÂ ERC accrualÂ in other non-current liabilities as of September 30, 2024, represents the proceeds the Company received from the ERC program during the first quarter of fiscal 2024. Please seeÂ Note 2 â€“Â Significant Accounting PoliciesÂ for further detail. Â Operating Lease LiabilitiesÂ Â The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment. Please refer to Note 6 - Leases for further detail. Â Other Â Other consists of taxes payable, deferred cost related to the Companyâ€™s technology transfer, andÂ various other accruals,Â none of which individually or in the aggregate represent greater than five percent of total liabilities. Â 17 Table of Contents Â Â Note 10 - Revolving Credit Facility Â On June 12, 2024, the Company and certain of its subsidiaries entered into consent, joinder and amendment No. 5 (the â€œEclipse Amendment No. 5â€) to the loan and security agreement dated October 2, 2019, as amended by amendment No. 1, dated March 19, 2021, amendment No. 2, dated January 26, 2022, amendment No. 3, dated June 1, 2022, amendment No. 4 dated March 24, 2023, and the Eclipse Amendment No. 5 (together the â€œEclipse Agreementâ€) with Eclipse Business Capital LLC (â€œEclipseâ€), as agent, and the lenders party thereto (agent and such lenders, collectively, the â€œEclipse Lenderâ€). Under the Eclipse Amendment No. 5, which provided for among other things, two loan agreements, a term loan (the â€œEclipse Term Loanâ€) and a revolving credit facility (the â€œEclipse Revolving Loanâ€). The Eclipse Term Loan is described further in Note 11 - Long-Term Debt. The Eclipse Revolving Loan provides for a maximum amount available under the revolving credit facility provided under the Eclipse Agreement of $14.5 million at an interest rate of the secured overnight financing rate as administered by the SOFR Administrator (â€œSOFRâ€) plus 4.5%. In addition, the Company is required to pay an unused line fee of 0.5% of the average unused portion of the maximum Eclipse Revolving Loan amount during the immediately preceding month. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Agreement remains subject to a borrowing base and reserve, and availability blockage requirements. The Eclipse Revolving Loan maturity date, as amended, is June 12, 2028, and the effective interest rate was 9.8% as of September 30, 2024. Â In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 2.0% of the Eclipse Revolving Loan commitment if such event occurs on or before June 12, 2025, (ii) 1.0% of the Eclipse Revolving Loan commitment if such event occurs after June 12, 2025, but on or before June 12, 2026, and (iii) 0.5% of the Eclipse Revolving Loan commitment if such event occurs after June 12, 2026, but on or before June 12, 2028. The Company may also be required to pay an early termination fee related to the Eclipse Term Loan as further described in Note 11 - Long-Term Debt. The Company may permanently terminate the Eclipse Agreement upon written notice to Eclipse. Â The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Companyâ€™s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Companyâ€™s obligations under the Eclipse Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. AsÂ of September 30, 2024, the Company was in compliance with the covenants under the Eclipse Agreement. The Companyâ€™s obligations under the Eclipse Agreement are secured by substantially all of the Companyâ€™s assets, as defined further in the Eclipse Agreement. Â Total interest expense on the Eclipse Revolving Loan, including amortization of deferred financing costs, was less than $0.1 million for bothÂ the three months ended SeptemberÂ 30, 2024, and 2023, respectively. TheÂ amountsÂ drawn on the Eclipse Revolving Loan wereÂ $4.3Â million and $2.4Â million asÂ of September 30, 2024, and June 30, 2024, respectively. The unused revolving credit facility amount as of SeptemberÂ 30, 2024, was $2.5Â million. Â Note 11 - Long-Term Debt Â Avenue Capital Loan Â On January 26, 2022 (â€œClosing Dateâ€), the Company entered into a loan and security agreement (the â€œAvenue Capital Agreementâ€) with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. as lenders (the â€œAvenue Capital Lendersâ€), and Avenue Capital Management II, L.P. as administrative agent (the â€œAvenue Capital Agentâ€), collectively (â€œAvenue Capitalâ€), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $15.0 million loan. The interest rate on the loan was the greater of the prime rate or 3.25%, plus 7.4%, payable monthly in arrears. The maturity date of the loan was January 26, 2025. The proceeds from the Avenue Capital Agreement were used towards the repayment of the term loans. Â Pursuant to the Avenue Capital Agreement, the Company was required to make interest only payments for the first 18 months following the Closing Date (the â€œInterest-only Periodâ€). The Interest-only Period could be extended automatically without any action by any party for six months provided as of the last day of the Interest-only Period then in effect, the Company received, prior to June 15, 2023, a specified amount of net proceeds from the sale and issuance of its equity securities (â€œInterest-only Milestone 1â€). The Interest-only Period was able to be further extended automatically without any action by any party for an additional six months provided, the Company had achieved, prior to December 31, 2023, (i) Interest-only Milestone 1 and (ii) a specified amount of trailing 12 months revenue as of the date of determination. Â 18 Table of Contents Â On January 26, 2022 (â€œIssuance Dateâ€), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the â€œAvenue Capital Warrantsâ€). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was not fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately $0.6 million. Â On March 7, 2022, the Company closed on an equity offering of shares of common stock and warrantsÂ at an offering price of $25.00 per share. As this offering precluded the Company from pursuing any equity financing prior to July 7, 2022, and the effective price of the March 7, 2022, offering was more than the exercise price of the Avenue Capital Warrants, the shares of common stock issuable upon exercise of the Avenue Capital Warrants were set at an exercise price of $24.20. Â On October 25, 2022, the Company entered into an agreement with Avenue Venture Opportunities Fund, L.P (â€œAvenueâ€) to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in January 2022, extended the interest-only period to January 2024. In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $8.60, corresponding to the warrant exercise price associated with the Companyâ€™s August 2022 equity financing. Â On June 13, 2023, in conjunction with the Securities Purchase Agreement described in Note 16 - Warrants, the interest-only period of the Avenue Capital Agreement was extended further upon the achievement of both the revenue-based milestone and equity raise-based milestone stipulated in the Avenue Capital Agreement. As a result, the interest-only period was extended to January 26, 2025. Â In addition to the debt discount discussed above, the Company also incurred $0.4 million loan origination, legal and other fees. The debt discount and issuance costs were being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 16.6%. Total interest expense on the Avenue Capital loan, including debt discount amortization, wasÂ $0.7Â million for the three months ended SeptemberÂ 30,Â 2023. Â On June 12, 2024, the Company used proceeds from the Eclipse Term Loan and a portion of the proceeds from the exercise of warrants to repay the Avenue Capital loan in full. Upon early repayment of the Avenue Capital loan, the Company was required to pay Avenue Capital a fee equal to 1.0% of the loan or $0.2 million. In addition, upon the payment in full of the obligations, the Company was required to pay Avenue Capital a fee in the amount of $0.6 million (â€œFinal Paymentâ€). At inception, the Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount. At retirement, the early termination fee, the Final Payment fee, and the write-off of all remaining related debt discount and deferred financing costs were included in the calculation of loss on extinguishment of debt. The Company recorded a loss on extinguishment of debt of $0.6 million related to the retirement of the Avenue Capital loan in the fourth quarter of fiscal 2024. Â Eclipse Term Loan Â On June 12,Â 2024, the Company and certain of its subsidiaries entered into Eclipse Amendment No. 5, which provided for among other things,Â the Eclipse Term LoanÂ and the Eclipse Revolving LoanÂ describedÂ further in Note 10 - Revolving Credit Facility. The Eclipse Term LoanÂ consists of a principal amount of $13.0 million, at an interest rate of SOFR plus 7.0%, with a four-year term maturing on June 12, 2028,Â and a straight-line loan amortization period of seven years, which would provide for a loan balance at the end of the four-year term ofÂ $5.6 million to be repaid on June 12, 2028, the maturity date. The Company used the proceeds of the Eclipse Term Loan and a portion of the proceeds from warrant exercises described below to repay in full the Avenue Capital loan.Â The effective interest rate on the Eclipse Term Loan was 12.3% as of September 30, 2024. Â In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal toÂ (i) 3.0% of the Eclipse Term LoanÂ if such event occurs on or before June 12, 2025, (ii) 2.0% of the Eclipse Term LoanÂ if such event occurs after June 12, 2025,Â but on or before June 12, 2026,Â (iii) 1.0% of the Eclipse Term LoanÂ if such event occurs after June 12, 2026,Â but on or before June 12, 2027, and (iv) 0.5% of the Eclipse Term LoanÂ if such event occurs after June 12, 2026,Â but on or before June 12, 2028. The Company may also be required to pay an early termination fee related to the Eclipse Revolving LoanÂ as further described in Note 10Â - Revolving Credit Facility. The Company may permanently terminate the Eclipse Agreement upon written notice to Eclipse. The Companyâ€™s obligations under the Eclipse AgreementÂ are secured by substantially all of the Companyâ€™s assets, as further defined in the Eclipse Agreement. Â 19 Table of Contents Â The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Companyâ€™s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make certain asset sales without the prior written consent of the Eclipse Lender. A failure to comply with these covenants could permit the Eclipse LenderÂ to declare the Companyâ€™s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of SeptemberÂ 30, 2024, the Company was in compliance with the covenants under the Eclipse Agreement. The Company incurredÂ interest expense on the Eclipse Term Loan, including debt discount and issuance costs amortization, of $0.4Â millionÂ for the three months ended September 30, 2024. Â Long-term debt consists of the following: Â Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Â Â (in thousands) Â Term loan principal amount Â $12,536Â Â $13,000Â Unamortized debt discount and issuance costs Â Â (249)Â Â (266) Total debt Â Â 12,287Â Â Â 12,734Â Less: current portion of debt Â Â (1,857)Â Â (1,857) Total debt, net of current portion Â $10,430Â Â $10,877Â Â Future principal payments of the Eclipse Term LoanÂ are as follows: Â Â Â Future Principal Payments Â Â Â (in thousands) Â 2025 (remaining 9 months) Â $1,393Â 2026 Â Â 1,857Â 2027 Â Â 1,857Â 2028 Â Â 7,429Â Total future principal payments Â Â 12,536Â Less: unamortized debt discount and issuance costs Â Â (249) Less: current portion of debt Â Â (1,857) Total debt, net of current portion Â $10,430Â Â Note 12 - Fair Value Considerations Â The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to determine fair value as follows: Â Â â€” Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; Â Â â€” Level 2: Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Â Â â€” Level 3: Unobservable inputs that are supported by little or no market activity. Â 20 Table of Contents Â TheÂ Companyâ€™s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities, contingent consideration liabilities, fixed payment arrangements, and currentÂ and non-currentÂ debt. The carrying amounts of certain short-termÂ financial instruments, including cash and cash equivalents, accounts receivable, accounts payableÂ and accrued liabilities approximate their fair value due to their short maturities. Current and non-currentÂ debt are reported at their amortized costs on theÂ Companyâ€™s consolidated balance sheets. The remaining financial instruments are reported on theÂ Companyâ€™sÂ consolidated balance sheets at amounts that approximate current fair values. The Companyâ€™s carrying value of its consolidated amounts of cash and cash equivalents approximate their fair value as of September 30, 2024, and June 30, 2024, and are categorized within level 1 of the U.S. GAP fair value hierarchy. The Companyâ€™s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented. Â Recurring Fair Value Measurements Â The Companyâ€™s financial assets and liabilities that were accounted for at fair value on a recurring basis as ofÂ September 30, 2024, and June 30, 2024, by level within the fair value hierarchy as follows: Â Â Â Fair Value at September 30,Â Â Â Fair Value Measurements at September 30, 2024Â Â Â 2024 Â Â (Level 1) Â Â (Level 2) Â Â (Level 3) Â Â Â Â (in thousands) Â Liabilities: Â Â Â

through 2025. The Company is required to pay Tris a royalty make-whole payment of $30 for each unit under the 70,000â€‘unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 millionÂ eachÂ year. The annual payment is due in AugustÂ of eachÂ year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net revenue from theÂ product, the first of which is triggered at $40.0 million. Â Legal Matters Â Witmer Class-Action Securities Litigation Â A stockholder derivative suit was filed on September12, 2022, in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armisticeâ€™s Chief Investment Officer and Managing Partner, and a former director of Aytu), and certain other current and former directors of Aytu, Joshua R. Disbrow, Gary Cantrell, John Donofrio, Jr., Michael Macaluso, Carl Dockery and Ketan B. Mehta. Plaintiff amended the complaint on April 5, 2023. The Amended Complaint dropped Mr. Macaluso as a defendant and alleges that (i) Armistice facilitated the sale of assets of Cerecor in 2019 and Innovus in 2020 to Aytu in exchange for convertible securities which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enriched and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendantsâ€™ breaches of fiduciary duties, in connection with these acquisitions. The Amended Complaint sought unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneysâ€™ fees. While the Company believesÂ that this lawsuit is without merit and have vigorously defended against it, the CompanyÂ agreed to settle the matter for various corporate governance modifications and the payment of plaintiffâ€™s attorneysâ€™ fees. That settlement is subject to court approval, the hearing on which has not yet been scheduled. Â 22 Table of Contents Â Â Note 14 - Stockholdersâ€™ Equity Â The Company has 200 million shares of common stock authorized with a par value of $0.0001 per share and 50 million shares of preferred stock authorized with a par value of $0.0001 per share. AsÂ of September 30, 2024, included inÂ common stock outstanding are 19,019Â shares of unvested restricted stock issued to executives, directors and employees. Â On September 28, 2021, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 7, 2021. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the â€œ2021 Shelfâ€). The 2021 Shelf expiredÂ in October 2024. Â On August 11, 2022, the Company closed on an underwritten public offering (the â€œAugust 2022 Offeringâ€) utilizing the 2021 Shelf, pursuant to which it sold an aggregate of (i) 1,075,290 shares of its common stock; (ii) in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock; and (iii) accompanying warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was $8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant was $8.58, which equated to the public offering price per share of the common stock and accompanying common warrant, less the $0.02 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in August 2022. The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The Company raised $10.0 million in gross proceeds through the August 2022 Offering before underwriting fees and other expenses of $0.9 million. The pre-funded and common warrants had a combined fair value of approximately $6.0 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholdersâ€™ equity in the Companyâ€™s consolidated financial statements (see Note 16 - Warrants). Â On June 8, 2023, using a placement agent, the Company entered into a securities purchase agreement (the â€œSecurities Purchase Agreementâ€) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Companyâ€™s common stock; (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the â€œJune 2023 Pre-Funded Warrantsâ€); (iii) accompanying tranche AÂ warrants to purchase 2,173,912 shares of common stock (the â€œTranche A Warrantsâ€); and (iv) accompanying tranche B warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the â€œTranche BÂ Warrantsâ€Â and theÂ Tranche A Warrants together with the Tranche B Warrants, the â€œCommon Warrantsâ€). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the June 2023 Pre-Funded Warrants (the â€œExchange Warrantsâ€). Each pre-funded warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. The Common Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance or (ii) 30 days following the closing price of the Companyâ€™s common stock equaling 200% of the exercise price ($3.18 per share) for at least 40 consecutive trading days. The Tranche B Warrants were exercised in June 2024 as further described below. The Company raised $4.0 million in gross proceeds and net proceeds were $3.4 million after deducting offering expenses. The June 2023 Pre-Funded Warrants do not have an expiration date. The warrants had a combined fair value of approximately $5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in derivative warrant liabilities (loss) gainÂ along with the issuance costs of $0.6 million in the unaudited consolidated financial statement of operations (see Note 16 - Warrants). Â On June 14, 2024, the Tranche B Warrants were exercised, generating proceeds of $3.5 million. The Tranche B Warrants were converted into 367,478 shares of common stock and 1,806,434 pre-fundedÂ warrants to purchase shares of common stock with an exercise price of $0.0001 per share (the â€œTranche B Pre-Funded Warrantsâ€). The Tranche B Pre-Funded Warrants had a fair value of approximately $5.1 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholdersâ€™ equity in the Companyâ€™s consolidated financial statements. The CompanyÂ used a portion of theÂ proceeds from the Tranche B Warrants exerciseÂ as part of the Avenue Capital loanÂ repayment described further in Note 11 - Long-Term Debt. Â On September 26, 2024, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 15, 2024. This shelf registration statement coversÂ the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the â€œ2024Â Shelfâ€). Through the filing date of this Form 10-Q,Â $100.0Â million remainsÂ available under the 2024Â Shelf. This availability is subject to the SECâ€™s â€œbaby shelfâ€ limitation as set forth in SEC Instruction I.B.6 limitation to the Form S-3. Â 23 Table of Contents Â Â Note 15 - Equity Incentive Plans Â 2023 Equity Incentive Plan Â On May 18, 2023, the Companyâ€™s stockholders approved the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the â€œ2023 Equity Incentive Planâ€). Prior to the Companyâ€™s adoption of the 2023 Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. 2015 Stock Option and Incentive Plan (the â€œAytu 2015 Planâ€) and the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan (the â€œNeos 2015 Planâ€, and collectively with the Aytu 2015 Plan, the â€œ2015 Plansâ€). For the 2023 Equity Incentive Plan, the stockholders approved (i) 200,000 new shares; (ii) 87,129 shares available for grant under the 2015 Plans be â€œrolled overâ€ to the 2023 Equity Incentive Plan; and (iii) any shares that are returned to the Company under the 2015 Plans be added to the 2023 Equity Incentive Plan. With the approval of the 2023 Equity Incentive Plan, no additional awards will be granted under the 2015 Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. Stock options granted under the 2023 Equity Incentive Plan have contractual terms of 10 years or less from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards and restricted stock units have a vesting period of 3 to 4 years. As of September 30, 2024, the Company had 187,422 shares that are available for grant under the 2023 Equity Incentive Plan. Â Aytu 2015 Plan Â On JuneÂ 1, 2015, the Companyâ€™s stockholders approved the Aytu 2015 Plan, which, as amended in JulyÂ 2017, provides for the award of stock options, stock appreciation rights, restricted stock, and other equity awards. On FebruaryÂ 13, 2020, the Companyâ€™s stockholders approved an increase to 250,000 total shares of common stock in the Aytu 2015 Plan. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu 2015 Plan will be added back to the shares of common stock available for issuance under the 2023 Equity Incentive Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, and the restricted stock units have a vesting period of 4 years. Â Neos 2015 Plan Â Pursuant to the Neos Acquisition, the Company assumed 3,486 stock options and 1,786 restricted stock units previously granted under the Neos 2015 Plan. Accordingly, on April 19, 2021, the Company registered 5,272 shares of its common stock under the Neos 2015 Plan with the SEC. The terms and conditions of the assumed equity securities remained the same as they were previously under the Neos 2015 Plan. The Company allocated costs of the replacement awards attributable to pre-combination and post-combination service periods. The pre-combination service costs were included in the consideration transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years. Â Stock Options Â Stock option activity is as follows: Â Â Â

Weighted Â Â Remaining Â Â Â Number of Â Â Average Â Â Contractual Â Â Â Warrants Â Â Exercise Price Â Â Life in Years (4) Â Outstanding June 30, 2024 (1) Â Â 6,075,880Â Â $3.71Â Â Â 3.6Â Warrants exercised (2) Â Â (176,000)Â $0.0001Â Â Â â€”Â Outstanding September 30, 2024 (3) Â Â 5,899,880Â Â $3.22Â Â Â 3.3Â (1)Â The number of warrants outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,806,434Â liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. (2)Â The warrants exercised during the three months ended September 30, 2024,Â were 176,000 of theÂ Tranche B Warrants, which were exercised at a price of $0.0001 per share. (3)Â The number of warrants outstanding as of September 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,630,424Â liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. (4)Â As pre-funded warrants do not have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years. Â 27 Table of Contents Â Â Note 17 - Earnings Per Share Â Basic net income (loss) per share is calculated by dividing the net income (loss) available to the common stockholders by the weighted average number of common shares outstanding during that period. Diluted net income (loss) per share reflects the potential of securities that could share in the net income (loss) of the Company. For the three months ended September 30, 2023, the Company incurred a net loss from continuing operations andÂ discontinued operationsÂ and thus did not include common equivalent shares in the computation of diluted net lossÂ per share because the effect would have been anti-dilutive. Â Basic net income or loss per common share is calculated by dividing net income or loss available to common stockholders by the basic weighted-average number of common shares outstanding for the respective period. Diluted net income or loss per common share is calculated by dividing adjusted net income or loss by the diluted weighted-average number of common shares outstanding, which includes the effect of potentially dilutive securities. Potentially dilutive securities for this calculation consist of warrants to purchase common stock that are either liability classified orÂ equity classified (see Note 16Â â€“ Warrants);Â employee stock options (see Note 15Â â€“Â Equity Incentive Plans);Â employee unvested restricted stock (see Note 15Â â€“Â Equity Incentive Plans); and employee unvested restricted stock units (see Note 15Â â€“Â Equity Incentive Plans).Â For the three months ended September 30, 2024, and 2023, if the Company incurred a net loss from continuing operations; a net loss from discontinued operations, net of tax; or a net loss then the CompanyÂ did not include common equivalent shares in the computation of diluted net loss from continuing operations per share; diluted net loss from discontinued operations, net of tax; or diluted net loss per shareÂ because the effect would have been anti-dilutive. Â The following is a reconciliation of the numeratorÂ and the denominator used in the basic per share calculations: Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands, except share and per share data) Â BASIC Â Â Â Â Â Â Â Â Numerators: Â Â Â Â Â Â Â Â Net income (loss) from continuing operations Â $1,093Â Â $(7,473) Net income (loss) from discontinued operations, net of tax Â Â 381Â Â Â (647) Net income (loss) Â $1,474Â Â $(8,120) Denominator: Â Â Â Â Â Â Â Â Basic weighted-average common shares outstanding Â Â 6,068,019Â Â Â 5,482,037Â Per share calculations: Â Â Â Â Â Â Â Â Net income (loss) per share from continuing operations Â $0.18Â Â $(1.36) Net income (loss) per share from discontinued operations, net of tax Â $0.06Â Â $(0.12) Net income (loss) per share Â $0.24Â Â $(1.48) Â 28 Table of Contents Â The following is a reconciliation of the numeratorÂ and the denominator used in the dilutedÂ per share calculations: Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands, except share and per share data) Â DILUTED: CONTINUING OPERATIONS Â Â Â Â Â Â Â Â Numerator: Â Â Â Â Â Â Â Â Net income (loss) from continuing operations Â $1,093Â Â $(7,473) Adjustment for change in fair value of warrant liabilities Â Â (2,880)Â Â Â â€”Â Adjusted numerator - net loss from continuing operations Â $(1,787)Â $(7,473) Denominator: Â Â Â Â Â Â Â Â Basic weighted-average common shares outstanding Â Â 6,068,019Â Â Â 5,482,037Â Dilutive effect of warrants to purchase common stock Â Â 3,028,862Â Â Â â€”Â Dilutive effect of unvested restricted stock and restricted stock units Â Â 2,720Â Â Â â€”Â Diluted weighted-average common shares outstanding Â Â 9,099,601Â Â Â 5,482,037Â Per share calculation: Â Â Â Â Â Â Â Â Net loss per share from continuing operations Â $(0.20)Â $(1.36) Â Â Â Â Â Â Â Â Â DILUTED: DISCONTINUED OPERATIONS Â Â Â Â Â Â Â Â Numerator: Â Â Â Â Â Â Â Â Net income (loss) from discontinued operations, net of tax Â $381Â Â $(647) Denominator: Â Â Â Â Â Â Â Â Basic weighted-average common shares outstanding Â Â 6,068,019Â Â Â 5,482,037Â Dilutive effect of warrants to purchase common stock Â Â 3,028,862Â Â Â â€”Â Dilutive effect of unvested restricted stock and restricted stock units Â Â 2,720Â Â Â â€”Â Diluted weighted-average common shares outstanding Â Â 9,099,601Â Â Â 5,482,037Â Per share calculation: Â Â Â Â Â Â Â Â Net income (loss) per share from discontinued operations, net of tax Â $0.04Â Â $(0.12) Â Â Â Â Â Â Â Â Â DILUTED: NET INCOME (LOSS) Â Â Â Â Â Â Â Â Numerator: Â Â Â Â Â Â Â Â Net income (loss) Â $1,474Â Â $(8,120) Adjustment for change in fair value of warrant liabilities Â Â (2,880)Â Â Â â€”Â Adjusted numerator - net loss Â $(1,406)Â $(8,120) Denominator: Â Â Â Â Â Â Â Â Basic weighted-average common shares outstanding Â Â 6,068,019Â Â Â 5,482,037Â Dilutive effect of warrants to purchase common stock Â Â 3,028,862Â Â Â â€”Â Dilutive effect of unvested restricted stock and restricted stock units Â Â 2,720Â Â Â â€”Â Diluted weighted-average common shares outstanding Â Â 9,099,601Â Â Â 5,482,037Â Per share calculation: Â Â Â Â Â Â Â Â Net loss per share Â $(0.15)Â $(1.48) Â 29 Table of Contents Â The following table sets forth securities that could be considered anti-dilutive, and therefore areÂ excluded from the calculation of diluted weighted-average common shares outstanding and related per share calculations: Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Warrants to purchase common stock - liability classified (note 16) Â Â 455,392Â Â Â 6,498,980Â Warrants to purchase common stock - equity classified (note 16) Â Â 18,114Â Â Â 39,072Â Employee unvested restricted stock (note 15) Â Â 10,644Â Â Â 46,656Â Employee unvested restricted stock units (note 15) Â Â 1,211Â Â Â 3,463Â Employee stock options (note 15) Â Â 141,439Â Â Â 162,683Â Total anti-dilutive securities Â Â 626,800Â Â Â 6,750,854Â Â Â Note 18 - License Agreements Â Actavis Â On October 17, 2017, the Company entered into an agreement granting Actavis Laboratories FL, Inc. (â€œActavisâ€) (acquired by Teva Pharmaceutical Industries) a non-exclusive license to certain patents owned by the Company by which Actavis has the right to manufacture and market its generic version of Adzenys under its ANDA beginning on September 1, 2025, or earlier under certain circumstances. The ANDA was approved by the FDA on June 22, 2023. Â Teva Â On December 21, 2018, the CompanyÂ and Teva Pharmaceuticals USA, Inc. (â€œTevaâ€)Â entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla under anÂ abbreviated new drug applicationÂ (â€œANDAâ€)Â filed by Teva beginning on July 1, 2026, or earlier under certain circumstances. The ANDA was approved by the FDA on June 19, 2020. Â Â Note 19 - Restructuring Costs Â As part of the Companyâ€™s previously announced restructuring activities related to the wind down and divestiture of the Consumer Health businessÂ and the closure of the Grand Prairie, Texas manufacturing site, the Company has incurred expenses that qualify as exit and disposal costs under U.S. GAAP. These include severance and employee benefit costs as well as other direct separation benefit costs, right of use asset impairment charges, fixed asset and other asset impairment charges, accelerated depreciation of fixed assets, contract termination costs, and inventory write-downs. Severance and employee benefit costs primarily relate to cash severance. Restructuring costs associated with the Consumer Health business are recorded within the net loss from discontinued operations, net of tax in the unaudited consolidated financial statement of operationsÂ (see Note 20Â - Discontinued Operations). Â The expense associated with the closure of the Grand Prairie, Texas manufacturing site such as severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations. There have been no inventory write-downs associated with this closure. During the three months ended September 30, 2024, the CompanyÂ incurred $0.8Â million of costs associated with exit and disposal activities related to its manufacturing facility inÂ Grand Prairie, Texas.Â The Company does not expect to incurÂ additional significant restructuring costs. Â 30 Table of Contents Â Â Note 20Â - Discontinued Operations Â On July 31, 2024, after the wind down of operations, the Company entered into a definitive agreement to divest its Consumer Health business to a private, e-commerce focused company. The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, external workforce and contracts, and provides for the Company to receive contingent consideration payments on certain future sales of former Consumer Health business products. Â The accounting requirements for reporting the Consumer Health business as discontinued operation were met when the wind down and divestiture was completed on July 31, 2024. Accordingly, the accompanying unaudited consolidated financial statements for all periods presented reflect this business as a discontinued operation and certain assets and liabilities of discontinued operations have been reclassified to the current assets of discontinued operations; non-current assets of discontinued operations; and current liabilities of discontinued operations financial statement line items on the accompanying unaudited consolidated balance sheet as of June 30, 2024. The Company elected to record the contingent consideration portion of the arrangement when the consideration is determined to be realizable and, therefore, the Company did not record a contingent consideration asset at the transaction date and any subsequent proceeds will not be recognized until the contingent consideration asset is realizable, at which point the Company will recognize it to income (loss) from discontinued operations. Â The key components of net income (loss) from discontinued operations, net of tax for the three months ended September 30, 2024, and 2023, were as follows: Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Net revenue Â $717Â Â $4,282Â Cost of sales Â Â (359)Â Â (2,536) Selling and marketing Â Â (155)Â Â (1,331) General and administrative Â Â (2)Â Â (670) Amortization of intangible assets Â Â â€”Â Â Â (382) Non-operating other expense, net Â Â (4)Â Â (10) Recognized contingent consideration Â Â 412Â Â Â â€”Â Loss on divestiture Â Â (254)Â Â â€”Â Income (loss) from discontinued operations before income taxes Â Â 355Â Â Â (647) Income tax benefit Â Â 26Â Â Â â€”Â Net income (loss) from discontinued operations, net of tax Â $381Â Â $(647) Â 31 Table of Contents Â The key components of assets and liabilities of discontinued operationsÂ as of June 30, 2024, wereÂ as follows: Â Â Â June 30, Â Â Â 2024 Â Â Â (in thousands)Â ASSETS Â Â Â Â Current assets of discontinued operations: Â Â Â Â Accounts receivable, net Â $91Â Inventories Â Â 492Â Prepaid expenses and other current assets Â Â 538Â Total current assets of discontinued operations Â Â 1,121Â Non-current assets of discontinued operations: Â Â Â Â Other non-current assets Â Â 44Â Total current and non-current assets of discontinued operations Â $1,165Â Â Â Â Â Â Â LIABILITIES Â Â Â Â Current liabilities of discontinued operations: Â Â Â Â Accounts payable Â $126Â Accrued liabilities Â Â 431Â Total current liabilities of discontinued operations Â $557Â Â 32 Table of Contents Â Â ITEM 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Â This discussion should be read in conjunction with the Companyâ€™sÂ 2024Â Form 10-K. The following discussion and analysis contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those projected in the forward-looking statements. For additional information regarding these risks and uncertainties, please see the risk factors included in the Companyâ€™sÂ 2024Â Form 10-K, and in Part II, Item 1A of this Form 10-Q. Â Objective Â The purpose of the Managementâ€™sÂ Discussion and Analysis (the â€œMD&Aâ€) is to present information that management believes is relevant to an assessment and understanding of our results of operations and cash flows for the three months ended September 30, 2024, and our financial condition as of September 30, 2024. The MD&A is provided as a supplement to, and should be read in conjunction with, our Unaudited Consolidated Financial Statements and Notes to the Unaudited Consolidated Financial Statements. Â Overview Â We are aÂ pharmaceutical company focused on commercializing novel therapeutics. OurÂ strategy is to become a leading pharmaceutical company that improves the lives of patients. We useÂ a focused approach of in-licensing, acquiring, developing, and commercializing novel prescription therapeutics in order to continue building ourÂ portfolio of revenue-generating products and leveraging our commercial teamâ€™s expertise to build leading brands within large therapeutic markets. Our primary focus is on commercializing innovative prescription products that address conditions frequently developed or diagnosed in childhood, including ADHD.Â We are focusingÂ our efforts on accelerating the growth of our commercialÂ business and achieving operating cash flows. To achieve these goals, we indefinitely suspended active development of our clinical development programs and have wound down and divested unprofitable operations.Â In July 2024 we completed the wind down and divestiture of our Consumer Health businessÂ (see Part I, Item 1,Â Note 20Â â€“ Discontinued Operations in this Form 10-Q for further detail) and now operate our business as a single operating and reporting segment, which is focused on ourÂ prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios, the ADHD Portfolio and the Pediatric Portfolio. The ADHD PortfolioÂ consists of products for the treatment of ADHD, primarilyÂ Adzenys (amphetamine),Â an extended-release orally disintegrating tabletÂ and CotemplaÂ (methylphenidate), an extended-release orally disintegrating tablet. The Pediatric Portfolio consists primarily of KarbinalÂ (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.Â During the fourth quarter of fiscal 2024, we successfully completed the transition ofÂ allÂ manufacturingÂ of our ADHD products to a United States-based third-party contract manufacturer to improve the profitability of these products. Â In July 2023, weÂ entered into an exclusive collaboration, distribution and supply agreement with Medomie, a privately owned pharmaceutical company, for Medomie to sell Adzenys and Cotempla in Israel and the Palestinian Authority. In September 2024, we entered into an exclusive collaboration, distribution and supply agreement with Lupin, a subsidiary of global pharmaceutical companyÂ Lupin Limited, for Lupin to sell Adzenys and Cotempla inÂ Canada. We will supplyÂ Adzenys and Cotempla to Medomie and Lupin based on forecasts and provide product training.Â Medomie and Lupin areÂ responsible for seeking local regulatory approvals and marketing authorizations for both Adzenys and Cotempla, which is expected to occur over the next 18 to 24 months. The agreement with Medomie and the agreement with Lupin represent ourÂ first and second international commercial agreements for Adzenys and Cotempla, respectively. Â In light of our own business activities and external developments in the biopharmaceutical industry, weÂ regularly review our performance, prospects and risks such as the potential impact to our business resulting from our competitive landscape (i.e., entry of generic competitors, payer pressures, new branded entrants, etc.). These reviews have included consideration of potential partnerships, collaborations, and other strategic transactions such as acquisitions or divestitures of programs or technology to enhance stockholder value. We continueÂ to evaluate potential strategic transactions and business combinations, but there can be no guarantee that we will be able to enter into such transactions and there can be no guarantee that such transactions will achieve our desired goals. Â 33 Table of Contents Â Business Environment Â WeÂ continueÂ to experience inflationary pressure and have experienced supply chain disruptions related to the sourcing of raw materials, energy, logistics and labor. While we do not have sales or operations in Russia or Ukraine and we do not expect to have material sales or operations in the Middle East, it is possible that the conflict or actions taken in response, could adversely affect some of our markets and suppliers, economic and financial markets, costs and availability of energy and materials, or cause further supply chain disruptions. We expect that inflationary pressures and supply chain disruptions could continue to be significant across the business throughoutÂ fiscal 2025. We have not experienced stock outagesÂ for ourÂ ADHD products since the launch of those products, and the pediatric product supply has remained adequate to satisfy demand for the preceding fourÂ years. Â In October 2024, we received a Paragraph IV Certification Notice Letter (â€œNotice Letterâ€) from Granules Pharmaceuticals, Inc. (â€œGranulesâ€), stating that it intends to market a generic version of Adzenys before the expiration of all patents currently listed in the Orange Book. The Notice Letter states that Granulesâ€™ NDA for the generic version of Adzenys contains a Paragraph IV certification alleging that these patents are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the generic version of Adzenys. We are currently reviewing the Notice Letter. We have 45 days from receipt of the Notice Letter to commence a patent infringement lawsuit against Granules to trigger a stay precluding the FDA from approving Granulesâ€™ NDA for a generic version of Adzenys for up to 30 months or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. We plan to vigorously enforce our intellectual property rights related to Adzenys. Â Results of Operations Â The results of operations for theÂ three months ended September 30, 2024, compared to the three months ended September 30, 2023, is as follows: Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Change Â Â Â (in thousands) Â Net revenue Â $ 16,574 Â Â $ 17,817 Â Â $ (1,243) Cost of sales Â Â 4,589 Â Â Â 4,779 Â Â Â (190) Gross profit Â Â 11,985 Â Â Â 13,038 Â Â Â (1,053) Â Â Â Â Â Â Â Â Â

During the three months ended September 30, 2024, net revenue decreased by $1.2Â million, or 7%, compared to the same periodÂ ended September 30, 2023.Â The decrease was primarily due to a decrease in net revenue from the Pediatric Portfolio driven by payer changes last year that negatively affected prescription coverage. We entered into negotiations with a vendor that resulted in aÂ reduction to the liability purportedly owed the vendor byÂ $3.3 million, which resulted in aÂ decrease in the estimated variable consideration accrualÂ as of September 30, 2024, and a related increase in net revenue for our ADHD Portfolio of $3.3 million for the three months ended September 30, 2024. Â Gross Profit Â During the three months ended September 30, 2024, gross profit decreased by 8%, compared to the same periodÂ ended September 30, 2023.Â Gross profitÂ percentage was 72% for the three months ended September 30, 2024, compared to 73% for the same periodÂ ended September 30, 2023. Â Selling and Marketing Â During the three months ended September 30, 2024, selling and marketing expense decreasedÂ by $0.4Â million, or 7%,Â compared to the same periods ended September 30, 2023. The decrease was primarily driven by reduced commission expense and variable commercial marketing program fees in response to the lower revenue. Â General and Administrative Â During the three months ended September 30, 2024, general and administrative expense decreased by $1.2Â million, or 19%,Â compared to the same periodÂ ended September 30, 2023. The decrease is primarily a result of continued cost reduction efforts and improved operational efficiencies. Â Research and Development Â During the three months ended September 30, 2024, research and development expense was relatively flatÂ compared to the same period ended September 30, 2023. Our research and development costs are primarily associated with support for our commercialized products and costs associated with maintaining our intellectual property on our AR-101 asset. Â Amortization of Intangible Assets Â During the three months ended September 30, 2024, amortization expense of intangible assets, excluding amounts included in cost of sales, were relatively consistent compared to the same periodÂ ended September 30, 2023. Â 35 Table of Contents Â Restructuring Costs Â During the three months ended September 30, 2024, we incurred $0.8Â million of restructuring costs related to our previously announced operational realignment and related costs. DuringÂ the three months ended September 30, 2023, no restructuringÂ costs were incurred. Â Other Income, Net Â During the three months ended September 30, 2024, other income, net wasÂ relatively consistent compared to the same periodÂ ended September 30, 2023. Â Interest Expense Â During the three months ended September 30, 2024, interest expense decreased by $0.3Â million, or 23%,Â compared to theÂ same periodÂ ended September 30, 2023,Â primarily due toÂ the extinguishment of our $15.0 million term loan while entering into theÂ $13.0 million Eclipse Term LoanÂ on more favorable termsÂ during the fourth quarter of fiscal 2024. Â Derivative Warrant Liabilities Gain (Loss) Â The fair value of derivative warrant liabilities is calculated using either the Black-Scholes option pricing model or the Monte Carlo simulationÂ model and isÂ revalued at each reporting period, and changes are reflected through income or expense. For the three months ended September 30, 2024, we recognized an unrealized gain of $2.9 million from the fair value adjustment primarily driven by a decreaseÂ in our stock price during the three months ended September 30, 2024. For the three months ended SeptemberÂ 30, 2023, we recognized an unrealized lossÂ of $5.9Â million from the fair value adjustment primarily driven by an increaseÂ in our stock price during the three months ended September 30, 2023.Â Â Income Tax Expense Â Income tax expense for continuing operationsÂ was $0.4 million forÂ the three months ended September 30, 2024, which was an effective tax rate of 27.0%. This income tax expense was primarily driven by the limitations on losses as a result of Section 382 of the Internal Revenue Code changes in ownership coupled with existing valuation allowances. Â ForÂ the three months ended September 30, 2023, income tax expense for continuing operations was zeroÂ with an effective tax rate of zero percent for those same periods,Â reflecting the full valuation allowance and no impact of Section 382 of the Internal Revenue Code. Â Net Income (Loss) from Discontinued Operations, Net of Tax Â Net income (loss) from discontinued operations, net of tax is related toÂ the wind down and divestiture of our Consumer Health business that was completed in the first quarter of fiscal 2025. See Part I, Item 1,Â Note 20Â â€“ Discontinued Operations in this Form 10-Q for further detail. Â Liquidity and Capital Resources Â Sources of Liquidity Â We have obligations related to our loan agreements, milestone payments for licensed products, and manufacturing purchase commitments. Â We finance our operations through a combination of sales of our common stock and warrants, borrowings under our line of credit facilityÂ and from cash generated from operations. Â Shelf Registrations Â On September 26, 2024, we filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 15, 2024. This shelf registration statement coversÂ the offering, issuance and sale by usÂ of up to an aggregate of $100.0 million of our common stock, preferred stock, debt securities, warrants, rights and units (the â€œ2024Â Shelfâ€). Through the filing date of this Form 10-Q,Â $100.0Â million remainsÂ available under the 2024Â Shelf. This availability is subject to the SECâ€™s â€œbaby shelfâ€ limitation as set forth in SEC Instruction I.B.6 limitation to the Form S-3. Â 36 Table of Contents Â Eclipse Agreement Â In JuneÂ 2024, we and certain of ourÂ subsidiariesÂ entered into the Eclipse Amendment No. 5, with the Eclipse Lender. Under the Eclipse Agreement No. 5, we haveÂ two loan agreements, the Eclipse Term LoanÂ and the Eclipse Revolving Loan. Â The Eclipse Term LoanÂ consists of a principal amount of $13.0 million, at an interest rate of SOFRÂ plus 7.0%, with aÂ four-year term and a straight-line loan amortization period of seven years, which would provide for a loan balance at the end of the four-year term ofÂ $5.6 million to be repaid on June 12, 2028, the maturity date. We usedÂ the proceeds of the Eclipse Term Loan and a portion of the proceeds from warrant exercises described belowÂ to repayÂ in full a $15.0 million term note. Â The Eclipse Revolving LoanÂ allows us to borrow up to $14.5 million at an interest rate of SOFR plus 4.5%. In addition, we are required to pay an unused line fee of 0.5% of the average unused portion of the maximum Eclipse Revolving LoanÂ amount during the immediately preceding month. The ability to make borrowings and obtain advances of the Eclipse Revolving Loan remains subject to a borrowing base and reserve, and availability blockage requirements and the maturity date, as amended, is June 12, 2028. Â Cash Flows Â The following table shows cash flows for the three months ended September 30, 2024, and 2023: Â Â Three Months Ended September 30, Â Â 2024 Â 2023 Â Change Â Â (in thousands) Â Net cash used in operating activities Â $ (1,190) Â $ (211) Â $ (979) Net cash provided by (used in) investing activities Â $ 381 Â Â $ (76) Â $ 457 Â Net cash provided by (used in) financing activities Â $ 911 Â Â $ (2,734) Â $ 3,645 Â Â Net Cash Used in Operating Activities Â Net cash used in operating activities during these periods primarily reflectsÂ our net income (loss) from continuing operations, partially offset by cash provided by discontinued operations and changes in working capital and non-cash charges including stock-based compensation expense, derivative warrant liabilities gain or loss, depreciation, amortization and accretion, and other charges. Â During the three months ended September 30, 2024, net cash used in operating activities totaled $1.2Â million. The use of cash was primarily the result of the decrease in accounts receivable, net;Â inventories;Â prepaid expenses and other assets; other accrued liabilities; and accrued liabilities, partially offset by positive cash earnings (net income (loss) offset by non-cash depreciation, amortization and accretion, derivative warrant liabilities adjustment, and stock compensation expense). Additionally, these were partially offset by an increase in accounts payable. Â During the three months ended September 30, 2023, net cash used in operating activities totaled $0.2Â million. The use of cash was primarily the result of the decrease in accrued liabilities, partially offset by funds from the ERCÂ program recorded in other operating liabilities (see Note 2 â€“ Summary of Significant Accounting Policies andÂ Note 9 â€“ Other Liabilities). Additionally, these were partially offset by positive cash earnings (net loss offset by non-cash depreciation, amortization and accretion, derivative warrant liabilities adjustment, and stock compensation expense). Â Net Cash Provided by (Used In) Investing Activities Â Net cash provided byÂ investing activities for the three months ended September 30, 2024, were driven by cash received from the sale of fixed assets, partially offset by cash payments for fixed asset purchases. Â Net cash used inÂ investing activities were nominal during the three months ended September 30, 2023. Â Net Cash Provided by (Used In) Financing Activities Â Net cash provided byÂ financing activities of $0.9Â million during the three months ended September 30, 2024, was primarily from net proceeds received from the revolving credit facility, partially offset by payments made to fixed payment arrangements and payments made on borrowings. Â Net cash used in financing activities of $2.7 million during the three months ended September 30, 2023, was primarily from payments made to fixed payment arrangements. Â 37 Table of Contents Â Contractual Obligations, Commitments and Contingencies Â As a result of our acquisitions and licensing agreements, we are contractually and contingently obliged to pay, when due, various fixed and contingent milestone payments. See Note 13 â€“Â Commitments and Contingencies in the accompanying notes to the unaudited consolidated financial statementsÂ for further information. Â In May 2022, we entered into an the Tuzistra License Agreement. Pursuant to such termination, as of SeptemberÂ 30, 2024, we have accrued a settlement liability of $5.8Â million payable to TrisÂ in other current liabilities on the consolidated balance sheet payable to Tris, with a provision that allows the CompanyÂ to pay interest on any principal amounts due but remaining unpaid past July 2024. Â Upon closing of the acquisition of a line of prescription pediatric products from Cerecor, Inc. in October 2019, we assumed payment obligations that require us to make fixed and product milestone payments.Â As of September 30, 2024, the Tris Karbinal Agreement accrued fixed payment arrangement balance was $1.7Â millionÂ recorded in other current liabilities on the consolidated balance sheet. Â In connection with our acquisition of the assets from Rumpus VEDS, LLC, Rumpus Therapeutics, LLC, Rumpus Vascular, LLC (collectively, â€œRumpusâ€), and only if we resume and ultimately complete clinical development of AR101 and gain regulatory clearances to commercialize the product in multiple markets around the world, we may be required to pay up to $67.5 million in regulatory and commercial-based earn-out payments to Rumpus, which are primarily paid against commercial milestone achievements. Under the licensing agreement with Denovo Biopharma LLC (â€œDenovoâ€), we made a payment of $0.6 million for a license fee in April 2022. In addition, upon the achievement of regulatory and commercial milestones, we may be required to pay up to $101.7 million. Under the licensing agreement with Johns Hopkins University (â€œJHUâ€), upon achievement of regulatory and commercial milestone, we may be required to pay up to $1.6 million to JHU. In fiscal 2022, two milestones payable to Rumpus were achieved totaling $4.0 million, which were paid in 109,447 shares of common stock and $2.6 million in cash. The Company also assumed the responsibility for royalties of 3.0% of net revenue from the product, with a minimum of $20,000 per year, and upon the achievement of certain regulatory and commercial milestones, up to $1.6 million. With clinical development currently suspended, only if and when we resume and ultimately complete clinical development of AR101, are substantially all milestones payable to these parties. Â Critical Accounting Estimates Â The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenueÂ and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a detailed discussion about ourÂ significant accounting policies, refer toÂ ourÂ 2024Â Form 10-K. Â Off-Balance Sheet Arrangements Â We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors. Â ITEMÂ 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Â We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide information under this item. Â 38 Table of Contents Â ITEMÂ 4. CONTROLS AND PROCEDURES Â Evaluation of Disclosure Controls and Procedures Â As required by Rules 13a-15(e) and 15d-15(e) under the Exchange Act, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures wereÂ effective as of September 30, 2024, at reasonable assurance levels,Â in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.Â Accordingly, we believeÂ that the financial statements presented in this Form 10-Q present fairly,Â in all material respects, our financial position, results of operations and cash flows for the periods presented herein. Â Inherent Limitations on Effectiveness of Internal Controls over Financial Reporting Â Our management team, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple errors or mistakes. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data. Â Changes in Internal Control over Financial Reporting Â There have been no changes in ourÂ internal control over financial reporting that occurred during the period covered by this Form 10-Q, that have a material effect, or are reasonably likely to have a material effect, on our internal control over financial reporting. Â 39 Table of Contents Â Â PARTÂ II. OTHER INFORMATION ITEM 1. LEGAL PROCEDINGS Â From time to time, we become involved in or are threatened with legal disputes arising from our business and operations in the normal course of business. Most of these disputes are not likely to have a material effect on our business, financial condition, or operations. There were no new material legal proceedings that were initiated or terminated during the period covered by this report and there have been no material developments in the material proceedings identified in Part I, Item 3 in our 2024 Form 10-K. For a description of our material pending legal proceedings, see Note 13 â€“ Commitments and Contingencies of the notes to the unaudited consolidated financial statements included in Part I, Item 1 of this Form 10-Q, which is incorporated herein by reference. As of the filing of this report, no legal proceedings are pending against us that we believe individually or collectively are likely to have a materially adverse effect upon our financial condition, results of operations, or cash flows. Â ITEM 1A. RISK FACTORS Â Our business faces significant risks and uncertainties. Certain important factors may have a material adverse effect on our business prospects, financial condition, and results of operations, and you should carefully consider them. There have not been any material changes to our risk factors from those reported inÂ our 2024Â Form 10-K. Â ITEM 5. OTHER INFORMATION Â Rule 10b5-1 Trading Plans Â During the quarter endedÂ September 30, 2024, none of our directors or executive officers (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangementâ€Â (as those terms are defined in Item 408 of Regulation S-K). Â ITEM 6. EXHIBITS Â Exhibit No. Â Description 31.1* Â Certificate of the Chief Executive Officer of Aytu BioPharma, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2* Â Certificate of the Chief Financial Officer of Aytu BioPharma, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1** Â Certificate of the Chief Executive Officer and the Chief Financial Officer of Aytu BioPharma, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS* Â XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH* Â Inline XBRL Taxonomy Schema Linkbase Document. 101.CAL* Â Inline XBRL Taxonomy Calculation Linkbase Document. 101.DEF* Â Inline XBRL Taxonomy Definition Linkbase Document. 101.LAB* Â Inline XBRL Taxonomy Labels Linkbase Document. 101.PRE* Â Inline XBRL Taxonomy Presentation Linkbase Document. 104* Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). Â *Â Â Â FiledÂ herewith. **Â Furnished herewith. Â Â Â Â Â Â Â Â Â Â Â Â Â Â 40 Table of Contents Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Â Â AYTU BIOPHARMA,Â INC. Â Â Â Date:Â November 13, 2024 By: /s/ Joshua R. Disbrow Â Â Joshua R. Disbrow Â Â Chief Executive Officer Â Â (Principal Executive Officer) Â Â Â Date:Â November 13, 2024 By: /s/ Ryan J. Selhorn Â Â Ryan J. Selhorn Â Â Chief Financial Officer Â Â (Principal Financial Officer) Â Â (Principal Accounting Officer) Â Â Â Â Â Â Â Â Â Â Â Â Â Â

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities particularly during the period in which this report is being prepared; Â Â b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting. Â 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â a) All significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 13, 2024 Â Â Â Â Â Â Â Â Â Â By: /s/ Joshua R. Disbrow Â Â Joshua R. Disbrow Â Â Chief Executive Officer Â Â (Principal Executive Officer) Â Â EX-31.2 3 ex_722661.htm EXHIBIT 31.2 ex_722661.htm Exhibit 31.2 Â AYTU BIOPHARMA, INC. Certification by Chief Financial Officer Pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002 Â I, Ryan J. Selhorn, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of Aytu BioPharma, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13aâ€“15(e) and 15dâ€“15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13aâ€“15(f) and 15dâ€“15(f)) for the registrant and have: Â Â a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities particularly during the period in which this report is being prepared; Â Â b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting. Â 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â a) All significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 13, 2024 Â Â Â Â Â Â Â Â Â Â By: /s/ Ryan J. Selhorn Â Â Ryan J. Selhorn Â Â Chief Financial Officer Â Â (Principal Financial Officer) Â Â (Principal Accounting Officer) Â Â EX-32.1 4 ex_722662.htm EXHIBIT 32.1 ex_722662.htm Exhibit 32.1 Â CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S. C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Joshua R. Disbrow, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanesâ€‘Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10â€‘Q of Aytu BioPharma, Inc. for the fiscal quarter ended September 30, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10â€‘Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. Â Â Date: November 13, 2024 Â Â Â Â Â Â Â Â Â Â By: /s/ Joshua R. Disbrow Â Â Joshua R. Disbrow Â Â Chief Executive Officer Â Â (Principal Executive Officer) Â Â Â I, Ryan J. Selhorn, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanesâ€‘Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10â€‘Q of Aytu BioPharma, Inc. for the fiscal quarter ended September 30, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10â€‘Q fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc. Â Â Date: November 13, 2024 Â Â Â Â Â Â Â Â Â Â By: /s/ Ryan J. Selhorn Â Â Ryan J. Selhorn Â Â Chief Financial Officer Â Â (Principal Financial Officer) Â Â (Principal Accounting Officer) Â Â EX-101.SCH 5 aytu-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Unaudited Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Unaudited Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Unaudited Consolidated Statements of Operations link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Unaudited Consolidated Statements of Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Unaudited Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Nature of Business link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Revenue link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Inventories link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Leases link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Intangible Assets link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Accrued Liabilities link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Other Liabilities link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Revolving Credit Facility link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Long-term Debt link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 13 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 15 - Equity Incentive Plans link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 16 - Warrants link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 17 - Earnings Per Share link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 18 - License Agreements link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 19 - Restructuring Costs link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 20 - Discontinued Operations link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 3 - Revenue (Tables) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 4 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 5 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 6 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 7 - Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 8 - Accrued Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 9 - Other Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 11 - Long-term Debt (Tables) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 12 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 15 - Equity Incentive Plans (Tables) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 16 - Warrants (Tables) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 17 - Earnings Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 20 - Discontinued Operations (Tables) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 3 - Revenue (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 3 - Revenue - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note 4 - Inventories (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995490 - Disclosure - Note 4 - Inventories - Schedule of Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note 5 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995492 - Disclosure - Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 995493 - Disclosure - Note 6 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995494 - Disclosure - Note 6 - Leases - Lease Cost (Details) link:calculationLink link:definitionLink link:presentationLink 995495 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details) link:calculationLink link:definitionLink link:presentationLink 995496 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 995497 - Disclosure - Note 6 - Leases - Schedule of Lease Liability Maturity (Details) link:calculationLink link:definitionLink link:presentationLink 995498 - Disclosure - Note 7 - Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995499 - Disclosure - Note 7 - Intangible Assets - Schedule of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995500 - Disclosure - Note 7 - Intangible Assets - Future Amortization Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995501 - Disclosure - Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995502 - Disclosure - Note 9 - Other Liabilities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995503 - Disclosure - Note 9 - Other Liabilities - Schedule of Other Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995504 - Disclosure - Note 10 - Revolving Credit Facility (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995505 - Disclosure - Note 11 - Long-term Debt (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995506 - Disclosure - Note 11 - Long-term Debt - Schedule of Long-term Debt (Details) link:calculationLink link:definitionLink link:presentationLink 995507 - Disclosure - Note 11 - Long-term Debt - Future Principal Payments (Details) link:calculationLink link:definitionLink link:presentationLink 995508 - Disclosure - Note 12 - Fair Value Measurements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995509 - Disclosure - Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details) link:calculationLink link:definitionLink link:presentationLink 995510 - Disclosure - Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) link:calculationLink link:definitionLink link:presentationLink 995511 - Disclosure - Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 995512 - Disclosure - Note 12 - Fair Value Measurements - Valuation Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 995513 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995514 - Disclosure - Note 14 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995515 - Disclosure - Note 15 - Equity Incentive Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995516 - Disclosure - Note 15 - Equity Incentive Plans - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995517 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995518 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995519 - Disclosure - Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995520 - Disclosure - Note 16 - Warrants (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995521 - Disclosure - Note 16 - Warrants - Schedule of Warrants Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 995522 - Disclosure - Note 17 - Earnings Per Share - Schedule of Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 995523 - Disclosure - Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 995524 - Disclosure - Note 20 - Discontinued Operations - Schedule of Discontinued Operations (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 6 aytu-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 aytu-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 aytu-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Derivative, Gain (Loss) on Derivative, Net Derivative warrant liabilities (gain) loss Significant Accounting Policies Note 3 - Revenue Note 4 - Inventories Note 5 - Property and Equipment Note 6 - Leases Note 7 - Intangible Assets Note 8 - Accrued Liabilities Liabilities, Noncurrent [Abstract] Note 9 - Other Liabilities Note 11 - Long-term Debt Note 12 - Fair Value Measurements Note 15 - Equity Incentive Plans Note 16 - Warrants Note 17 - Earnings Per Share Reverse Stock Split [Member] The conversion of a reverse stock split where there is a reduction in the shares outstanding. Note 20 - Discontinued Operations us-gaap_LiabilitiesCurrent Total current liabilities Schedule of Maturities of Long-Term Debt [Table Text Block] Note 3 - Revenue - Disaggregation of Revenue (Details) Current liabilities of discontinued operations Total current liabilities of discontinued operations Note 4 - Inventories - Schedule of Inventories (Details) Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) Other Liabilities, Current Less: current portion of other liabilities Note 6 - Leases - Lease Cost (Details) Note 6 - Leases - Lease Balance Sheet Information (Details) Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals) Note 6 - Leases - Schedule of Lease Liability Maturity (Details) Note 7 - Intangible Assets - Schedule of Intangible Assets (Details) Note 7 - Intangible Assets - Future Amortization Expense (Details) Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) Note 9 - Other Liabilities - Schedule of Other Liabilities (Details) Note 11 - Long-term Debt - Schedule of Long-term Debt (Details) Note 11 - Long-term Debt - Future Principal Payments (Details) Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details) Share-Based Payment Arrangement, Option, Activity [Table Text Block] Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals) Note 12 - Fair Value Measurements - Valuation Assumptions (Details) Vested, weighted average grant date fair value (in dollars per share) Note 15 - Equity Incentive Plans - Stock Option Activity (Details) Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Unvested, weighted average grant date fair value (in dollars per share) Unvested, weighted average grant date fair value (in dollars per share) Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details) Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details) Note 16 - Warrants - Schedule of Warrants Outstanding (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares) Unvested, shares (in shares) Unvested, shares (in shares) Note 17 - Earnings Per Share - Schedule of Earnings Per Share (Details) Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details) us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent Less: current portion of debt Note 20 - Discontinued Operations - Schedule of Discontinued Operations (Details) Notes To Financial Statements us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Notes To Financial Statements [Abstract] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Vested, shares (in shares) Share-Based Payment Arrangement,

Cost by Plan [Table Text Block] Nonvested Restricted Stock Shares Activity [Table Text Block] Current portion of debt Less: current portion of debt Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] aytu_SupplyAndDistributionAgreementExtensionTerm Supply and Distribution Agreement, Extension Term (Year) Represents the extension term of a supply and distribution agreement. Exercisable, options, weighted average exercise price (in dollars per share) Exercisable, options, weighted average remaining contractual life (Year) Exercisable, options (in shares) Outstanding, options, weighted average remaining contractual life (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, options, weighted average exercise price (in dollars per share) Outstanding, options, weighted average exercise price (in dollars per share) Forfeited/Cancelled, options, weighted average exercise price (in dollars per share) Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Goodwill and Intangible Assets Disclosure [Text Block] Accrued liabilities Total accrued liabilities Accrued employee compensation us-gaap_SettlementLiabilitiesCurrent Settlement Liabilities, Current Accounts payable Secured Debt [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) Outstanding, options (in shares) Outstanding, options (in shares) Cash received from sales of fixed assets Other accrued liabilities us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_PaymentsToAcquireProductiveAssets Cash payments for fixed asset purchases us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Dilutive effect of warrants to purchase common stock (in shares) The Pediatric Portfolio [Member] Represents the Pediatric Portfolio. Dilutive effect of unvested restricted stock and restricted stock units (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) Non-cash investing and financing activities: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Cash paid for income taxes Tris Karbinal Agreement [Member] Relating to Tris Karbinal Agreement. Product and Service, Other [Member] aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year) Represents the renewable period for a finite-lived intangible asset. Employee retention credit Employee Retention Credit Represents the amount of employee retention credit. Liabilities, Current [Abstract] Developed Technology Rights [Member] Return reserve Represents the amount of return reserve classified as current. Accrued customer and product related fees Represents the amount of accrued customer and product related fees classified as current. Fixed payment arrangements Fixed Payment Arrangements Represents the amount of fixed payment arrangements. us-gaap_Assets Total assets Supplemental disclosure of cash flow information: Equity Warrants [Member] Relating to Equity Warrants. us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation Total current and non-current assets of discontinued operations Plan Name [Axis] Technology-Based Intangible Assets [Member] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Net income (loss) us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Adjusted numerator - net loss us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet Accounts receivable, net Adjustment for change in fair value of warrant liabilities Manufacturing Equipment [Member] Represents manufacturing equipment. Share-Based Payment Arrangement [Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Office Equipment, Furniture and Other [Member] Represents office equipment, furniture and other. Finite-Lived Intangible Assets, Major Class Name [Domain] Award Type [Domain] Net income (loss) from continuing operations Net income (loss) from continuing operations us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity Net income (loss) from discontinued operations, net of tax Award Type [Axis] Net income (loss) Net income (loss) Net income (loss) us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Finite-lived intangible assets, amortization Finite-lived intangible assets, net Total future amortization expense Intangible assets, net Restricted Stock Units (RSUs) [Member] Finite-lived intangible assets, gross Restricted Stock [Member] Accrued program liabilities Carrying value as of the balance sheet date of obligations incurred and payable for program related liabilities. Share-Based Payment Arrangement, Option [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] aytu_ClassOfWarrantOrRightIssuedDuringPeriod Class of Warrant or Right, Issued During Period (in shares) The number of warrants or rights issued during period. Warrants or Rights Disclosure [Text Block] The entire disclosure for warrants or rights. Commitments and Contingencies Disclosure [Text Block] The 2015 Plan [Member] Represents the Aytu BioScience 2015 Stock Option and Incentive Plan (the â€œ2015 Planâ€). us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less: accumulated depreciation and amortization Property and equipment, net Property and equipment, net Property and equipment, gross Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] aytu_EmployeeRetentionCreditVendorFee Employee Retention Credit, Vendor Fee Represents the amount of vendor fee from employee retention credit during the period. aytu_ClassOfWarrantOrRightExercisedDuringPeriod Class of Warrant or Right, Exercised During Period (in shares) Warrants exercised (2) (in shares) The number of warrants or rights exercised during period. us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax Income (loss) from discontinued operations before income taxes us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation Income tax benefit Net income (loss) from discontinued operations, net of tax Net income (loss) from discontinued operations, net of tax On or Before January 26, 2023 [Member] Relating to on or before January 26, 2023. aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment Line of Credit Facility, Termination, Fee, Percentage of Commitment Represents the percentage of commitment used as a termination fee of a line of credit facility. Cash flows from investing activities: us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax Loss on divestiture Eclipse Business Capital LLC Loan Agreement [Member] Relating to Eclipse Business Capital LLC Loan Agreement. Outstanding, weighted average remaining contractual term (Year) The weighted average period of remaining contractual life of warrants or rights. Liability Warrants [Member] Represents liability warrants. us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet Other operating assets and liabilities, net Equity-based Warrants [Member] Represents equity-based warrants. Net income (loss) per share (note 17): Earnings Per Share [Text Block] After January 26, 2024 But Before January 26, 2025 [Member] Relating to after January 26, 2024 but before January 26, 2025. After January 26, 2023 But Before January 26, 2024 [Member] Relating to after January 26, 2023 but before January 26, 2024. Office Space in Berwyn, Pennsylvania [Member] Relating to an office space in Berwyn, Pennsylvania. Other Warrants [Member] Relating to other warrants. aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment Operating Lease, Undiscounted Minimum Monthly Payment Represents the undiscounted minimum monthly payment on an operating lease. aytu_DebtInstrumentFinalPayment Debt Instrument, Final Payment Represents the final payment of a debt instrument. aytu_DebtInstrumentPrepaymentFeePercentage Debt Instrument, Prepayment Fee, Percentage Represents the percentage of loan that is payable as a prepayment fee. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Avenue Capital Warrants [Member] Relating to the Avenue Capital Warrants. Avenue Capital Loan [Member] Relating to the Avenue Capital Loan. Accrued liabilities us-gaap_IncreaseDecreaseInAccruedLiabilities us-gaap_IncomeTaxExpenseBenefit Income tax expense The 2020 Shelf [Member] Relating to the 2020 Shelf. aytu_SupplyAndDistributionCommitmentPeriod Supply and Distribution Commitment, Period (Year) Period covered by the supply and distribution commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Avenue Capital Issuance [Member] Relating to Avenue Capital Issuance. aytu_SaleOfStockMaximumAmountOfEquityIssuable Sale of Stock, Maximum Amount of Equity Issuable Represents the maximum monetary amount of equity issuable. Securities Purchase Agreement [Member] Relating to the Securities Purchase Agreement. us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment Supply and Distribution Agreement, Maximum Yearly Make-whole Payment The maximum amount of make-whole payment per year under supply and distribution agreement. August 2022 Common and Prefunded Warrants [Member] Relating to the August 2022 Common and Prefunded Warrants. aytu_SupplyAndDistributionAgreementMinimumSalesPerYear Supply and Distribution Agreement, Minimum Sales Per Year Th minimum amount of units to be sold per year under supply and distribution agreement. Tranche A Common Warrants [Member] Relating to Tranche A Common Warrants. aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit The amount of royalty make-whole payment per unit for sales under the minimum units for the supply and distribution agreement. Pre-Funded Warrants [Member] Relating to the Pre-Funded Warrants. Employee Retention Credit [Policy Text Block] Represents the accounting policy for employee retention credits. The August 2022 Offering [Member] Relating to the August 2022 Offering. aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales Supply and Distribution Commitment, Royalty, Percentage of Net Sales The percentage of net sales to be paid for royalties under supply and distribution agreement. August 2022 Common Warrants [Member] Relating to the August 2022 Common Warrants. August 2022 Prefunded Warrants [Member] Relating to August 2022 prefunded warrants. aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations Supply and Distribution Agreement, Maximum Milestone Obligations The maximum amount of milestone obligations of the supply and distribution agreement. Common Warrants [Member] Relating to the Common Warrants. Tranche B Common Warrants [Member] Relating to the Tranche B Common Warrants. us-gaap_OperatingExpenses Total operating expenses Securities Purchase Agreement Warrants [Member] Relating to the Securities Purchase Agreement Warrants. aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues Supply and Distribution Agreement, First Milestone, Minimum Net Revenues The amount of net revenues to be reached to trigger the first milestone obligation of the supply and distribution agreement. us-gaap_DebtInstrumentTerm Debt Instrument, Term (Year) Common Warrants Exchanged for PreFunded Warrants [Member] Relating to Common Warrants exchanged for Pre-Funded Warrants. Restricted Stock and Restricted Stock Units (RSUs) [Member] Share instruments in which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met. Outside Equity Incentive Plan [Member] Relating to outside the equity incentive plan. General and administrative The 2023 Equity Incentive Plan [Member] Relating to the 2023 Equity Incentive Plan. Cash and cash equivalents us-gaap_InterestExpenseNonoperating Interest expense Total stock-based compensation expense Included in earnings Liability Pre-Funded Warrants [Member] Represents information pertaining to pre-funded warrants classified as liabilities. Amendment Flag City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Reclassification, Comparability Adjustment [Policy Text Block] us-gaap_GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, outstanding (in shares) Common Stock, Shares, Outstanding (in shares) Preferred stock, outstanding (in shares) Current Fiscal Year End Date us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_LeaseCost Total lease cost us-gaap_DebtInstrumentInterestRateEffectivePercentage Debt Instrument, Interest Rate, Effective Percentage us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Operating lease assets Document Fiscal Period Focus Operating lease cost Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Short-term lease cost Lease, Cost [Table Text Block] Document Period End Date Operating lease assets (Year) Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type us-gaap_GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Balance Balance Settlements (1) Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] Restructuring costs Variable Rate [Domain] Prime Rate [Member] Schedule of Long-Term Debt Instruments [Table Text Block] Variable Rate [Axis] us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable, net Entity Tax Identification Number Entity Central Index Key Entity Registrant Name Entity [Domain] Legal Entity [Axis] Entity Address, Address Line One Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] Amortization of intangible assets Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code Entity Address, State or Province ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Material Terms of Trading Arrangement [Text Block] Entity Common Stock, Shares Outstanding Long-Term Debt [Text Block] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Local Phone Number us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Line of Credit Facility, Remaining Borrowing Capacity us-gaap_TableTextBlock Notes Tables us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity aytu_DisposalGroupIncludingDiscontinuedOperationRecognizedContingentConsideration Recognized contingent consideration Amount of recognized contingent consideration attributable to disposal group, including, but not limited to, discontinued operation. us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Adjusted numerator - net loss from continuing operations Amount after tax of income (loss) from continuing operations attributable to the parent for diluted calculation. Non-cash adjustments from discontinued operations The amount of adjustments to net income or loss from discontinued operations. Other non-cash investing and financing activities Represents the amount of other noncash investing and financing items. Stock-based compensation expense (in shares) Stock-based compensation expense Secured Overnight Financing Rate (SOFR) [Member] aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced Total lease payments Amount of lessee's undiscounted obligation for lease payment for operating lease, including lease not yet commenced. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited/Cancelled, options (in shares) us-gaap_WarrantsAndRightsOutstandingTerm Warrants and Rights Outstanding, Term (Year) Selling and marketing Line of Credit Facility, Lender [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] us-gaap_StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues (in shares) Raw materials Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholdersâ€™ equity Finished goods Work in process Derivative liability, measurement input Non-current assets of discontinued operations aytu_IncreaseDecreaseInOperatingCapitalAttributableToDiscontinuedOperations Changes in operating assets and liabilities from discontinued operations The increase (decrease) during the reporting period of all assets and liabilities used in operating activities of discontinued operations. Accumulated deficit Research and development us-gaap_AssetsNoncurrent Total non-current assets Measurement Input, Share Price [Member] Non-current assets of discontinued operations: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets Other non-current assets Short-Term Debt [Text Block] us-gaap_InterestExpenseDebt Interest Expense, Debt Measurement Input, Price Volatility [Member] Changes in operating assets and liabilities: Measurement Input, Risk Free Interest Rate [Member] us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements us-gaap_OtherNoncashIncomeExpense Other non-cash adjustments Inventory Disclosure [Text Block] Measurement Input, Expected Dividend Rate [Member] us-gaap_OperatingLeaseLiabilityNoncurrent Non-current: operating leases Schedule of Inventory, Current [Table Text Block] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Measurement Input, Expected Term [Member] Total lease liabilities us-gaap_OperatingLeaseLiability Operating Lease, Liability Less: tenant improvement allowance aytu_LesseeOperatingLeaseLiabilityTenantImprovementAllowance The amount of tenant

improvement allowance for operating lease liability of lessee. Current: operating leases Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset us-gaap_FinanceLeaseLiability Finance Lease, Liability us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: imputed interest Financing cash flows from finance leases 2028 Thereafter, future amortization expense Measurement Input Type [Axis] 2029 2025 (remaining 9 months), future amortization expense Measurement Input Type [Domain] 2030 Thereafter 2027, future amortization expense 2028, future amortization expense 2026 2029, future amortization expense 2027 2030, future amortization expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] 2026, future amortization expense Other non-current assets Stock-based compensation expense us-gaap_ShareBasedCompensation 2025 (remaining 9 months) Finite-lived intangible assets, remaining life (Year) Amortization of debt discount and issuance costs Operating expenses: Income Tax, Policy [Policy Text Block] Schedule of Finite-Lived Intangible Assets [Table Text Block] us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio Depreciation, amortization and accretion Financial liabilities, fair value us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) Non-current assets: Equity [Text Block] Current assets of discontinued operations Total current assets of discontinued operations Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Common stock, par value $.0001; 200,000,000 shares authorized; 6,149,202, and 5,972,638 shares issued and outstanding, respectively Adjustments to reconcile net income (loss) to cash used in operating activities: Common stock, authorized (in shares) Common Stock, Shares Authorized (in shares) us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent Inventories Common stock, issued (in shares) us-gaap_LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent Prepaid expenses and other current assets Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) Current assets of discontinued operations: Statistical Measurement [Domain] Operating cash flows from operating leases Maximum [Member] Minimum [Member] Weighted Average [Member] us-gaap_OtherAssetsCurrent Total current assets Product and Service [Axis] Product and Service [Domain] Statistical Measurement [Axis] Operating cash flows from finance leases Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding Preferred stock, issued (in shares) Cash paid for interest Prepaid expenses and other current assets Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized (in shares) Inventories Inventories Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share (in dollars per share) Fair Value, Inputs, Level 3 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Issuance of common stock from exercise of warrants (in shares) Stock Issued During Period, Shares, Warrants Exercised (in shares) The number of shares issued for the warrants exercised. Issuance of common stock from exercise of warrants The value of stock issued for warrants exercised Fair Value Hierarchy and NAV [Axis] Cash flows from operating activities: us-gaap_WarrantsAndRightsOutstanding Warrants and Rights Outstanding Statement [Line Items] Accounts receivable, net Additional paid-in capital Stockholdersâ€™ equity: Tranche B Pre-Funded Warrants [Member] Represents the Tranche B Pre-Funded Warrants Leasehold Improvements [Member] Other income, net Long-Lived Tangible Asset [Axis] The 2024 Shelf [Member] Represents the The 2021 Shelf registration. Long-Lived Tangible Asset [Domain] Current assets: us-gaap_SaleOfStockPricePerShare Sale of Stock, Price Per Share (in dollars per share) Fair Value Disclosures [Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Eclipse Term loan [Member] Represents the Eclipse Term loan Net Loss From Discontinued Operations [Member] Relating to net loss from discontinued operations. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net change in cash and cash equivalents June 2023 Warrants Tranche A [Member] Represents the June 2023 Warrants Tranche A. aytu_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense Selling and marketing Amount of selling and marketing expense attributable to disposal group, including, but not limited to, discontinued operation. Consumer Health Divesture [Member] Relating to Consumer Health Divesture. us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by (used in) financing activities us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price aytu_DebtInstrumentTerminationFeePercentage Debt Instrument, Termination Fee, Percentage The termination fee if the debt is terminated before or on a certain date. Commitments and contingencies (note 13) Sale of Stock [Axis] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss Loss from operations aytu_DebtInstrumentAmortizationPeriod Debt Instrument, Amortization Period (Year) The duration in which the debt will amortize. us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities aytu_DebtInstrumentPrepaymentFeeAmount Debt Instrument, Prepayment Fee, Amount The prepayment fee amount. us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash provided by (used in) investing activities us-gaap_OtherLiabilities Total other liabilities After June 12, 2026, but on or before June 12, 2028 [Member] Represents the termination fee if the termination is after June 12, 2026, but on or before June 12, 2028. us-gaap_GrossProfit Gross profit On or Before June 12 2025 [Member] Termination is on or before the date of June 12 2025 Cost of sales Counterparty Name [Axis] Counterparty Name [Domain] After June 12, 2026, but on or before June 12, 2027 [Member] Represents the termination fee if the termination is after June 12, 2026, but on or before June 12, 2027 Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] After June 12, 2025, but on or before June 12, 2026 [Member] Represents the termination fee if the termination is after June 12, 2025, but on or before June 12, 2026. Inventory write-down Inventory Write-down Other Liabilities [Table Text Block] us-gaap_OtherSundryLiabilities Other us-gaap_PaymentOfFinancingAndStockIssuanceCosts Payment of Financing and Stock Issuance Costs us-gaap_PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs Payment of stock issuance costs Other Liabilities Disclosure [Text Block] us-gaap_ProceedsFromIssuanceOrSaleOfEquity Proceeds from Issuance or Sale of Equity Scenario [Domain] us-gaap_ProceedsFromWarrantExercises Proceeds from Warrant Exercises us-gaap_LoanProcessingFee Loan Processing Fee Retained Earnings [Member] Revenue Net revenue Scenario [Axis] Additional Paid-in Capital [Member] Common Stock [Member] Equity Components [Axis] Equity Component [Domain] us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Other Current Liabilities [Member] Class of Warrant or Right [Axis] Other Noncurrent Liabilities [Member] Class of Warrant or Right [Domain] us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) us-gaap_ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding (in shares) Outstanding, balance (in shares) Outstanding, balance (in shares) us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (loss) from continuing operations before income tax expense us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) us-gaap_LineOfCredit Long-Term Line of Credit us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Less: unamortized debt discount and issuance costs Disaggregation of Revenue [Table Text Block] us-gaap_RepaymentsOfLongTermDebt Payments made to borrowings Revenue from Contract with Customer [Text Block] Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Domain] Document Quarterly Report Entity Incorporation, State or Country Code Term loan principal amount General and Administrative Expense [Member] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Document Transition Report Basis of Accounting, Policy [Policy Text Block] Revolving credit facility Entity Interactive Data Current Selling and Marketing Expense [Member] Accrued savings offers Represents information related to accrued saving offers. Security Exchange Name Operating Expense [Member] Other Expense [Member] Title of 12(b) Security Total debt, net of current portion us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities Total debt Cost of Sales [Member] Research and Development Expense [Member] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Nonmonetary Transaction Type [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Nonmonetary Transaction Type [Axis] Licensing Agreements [Text Block] The entire disclosure for licensing agreements. Warrants exercised, weighted average exercise price (in dollars per share) Class of Warrant or Right, Exercise Price, Exercised During Period (in dollars per share) Represents the exercise price of warrants or rights exercised during the period. Segments [Axis] Segments [Domain] LIABILITIES Neos 2015 Plan [Member] Represents Neos 2015 plan. Antidilutive securities (in shares) Diluted weighted-average common shares outstanding (note 17) (in shares) Diluted weighted-average common shares outstanding (in shares) us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent Accounts payable us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent Accrued liabilities Statement [Table] Diluted - discontinued operations, net of tax (in dollars per share) Statement of Financial Position [Abstract] Diluted - net loss (in dollars per share) Basic weighted-average common shares outstanding (note 17) (in shares) us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense Non-operating other expense, net Diluted - continuing operations (in dollars per share) us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent Basic - discontinued operations, net of tax (in dollars per share) Basic - net income (loss) (in dollars per share) Net income (loss) per share (in dollars per share) us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization Amortization of intangible assets Net proceeds received from (payments made on) revolving credit facility us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense General and administrative Basic - continuing operations (in dollars per share) us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Net revenue Statement of Cash Flows [Abstract] aytu_LongTermDebtAndCapitalLeaseObligationsGross Total future principal payments Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt and capital lease obligations. us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold Cost of sales us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear 2025 (remaining 9 months) Lease Contractual Term [Domain] Statement of Stockholders' Equity [Abstract] Lease Contractual Term [Axis] Income Statement [Abstract] Disposal Groups, Including Discontinued Operations [Table Text Block] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree 2028 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Long-Term Debt, Maturity, Year Four Disposal Group Name [Axis] us-gaap_BusinessCombinationContingentConsiderationLiability Business Combination, Contingent Consideration, Liability Disposal Group Name [Domain] Schedule of Accrued Liabilities [Table Text Block] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths 2026 Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2027 aytu_PaymentsOfFixedPaymentArrangements Payment made to fixed payment arrangements The cash outflow for fixed payments arrangements. Interest on lease liabilities Amortization of leased assets Restructuring and Related Activities Disclosure [Text Block] Liabilities, Noncurrent Total non-current liabilities Asset Acquisition, Contingent Consideration, Liability, Current us-gaap_PaymentsForProceedsFromOtherInvestingActivities Other investing activities Cash flows from financing activities: Warrants [Policy Text Block] Disclosure of the company's accounting policy regarding warrants. Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Total non-current portion of other liabilities Other Liabilities, Noncurrent Derivative warrant liabilities Rx Segment [Member] Relating to the Rx Segment. ADHD Portfolio [Member] Relating to the ADHS Portfolio. Leases Disclosure [Text Block] The entire disclosure for leases. us-gaap_StockholdersEquity Total stockholdersâ€™ equity Balance Balance Schedule of Lease by Balance Sheet Information [Table Text Block] Tabular disclosure of leases by balance sheet information. Class of Stock [Axis] Debt, net of current portion Total debt, net of current portion Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Lessee, Liability, Maturity [Table Text Block] Tabular disclosure of undiscounted cash flows of lessee's lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to lease liability recognized in statement of financial position. Accrued Liabilities [Text Block] The entire disclosure regarding accrued liabilities. aytu_AmortizationExpenseOfIntangibleAssets Amortization Expense of Intangible Assets The value of amortization expense of intangible assets. EX-101.PRE 9 aytu-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 10 aytu20231231_10qimg001.jpg begin 644 aytu20231231_10qimg001.jpg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htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 3 Months Ended Sep. 30, 2024 Nov. 01, 2024 Document Information [Line Items] Â Â Entity Central Index Key 0001385818 Â Entity Registrant Name AYTU BIOPHARMA, INC Â Amendment Flag false Â Current Fiscal Year End Date --06-30 Â Document Fiscal Period Focus Q1 Â Document Fiscal Year Focus 2025 Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-38247 Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 47-0883144 Â Entity Address, Address Line One 7900 East Union Avenue, SuiteÂ 920 Â Entity Address, City or Town Denver Â Entity Address, State or Province CO Â Entity Address, Postal Zip Code 80237 Â City Area Code 720 Â Local Phone Number 437-6580 Â Title of 12(b) Security Common Stock, par value $0.0001 per share Â Trading Symbol AYTU Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 6,149,369 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name:

dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 Current assets: Â Â Cash and cash equivalents $ 20,108 $ 20,006 Accounts receivable, net 23,159 23,526 Inventories 11,739 12,141 Prepaid expenses and other current assets 5,732 5,097 Current assets of discontinued operations 0 1,121 Total current assets 60,738 61,891 Non-current assets: Â Â Property and equipment, net 692 693 Operating lease right-of-use assets 1,225 829 Intangible assets, net 51,205 52,453 Other non-current assets 1,971 2,185 Non-current assets of discontinued operations 0 44 Total non-current assets 55,093 56,204 Total assets 115,831 118,095 Liabilities, Current [Abstract] Â Â Accounts payable 13,513 10,314 Accrued liabilities 33,723 38,143 Revolving credit facility 4,270 2,395 Current portion of debt 1,857 1,857 Other Liabilities, Current 7,889 8,962 Current liabilities of discontinued operations 0 557 Total current liabilities 61,252 62,228 Liabilities, Noncurrent [Abstract] Â Â Debt, net of current portion 10,430 10,877 Derivative warrant liabilities 9,402 12,745 Other Liabilities, Noncurrent 4,921 4,529 Total non-current liabilities 24,753 28,151 Commitments and contingencies (note 13) Stockholdersâ€™ equity: Â Â Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding 0 0 Common stock, par value $.0001; 200,000,000 shares authorized; 6,149,202, and 5,972,638 shares issued and outstanding, respectively 1 1 Additional paid-in capital 348,324 347,688 Accumulated deficit (318,499) (319,973) Total stockholdersâ€™ equity 29,826 27,716 Total liabilities and stockholdersâ€™ equity $ 115,831 $ 118,095 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section

S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_ShortTermBorrowings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Consolidated Balance Sheets (Parentheticals) - $ / shares Sep. 30, 2024 Jun. 30, 2024 Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Preferred stock, authorized (in shares) 50,000,000 50,000,000 Preferred stock, issued (in shares) 0 0 Preferred stock, outstanding (in shares) 0 0 Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Common stock, authorized (in shares) 200,000,000 200,000,000 Common stock, issued (in shares) 6,149,202 5,972,638 Common stock, outstanding (in shares) 6,149,202 5,972,638 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Consolidated Statements of Operations - USD ($) $ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Net revenue $ 16,574 $ 17,817 Cost of sales 4,589 4,779 Gross profit 11,985 13,038 Operating expenses: Â Â Selling and marketing 5,659 6,091 General and administrative 5,125 6,295 Research and development 426 595 Amortization of intangible assets 921 924 Restructuring costs 784 0 Total operating expenses 12,915 13,905 Loss from operations (930) (867) Other income, net 542 584 Interest expense (994) (1,283) Derivative, Gain (Loss) on Derivative, Net 2,880 (5,907) Income (loss) from continuing operations before income tax expense 1,498 (7,473) Income tax expense (405) 0 Net income (loss) from continuing operations 1,093 (7,473) Net income (loss) from discontinued operations, net of tax 381 (647) Net income (loss) $ 1,474 $ (8,120) Basic weighted-average common shares outstanding (note 17) (in shares) 6,068,019 5,482,037 Diluted weighted-average common shares outstanding (note 17) (in shares) 9,099,601 5,482,037 Net income (loss) per share (note 17): Â Â Basic - continuing operations (in dollars per share) $ 0.18 $ (1.36) Diluted - continuing operations (in dollars per share) (0.2) (1.36) Basic - discontinued operations, net of tax (in dollars per share) 0.06 (0.12) Diluted - discontinued operations, net of tax (in dollars per share) 0.04 (0.12) Basic - net income (loss) (in dollars per share) 0.24 (1.48) Diluted - net loss (in dollars per share) $ (0.15) $ (1.48) X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic

10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-18 + Details Name: us-gaap_IncomeLossFromContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPer basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPer diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 5.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479836/810-10-S99-5 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Total Balance (in shares) at Jun. 30, 2023 5,517,174 Â Â Â Balance at Jun. 30, 2023 $ 1 $ 343,485 $ (304,129) $ 39,357 Stock-based compensation expense (in shares) 13,061 Â Â Â Stock-based compensation expense Â 930 Â 930 Net income (loss) $ 0 Â (8,120) (8,120) Balance (in shares) at Sep. 30, 2023 5,530,235 Â Â Â Balance at Sep. 30, 2023 $ 1 344,415 (312,249) 32,167 Balance (in shares) at Jun. 30, 2024 5,972,638 Â Â Â Balance at Jun. 30, 2024 $ 1 347,688 (319,973) 27,716 Stock-based compensation expense (in shares) 564 Â Â Â Stock-based compensation expense Â 173 Â 173 Issuance of common stock from exercise of warrants (in shares) 176,000 Â Â Â Issuance of common stock from exercise of warrants $ 0 463 0 463 Net income (loss) $ 0 0 1,474 1,474 Balance (in shares) at Sep. 30, 2024 6,149,202 Â Â Â Balance at Sep. 30, 2024 $ 1 $ 348,324 $ (318,499) $ 29,826 X - DefinitionThe number of shares issued for the warrants exercised. + ReferencesNo definition available. + Details Name: aytu_StockIssuedDuringPeriodSharesWarrantsExercised Namespace Prefix: aytu_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe value of stock issued for warrants exercised + ReferencesNo definition available. + Details Name: aytu_StockIssuedDuringPeriodValueWarrantsExercised Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -

Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Consolidated Statements of Cash Flows - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â Net income (loss) $ 1,474 $ (8,120) Adjustments to reconcile net income (loss) to cash used in operating activities: Â Â Depreciation, amortization and accretion 1,427 1,843 Stock-based compensation expense 173 725 Derivative warrant liabilities (gain) loss (2,880) 5,907 Amortization of debt discount and issuance costs 27 148 Inventory write-down 68 51 Other non-cash adjustments (468) (6) Non-cash adjustments from discontinued operations (157) 592 Changes in operating assets and liabilities: Â Â Accounts receivable, net 478 (1,684) Inventories 334 (1,121) Prepaid expenses and other current assets 119 467 Accounts payable 3,143 946 Accrued liabilities (4,969) (4,827) Other operating assets and liabilities, net 101 3,744 Changes in operating assets and liabilities from discontinued operations (60) 1,124 Net cash used in operating activities (1,190) (211) Cash flows from investing activities: Â Â Cash received from sales of fixed assets 517 0 Cash payments for fixed asset purchases (136) 0 Other investing activities 0 (76) Net cash provided by (used in) investing activities 381 (76) Cash flows from financing activities: Â Â Net proceeds received from (payments made on) revolving credit facility 1,875 (348) Payment made to fixed payment arrangements (500) (2,204) Payment of stock issuance costs 0 (160) Payments made to borrowings (464) (22) Net cash provided by (used in) financing activities 911 (2,734) Net change in cash and cash equivalents 102 (3,021) Cash and cash equivalents at beginning of period 20,006 22,985 Cash and cash equivalents at end of period 20,108 19,964 Supplemental disclosure of cash flow information: Â Â Cash paid for interest 366 1,359 Cash paid for income taxes 446 246 Non-cash investing and financing activities: Â Â Other non-cash investing and financing activities $ 483 $ 0 X - DefinitionThe amount of adjustments to net income or loss from discontinued operations. + ReferencesNo definition available. + Details Name: aytu_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInDiscontinuedOperations Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period of all assets and liabilities used in operating activities of discontinued operations. + ReferencesNo definition available. + Details Name: aytu_IncreaseDecreaseInOperatingCapitalAttributableToDiscontinuedOperations Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the amount of other noncash investing and financing items. + ReferencesNo definition available. + Details Name: aytu_OtherNoncashInvestingAndFinancingItems Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for fixed payments arrangements. + ReferencesNo definition available. + Details Name: aytu_PaymentsOfFixedPaymentArrangements Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity

that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets after deduction of operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash (inflow) outflow from investing activities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets). + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromRepaymentsOfLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Note 1 - Nature of Business 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Note 1 - Nature of Business Â AytuÂ BioPharma, Inc. (â€œAytu,â€ the â€œCompany,â€ â€œwe,â€ â€œus,â€ or â€œourâ€), is a pharmaceutical company focused on commercializing novel therapeutics. The Company was originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and was re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (â€œNeosâ€) in March 2021 (the â€œNeos Acquisitionâ€), the Company changed its name to Aytu BioPharma, Inc. Â The Companyâ€™s strategy is to become a leading pharmaceutical company that improves the lives of patients. The Company uses a focused approach of in-licensing, acquiring, developing, and commercializing novel prescription therapeutics in order to continue building its portfolio of revenue-generating products and leveraging its commercial teamâ€™s expertise to build leading brands within large therapeutic markets. The Companyâ€™s primary focus is on commercializing innovative prescription products that address conditions frequently developed or diagnosed in childhood. Â The Companyâ€™s business from continuing operations is focused on itsÂ prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment ofÂ attention deficit hyperactivity disorder (â€œADHDâ€):Â Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (â€œAdzenysâ€) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets (â€œCotemplaâ€ and Adzenys together with Cotempla the â€œADHD Portfolioâ€). The second consists primarily of KarbinalÂ® ER (carbinoxamine maleate extended-release oral suspension) (â€œKarbinalâ€), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency (the â€œPediatric Portfolioâ€). Â Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (â€œCODMâ€). After the previously announced successful wind down and divestiture of the Consumer Health business that occurred during the first quarter of fiscal 2025, the CompanyÂ determined that its continuing operations now operateÂ in a single operating and reportable segment. The Companyâ€™s CODM is its Chief Executive Officer who manages operations and regularly reviews the financial information of the Companyâ€™s continuing operations as a single operating segment for the purposes of allocating resources and evaluating its financial performance, and for which discrete financial information is available. The results of the Consumer Health business have been reported as discontinued operations (see Note 20Â â€“ Discontinued Operations). Â In July 2023, the CompanyÂ entered into an exclusive collaboration, distribution and supply agreement with Medomie Pharma Ltd (â€œMedomieâ€), a privately owned pharmaceutical company, for Medomie to sell Adzenys and Cotempla in Israel and the Palestinian Authority. In September 2024, the Company entered into an exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada Ltd (â€œLupinâ€), a subsidiary of global pharmaceutical company Lupin Limited, for Lupin to sell Adzenys and Cotempla inÂ Canada. The Company will supplyÂ Adzenys and Cotempla to Medomie and Lupin based on forecasts and provide product training.Â Medomie and Lupin areÂ responsible for seeking local regulatory approvals and marketing authorizations for both Adzenys and Cotempla, which is expected to occur over the next 18 to 24 months. The agreement with Medomie and the agreement with Lupin represent the Companyâ€™s first and second international commercial agreements for Adzenys and Cotempla, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Significant Accounting Policies [Text Block] Note 2Â - Summary of Significant Accounting Policies Â Principals of Consolidation Â The Companyâ€™s unaudited consolidated financial statementsÂ and notes thereto include the accounts of its wholly owned subsidiaries Aytu Therapeutics, LLC and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries, as well as Innovus Pharmaceuticals, Inc. and its wholly ownedÂ subsidiaries prior to the divestiture of Innovus Pharmaceuticals, Inc. on July 31, 2024. All significant inter-company balances and transactions have been eliminated in consolidation. Â Basis of Presentation Â The unaudited consolidated financial statements and notes thereto contained in this Form 10-Q represent the financial statements of the Company and its wholly owned subsidiaries and have been prepared pursuant to the rules and regulations of the SEC regarding interim financial reporting.Â Accordingly, certain information and disclosures normally included in the complete financial statements prepared in accordance with accounting principles generally accepted in the United States (â€œU.S. GAAPâ€) have been omitted pursuant to such rules and regulations.Â The unaudited consolidated financial statements and notes thereto should be read in conjunction with the Companyâ€™sÂ 2024Â Form 10-K, which included all disclosures required by U.S. GAAP. In the opinion of management, these unaudited consolidated financial statements and notes thereto contain all adjustments necessary for the fair statement of the financial position of the Company and the results of operations and cash flows for the interim periods presented. The consolidated balance sheet as ofÂ June 30, 2024, was derived from the audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements.Â The results of operations for the period ended September 30, 2024, are not necessarily indicative of expected operating results for the full year or any future period. Â Use of Estimates Â The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results may differ from estimates. In the accompanying unaudited consolidated financial statements and notes thereto, estimates are used for, but not limited to, stock-based compensation; revenue recognition,Â determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for credit losses; inventory impairment; determination of right-of-use (â€œROUâ€) assets and lease liabilities; valuation of financial instruments, warrants and derivative warrant liabilities, intangible assets, and long-lived assets; purchase price allocations and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance.Â Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. The CompanyÂ periodically evaluates estimates used in the preparation of the financial statements for reasonableness. Â Prior Period Reclassification Â Certain prior year amounts in the Companyâ€™s unaudited consolidated financial statements and the notes thereto have been reclassified to conform to the current year presentation. These reclassifications did not impact operating results or cash flows for theÂ three months ended September 30, 2024, and 2023, or the Companyâ€™s financial position as of September 30, 2024, or June 30, 2024. Â Warrants Â The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrantâ€™s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) Topic 480, Distinguishing Liabilities from Equity (â€œASC 480â€) and ASC Topic 815, Derivatives and Hedging (â€œASC 815â€). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Companyâ€™s own common shares and whether the warrant holders could potentially require â€œnet cash settlementâ€ in a circumstance outside of the Companyâ€™s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option pricing model or Monte Carlo simulation model at issuance and for each reporting period when applicable. Â Income Taxes Â The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three months ended September 30, 2024. The effective tax rate was 27.0% and zero percent for the three months ended September 30, 2024, and 2023, respectively, primarily driven by the limitations on losses as a result of Section 382 of the Internal Revenue CodeÂ changes in ownership coupled with existing valuation allowances. Â An ownership change has limited the Companyâ€™s ability to offset, post-change, United StatesÂ federal taxable income. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past five years have caused a significant limitation on the Companyâ€™s ability to use the change in controlÂ net operating loss carryovers. The ownership changes result in increased future tax liability and are a driver of the change from a zero percent effective tax rate. Â The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of theÂ balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized. Â The Company recognizes the effect of income tax positions only if those positions are more likely than notÂ to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense in the unaudited consolidated statements of operations. Â Employee Retention Credit Â On March 27, 2020, the United StatesÂ government enacted the Coronavirus Aid, Relief, and Economic Security Act (theÂ â€œCARES Actâ€) to provide certain relief as a result of the COVID-19 pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (â€œERCâ€), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to 70% of the qualified wages paid to employees after December 31, 2020, through September 30, 2021. The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-19 pandemic. Â As there is no authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company accounted for the ERC by analogy to International Accounting Standard (â€œIASâ€) 20, Accounting for Government Grants and Disclosure of Government Assistance (â€œIAS 20â€). In accordance with IAS 20, the Company recorded a $3.8 million ERC accrual in other non-current liabilities, which represents the proceeds the Company received from the ERC program during the first quarter of fiscal 2024. Further in accordance with IAS 20, when management determines it has reasonable assurance that the Company has substantially met all eligibility requirements of the ERC and following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Code of 1986, as amended (the â€œIRCâ€), the ERC accrual shall be recognized as a benefit in other income in the unaudited consolidated statement of operations. The associated vendor fee of $0.4 million was expensed as incurred in the first quarter of fiscal 2024. Â RecentlyÂ Adopted Accounting Pronouncements Â Debt - DebtÂ with Conversion and Other Option Â In August 2020, the FASB issued Accounting Standards Update

(â€œASUâ€) No. 2020-06, Debtâ€”Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedgingâ€”Contracts in Entityâ€™s Own Equity (Subtopic 815-40)â€”Accounting for Convertible Instruments and Contracts in an Entityâ€™s Own Equity, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The CompanyÂ adopted the guidance on July 1, 2024, and the adoption of the standard did not have a material impact on the Companyâ€™sÂ consolidated financial statements. Â Recent Accounting Pronouncements Not Yet Adopted Â Segment Reporting - Improvements to Reportable Segment Disclosures Â InÂ November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€). ASU 2023-07 was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Companyâ€™s consolidated financial statements and disclosures. Â Disaggregation of Income Statement Expenses Â In November 2024, the FASB issuedÂ ASU No. 2024-03,Â Income Statement â€“ Reporting Comprehensive Income â€“ Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement ExpensesÂ (â€œASU 2024-03â€). The amendments inÂ ASU 2024-03Â require public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory;Â employee compensation; andÂ depreciation, amortizationÂ and depletion expenses for each caption on the income statement where such expenses are included.Â ASU 2024-03Â is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Companyâ€™s consolidated financial statements and disclosures. Â For a complete set of the Companyâ€™s significant accounting policies, refer to the Companyâ€™s 2024Â Form 10-K. There have been no significant changes to the Companyâ€™s significant accounting policies and thereÂ is no other accounting guidance has been issued and not yet adopted that is applicable to the Company and that would have a material effect on the Companyâ€™s unaudited consolidated financial statements and related disclosuresÂ as of September 30, 2024, and through the filing of this Form 10-Q. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Revenue 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Revenue from Contract with Customer [Text Block] Note 3Â - Revenue Â NetÂ revenueÂ from continuing operations consists of sales of prescription pharmaceutical products from the Companyâ€™s ADHD Portfolio and Pediatric Portfolio, principally to a limited number of wholesale distributors and pharmacies in the United States. NetÂ revenue is recognized at the point in time that control of the product transfers to the customer, which typically aligns with shipping terms (i.e., upon delivery), generally â€œfree-on-boardâ€ destination when shipped domestically within the United States, consistent with contractual terms. Â Savings offers, rebates, and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. The Companyâ€™s periodic adjustments of its estimates are subject to time delays between the initial product sale, and the ultimate reporting and settlement of deductions. The Company entered into negotiations with a vendor related to certain variable interest accruals that reduce revenue for the Companyâ€™sÂ ADHD Portfolio. As a result of these negotiations, the Company and the vendor agreed to a reduction to the liability purportedly owed by the Company ofÂ $3.3 million, which resulted in a decrease in the estimated variable consideration accrualÂ as of September 30, 2024, and a related increase in net revenue of $3.3 million for the three months ended September 30, 2024. Â RevenueÂ by Product Portfolio Â Net revenue disaggregated by significant product portfolio for theÂ three months ended September 30, 2024, and 2023, were as follows: Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â Â 2023 Â Â Â (in thousands) Â ADHD Portfolio Â $15,264Â Â Â $15,128Â Pediatric Portfolio Â Â 1,293Â Â Â 2,565Â Other Â Â 17Â Â Â 124Â Total net revenue Â $16,574Â Â $17,817Â Â Other includes net revenue from various discontinued deprioritized products. The Consumer Health business was divested in the first quarter of fiscal 2025 and is reported within discontinued operationsÂ (see Note 20Â â€“ Discontinued Operations). Â RevenueÂ by Geographic Location Â The Companyâ€™s net revenue isÂ predominately within the United States, with insignificant international sales. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Inventories 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Inventory Disclosure [Text Block] Note 4Â - Inventories Â Inventories consist of raw materials, work in processÂ and finished goods, and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of its inventories to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identifiedÂ and there are no alternate uses for the inventory, the Company will record a charge to reduce the value of the inventory to net realizable value in the period first recognized. The Company incurred inventory write-downs ofÂ $0.1 millionÂ for both the three months ended September 30, 2024, and 2023, primarily as a result of unsalable and slow-moving products. Â InventoriesÂ consist of the following: Â Â Â September 30, Â Â Â June 30, Â Â Â 2024 Â Â Â 2024 Â Â Â (in thousands) Â Raw materials Â $720Â Â $266Â Work in process Â Â 3,363Â Â Â 5,725Â Finished goods Â Â 7,656Â Â Â 6,150Â Inventories Â $11,739Â Â $12,141Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Property and Equipment 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Property, Plant and Equipment Disclosure [Text Block] Note 5Â - Property and Equipment Â Properties and equipment are recorded at cost and depreciated on a straight-line basis over the assetsâ€™ estimated economic life. Leasehold improvements are amortized over the shorter of the estimated economic life or remaining lease term. Â Property and equipment, net, consist of the following: Â Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Â Â (in thousands) Â Manufacturing and lab equipment Â $1,443Â Â $1,838Â Office equipment, furniture and other Â Â 956Â Â Â 945Â Leasehold improvements Â Â 158Â Â Â 35Â Property and equipment, gross Â Â 2,557Â Â Â 2,818Â Less: accumulated depreciation and amortization Â Â (1,865)Â Â (2,125) Property and equipment, net Â $692Â Â $693Â Â Depreciation and amortization expense from property and equipment was $0.1Â million and $0.3Â million forÂ the three months ended September 30, 2024, and 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Leases 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Leases Disclosure [Text Block] Note 6Â - Leases Â The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment, and finance lease agreements for certain equipment. These leases have original lease periods expiring between calendar year 2024 and calendarÂ year 2030. Most leases include one or more options to renew, and the exercise of a lease renewal option typically occurs at the discretion of both parties. Certain non-real estate leases also include options to purchase the leased property. The Companyâ€™s lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.Â The Company had no remaining finance leases recorded as of June 30, 2024. Â In June 2024, the Company entered into a forward-starting operating lease agreement to lease office space in Berwyn, Pennsylvania from the owner of the office space that the Company is currently renting under a sublease arrangement. The Company determined that it is an operating lease, and that lease commencement occurred in July 2024. The initial lease termination date is July 31, 2030, and under the lease agreement the Company has one five-year renewal option to extend the lease through July 2035. Undiscounted minimum monthly rent payments average approximately $13,000 over the initial term of the lease. The Company has elected to utilize the practical expedient to not separate lease and non-lease components upon recognition and variable lease payments will be expensed as incurred. The Company recorded anÂ operating lease ROU asset of $0.5 million and a lease liability of $0.5 million at lease commencement in July 2024. The ROU asset and lease liability will be recorded at present value using an incremental borrowing rate of 12.3%. Â The components of lease costs areÂ as follows: Â Â Â Three Months Ended Â Â Â Â September 30, Â Â Â Â 2024 Â Â 2023 Â Statement of Operations Classification Â Â (in thousands) Â Â Lease cost: Â Â Â Â Â Â Â Â Â Â Operating lease cost Â $122Â Â $360Â Operating expenses Short-term lease cost Â Â 91Â Â Â Â 23Â Operating expenses Finance lease cost: Â Â Â Â Â Â Â Â Â Â Amortization of leased assets Â Â â€”Â Â Â 14Â Cost of sales Interest on lease liabilities Â Â â€”Â Â Â 1Â Interest expense Total lease cost Â $213Â Â $398Â Â Â Supplemental balance sheet information related to leases is as follows: Â Â Â September 30, Â Â June 30, Â Â Â Â 2024Â Â 2024Â Balance Sheet Classification Â Â (in thousands) Â Â Assets: Â Â Â Â Â Â Â Â Â Â Operating lease assets Â $1,225Â Â $829Â Operating lease right-of-use assets Â Â Â Â Â Â Â Â Â Â Liabilities: Â Â Â Â Â Â Â Â Â Â Current: operating leases Â $484Â Â $712Â Other current liabilities Non-current: operating leases Â Â 1,144Â Â Â Â 577Â Other non-current liabilities Total lease liabilities Â $1,628Â Â $1,289Â Â Â The remaining weighted-average lease term and discount rate used are as follows: Â Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Weighted-average remaining lease term (years): Â Â Â Â Â Â Â Â Operating lease assets Â Â 4.2Â Â Â 2.7Â Weighted-average discount rate: Â Â Â Â Â Â Â Â Operating lease assets Â Â 11.1%Â Â 10.0% Â Supplemental cash flow information related to leases is as follows: Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â Â 2023 Â Â Â (in thousands) Â Cash flow classification of lease payments: Â Â Â Â Â Â Â Â Â Operating cash flows from operating leases Â $168Â Â $360Â Operating cash flows from finance leases Â $â€”Â Â Â 1Â Financing cash flows from finance leases Â $â€”Â Â Â $23Â Â Â As of June 30, 2024, theÂ Company did not have any remaining finance leases. As of September 30, 2024, theÂ Companyâ€™s future minimum lease payments were as follows: Â Â Â Â Operating Â Â Â Â (in thousands) Â 2025 (remaining 9 months) Â $792Â 2026 Â Â 399Â 2027 Â Â 377Â 2028 Â Â 386Â 2029 Â Â 358Â 2030 Â Â 230Â Thereafter Â Â 19Â Total lease payments Â Â 2,561Â Less: imputed interest Â Â (520) Less: tenant improvement allowance Â Â (413) Lease liabilities Â $1,628Â Â X - DefinitionThe entire disclosure for leases. + ReferencesNo definition available. + Details Name: aytu_LeasesDisclosureTextBlock Namespace Prefix: aytu_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Intangible Assets 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Goodwill and Intangible Assets Disclosure [Text Block] Note 7Â - Intangible Assets Â A summary of the Companyâ€™s definite-lived intangible assets as of September 30, 2024, and June 30, 2024, respectively, isÂ as follows: Â Â Â September 30, 2024 Â Â Â Gross Carrying Amount Â Â Accumulated Amortization Â Â Net Carrying Amount Â Â Weighted-Average Remaining Life Â Â Â (in thousands) Â Â (in years) Â Acquired product technology rights Â $41,268Â Â $(13,988)Â $27,280Â Â Â 10.5Â Acquired technology rights Â Â 30,200Â Â Â (6,275)Â Â 23,925Â Â Â 13.5Â Total intangible assets Â $71,468Â Â $(20,263)Â $51,205Â Â Â 11.9Â Â Â Â June 30, 2024 Â Â Â Gross Carrying Amount Â Â Accumulated Amortization Â Â Net Carrying Amount Â Â Weighted-Average Remaining Life Â Â Â (in thousands) Â Â (in years) Â Acquired product technology rights Â $41,268Â Â $(13,184)Â $28,084Â Â Â 10.7Â Acquired technology rights Â Â 30,200Â Â Â (5,831)Â Â 24,369Â Â Â 13.8Â Total intangible assets Â $71,468Â Â $(19,015)Â $52,453Â Â Â 12.0Â Â Carrying amounts are net of any impairment charges from prior periods. An intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period. Certain of the Companyâ€™s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximatelyÂ 1Â toÂ 20 yearsÂ depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $1.2Â millionÂ and $1.5 million for the three months ended September 30, 2024, and 2023, respectively. Â The following table summarizes the estimated future amortization expense to be recognized over the next five fiscalÂ years and periods thereafter: Â Â Â Estimated Future Amortization Expense Â Â Â (in thousands) Â 2025 (remaining 9 months) Â $3,742Â 2026 Â Â 4,989Â 2027 Â Â 4,989Â 2028 Â Â 4,989Â 2029 Â Â 4,989Â 2030 Â Â 2,847Â Thereafter Â Â 24,660Â Total future amortization expense Â $51,205Â Â Acquired Product Technology Rights Â The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of the Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021. Â ADHD Portfolio Â As part of the Neos Acquisition, the Company acquired developed

product technology for the production and sale of AdzenysÂ and Cotempla. The formulations for the ADHD products are protected by patented technology. The estimated remaining economic life of these proprietary technologies is 14Â years. Â Karbinal Â The Company acquired and assumed all rights and obligations pursuant to the supply and distribution agreement, as amended, with Tris Pharma, Inc. (â€œTrisâ€) for the exclusive rights to commercialize KarbinalÂ in the United States (the â€œTris Karbinal Agreementâ€). The Tris Karbinal Agreementâ€™s initial term terminates in AugustÂ of 2033, with an optional initial 20-year extension. Â Poly-Vi-FlorÂ and Tri-Vi-Flor Â The Company acquired and assumed all rights and obligations pursuant to a supply and license agreement and various assignment and release agreements, including a previously agreed to settlement and license agreements (the â€œPoly-Tri Agreementsâ€) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States. Â Acquired Technology Rights Â TRRP Technology Â As part of the Neos Acquisition, the Company acquired time release resin particle (â€œTRRPâ€) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlines each of the ADHD Portfolio core products and can potentially be used in future product development initiatives as well. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Accrued Liabilities 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Accrued Liabilities [Text Block] Note 8Â - Accrued Liabilities Â Accrued liabilities consist of the following: Â Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Â Â (in thousands) Â Accrued savings offers Â $9,929Â Â $11,054Â Accrued program liabilities Â Â 5,990Â Â Â 9,964Â Accrued customer and product related fees Â Â 5,540Â Â Â 5,395Â Accrued employee compensation Â Â 5,212Â Â Â 4,603Â Return reserve Â Â 4,218Â Â Â 4,832Â Other accrued liabilities Â Â 2,834Â Â Â 2,295Â Total accrued liabilities Â $33,723Â Â $38,143Â Â AccruedÂ savings offers represent programs for the Companyâ€™s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Accrued program liabilities include government and commercial rebates. Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. The return reserve represents the Companyâ€™s accrual for estimated product returns. Accrued employee compensation includes sales commissions, paid time off earned, accrued payroll and accrued bonus. Other accrued liabilities consist of various other accruals, none of which individually or in the aggregate represent greater than five percent of total liabilities. Â X - DefinitionThe entire disclosure regarding accrued liabilities. + ReferencesNo definition available. + Details Name: aytu_AccruedLiabilitiesTextBlock Namespace Prefix: aytu_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Other Liabilities 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Other Liabilities Disclosure [Text Block] Note 9Â - Other Liabilities Â Other liabilities consist of the following: Â Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Â Â (in thousands) Â Fixed payment arrangements Â $7,405Â Â $8,337Â Employee retention credit Â Â 3,759Â Â Â 3,759Â Operating lease liabilities Â Â 1,628Â Â Â 1,289Â Other Â Â 18Â Â Â 106Â Total other liabilities Â Â 12,810Â Â Â 13,491Â Less: current portion of other liabilities Â Â (7,889)Â Â (8,962) Total non-current portion of other liabilities Â $4,921Â Â $4,529Â Â Fixed Payment Arrangements Â Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in 2019, including fixed and variable payments. Â In May 2022, the Company entered into an agreement with Tris to terminate the license, development, manufacturing and supply agreement dated November 2, 2018, related to Tuzistra XR (the â€œTuzistra License Agreementâ€). Pursuant to such termination, as of September 30, 2024, the Company has accrued a settlement liability of $5.8Â million in other current liabilities on the consolidated balance sheet payable to Tris, with a provision that allows the CompanyÂ to pay interest on any principal amounts due but remaining unpaid past July 2024. Â The Tris Karbinal Agreement grants the Company the exclusive right to distribute and sell Karbinal in the United States. The initial term of the agreement was 20 years. The Company pays Tris a royalty equal to 23.5% of net revenue from the product. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make-whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net revenue from the product, the first of which is triggered at $40.0 million. As of September 30, 2024, the Tris Karbinal Agreement accrued fixed payment arrangement balance was $1.7Â millionÂ recorded in other current liabilities on the consolidated balance sheet. Â Employee Retention CreditÂ Â The $3.8 millionÂ ERC accrualÂ in other non-current liabilities as of September 30, 2024, represents the proceeds the Company received from the ERC program during the first quarter of fiscal 2024. Please seeÂ Note 2 â€“Â Significant Accounting PoliciesÂ for further detail. Â Operating Lease LiabilitiesÂ Â The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment. Please refer to Note 6 - Leases for further detail. Â Other Â Other consists of taxes payable, deferred cost related to the Companyâ€™s technology transfer, andÂ various other accruals,Â none of which individually or in the aggregate represent greater than five percent of total liabilities. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for other liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405/tableOfContent + Details Name: us-gaap_OtherLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Note 10 - Revolving Credit Facility 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Short-Term Debt [Text Block] Note 10 - Revolving Credit Facility Â On June 12, 2024, the Company and certain of its subsidiaries entered into consent, joinder and amendment No. 5 (the â€œEclipse Amendment No. 5â€) to the loan and security agreement dated October 2, 2019, as amended by amendment No. 1, dated March 19, 2021, amendment No. 2, dated January 26, 2022, amendment No. 3, dated June 1, 2022, amendment No. 4 dated March 24, 2023, and the Eclipse Amendment No. 5 (together the â€œEclipse Agreementâ€) with Eclipse Business Capital LLC (â€œEclipseâ€), as agent, and the lenders party thereto (agent and such lenders, collectively, the â€œEclipse Lenderâ€). Under the Eclipse Amendment No. 5, which provided for among other things, two loan agreements, a term loan (the â€œEclipse Term Loanâ€) and a revolving credit facility (the â€œEclipse Revolving Loanâ€). The Eclipse Term Loan is described further in Note 11 - Long-Term Debt. The Eclipse Revolving Loan provides for a maximum amount available under the revolving credit facility provided under the Eclipse Agreement of $14.5 million at an interest rate of the secured overnight financing rate as administered by the SOFR Administrator (â€œSOFRâ€) plus 4.5%. In addition, the Company is required to pay an unused line fee of 0.5% of the average unused portion of the maximum Eclipse Revolving Loan amount during the immediately preceding month. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Agreement remains subject to a borrowing base and reserve, and availability blockage requirements. The Eclipse Revolving Loan maturity date, as amended, is June 12, 2028, and the effective interest rate was 9.8% as of September 30, 2024. Â In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 2.0% of the Eclipse Revolving Loan commitment if such event occurs on or before June 12, 2025, (ii) 1.0% of the Eclipse Revolving Loan commitment if such event occurs after June 12, 2025, but on or before June 12, 2026, and (iii) 0.5% of the Eclipse Revolving Loan commitment if such event occurs after June 12, 2026, but on or before June 12, 2028. The Company may also be required to pay an early termination fee related to the Eclipse Term Loan as further described in Note 11 - Long-Term Debt. The Company may permanently terminate the Eclipse Agreement upon written notice to Eclipse. Â The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Companyâ€™s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Companyâ€™s obligations under the Eclipse Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. AsÂ of September 30, 2024, the Company was in compliance with the covenants under the Eclipse Agreement. The Companyâ€™s obligations under the Eclipse Agreement are secured by substantially all of the Companyâ€™s assets, as defined further in the Eclipse Agreement. Â Total interest expense on the Eclipse Revolving Loan, including amortization of deferred financing costs, was less than $0.1 million for bothÂ the three months ended SeptemberÂ 30, 2024, and 2023, respectively. TheÂ amountsÂ drawn on the Eclipse Revolving Loan wereÂ $4.3Â million and $2.4Â million asÂ of September 30, 2024, and June 30, 2024, respectively. The unused revolving credit facility amount as of SeptemberÂ 30, 2024, was $2.5Â million. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for short-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent + Details Name: us-gaap_ShortTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Long-term Debt 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Long-Term Debt [Text Block] Note 11 - Long-Term Debt Â Avenue Capital Loan Â On January 26, 2022 (â€œClosing Dateâ€), the Company entered into a loan and security agreement (the â€œAvenue Capital Agreementâ€) with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. as lenders (the â€œAvenue Capital Lendersâ€), and Avenue Capital Management II, L.P. as administrative agent (the â€œAvenue Capital Agentâ€), collectively (â€œAvenue Capitalâ€), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $15.0 million loan. The interest rate on the loan was the greater of the prime rate or 3.25%, plus 7.4%, payable monthly in arrears. The maturity date of the loan was January 26, 2025. The proceeds from the Avenue Capital Agreement were used towards the repayment of the term loans. Â Pursuant to the Avenue Capital Agreement, the Company was required to make interest only payments for the first 18 months following the Closing Date (the â€œInterest-only Periodâ€). The Interest-only Period could be extended automatically without any action by any party for six months provided as of the last day of the Interest-only Period then in effect, the Company received, prior to June 15, 2023, a specified amount of net proceeds from the sale and issuance of its equity securities (â€œInterest-only Milestone 1â€). The Interest-only Period was able to be further extended automatically without any action by any party for an additional six months provided, the Company had achieved, prior to December 31, 2023, (i) Interest-only Milestone 1 and (ii) a specified amount of trailing 12 months revenue as of the date of determination. Â On January 26, 2022 (â€œIssuance Dateâ€), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the â€œAvenue Capital Warrantsâ€). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was not fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately $0.6 million. Â On March 7, 2022, the Company closed on an equity offering of shares of common stock and warrantsÂ at an offering price of $25.00 per share. As this offering precluded the Company from pursuing any equity financing prior to July 7, 2022, and the effective price of the March 7, 2022, offering was more than the exercise price of the Avenue Capital Warrants, the shares of common stock issuable upon exercise of the Avenue Capital Warrants were set at an exercise price of $24.20. Â On October 25, 2022, the Company entered into an agreement with Avenue Venture Opportunities Fund, L.P (â€œAvenueâ€) to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in January 2022, extended the interest-only period to January 2024. In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $8.60, corresponding to the warrant exercise price associated with the Companyâ€™s August 2022 equity financing. Â On June 13, 2023, in conjunction with the Securities Purchase Agreement described in Note 16 - Warrants, the interest-only period of the Avenue Capital Agreement was extended further upon the achievement of both the revenue-based milestone and equity raise-based milestone stipulated in the Avenue Capital Agreement. As a result, the interest-only period was extended to January 26, 2025. Â In addition to the debt discount discussed above, the Company also incurred $0.4 million loan origination, legal and other fees. The debt discount and issuance costs were being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 16.6%. Total interest expense on the Avenue Capital loan, including debt discount amortization, wasÂ $0.7Â million for the three months ended SeptemberÂ 30,Â 2023. Â On June 12, 2024, the Company used proceeds from the Eclipse Term Loan and a portion of the proceeds from the exercise of warrants to repay the Avenue Capital loan in full. Upon early repayment of the Avenue Capital loan, the Company was required to pay Avenue Capital a fee equal to 1.0% of the loan or $0.2 million. In addition, upon the payment in full of the obligations, the Company was required to pay Avenue Capital a fee in the amount of $0.6 million (â€œFinal Paymentâ€). At inception, the Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount. At retirement, the early termination fee, the Final Payment fee, and the write-off of all remaining related debt discount and deferred financing costs were included in the calculation of loss on extinguishment of debt. The Company recorded a loss on extinguishment of debt of $0.6 million related to the retirement of the Avenue Capital loan in the fourth quarter of fiscal 2024. Â Eclipse Term Loan Â On June 12,Â 2024, the Company and certain of its subsidiaries entered into Eclipse Amendment No. 5, which provided for among other things,Â the Eclipse Term LoanÂ and the Eclipse Revolving LoanÂ describedÂ further in Note 10 - Revolving Credit Facility. The Eclipse Term LoanÂ consists of a principal amount of $13.0 million, at an interest rate of SOFR plus 7.0%, with a four-year term maturing on June 12, 2028,Â and a straight-line loan amortization period of seven years, which would provide for a loan balance at the end of the four-year term ofÂ $5.6 million to be repaid on June 12, 2028, the maturity date. The Company used the proceeds of the Eclipse Term Loan and a portion of the proceeds from warrant exercises described below to repay in full the Avenue Capital loan.Â The effective interest rate on the Eclipse Term Loan was 12.3% as of September 30, 2024. Â In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal toÂ (i) 3.0% of the Eclipse Term LoanÂ if such event occurs on or before June 12, 2025, (ii) 2.0% of the Eclipse Term LoanÂ if such event occurs after June 12, 2025,Â but on or before June 12, 2026,Â (iii) 1.0% of the Eclipse Term LoanÂ if such event occurs after June 12, 2026,Â but on or before June 12, 2027, and (iv) 0.5% of the Eclipse Term LoanÂ if such event occurs after June 12, 2026,Â but on or before June 12, 2028. The Company may also be required to pay an early termination fee related to the Eclipse Revolving LoanÂ as further described in Note 10Â - Revolving Credit Facility. The Company may permanently terminate the Eclipse Agreement upon written notice to Eclipse. The Companyâ€™s obligations under the Eclipse AgreementÂ are secured by substantially all of the Companyâ€™s assets, as further defined in the Eclipse Agreement. Â The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Companyâ€™s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make certain asset sales without the prior written consent of the Eclipse Lender. A failure to comply with these covenants could permit the Eclipse LenderÂ to declare the Companyâ€™s obligations under the agreement, together with

accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of SeptemberÂ 30, 2024, the Company was in compliance with the covenants under the Eclipse Agreement. The Company incurredÂ interest expense on the Eclipse Term Loan, including debt discount and issuance costs amortization, of $0.4Â millionÂ for the three months ended September 30, 2024. Â Long-term debt consists of the following: Â Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Â Â (in thousands) Â Term loan principal amount Â $12,536Â Â $13,000Â Unamortized debt discount and issuance costs Â Â (249)Â Â (266) Total debt Â Â 12,287Â Â Â 12,734Â Less: current portion of debt Â Â (1,857)Â Â (1,857) Total debt, net of current portion Â $10,430Â Â $10,877Â Â Future principal payments of the Eclipse Term LoanÂ are as follows: Â Â Â Future Principal Payments Â Â Â (in thousands) Â 2025 (remaining 9 months) Â $1,393Â 2026 Â Â 1,857Â 2027 Â Â 1,857Â 2028 Â Â 7,429Â Total future principal payments Â Â 12,536Â Less: unamortized debt discount and issuance costs Â Â (249) Less: current portion of debt Â Â (1,857) Total debt, net of current portion Â $10,430Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent + Details Name: us-gaap_LongTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Fair Value Measurements 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Fair Value Disclosures [Text Block] Note 12 - Fair Value Considerations Â The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to determine fair value as follows: Â Â â— Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; Â Â â— Level 2: Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Â Â â— Level 3: Unobservable inputs that are supported by little or no market activity. Â TheÂ Companyâ€™s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities, contingent consideration liabilities, fixed payment arrangements, and currentÂ and non-currentÂ debt. The carrying amounts of certain short-termÂ financial instruments, including cash and cash equivalents, accounts receivable, accounts payableÂ and accrued liabilities approximate their fair value due to their short maturities. Current and non-currentÂ debt are reported at their amortized costs on theÂ Companyâ€™s consolidated balance sheets. The remaining financial instruments are reported on theÂ Companyâ€™sÂ consolidated balance sheets at amounts that approximate current fair values. The Companyâ€™s carrying value of its consolidated amounts of cash and cash equivalents approximate their fair value as of September 30, 2024, and June 30, 2024, and are categorized within level 1 of the U.S. GAAP fair value hierarchy. The Companyâ€™s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented. Â Recurring Fair Value Measurements Â The Companyâ€™s financial assets and liabilities that were accounted for at fair value on a recurring basis as ofÂ September 30, 2024, and June 30, 2024, by level within the fair value hierarchy as follows: Â Â Â Fair Value at September 30,Â Â Fair Value Measurements at September 30, 2024Â Â Â Â 2024 Â Â (Level 1) Â Â (Level 2) Â Â (Level 3) Â Â Â (in thousands) Â Liabilities: Â Â Â Â

this Form 10-Q,Â $100.0Â million remainsÂ available under the 2024Â Shelf. This availability is subject to the SECâ€™s â€œbaby shelfâ€ limitation as set forth in SEC Instruction I.B.6 limitation to the Form S-3. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Note 15 - Equity Incentive Plans 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Share-Based Payment Arrangement [Text Block] Note 15 - Equity Incentive Plans Â 2023 Equity Incentive Plan Â On May 18, 2023, the Companyâ€™s stockholders approved the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the â€œ2023 Equity Incentive Planâ€). Prior to the Companyâ€™s adoption of the 2023 Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. 2015 Stock Option and Incentive Plan (the â€œAytu 2015 Planâ€) and the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan (the â€œNeos 2015 Planâ€, and collectively with the Aytu 2015 Plan, the â€œ2015 Plansâ€). For the 2023 Equity Incentive Plan, the stockholders approved (i) 200,000 new shares; (ii) 87,129 shares available for grant under the 2015 Plans be â€œrolled overâ€ to the 2023 Equity Incentive Plan; and (iii) any shares that are returned to the Company under the 2015 Plans be added to the 2023 Equity Incentive Plan. With the approval of the 2023 Equity Incentive Plan, no additional awards will be granted under the 2015 Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. Stock options granted under the 2023 Equity Incentive Plan have contractual terms of 10 years or less from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards and restricted stock units have a vesting period of 3 to 4 years. As of September 30, 2024, the Company had 187,422 shares that are available for grant under the 2023 Equity Incentive Plan. Â Aytu 2015 Plan Â On JuneÂ 1, 2015, the Companyâ€™s stockholders approved the Aytu 2015 Plan, which, as amended in JulyÂ 2017, provides for the award of stock options, stock appreciation rights, restricted stock, and other equity awards. On FebruaryÂ 13, 2020, the Companyâ€™s stockholders approved an increase to 250,000 total shares of common stock in the Aytu 2015 Plan. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu 2015 Plan will be added back to the shares of common stock available for issuance under the 2023 Equity Incentive Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, and the restricted stock units have a vesting period of 4 years. Â Neos 2015 Plan Â Pursuant to the Neos Acquisition, the Company assumed 3,486 stock options and 1,786 restricted stock units previously granted under the Neos 2015 Plan. Accordingly, on April 19, 2021, the Company registered 5,272 shares of its common stock under the Neos 2015 Plan with the SEC. The terms and conditions of the assumed equity securities remained the same as they were previously under the Neos 2015 Plan. The Company allocated costs of the replacement awards attributable to pre-combination and post-combination service periods. The pre-combination service costs were included in the consideration transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years. Â Stock Options Â Stock option activity is as follows: Â Â Â Â

been excluded from the calculation of the weighted average remaining contractual life in years. Â X - DefinitionThe entire disclosure for warrants or rights. + ReferencesNo definition available. + Details Name: aytu_WarrantsOrRightsDisclosureTextBlock Namespace Prefix: aytu_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Note 17 - Earnings Per Share 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Earnings Per Share [Text Block] Note 17 - Earnings Per Share Â Basic net income (loss) per share is calculated by dividing the net income (loss) available to the common stockholders by the weighted average number of common shares outstanding during that period. Diluted net income (loss) per share reflects the potential of securities that could share in the net income (loss) of the Company. For the three months ended September 30, 2023, the Company incurred a net loss from continuing operations andÂ discontinued operationsÂ and thus did not include common equivalent shares in the computation of diluted net lossÂ per share because the effect would have been anti-dilutive. Â Basic net income or loss per common share is calculated by dividing net income or loss available to common stockholders by the basic weighted-average number of common shares outstanding for the respective period. Diluted net income or loss per common share is calculated by dividing adjusted net income or loss by the diluted weighted-average number of common shares outstanding, which includes the effect of potentially dilutive securities. Potentially dilutive securities for this calculation consist of warrants to purchase common stock that are either liability classified orÂ equity classified (see Note 16Â â€“ Warrants);Â employee stock options (see Note 15Â â€“Â Equity Incentive Plans);Â employee unvested restricted stock (see Note 15Â â€“Â Equity Incentive Plans); and employee unvested restricted stock units (see Note 15Â â€“Â Equity Incentive Plans).Â For the three months ended September 30, 2024, and 2023, if the Company incurred a net loss from continuing operations; a net loss from discontinued operations, net of tax; or a net loss then the CompanyÂ did not include common equivalent shares in the computation of diluted net loss from continuing operations per share; diluted net loss from discontinued operations, net of tax; or diluted net loss per shareÂ because the effect would have been anti-dilutive. Â The following is a reconciliation of the numeratorÂ and the denominator used in the basic per share calculations: Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands, except share and per share data) Â BASIC Â Â Â Â Â Â Â Â Â Numerators: Â Â Â Â Â Â Â Â Â Net income (loss) from continuing operations Â $1,093Â Â $(7,473) Net income (loss) from discontinued operations, net of tax Â Â 381Â Â Â (647) Net income (loss) Â $1,474Â Â $(8,120) Denominator: Â Â Â Â Â Â Â Â Â Basic weighted-average common shares outstanding Â Â 6,068,019Â Â Â Â 5,482,037Â Per share calculations: Â Â Â Â Â Â Â Â Â Net income (loss) per share from continuing operations Â $0.18Â Â $(1.36) Net income (loss) per share from discontinued operations, net of tax Â $0.06Â Â $(0.12) Net income (loss) per share Â $0.24Â Â $(1.48) Â The following is a reconciliation of the numeratorÂ and the denominator used in the dilutedÂ per share calculations: Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands, except share and per share data) Â DILUTED: CONTINUING OPERATIONS Â Â Â Â Â Â Â Â Â Numerator: Â Â Â Â Â Â Â Â Â Net income (loss) from continuing operations Â $1,093Â Â $(7,473) Adjustment for change in fair value of warrant liabilities Â Â (2,880)Â Â Â€”Â Adjusted numerator - net loss from continuing operations Â $(1,787)Â $(7,473) Denominator: Â Â Â Â Â Â Â Â Â Basic weighted-average common shares outstanding Â Â 6,068,019Â Â Â Â 5,482,037Â Dilutive effect of warrants to purchase common stock Â Â 3,028,862Â Â Â Â€”Â Dilutive effect of unvested restricted stock and restricted stock units Â Â 2,720Â Â Â Â€”Â Diluted weighted-average common shares outstanding Â Â 9,099,601Â Â Â Â 5,482,037Â Per share calculation: Â Â Â Â Â Â Â Â Â Net loss per share from continuing operations Â $(0.20)Â $(1.36) Â Â Â Â Â Â Â Â Â DILUTED: DISCONTINUED OPERATIONS Â Â Â Â Â Â Â Â Â Numerator: Â Â Â Â Â Â Â Â Â Net income (loss) from discontinued operations, net of tax Â $381Â Â $(647) Denominator: Â Â Â Â Â Â Â Â Â Basic weighted-average common shares outstanding Â Â 6,068,019Â Â Â Â 5,482,037Â Dilutive effect of warrants to purchase common stock Â Â 3,028,862Â Â Â Â€”Â Dilutive effect of unvested restricted stock and restricted stock units Â Â 2,720Â Â Â Â€”Â Diluted weighted-average common shares outstanding Â Â 9,099,601Â Â Â Â 5,482,037Â Per share calculation: Â Â Â Â Â Â Â Â Â Net income (loss) per share from discontinued operations, net of tax Â $0.04Â Â $(0.12) Â Â Â Â Â Â Â Â Â DILUTED: NET INCOME (LOSS) Â Â Â Â Â Â Â Â Â Numerator: Â Â Â Â Â Â Â Â Â Net income (loss) Â $1,474Â Â $(8,120) Adjustment for change in fair value of warrant liabilities Â Â (2,880)Â Â Â€”Â Adjusted numerator - net loss Â $(1,406)Â $(8,120) Denominator: Â Â Â Â Â Â Â Â Â Basic weighted-average common shares outstanding Â Â 6,068,019Â Â Â Â 5,482,037Â Dilutive effect of warrants to purchase common stock Â Â 3,028,862Â Â Â Â€”Â Dilutive effect of unvested restricted stock and restricted stock units Â Â 2,720Â Â Â Â€”Â Diluted weighted-average common shares outstanding Â Â 9,099,601Â Â Â Â 5,482,037Â Per share calculation: Â Â Â Â Â Â Â Â Â Net loss per share Â $(0.15)Â $(1.48) Â The following table sets forth securities that could be considered anti-dilutive, and therefore areÂ excluded from the calculation of diluted weighted-average common shares outstanding and related per share calculations: Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Warrants to purchase common stock - liability classified (note 16) Â Â 455,392Â Â Â Â 6,498,980Â Warrants to purchase common stock - equity classified (note 16) Â Â 18,114Â Â Â 39,072Â Employee unvested restricted stock (note 15) Â Â 10,644Â Â Â Â 46,656Â Employee unvested restricted stock units (note 15) Â Â 1,211Â Â Â 3,463Â Employee stock options (note 15) Â Â 141,439Â Â Â Â 162,683Â Total anti-dilutive securities Â Â 626,800Â Â Â Â 6,750,854Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Note 18 - License Agreements 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Licensing Agreements [Text Block] Note 18 - License Agreements Â Actavis Â On October 17, 2017, the Company entered into an agreement granting Actavis Laboratories FL, Inc. (â€œActavisâ€) (acquired by Teva Pharmaceutical Industries) a non-exclusive license to certain patents owned by the Company by which Actavis has the right to manufacture and market its generic version of Adzenys under its ANDA beginning on September 1, 2025, or earlier under certain circumstances. The ANDA was approved by the FDA on June 22, 2023. Â Teva Â On December 21, 2018, the CompanyÂ and Teva Pharmaceuticals USA, Inc. (â€œTevaâ€)Â entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla under anÂ abbreviated new drug applicationÂ (â€œANDAâ€)Â filed by Teva beginning on July 1, 2026, or earlier under certain circumstances. The ANDA was approved by the FDA on June 19, 2020. Â X - DefinitionThe entire disclosure for licensing agreements. + ReferencesNo definition available. + Details Name: aytu_LicensingAgreementsTextBlock Namespace Prefix: aytu_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Note 19 - Restructuring Costs 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Restructuring and Related Activities Disclosure [Text Block] Note 19 - Restructuring Costs Â As part of the Companyâ€™s previously announced restructuring activities related to the wind down and divestiture of the Consumer Health businessÂ and the closure of the Grand Prairie, Texas manufacturing site, the Company has incurred expenses that qualify as exit and disposal costs under U.S. GAAP. These include severance and employee benefit costs as well as other direct separation benefit costs, right of use asset impairment charges, fixed asset and other asset impairment charges, accelerated depreciation of fixed assets, contract termination costs, and inventory write-downs. Severance and employee benefit costs primarily relate to cash severance. Restructuring costs associated with the Consumer Health business are recorded within the net loss from discontinued operations, net of tax in the unaudited consolidated financial statement of operationsÂ (see Note 20Â - Discontinued Operations). Â The expense associated with the closure of the Grand Prairie, Texas manufacturing site such as severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations. There have been no inventory write-downs associated with this closure. During the three months ended September 30, 2024, the CompanyÂ incurred $0.8Â million of costs associated with exit and disposal activities related to its manufacturing facility inÂ Grand Prairie, Texas.Â The Company does not expect to incurÂ additional significant restructuring costs. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/420/tableOfContentReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Note 20 - Discontinued Operations 3 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Note 20Â - Discontinued Operations Â On July 31, 2024, after the wind down of operations, the Company entered into a definitive agreement to divest its Consumer Health business to a private, e-commerce focused company. The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, external workforce and contracts, and provides for the Company to receive contingent consideration payments on certain future sales of former Consumer Health business products. Â The accounting requirements for reporting the Consumer Health business as discontinued operation were met when the wind down and divestiture was completed on July 31, 2024. Accordingly, the accompanying unaudited consolidated financial statements for all periods presented reflect this business as a discontinued operation and certain assets and liabilities of discontinued operations have been reclassified to the current assets of discontinued operations; non-current assets of discontinued operations; and current liabilities of discontinued operations financial statement line items on the accompanying unaudited consolidated balance sheet as of June 30, 2024. The Company elected to record the contingent consideration portion of the arrangement when the consideration is determined to be realizable and, therefore, the Company did not record a contingent consideration asset at the transaction date and any subsequent proceeds will not be recognized until the contingent consideration asset is realizable, at which point the Company will recognize it to income (loss) from discontinued operations. Â The key components of net income (loss) from discontinued operations, net of tax for the three months ended September 30, 2024, and 2023, were as follows: Â Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Net revenue Â $717Â Â $4,282Â Cost of sales Â Â (359)Â Â (2,536) Selling and marketing Â Â (155)Â Â (1,331) General and administrative Â Â (2)Â Â (670) Amortization of intangible assets Â Â â€”Â Â Â Â (382) Non-operating other expense, net Â Â (4)Â Â (10) Recognized contingent consideration Â Â 412Â Â Â Â â€”Â Loss on divestiture Â Â (254)Â Â â€”Â Income (loss) from discontinued operations before income taxes Â Â 355Â Â Â (647) Income tax benefit Â Â 26Â Â Â Â â€”Â Net income (loss) from discontinued operations, net of tax Â $381Â Â $(647) Â The key components of assets and liabilities of discontinued operationsÂ as of June 30, 2024, wereÂ as follows: Â Â Â June 30, Â Â Â 2024 Â Â Â (in thousands)Â ASSETS Â Â Â Â Current assets of discontinued operations: Â Â Â Â Accounts receivable, net Â $91Â Inventories Â Â 492Â Prepaid expenses and other current assets Â Â 538Â Total current assets of discontinued operations Â Â 1,121Â Non-current assets of discontinued operations: Â Â Â Â Other non-current assets Â Â 44Â Total current and non-current assets of discontinued operations Â $1,165Â Â Â Â Â Â LIABILITIES Â Â Â Â Current liabilities of discontinued operations: Â Â Â Â Accounts payable Â $126Â Accrued liabilities Â Â 431Â Total current liabilities of discontinued operations Â $557Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent + Details Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Insider Trading Arr Line Items Â Rule 10b5-1 Arrangement Adopted [Flag] false Non-Rule 10b5-1 Arrangement Adopted [Flag] false Rule 10b5-1 Arrangement Terminated [Flag] false Non-Rule 10b5-1 Arrangement Terminated [Flag] false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd_InsiderTradingArrLineItems Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Policies) 3 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Consolidation, Policy [Policy Text Block] Principals of Consolidation Â The Companyâ€™s unaudited consolidated financial statementsÂ and notes thereto include the accounts of its wholly owned subsidiaries Aytu Therapeutics, LLC and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries, as well as Innovus Pharmaceuticals, Inc. and its wholly ownedÂ subsidiaries prior to the divestiture of Innovus Pharmaceuticals, Inc. on July 31, 2024. All significant inter-company balances and transactions have been eliminated in consolidation. Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Â The unaudited consolidated financial statements and notes thereto contained in this Form 10-Q represent the financial statements of the Company and its wholly owned subsidiaries and have been prepared pursuant to the rules and regulations of the SEC regarding interim financial reporting.Â Accordingly, certain information and disclosures normally included in the complete financial statements prepared in accordance with accounting principles generally accepted in the United States (â€œU.S. GAAPâ€) have been omitted pursuant to such rules and regulations.Â The unaudited consolidated financial statements and notes thereto should be read in conjunction with the Companyâ€™sÂ 2024Â Form 10-K, which included all disclosures required by U.S. GAAP. In the opinion of management, these unaudited consolidated financial statements and notes thereto contain all adjustments necessary for the fair statement of the financial position of the Company and the results of operations and cash flows for the interim periods presented. The consolidated balance sheet as ofÂ June 30, 2024, was derived from the audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements.Â The results of operations for the period ended September 30, 2024, are not necessarily indicative of expected operating results for the full year or any future period. Use of Estimates, Policy [Policy Text Block] Use of Estimates Â The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results may differ from estimates. In the accompanying unaudited consolidated financial statements and notes thereto, estimates are used for, but not limited to, stock-based compensation; revenue

recognition,Â determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for credit losses; inventory impairment; determination of right-of-use (â€œROUâ€) assets and lease liabilities; valuation of financial instruments, warrants and derivative warrant liabilities, intangible assets, and long-lived assets; purchase price allocations and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance.Â Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. The CompanyÂ periodically evaluates estimates used in the preparation of the financial statements for reasonableness. Reclassification, Comparability Adjustment [Policy Text Block] Prior Period Reclassification Â Certain prior year amounts in the Companyâ€™s unaudited consolidated financial statements and the notes thereto have been reclassified to conform to the current year presentation. These reclassifications did not impact operating results or cash flows for theÂ three months ended September 30, 2024, and 2023, or the Companyâ€™s financial position as of September 30, 2024, or June 30, 2024. Warrants [Policy Text Block] Warrants Â The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrantâ€™s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) Topic 480, Distinguishing Liabilities from Equity (â€œASC 480â€) and ASC Topic 815, Derivatives and Hedging (â€œASC 815â€). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Companyâ€™s own common shares and whether the warrant holders could potentially require â€œnet cash settlementâ€ in a circumstance outside of the Companyâ€™s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option pricing model or Monte Carlo simulation model at issuance and for each reporting period when applicable. Income Tax, Policy [Policy Text Block] Income Taxes Â The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three months ended September 30, 2024. The effective tax rate was 27.0% and zero percent for the three months ended September 30, 2024, and 2023, respectively, primarily driven by the limitations on losses as a result of Section 382 of the Internal Revenue CodeÂ changes in ownership coupled with existing valuation allowances. Â An ownership change has limited the Companyâ€™s ability to offset, post-change, United StatesÂ federal taxable income. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past five years have caused a significant limitation on the Companyâ€™s ability to use the change in controlÂ net operating loss carryovers. The ownership changes result in increased future tax liability and are a driver of the change from a zero percent effective tax rate. Â The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of theÂ balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized. Â The Company recognizes the effect of income tax positions only if those positions are more likely than notÂ to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense in the unaudited consolidated statements of operations. Employee Retention Credit [Policy Text Block] Employee Retention Credit Â On March 27, 2020, the United StatesÂ government enacted the Coronavirus Aid, Relief, and Economic Security Act (theÂ â€œCARES Actâ€) to provide certain relief as a result of the COVID-19 pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (â€œERCâ€), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to 70% of the qualified wages paid to employees after December 31, 2020, through September 30, 2021. The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-19 pandemic. Â As there is no authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company accounted for the ERC by analogy to International Accounting Standard (â€œIASâ€) 20, Accounting for Government Grants and Disclosure of Government Assistance (â€œIAS 20â€). In accordance with IAS 20, the Company recorded a $3.8 million ERC accrual in other non-current liabilities, which represents the proceeds the Company received from the ERC program during the first quarter of fiscal 2024. Further in accordance with IAS 20, when management determines it has reasonable assurance that the Company has substantially met all eligibility requirements of the ERC and following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Code of 1986, as amended (the â€œIRCâ€), the ERC accrual shall be recognized as a benefit in other income in the unaudited consolidated statement of operations. The associated vendor fee of $0.4 million was expensed as incurred in the first quarter of fiscal 2024. New Accounting Pronouncements, Policy [Policy Text Block] RecentlyÂ Adopted Accounting Pronouncements Â Debt - DebtÂ with Conversion and Other Option Â In August 2020, the FASB issued Accounting Standards Update (â€œASUâ€) No. 2020-06, Debtâ€”Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedgingâ€”Contracts in Entityâ€™s Own Equity (Subtopic 815-40)â€”Accounting for Convertible Instruments and Contracts in an Entityâ€™s Own Equity, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The CompanyÂ adopted the guidance on July 1, 2024, and the adoption of the standard did not have a material impact on the Companyâ€™sÂ consolidated financial statements. Â Recent Accounting Pronouncements Not Yet Adopted Â Segment Reporting - Improvements to Reportable Segment Disclosures Â InÂ November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€). ASU 2023-07 was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Companyâ€™s consolidated financial statements and disclosures. Â Disaggregation of Income Statement Expenses Â In November 2024, the FASB issuedÂ ASU No. 2024-03,Â Income Statement â€“ Reporting Comprehensive Income â€“ Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement ExpensesÂ (â€œASU 2024-03â€). The amendments inÂ ASU 2024-03Â require public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory;Â employee compensation; andÂ depreciation, amortizationÂ and depletion expenses for each caption on the income statement where such expenses are included.Â ASU 2024-03Â is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Companyâ€™s consolidated financial statements and disclosures. Â For a complete set of the Companyâ€™s significant accounting policies, refer to the Companyâ€™s 2024Â Form 10-K. There have been no significant changes to the Companyâ€™s significant accounting policies and thereÂ is no other accounting guidance has been issued and not yet adopted that is applicable to the Company and that would have a material effect on the Companyâ€™s unaudited consolidated financial statements and related disclosuresÂ as of September 30, 2024, and through the filing of this Form 10-Q. X - DefinitionRepresents the accounting policy for employee retention credits. + ReferencesNo definition available. + Details Name: aytu_EmployeeRetentionCreditPolicyTextBlock Namespace Prefix: aytu_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of the company's accounting policy regarding warrants. + ReferencesNo definition available. + Details Name: aytu_WarrantsPolicyTextBlock Namespace Prefix: aytu_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Revenue (Tables) 3 Months Ended Sep. 30, 2024 Notes Tables Â Disaggregation of Revenue [Table Text Block] Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â ADHD Portfolio Â $15,264Â Â $15,128Â Pediatric Portfolio Â Â 1,293Â Â Â Â 2,565Â Other Â Â 17Â Â Â Â 124Â Total net revenue Â $16,574Â Â $17,817Â X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Inventories (Tables) 3 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Inventory, Current [Table Text Block] Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Â Â (in thousands) Â Raw materials Â $720Â Â $266Â Work in process Â Â 3,363Â Â Â Â 5,725Â Finished goods Â Â 7,656Â Â Â Â 6,150Â Inventories Â $11,739Â Â $12,141Â X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R31.htm IDEA: XBRL

DOCUMENT v3.24.3 Note 5 - Property and Equipment (Tables) 3 Months Ended Sep. 30, 2024 Notes Tables Â Property, Plant and Equipment [Table Text Block] Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Â Â (in thousands) Â Manufacturing and lab equipment Â $1,443Â Â $1,838Â Office equipment, furniture and other Â Â 956Â Â Â 945Â Leasehold improvements Â Â 158Â Â Â 35Â Property and equipment, gross Â Â 2,557Â Â Â 2,818Â Less: accumulated depreciation and amortization Â Â (1,865)Â Â (2,125) Property and equipment, net Â $692Â Â $693Â X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Leases (Tables) 3 Months Ended Sep. 30, 2024 Notes Tables Â Lease, Cost [Table Text Block] Â Â Three Months Ended Â Â Â Â September 30, Â Â Â Â 2024 Â Â 2023 Â Statement of Operations Classification Â Â (in thousands) Â Â Lease cost: Â Â Â Â Â Â Â Â Â Operating lease cost Â $122Â Â $360Â Operating expenses Short-term lease cost Â Â 91Â Â Â 23Â Operating expenses Finance lease cost: Â Â Â Â Â Â Â Â Â Â Amortization of leased assets Â Â â€”Â Â Â 14Â Cost of sales Interest on lease liabilities Â Â â€”Â Â Â 1Â Interest expense Total lease cost Â $213Â Â $398Â Â Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Weighted-average remaining lease term (years): Â Â Â Â Â Â Â Â Â Operating lease assets Â Â 4.2Â Â Â 2.7Â Weighted-average discount rate: Â Â Â Â Â Â Â Â Â Operating lease assets Â Â 11.1%Â Â 10.0% Â Â Three Months Ended Â Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Cash flow classification of lease payments: Â Â Â Â Â Â Â Â Â Operating cash flows from operating leases Â $168Â Â $360Â Operating cash flows from finance leases Â $â€”Â Â $1Â Financing cash flows from finance leases Â $â€”Â Â $23Â Schedule of Lease by Balance Sheet Information [Table Text Block] Â Â September 30, Â Â June 30, Â Â Â 2024Â Â 2024Â Balance Sheet Classification Â Â (in thousands) Â Â Assets: Â Â Â Â Â Â Â Â Â Operating lease assets Â $1,225Â Â $829Â Operating lease right-of-use assets Â Â Â Â Â Â Â Â Â Â Liabilities: Â Â Â Â Â Â Â Â Â Current: operating leases Â $484Â Â $712Â Other current liabilities Non-current: operating leases Â Â 1,144Â Â Â 577Â Other non-current liabilities Total lease liabilities Â $1,628Â Â $1,289Â Â Lessee, Liability, Maturity [Table Text Block] Â Â Operating Â Â Â (in thousands) Â 2025 (remaining 9 months) Â $792Â 2026 Â Â 399Â 2027 Â Â 377Â 2028 Â Â 386Â 2029 Â Â 358Â 2030 Â Â 230Â Thereafter Â Â 19Â Total lease payments Â Â 2,561Â Less: imputed interest Â Â (520) Less: tenant improvement allowance Â Â (413) Lease liabilities Â $1,628Â X - DefinitionTabular disclosure of undiscounted cash flows of lessee's lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to lease liability recognized in statement of financial position. + ReferencesNo definition available. + Details Name: aytu_LesseeLiabilityMaturityTableTextBlock Namespace Prefix: aytu_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of leases by balance sheet information. + ReferencesNo definition available. + Details Name: aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock Namespace Prefix: aytu_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Intangible Assets (Tables) 3 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Finite-Lived Intangible Assets [Table Text Block] Â Â September 30, 2024 Â Â Â Gross Carrying Amount Â Â Accumulated Amortization Â Â Net Carrying Amount Â Â Weighted-Average Remaining Life Â Â Â (in thousands) Â Â (in years) Â Acquired product technology rights Â $41,268Â Â $(13,988)Â $27,280Â Â Â 10.5Â Acquired technology rights Â Â 30,200Â Â Â (6,275)Â Â 23,925Â Â Â 13.5Â Total intangible assets Â $71,468Â Â $(20,263)Â $51,205Â Â Â 11.9Â Â Â June 30, 2024 Â Â Â Gross Carrying Amount Â Â Accumulated Amortization Â Â Net Carrying Amount Â Â Weighted-Average Remaining Life Â Â Â (in thousands) Â Â (in years) Â Acquired product technology rights Â $41,268Â Â $(13,184)Â $28,084Â Â Â 10.7Â Acquired technology rights Â Â 30,200Â Â Â (5,831)Â Â 24,369Â Â Â 13.8Â Total intangible assets Â $71,468Â Â $(19,015)Â $52,453Â Â Â 12.0Â Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Â Â Estimated Future Amortization Expense Â Â Â (in thousands) Â 2025 (remaining 9 months) Â $3,742Â 2026 Â Â 4,989Â 2027 Â Â 4,989Â 2028 Â Â 4,989Â 2029 Â Â 4,989Â 2030 Â Â 2,847Â Thereafter Â Â 24,660Â Total future amortization expense Â $51,205Â X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Accrued Liabilities (Tables) 3 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Accrued Liabilities [Table Text Block] Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Â Â (in thousands) Â Accrued savings offers Â $9,929Â Â $11,054Â Accrued program liabilities Â Â 5,990Â Â Â 9,964Â Accrued customer and product related fees Â Â 5,540Â Â Â 5,395Â Accrued employee compensation Â Â 5,212Â Â Â 4,603Â Return reserve Â Â 4,218Â Â Â 4,832Â Other accrued liabilities Â Â 2,834Â Â Â 2,295Â Total accrued liabilities Â $33,723Â Â $38,143Â X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Other Liabilities (Tables) 3 Months Ended Sep. 30, 2024 Notes Tables Â Other Liabilities [Table Text Block] Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Â Â (in thousands) Â Fixed payment arrangements Â $7,405Â Â $8,337Â Employee retention credit Â Â 3,759Â Â Â 3,759Â Operating lease liabilities Â Â 1,628Â Â Â 1,289Â Other Â Â 18Â Â Â 106Â Total other liabilities Â Â 12,810Â Â Â 13,491Â Less: current portion of other liabilities Â Â (7,889)Â Â (8,962) Total non-current portion of other liabilities Â $4,921Â Â $4,529Â X - DefinitionTabular disclosure of other liabilities. + ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Long-term Debt (Tables) 3 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Long-Term Debt Instruments [Table Text Block] Â Â September 30, Â Â June 30, Â Â Â 2024 Â Â 2024 Â Â Â (in thousands) Â Term loan principal amount Â $12,536Â Â $13,000Â Unamortized debt discount and issuance costs Â Â (249)Â Â (266) Total debt Â Â 12,287Â Â Â 12,734Â Less: current portion of debt Â Â (1,857)Â Â (1,857) Total debt, net of current portion Â $10,430Â Â $10,877Â Schedule of Maturities of Long-Term Debt [Table Text Block] Â Â Future Principal Payments Â Â Â (in thousands) Â 2025 (remaining 9 months) Â $1,393Â 2026 Â Â 1,857Â 2027 Â Â 1,857Â 2028 Â Â 7,429Â Total future principal payments Â Â 12,536Â Less: unamortized debt discount and issuance costs Â Â (249) Less: current portion of debt Â Â (1,857) Total debt, net of current portion Â $10,430Â X - DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Fair Value Measurements (Tables) 3 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Â Â Fair Value at September 30,Â Â Fair Value Measurements at September 30, 2024Â Â Â Â 2024 Â Â (Level 1) Â Â (Level 2) Â Â (Level 3) Â Â Â (in thousands) Â Liabilities: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Derivative warrant liabilities Â $9,402Â Â $â€”Â Â $â€”Â Â $9,402Â Total Â $9,402Â Â $â€”Â Â $â€”Â Â $9,402Â Â Â Â Â Fair Value at June 30,Â Â Fair Value Measurements at June 30, 2024Â Â Â Â 2024 Â Â (Level 1) Â Â (Level 2) Â Â (Level 3) Â Â Â (in thousands) Â Liabilities: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Derivative warrant liabilities Â $12,745Â Â $â€”Â Â $â€”Â Â $12,745Â Total Â $12,745Â Â $â€”Â Â $â€”Â Â $12,745Â Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Â Â Derivative Â Â Â Warrant Liabilities Â Â Â (in thousands) Â Balance as of June 30, 2024 Â $12,745Â Settlements (1) Â Â (463) Included in earnings Â Â (2,880) Balance as of September 30, 2024 Â $9,402Â Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Â Â June 2023 Warrants Â Â Warrants Â Â Â Tranche A Â Â Other (1) Â Â Â Monte Carlo Â Â Â Â Â Black-Scholes Â Â Black-Scholes Â Aytu closing stock price Â $ 2.35 Â Â $ 2.35 Â Equivalent term (years) Â 3.7Â Â 2.3-2.9Â Expected volatility Â 79.9% Â Â 79.9%-82.7% Â Risk-free rate Â 3.6% Â Â 3.6% Â Dividend yield Â 0.0% Â Â 0.0% Â X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Note 15 - Equity Incentive Plans (Tables) 3 Months Ended Sep. 30, 2024 Notes Tables Â Share-Based Payment Arrangement, Option, Activity [Table Text Block] Â Â Â Â Â Â Â Â Â Â Weighted Â Â Â Â Â Â Â Â Â Â Average Â Â Â Â Â Â Â Weighted Â Â Remaining Â Â Â Number of Â Â Average Â Â Contractual Â Â Â Options Â Â Exercise Price Â Â Life in Years Â Outstanding at June 30, 2024 Â Â Â 146,539Â Â $6.18Â Â Â 8.8Â Forfeited/cancelled Â Â (5,100)Â Â $4.18Â Â Â Â â€”Â Outstanding at September 30, 2024 Â Â Â 141,439Â Â $6.25Â Â Â 8.6Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Exercisable at September 30, 2024 Â Â Â 63,059Â Â $11.32Â Â Â Â 8.4Â Nonvested Restricted Stock Shares Activity [Table Text Block] Â Â Â Â Â Â Â Weighted Â Â Â Â Â Â Â Â Average Grant Â Â Â Number of Â Â Date Fair Â Â Â

Shares Â Â Value Â Unvested at June 30, 2024 Â Â 24,105Â Â $100.34Â Vested Â Â (5,924)Â $16.84Â Unvested at September 30, 2024 Â Â 18,181Â Â $127.54Â Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Â Â Â Â Â Â Weighted Â Â Â Â Â Â Â Average Grant Â Â Â Number of Â Â Date Fair Â Â Â Shares Â Â Value Â Unvested at June 30, 2024 Â Â 1,775Â Â $24.14Â Vested Â Â (564)Â $24.29Â Unvested at September 30, 2024 Â Â 1,211Â Â $24.07Â Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Cost of sales Â $1Â Â $â€”Â Research and development Â Â 2Â Â Â 1Â Selling and marketing Â Â 32Â Â Â â€”Â General and administrative Â Â 138Â Â Â 724Â Net income (loss) from discontinued operations, net of tax Â Â â€”Â Â Â 205Â Total stock-based compensation expense Â $173Â Â $930Â X - DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Subparagraph (c) -Paragraph 2 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock units. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Note 16 - Warrants (Tables) 3 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Â Â Â Â Â Â Â Â Â Â Weighted Â Â Â Â Â Â Â Â Â Â Â Average Â Â Â Â Â Â Â Weighted Â Â Remaining Â Â Â Number of Â Â Average Â Â Contractual Â Â Â Warrants Â Â Exercise Price Â Â Life in Years (4) Â Outstanding June 30, 2024 (1) Â Â 6,075,880Â Â $3.71Â Â Â 3.6Â Warrants exercised (2) Â Â (176,000)Â $0.0001Â Â Â â€”Â Outstanding September 30, 2024 (3) Â Â 5,899,880Â Â $3.22Â Â Â 3.3Â X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Note 17 - Earnings Per Share (Tables) 3 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands, except share and per share data) Â BASIC Â Â Â Â Â Â Â Â Numerators: Â Â Â Â Â Â Â Â Net income (loss) from continuing operations Â $1,093Â Â $(7,473) Net income (loss) from discontinued operations, net of tax Â Â 381Â Â Â (647) Net income (loss) Â $1,474Â Â $(8,120) Denominator: Â Â Â Â Â Â Â Â Basic weighted-average common shares outstanding Â Â 6,068,019Â Â Â 5,482,037Â Per share calculations: Â Â Â Â Â Â Â Â Net income (loss) per share from continuing operations Â $0.18Â Â $(1.36) Net income (loss) per share from discontinued operations, net of tax Â $0.06Â Â $(0.12) Net income (loss) per share Â $0.24Â Â $(1.48) Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands, except share and per share data) Â DILUTED: CONTINUING OPERATIONS Â Â Â Â Â Â Â Â Numerator: Â Â Â Â Â Â Â Â Net income (loss) from continuing operations Â $1,093Â Â $(7,473) Adjustment for change in fair value of warrant liabilities Â Â (2,880)Â Â â€”Â Adjusted numerator - net loss from continuing operations Â $(1,787)Â $(7,473) Denominator: Â Â Â Â Â Â Â Â Basic weighted-average common shares outstanding Â Â 6,068,019Â Â Â 5,482,037Â Dilutive effect of warrants to purchase common stock Â Â 3,028,862Â Â Â â€”Â Dilutive effect of unvested restricted stock and restricted stock units Â Â 2,720Â Â Â â€”Â Diluted weighted-average common shares outstanding Â Â 9,099,601Â Â Â 5,482,037Â Per share calculation: Â Â Â Â Â Â Â Â Net loss per share from continuing operations Â $(0.20)Â $(1.36) Â Â Â Â Â Â Â Â DILUTED: DISCONTINUED OPERATIONS Â Â Â Â Â Â Â Â Numerator: Â Â Â Â Â Â Â Â Net income (loss) from discontinued operations, net of tax Â $381Â Â $(647) Denominator: Â Â Â Â Â Â Â Â Basic weighted-average common shares outstanding Â Â 6,068,019Â Â Â 5,482,037Â Dilutive effect of warrants to purchase common stock Â Â 3,028,862Â Â Â â€”Â Dilutive effect of unvested restricted stock and restricted stock units Â Â 2,720Â Â Â â€”Â Diluted weighted-average common shares outstanding Â Â 9,099,601Â Â Â 5,482,037Â Per share calculation: Â Â Â Â Â Â Â Â Net income (loss) per share from discontinued operations, net of tax Â $0.04Â Â $(0.12) Â Â Â Â Â Â Â Â DILUTED: NET INCOME (LOSS) Â Â Â Â Â Â Â Â Numerator: Â Â Â Â Â Â Â Â Net income (loss) Â $1,474Â Â $(8,120) Adjustment for change in fair value of warrant liabilities Â Â (2,880)Â Â â€”Â Adjusted numerator - net loss Â $(1,406)Â $(8,120) Denominator: Â Â Â Â Â Â Â Â Basic weighted-average common shares outstanding Â Â 6,068,019Â Â Â 5,482,037Â Dilutive effect of warrants to purchase common stock Â Â 3,028,862Â Â Â â€”Â Dilutive effect of unvested restricted stock and restricted stock units Â Â 2,720Â Â Â â€”Â Diluted weighted-average common shares outstanding Â Â 9,099,601Â Â Â 5,482,037Â Per share calculation: Â Â Â Â Â Â Â Â Net loss per share Â $(0.15)Â $(1.48) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Warrants to purchase common stock - liability classified (note 16) Â Â 455,392Â Â Â 6,498,980Â Warrants to purchase common stock - equity classified (note 16) Â Â 18,114Â Â Â 39,072Â Employee unvested restricted stock (note 15) Â Â 10,644Â Â Â 46,656Â Employee unvested restricted stock units (note 15) Â Â 1,211Â Â Â 3,463Â Employee stock options (note 15) Â Â 141,439Â Â Â 162,683Â Total anti-dilutive securities Â Â 626,800Â Â Â 6,750,854Â X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Note 20 - Discontinued Operations (Tables) 3 Months Ended Sep. 30, 2024 Notes Tables Â Disposal Groups, Including Discontinued Operations [Table Text Block] Â Â Three Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Net revenue Â $717Â Â $4,282Â Cost of sales Â Â (359)Â Â (2,536) Selling and marketing Â Â (155)Â Â (1,331) General and administrative Â Â (2)Â Â (670) Amortization of intangible assets Â Â â€”Â Â Â (382) Non-operating other expense, net Â Â (4)Â Â (10) Recognized contingent consideration Â Â 412Â Â Â â€”Â Loss on divestiture Â Â (254)Â Â â€”Â Income (loss) from discontinued operations before income taxes Â Â 355Â Â Â (647) Income tax benefit Â Â 26Â Â Â â€”Â Net income (loss) from discontinued operations, net of tax Â $381Â Â $(647) Â Â June 30, Â Â Â 2024 Â Â Â (in thousands)Â ASSETS Â Â Â Â Current assets of discontinued operations: Â Â Â Â Accounts receivable, net Â $91Â Inventories Â Â 492Â Prepaid expenses and other current assets Â Â 538Â Total current assets of discontinued operations Â Â 1,121Â Non-current assets of discontinued operations: Â Â Â Â Other non-current assets Â Â 44Â Total current and non-current assets of discontinued operations Â $1,165Â Â Â Â Â Â Â LIABILITIES Â Â Â Â Current liabilities of discontinued operations: Â Â Â Â Accounts payable Â $126Â Accrued liabilities Â Â 431Â Total current liabilities of discontinued operations Â $557Â X - DefinitionTabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5D -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5DReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3AReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3 + Details Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands 3 Months Ended Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2024 Effective Income Tax Rate Reconciliation, Percent 27.00% Â 0.00% Â Employee Retention Credit $ 3,759 Â Â $ 3,759 Employee Retention Credit, Vendor Fee Â $ 400 Â Â Other Noncurrent Liabilities [Member] Â Â Â Â Employee Retention Credit $ 3,800 $ 3,800 Â Â X - DefinitionRepresents the amount of employee retention credit. + ReferencesNo definition available. + Details Name: aytu_EmployeeRetentionCredit Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the amount of vendor fee from employee retention credit during the period. + ReferencesNo definition available. + Details Name: aytu_EmployeeRetentionCreditVendorFee Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Revenue (Details Textual) $ in Millions 3 Months Ended Sep. 30, 2024 USD ($) Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price $ 3.3 X - DefinitionAmount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Revenue $ 16,574 $ 17,817 Rx Segment [Member] Â Â Revenue 16,574 17,817 Rx Segment [Member] | ADHD Portfolio [Member] Â Â Revenue 15,264 15,128 Rx Segment [Member] | The Pediatric Portfolio [Member] Â Â Revenue 1,293 2,565 Rx Segment [Member] | Product and Service, Other [Member] Â Â Revenue $ 17 $ 124 X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4:

http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=aytu_RxSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=aytu_AdhdPortfolioMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=aytu_ThePediatricPortfolioMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Inventories (Details Textual) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Inventory Write-down $ 100 $ 100 $ 68 $ 51 X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 Raw materials $ 720 $ 266 Work in process 3,363 5,725 Finished goods 7,656 6,150 Inventories $ 11,739 $ 12,141 X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcessNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Property and Equipment (Details Textual) - USD ($) $ in Millions 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Gain (Loss) on Disposition of Property Plant Equipment $ 0.1 $ 0.3 X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 Property and equipment, gross $ 2,557 $ 2,818 Less: accumulated depreciation and amortization (1,865) (2,125) Property and equipment, net 692 693 Manufacturing Equipment [Member] Â Â Property and equipment, gross 1,443 1,838 Office Equipment, Furniture and Other [Member] Â Â Property and equipment, gross 956 945 Leasehold Improvements [Member] Â Â Property and equipment, gross $ 158 $ 35 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_ManufacturingEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_OfficeEquipmentFurnitureAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Leases (Details Textual) - USD ($) Sep. 30, 2024 Jun. 30, 2024 Finance Lease, Liability $ 0 Â Operating Lease, Right-of-Use Asset 1,225,000 $ 829,000 Operating Lease, Liability 1,628,000 $ 1,289,000 Office Space in Berwyn, Pennsylvania [Member] Â Â Operating Lease, Undiscounted Minimum Monthly Payment 13,000 Â Operating Lease, Right-of-Use Asset 500,000 Â Operating Lease, Liability $ 500,000 Â Lessee, Operating Lease, Discount Rate 12.30% Â X - DefinitionRepresents the undiscounted minimum monthly payment on an operating lease. + ReferencesNo definition available. + Details Name: aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDiscount rate used by lessee to determine present value of operating lease payments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseDiscountRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_LeaseContractualTermAxis=aytu_OfficeSpaceInBerwynPennsylvaniaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Leases - Lease Cost (Details) - USD ($) $ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2024 Total lease cost $ 213 $ 398 Â Operating lease assets (Year) 4 years 2 months 12 days Â 2 years 8 months 12 days Operating lease assets 11.10% Â 10.00% Operating cash flows from operating leases $ 168 360 Â Operating cash flows from finance leases 0 1 Â Financing cash flows from finance leases 0 23 Â Operating Expense [Member] Â Â Â Operating lease cost 122 360 Â Short-term lease cost 91 23 Â Cost of Sales [Member] Â Â Â Amortization of leased assets 0 14 Â Other Expense [Member] Â Â Â Interest on lease liabilities $ 0 $ 1 Â X - DefinitionAmount of interest expense on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest paid on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeaseInterestPaymentOnLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of amortization expense attributable to right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2:

http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_ShortTermLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Leases - Lease Balance Sheet Information (Details) - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 Operating lease right-of-use assets $ 1,225 $ 829 Current: operating leases 484 712 Non-current: operating leases 1,144 577 Total lease liabilities $ 1,628 $ 1,289 X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals) Sep. 30, 2024 Jun. 30, 2024 Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Current Other Liabilities, Current Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Noncurrent Other Liabilities, Noncurrent X - DefinitionIndicates line item in statement of financial position that includes current operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes noncurrent operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Leases - Schedule of Lease Liability Maturity (Details) - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 2025 (remaining 9 months) $ 792 Â 2026 399 Â 2027 377 Â 2028 386 Â 2029 358 Â 2030 230 Â Thereafter 19 Â Total lease payments 2,561 Â Less: imputed interest (520) Â Less: tenant improvement allowance 413 Â Operating Lease, Liability $ 1,628 $ 1,289 X - DefinitionThe amount of tenant improvement allowance for operating lease liability of lessee. + ReferencesNo definition available. + Details Name: aytu_LesseeOperatingLeaseLiabilityTenantImprovementAllowance Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease, including lease not yet commenced. + ReferencesNo definition available. + Details Name: aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Intangible Assets (Details Textual) - USD ($) $ in Millions 3 Months Ended 15 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Amortization Expense of Intangible Assets $ 1.2 $ 1.5 Â Tris Karbinal Agreement [Member] Â Â Â Supply and Distribution Agreement, Extension Term (Year) Â Â 20 years Minimum [Member] Â Â Â Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year) 1 year Â Â Maximum [Member] Â Â Â Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year) 20 years Â Â X - DefinitionThe value of amortization expense of intangible assets. + ReferencesNo definition available. + Details Name: aytu_AmortizationExpenseOfIntangibleAssets Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the renewable period for a finite-lived intangible asset. + ReferencesNo definition available. + Details Name: aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod Namespace Prefix: aytu_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the extension term of a supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu_SupplyAndDistributionAgreementExtensionTerm Namespace Prefix: aytu_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=aytu_TrisKarbinalAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 Finite-lived intangible assets, gross $ 71,468 $ 71,468 Finite-lived intangible assets, amortization (20,263) (19,015) Finite-lived intangible assets, net $ 51,205 $ 52,453 Finite-lived intangible assets, remaining life (Year) 11 years 10 months 24 days 12 years Technology-Based Intangible Assets [Member] Â Â Finite-lived intangible assets, gross $ 41,268 $ 41,268 Finite-lived intangible assets, amortization (13,988) (13,184) Finite-lived intangible assets, net $ 27,280 $ 28,084 Finite-lived intangible assets, remaining life (Year) 10 years 6 months 10 years 8 months 12 days Developed Technology Rights [Member] Â Â Finite-lived intangible assets, gross $ 30,200 $ 30,200 Finite-lived intangible assets, amortization (6,275) (5,831) Finite-lived intangible assets, net $ 23,925 $ 24,369 Finite-lived intangible assets, remaining life (Year) 13 years 6 months 13 years 9 months 18 days X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -

Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRemaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Intangible Assets - Future Amortization Expense (Details) - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 2025 (remaining 9 months), future amortization expense $ 3,742 Â 2026, future amortization expense 4,989 Â 2027, future amortization expense 4,989 Â 2028, future amortization expense 4,989 Â 2029, future amortization expense 4,989 Â 2030, future amortization expense 2,847 Â Thereafter, future amortization expense 24,660 Â Total future amortization expense $ 51,205 $ 52,453 X - DefinitionAmount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 Accrued savings offers $ 9,929 $ 11,054 Accrued program liabilities 5,990 9,964 Accrued customer and product related fees 5,540 5,395 Accrued employee compensation 5,212 4,603 Return reserve 4,218 4,832 Other accrued liabilities 2,834 2,295 Total accrued liabilities $ 33,723 $ 38,143 X - DefinitionRepresents the amount of accrued customer and product related fees classified as current. + ReferencesNo definition available. + Details Name: aytu_AccruedCustomerAndProductRelatedFeesCurrent Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for program related liabilities. + ReferencesNo definition available. + Details Name: aytu_AccruedProgramRelatedLiabilities Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents information related to accrued saving offers. + ReferencesNo definition available. + Details Name: aytu_AccruedSavingOffers Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the amount of return reserve classified as current. + ReferencesNo definition available. + Details Name: aytu_ReturnReserveCurrent Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Other Liabilities (Details Textual) 3 Months Ended Sep. 30, 2024 USD ($) Jun. 30, 2024 USD ($) Mar. 31, 2024 USD ($) Fixed Payment Arrangements $ 7,405,000 $ 8,337,000 Â Employee Retention Credit 3,759,000 $ 3,759,000 Â Business Combination, Contingent Consideration, Liability 0 Â Â Other Noncurrent Liabilities [Member] Â Â Â Employee Retention Credit $ 3,800,000 Â $ 3,800,000 Tris Karbinal Agreement [Member] Â Â Â Supply and Distribution Commitment, Period (Year) 20 years Â Â Supply and Distribution Commitment, Royalty, Percentage of Net Sales 23.50% Â Â Supply and Distribution Agreement, Minimum Sales Per Year 70,000 Â Â Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit $ 30 Â Â Supply and Distribution Agreement, Maximum Yearly Make-whole Payment 2,100,000 Â Â Supply and Distribution Agreement, Maximum Milestone Obligations 3,000,000 Â Â Supply and Distribution Agreement, First Milestone, Minimum Net Revenues 40,000,000 Â Â Tris Karbinal Agreement [Member] | Other Current Liabilities [Member] Â Â Â Settlement Liabilities, Current 5,800,000 Â Â Fixed Payment Arrangements $ 1,700,000 Â Â X - DefinitionRepresents the amount of employee retention credit. + ReferencesNo definition available. + Details Name: aytu_EmployeeRetentionCredit Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the amount of fixed payment arrangements. + ReferencesNo definition available. + Details Name: aytu_FixedPaymentArrangements Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of net revenues to be reached to trigger the first milestone obligation of the supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe maximum amount of milestone obligations of the supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe maximum amount of make-whole payment per year under supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTh minimum amount of units to be sold per year under supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu_SupplyAndDistributionAgreementMinimumSalesPerYear Namespace Prefix: aytu_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionThe amount of royalty make-whole payment per unit for sales under the minimum units for the supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPeriod covered by the supply and distribution commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: aytu_SupplyAndDistributionCommitmentPeriod Namespace Prefix: aytu_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe percentage of net sales to be paid for royalties under supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales Namespace Prefix: aytu_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers. + ReferencesNo definition available. + Details Name: us-gaap_SettlementLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=aytu_TrisKarbinalAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Other Liabilities - Schedule of Other Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 Fixed payment arrangements $ 7,405 $ 8,337 Employee retention credit 3,759 3,759 Operating Lease, Liability 1,628 1,289 Other 18 106 Total other liabilities 12,810 13,491 Less: current portion of other liabilities (7,889) (8,962) Total non-current portion of other liabilities $ 4,921 $ 4,529 X - DefinitionRepresents the amount of employee retention credit. + ReferencesNo definition available. + Details Name: aytu_EmployeeRetentionCredit Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the amount of fixed payment arrangements. + ReferencesNo definition available. + Details Name:

aytu_FixedPaymentArrangements Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe aggregate carrying amount, as of the balance sheets date, of obligations not otherwise itemized or categorized in the footnotes to the financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_OtherSundryLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Note 10 - Revolving Credit Facility (Details Textual) - Eclipse Business Capital LLC Loan Agreement [Member] - Secured Debt [Member] - USD ($) $ in Millions 3 Months Ended Jun. 12, 2024 Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2024 Mar. 24, 2024 Line of Credit Facility, Maximum Borrowing Capacity $ 14.5 Â Â Â Â Debt Instrument, Basis Spread on Variable Rate 4.50% Â Â Â Â Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.50% Â Â Â Â Debt Instrument, Interest Rate, Effective Percentage Â 9.80% Â Â Â Interest Expense, Debt Â $ 0.1 $ 0.1 Â Â Long-Term Line of Credit Â 4.3 Â $ 2.4 Â Line of Credit Facility, Remaining Borrowing Capacity Â $ 2.5 Â Â Â On or Before January 26, 2023 [Member] Â Â Â Â Â Line of Credit Facility, Termination, Fee, Percentage of Commitment Â Â Â Â 2.00% After January 26, 2023 But Before January 26, 2024 [Member] Â Â Â Â Â Line of Credit Facility, Termination, Fee, Percentage of Commitment Â Â Â Â 1.00% After January 26, 2024 But Before January 26, 2025 [Member] Â Â Â Â Â Line of Credit Facility, Termination, Fee, Percentage of Commitment Â Â Â Â 0.50% X - DefinitionRepresents the percentage of commitment used as a termination fee of a line of credit facility. + ReferencesNo definition available. + Details Name: aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment Namespace Prefix: aytu_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LineOfCreditFacilityAxis=aytu_EclipseBusinessCapitalLlcLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=aytu_OnOrBeforeJanuary262023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=aytu_AfterJanuary262023ButBeforeJanuary262024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=aytu_AfterJanuary262024ButBeforeJanuary262025Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Long-term Debt (Details Textual) - USD ($) $ / shares in Units, $ in Millions 3 Months Ended Jun. 12, 2024 Jan. 26, 2022 Sep. 30, 2024 Jun. 30, 2024 Sep. 30, 2023 Oct. 25, 2022 Mar. 07, 2022 Avenue Capital Issuance [Member] Â Â Â Â Â Â Â Shares Issued, Price Per Share (in dollars per share) Â Â Â Â Â Â $ 25 Avenue Capital Warrants [Member] Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â $ 24.2 Â Â Â $ 8.6 $ 24.2 Warrants and Rights Outstanding Â $ 0.6 Â Â Â Â Â Avenue Capital Loan [Member] Â Â Â Â Â Â Â Debt Instrument, Face Amount Â $ 15.0 Â Â Â Â Â Debt Instrument, Interest Rate, Stated Percentage Â 3.25% Â Â Â Â Â Loan Processing Fee Â $ 0.4 Â Â Â Â Â Debt Instrument, Prepayment Fee, Percentage Â Â 16.60% Â Â Â Â Interest Expense, Debt Â Â Â Â $ 0.7 Â Â Debt Instrument, Final Payment Â Â $ 0.6 Â Â Â Â Gain (Loss) on Extinguishment of Debt Â Â Â $ (0.6) Â Â Â Avenue Capital Loan [Member] | After January 26, 2024 But Before January 26, 2025 [Member] Â Â Â Â Â Â Â Debt Instrument, Prepayment Fee, Percentage Â Â 1.00% Â Â Â Â Debt Instrument, Prepayment Fee, Amount Â Â $ 0.2 Â Â Â Â Avenue Capital Loan [Member] | Prime Rate [Member] Â Â Â Â Â Â Â Debt Instrument, Basis Spread on Variable Rate Â 7.40% Â Â Â Â Â Eclipse Term loan [Member] Â Â Â Â Â Â Â Debt Instrument, Face Amount $ 13.0 Â Â Â Â Â Â Â Interest Expense, Debt Â Â $ 0.4 Â Â Â Â Debt Instrument, Term (Year) 4 years Â Â Â Â Â Â Debt Instrument, Amortization Period (Year) 7 years Â Â Â Â Â Â Long-Term Debt, Maturity, Year Four $ 5.6 Â Â Â Â Â Â Debt Instrument, Interest Rate, Effective Percentage Â Â 12.30% Â Â Â Â Eclipse Term loan [Member] | On or Before June 12 2025 [Member] Â Â Â Â Â Â Â Debt Instrument, Termination Fee, Percentage 3.00% Â Â Â Â Â Â Eclipse Term loan [Member] | After June 12, 2025, but on or before June 12, 2026 [Member] Â Â Â Â Â Â Â Debt Instrument, Termination Fee, Percentage 2.00% Â Â Â Â Â Â Eclipse Term loan [Member] | After June 12, 2026, but on or before June 12, 2027 [Member] Â Â Â Â Â Â Â Debt Instrument, Termination Fee, Percentage 1.00% Â Â Â Â Â Â Eclipse Term loan [Member] | After June 12, 2026, but on or before June 12, 2028 [Member] Â Â Â Â Â Â Â Debt Instrument, Termination Fee, Percentage 0.50% Â Â Â Â Â Â Eclipse Term loan [Member] | Secured Overnight Financing Rate (SOFR) [Member] Â Â Â Â Â Â Â Debt Instrument, Basis Spread on Variable Rate 7.00% Â Â Â Â Â Â X - DefinitionThe duration in which the debt will amortize. + ReferencesNo definition available. + Details Name: aytu_DebtInstrumentAmortizationPeriod Namespace Prefix: aytu_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the final payment of a debt instrument. + ReferencesNo definition available. + Details Name: aytu_DebtInstrumentFinalPayment Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe prepayment fee amount. + ReferencesNo definition available. + Details Name: aytu_DebtInstrumentPrepaymentFeeAmount Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the percentage of loan that is payable as a prepayment fee. + ReferencesNo definition available. + Details Name: aytu_DebtInstrumentPrepaymentFeePercentage Namespace Prefix: aytu_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe termination fee if the debt is terminated before or on a certain date. + ReferencesNo definition available. + Details Name: aytu_DebtInstrumentTerminationFeePercentage Namespace Prefix: aytu_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:

credit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionExpenses paid for obtaining loans which includes expenses such as application and origination fees. + ReferencesNo definition available. + Details Name: us-gaap_LoanProcessingFee Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=aytu_AvenueCapitalIssuanceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_AvenueCapitalWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=aytu_AfterJanuary262024ButBeforeJanuary262025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_PrimeRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=aytu_EclipseTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=aytu_OnOrBeforeJune122025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=aytu_AfterJune122025ButOnOrBeforeJune122026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=aytu_AfterJune122026ButOnOrBeforeJune122027Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=aytu_AfterJune122026ButOnOrBeforeJune122028Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Long-term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 Term loan principal amount $ 12,536 $ 13,000 Less: unamortized debt discount and issuance costs (249) (266) Total debt 12,287 12,734 Less: current portion of debt (1,857) (1,857) Total debt, net of current portion $ 10,430 $ 10,877 X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of long-term debt and lease obligation, classified as noncurrent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt and lease obligation, classified as current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt and lease obligation, including portion classified as current. + ReferencesNo definition available. + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Long-term Debt - Future Principal Payments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 2025 (remaining 9 months) $ 1,393 Â 2026 1,857 Â 2027 1,857 Â 2028 7,429 Â Total future principal payments 12,536 Â Less: unamortized debt discount and issuance costs (249) $ (266) Less: current portion of debt (1,857) (1,857) Total debt, net of current portion $ 10,430 $ 10,877 X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt and capital lease obligations. + ReferencesNo definition available. + Details Name: aytu_LongTermDebtAndCapitalLeaseObligationsGross Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities

issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Fair Value Measurements (Details Textual) - Tranche B Pre-Funded Warrants [Member] - $ / shares Sep. 30, 2024 Jun. 14, 2024 Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 176,000 1,806,434 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.0001 $ 0.0001 X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBPrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details) - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 Derivative warrant liabilities $ 9,402 $ 12,745 Financial liabilities, fair value 9,402 12,745 Fair Value, Inputs, Level 1 [Member] Â Â Derivative warrant liabilities 0 0 Financial liabilities, fair value 0 0 Fair Value, Inputs, Level 2 [Member] Â Â Derivative warrant liabilities 0 0 Financial liabilities, fair value 0 0 Fair Value, Inputs, Level 3 [Member] Â Â Derivative warrant liabilities 9,402 12,745 Financial liabilities, fair value $ 9,402 $ 12,745 X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FinancialLiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands 3 Months Ended Sep. 30, 2024 USD ($) Balance $ 12,745 Settlements (1) (463) [1] Included in earnings (2,880) Balance $ 9,402 [1] Relates to the exercise of 176,000 of the Tranche B Pre-Funded Warrants, which were liability classified and exercised at a price of $0.0001 per share. X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Â Â Â Â Derivative, Gain (Loss) on Derivative, Net $ 2,880 $ (5,907) $ 2,880 $ (5,907) Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative, Gain (Loss) on Derivative, Net Â Â Â X - DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIndicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Fair Value Measurements - Valuation Assumptions (Details) Sep. 30, 2024 Measurement Input, Share Price [Member] | June 2023 Warrants Tranche A [Member] Â Derivative liability, measurement input 2.35 Measurement Input, Share Price [Member] | Other Warrants [Member] Â Derivative liability, measurement input 2.35 [1] Measurement Input, Expected Term [Member] | June 2023 Warrants Tranche A [Member] Â Derivative liability, measurement input 3.7 Measurement Input, Expected Term [Member] | Other Warrants [Member] | Minimum [Member] Â Derivative liability, measurement input 2.3 [1] Measurement Input, Expected Term [Member] | Other Warrants [Member] | Maximum [Member] Â Derivative liability, measurement input 2.9 [1] Measurement Input, Price Volatility [Member] | June 2023 Warrants Tranche A [Member] Â Derivative liability, measurement input 0.799 Measurement Input, Price Volatility [Member] | Other Warrants [Member] | Minimum [Member] Â Derivative liability, measurement input 0.799 [1] Measurement Input, Price Volatility [Member] | Other Warrants [Member] | Maximum [Member] Â Derivative liability, measurement input 0.827 [1] Measurement Input, Risk Free Interest Rate [Member] | June 2023 Warrants Tranche A [Member] Â Derivative liability, measurement input 0.036 Measurement Input, Expected Dividend Rate [Member] | June 2023 Warrants Tranche A [Member] Â Derivative liability, measurement input 0 Measurement Input, Expected Dividend Rate [Member] | Other Warrants [Member] Â Derivative liability, measurement input 0 [1] [1] Includes August 2022 Warrants, March 2022 Warrants and Avenue Capital Warrants. X - DefinitionValue of input used to measure derivative liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_DerivativeLiabilityMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_June2023WarrantsTrancheAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_OtherWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.3 Note 13 - Commitments and Contingencies (Details Textual) - Tris Karbinal Agreement [Member] 3 Months Ended Sep. 30, 2024 USD ($) Supply and Distribution Commitment, Period (Year) 20 years Supply and Distribution Commitment, Royalty, Percentage of Net Sales 23.50% Supply and Distribution Agreement, Minimum Sales Per Year 70,000 Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit $ 30 Supply and Distribution Agreement, Maximum Milestone Obligations 3,000,000 Supply and Distribution Agreement, First Milestone, Minimum Net Revenues 40,000,000 Maximum [Member] Â Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit $ 2,100 X - DefinitionThe amount of net revenues to be reached to trigger the first milestone obligation of the supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe maximum amount of milestone obligations of the supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTh minimum amount of units to be sold per year under supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu_SupplyAndDistributionAgreementMinimumSalesPerYear Namespace Prefix: aytu_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionThe amount of royalty make-whole payment per unit for sales under the minimum units for the supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPeriod covered by the supply and distribution commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: aytu_SupplyAndDistributionCommitmentPeriod Namespace Prefix: aytu_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe percentage of net sales to be paid for royalties under supply and distribution agreement. + ReferencesNo definition available. + Details Name: aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales Namespace Prefix: aytu_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=aytu_TrisKarbinalAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.3 Note 14 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands 9 Months Ended Jun. 14, 2024 Jun. 08, 2023 Aug. 11, 2022 Sep. 30, 2024 Sep. 30, 2023 Sep. 26, 2024 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2022 Jun. 17, 2020 Common Stock, Shares Authorized (in shares) Â Â Â 200,000,000 Â Â 200,000,000 Â Â Â Common Stock, Par or Stated Value Per Share (in dollars per share) Â Â Â $ 0.0001 Â Â $ 0.0001 Â Â Â Preferred Stock, Shares Authorized (in shares) Â Â Â 50,000,000 Â Â 50,000,000 Â Â Â Preferred Stock, Par or Stated Value Per Share (in dollars per share) Â Â Â $ 0.0001 Â Â $ 0.0001 Â Â Â Common Stock, Shares, Outstanding (in shares) Â Â Â 6,149,202 Â Â 5,972,638 Â Â Â Payments of Stock Issuance Costs Â Â Â $ (0) $ 160 Â Â Â Â Â August 2022 Prefunded Warrants [Member] Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â 87,500 Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â Â $ 0.02 Â Â Â Â Â Â Â August 2022 Common Warrants [Member] Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â 1,265,547 Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Each

Warrant or Right (in shares) Â Â 1 Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â Â $ 8.6 Â Â Â Â $ 2.32 $ 3.3 Â Warrants and Rights Outstanding, Term (Year) Â Â 5 years Â Â Â Â Â Â Â August 2022 Common and Prefunded Warrants [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) Â Â 1 Â Â Â Â Â Â Â Sale of Stock, Price Per Share (in dollars per share) Â Â $ 8.58 Â Â Â Â Â Â Â Warrants and Rights Outstanding, Term (Year) Â Â 5 years Â Â Â Â Â Â Â Warrants and Rights Outstanding Â Â $ 6,000 Â Â Â Â Â Â Â Pre-Funded Warrants [Member] Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â 430,217 Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) Â 1 Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â $ 0.0001 $ 0.02 Â Â Â Â Â Â Â Tranche A Common Warrants [Member] Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â 2,173,912 Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â $ 3.18 Â Â Â Â Â Â Â Â Warrants and Rights Outstanding, Term (Year) Â 5 years Â Â Â Â Â Â Â Â Tranche B Common Warrants [Member] Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â 2,173,912 Â 1,630,424 Â Â 1,806,434 Â Â Â Proceeds from Warrant Exercises $ 3,500 Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, Warrants Exercised (in shares) 367,478 Â Â Â Â Â Â Â Â Common Warrants [Member] Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â $ 1.59 Â Â Â Â Â Â Â Common Warrants Exchanged for PreFunded Warrants [Member] Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â $ 1.5899 Â Â Â Â Â Â Â Â Securities Purchase Agreement Warrants [Member] Â Â Â Â Â Â Â Â Â Â Warrants and Rights Outstanding Â $ 5,000 Â Â Â Â Â Â Â Â Payments of Stock Issuance Costs Â $ 600 Â Â Â Â Â Â Â Â Tranche B Pre-Funded Warrants [Member] Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 1,806,434 Â Â 176,000 Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â $ 0.0001 Â Â $ 0.0001 Â Â Â Â Â Â Â Warrants and Rights Outstanding $ 5,100 Â Â Â Â Â Â Â Â Class of Warrant or Right, Issued During Period (in shares) 1,806,434 Â Â Â Â Â Â Â Â The 2020 Shelf [Member] Â Â Â Â Â Â Â Â Â Sale of Stock, Maximum Amount of Equity Issuable Â Â Â Â Â Â Â Â Â $ 100,000 The August 2022 Offering [Member] Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) Â Â 1,075,290 Â Â Â Â Â Â Â Â Sale of Stock, Price Per Share (in dollars per share) Â Â $ 8.6 Â Â Â Â Â Â Â Proceeds from Issuance or Sale of Equity Â Â $ 10,000 Â Â Â Â Â Â Â Payment of Financing and Stock Issuance Costs Â Â $ 900 Â Â Â Â Â Â Â Securities Purchase Agreement [Member] Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) Â 1,743,695 Â Â Â Â Â Â Â Â Proceeds from Issuance or Sale of Equity Â $ 4,000 Â Â Â Â Â Â Â Payment of Financing and Stock Issuance Costs Â $ 3,400 Â Â Â Â Â Â Â The 2024 Shelf [Member] Â Â Â Â Â Â Â Â Â Â Sale of Stock, Maximum Amount of Equity Issuable Â Â Â Â Â Â $ 100,000 Â Â Â Â Restricted Stock [Member] Â Â Â Â Â Â Â Â Â Common Stock, Shares, Outstanding (in shares) Â Â Â 19,019 Â Â Â Â Â Â X - DefinitionThe number of warrants or rights issued during period. + ReferencesNo definition available. + Details Name: aytu_ClassOfWarrantOrRightIssuedDuringPeriod Namespace Prefix: aytu_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresents the maximum monetary amount of equity issuable. + ReferencesNo definition available. + Details Name: aytu_SaleOfStockMaximumAmountOfEquityIssuable Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe number of shares issued for the warrants exercised. + ReferencesNo definition available. + Details Name: aytu_StockIssuedDuringPeriodSharesWarrantsExercised Namespace Prefix: aytu_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentOfFinancingAndStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonAndPrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheACommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBCommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsExchangedForPrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_SecuritiesPurchaseAgreementWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBPrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=aytu_The2020ShelfMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=aytu_TheAugust2022OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=aytu_The2024ShelfMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 82 R71.htm IDEA: XBRL DOCUMENT v3.24.3 Note 15 - Equity Incentive Plans (Details Textual) - USD ($) $ in Millions 3 Months Ended May 18, 2023 Apr. 19, 2021 Jun. 01, 2015 Sep. 30, 2024 Jun. 30, 2024 Feb. 13, 2020 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) Â Â Â 141,439 146,539 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) Â Â Â 0 Â Â Share-Based Payment Arrangement, Option [Member] Â Â Â Â Â Â Â Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Â Â Â $ 0.1 Â Â Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Â Â Â 1 year 8 months 12 days Â Â Restricted Stock

[Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares) Â Â Â 18,181 24,105 Â Restricted Stock Units (RSUs) [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares) Â Â Â 1,211 1,775 Â Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Â Â Â 4 months 24 days Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Â Â Â 0 Â Â Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Â Â Â $ 0.1 Â Â The 2023 Equity Incentive Plan [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) 200,000 Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) 87,129 Â Â 187,422 Â Â The 2023 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) 10 years Â Â Â Â Â The 2023 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) 3 years Â Â Â Â The 2023 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) 4 years Â Â Â Â Â The 2023 Equity Incentive Plan [Member] | Restricted Stock and Restricted Stock Units (RSUs) [Member] | Minimum [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) 3 years Â Â Â Â Â The 2023 Equity Incentive Plan [Member] | Restricted Stock and Restricted Stock Units (RSUs) [Member] | Maximum [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) 4 years Â Â Â Â Â The 2015 Plan [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) Â Â Â Â Â 250,000 The 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) Â Â 10 years Â Â Â The 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Â Â 3 years Â Â Â The 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Â Â 4 years Â Â Â The 2015 Plan [Member] | Restricted Stock [Member] Â Â Â Â Â Â Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Â Â Â 2 years 6 months Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Â Â Â 0 Â Â Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Â Â Â $ 0.9 Â Â The 2015 Plan [Member] | Restricted Stock [Member] | Minimum [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Â Â 4 years Â Â Â The 2015 Plan [Member] | Restricted Stock [Member] | Maximum [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Â Â 10 years Â Â Â The 2015 Plan [Member] | Restricted Stock Units (RSUs) [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Â Â 4 years Â Â Â Neos 2015 Plan [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Â 5,272 Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) Â 3,486 Â Â Â Â Neos 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) Â 10 years Â Â Â Â Neos 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Â 1 year Â Â Â Â Neos 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Â 4 years Â Â Â Â Neos 2015 Plan [Member] | Restricted Stock Units (RSUs) [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares) Â 1,786 Â Â Â Â Outside Equity Incentive Plan [Member] | Restricted Stock [Member] Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares) Â Â Â 838 Â Â Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Â Â Â 3 months 18 days Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Â Â Â 0 Â Â Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Â Â Â $ 0.2 Â Â X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=aytu_The2023EquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=aytu_RestrictedStockAndRestrictedStockUnitsRsusMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=aytu_The2015PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=aytu_Neos2015PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=aytu_OutsideEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 83 R72.htm IDEA: XBRL DOCUMENT v3.24.3 Note 15 - Equity Incentive Plans - Stock Option Activity (Details) - $ / shares 3 Months Ended 12 Months Ended Sep. 30, 2024 Jun. 30, 2024 Outstanding, options (in shares) 146,539 Â Outstanding, options, weighted average exercise price (in dollars per share) $ 6.18 Â Outstanding, options, weighted average remaining contractual life (Year) 8 years 7 months 6 days 8 years 9 months 18 days Forfeited/Cancelled, options (in shares) (5,100) Â Forfeited/Cancelled, options, weighted average exercise price (in dollars per share) $ 4.18 Â Outstanding, options (in shares) 141,439 146,539 Outstanding, options, weighted average exercise price (in dollars per share) $ 6.25 $ 6.18 Exercisable, options (in shares) 63,059 Â Exercisable, options, weighted average exercise price (in dollars per share) $ 11.32 Â Exercisable, options, weighted average remaining contractual life (Year) 8 years 4 months 24 days Â X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.3 Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details) - Restricted Stock [Member] 3 Months Ended Sep. 30, 2024 $ / shares shares Unvested, shares (in shares) | shares 24,105 Unvested, weighted average grant date fair value (in dollars per share) | $ / shares $ 100.34 Vested, shares (in shares) | shares (5,924) Vested, weighted average grant date fair value (in dollars per share) | $ / shares $ 16.84 Unvested, shares (in shares) | shares 18,181 Unvested, weighted average grant date fair value (in dollars per share) | $ / shares $ 127.54 X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 85 R74.htm IDEA: XBRL DOCUMENT v3.24.3 Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member] 3 Months Ended Sep. 30, 2024 $ / shares shares Unvested, shares (in shares) | shares 1,775 Unvested, weighted average grant date fair value (in dollars per share) | $ / shares $ 24.14 Vested, shares (in shares) | shares (564) Vested, weighted average grant date fair value (in dollars per share) | $ / shares $ 24.29 Unvested, shares (in shares) | shares 1,211 Unvested, weighted average grant date fair value (in dollars per share) | $ / shares $ 24.07 X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 86 R75.htm IDEA: XBRL DOCUMENT v3.24.3 Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details) - USD ($) $ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Total stock-based compensation expense $ 173 $ 930 Cost of Sales [Member] Â Â Total stock-based compensation expense 1 0 Research and Development Expense [Member] Â Â Total stock-based compensation expense 2 1 Selling and Marketing Expense [Member] Â Â Total stock-based compensation expense 32 0 General and Administrative Expense [Member] Â Â Total stock-based compensation expense 138 724 Net Loss From Discontinued Operations [Member] Â Â Total stock-based compensation expense $ 0 $ 205 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=aytu_NetLossFromDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 87 R76.htm IDEA: XBRL DOCUMENT v3.24.3 Note 16 - Warrants (Details Textual) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Jun. 14, 2024 USD ($) $ / shares shares Jun. 08, 2023 USD ($) $ / shares shares Jan. 06, 2023 Sep. 30, 2024 $ / shares shares Sep. 30, 2024 USD ($) $ / shares shares Sep. 30, 2023 USD ($) Jun. 30, 2024 shares Jun. 30, 2023 $ / shares Dec. 31, 2022 $ / shares Aug. 11, 2022 $ / shares shares Payments of Stock Issuance Costs | $ Â Â Â Â $ (0) $ 160 Â Â Â Â Class of Warrant or Right, Outstanding (in shares) Â Â Â 5,899,880 [1] 5,899,880 [1] Â 6,075,880 [2] Â Â Â Class of Warrant or Right, Exercised During Period (in shares) [3] Â Â Â 176,000 Â Â Â Â Â Â Reverse Stock Split [Member] Â Â Â Â Â Â Â Â Â Stockholders' Equity Note, Stock Split, Conversion Ratio Â Â 20 Â Â Â Â Â Â Â Pre-Funded Warrants [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â 430,217 Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares Â $ 0.0001 Â Â Â Â Â Â Â $ 0.02 Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) Â 1 Â Â Â Â Â Â Â Â Tranche A Common Warrants [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â 2,173,912 Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares Â $ 3.18 Â Â Â Â Â Â Â Â Warrants and Rights Outstanding, Term (Year) Â 5 years Â Â Â Â Â Â Â Â Tranche B Common Warrants [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â 2,173,912 Â 1,630,424 1,630,424 Â 1,806,434 Â Â Â Proceeds from Warrant Exercises | $ $ 3,500 Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, Warrants Exercised (in shares) 367,478 Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercised During Period (in shares) Â Â Â 176,000 Â Â Â Â Â Â Class of Warrant or Right, Exercise Price, Exercised During Period (in dollars per share) | $ / shares Â Â Â $ 0.0001 Â Â Â Â Â Â Common Warrants [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares Â $ 1.59 Â Â Â Â Â Â Â Â Common Warrants Exchanged for PreFunded Warrants [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares Â $ 1.5899 Â Â Â Â Â Â Â Â Tranche B Pre-Funded Warrants [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 1,806,434 Â Â 176,000 176,000 Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares $ 0.0001 Â Â $ 0.0001 $ 0.0001 Â Â Â Â Â Â Warrants and Rights Outstanding | $ $ 5,100 Â Â Â Â Â Â Â Â Â August 2022 Prefunded Warrants [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â Â Â Â Â Â Â Â 87,500 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares Â Â Â Â Â Â Â Â $ 0.02 August 2022 Common Warrants [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â Â Â Â Â Â Â Â 1,265,547 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares Â Â Â Â Â Â Â $ 2.32 $ 3.3 $ 8.6 Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) Â Â Â Â Â Â Â Â Â 1 Warrants and Rights Outstanding, Term (Year) Â Â Â Â Â Â Â Â 5 years August 2022 Common Warrants [Member] | Minimum [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares Â Â Â Â Â Â Â Â $ 2.32 August 2022 Common Warrants [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â Â Â Â Â Â Â 2,325,581 Liability Warrants [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Outstanding (in shares) Â Â Â 3,821,115 3,821,115 Â 3,821,115 Â Â Â Liability Pre-Funded Warrants [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Outstanding (in shares) Â Â Â 430,217 430,217 Â 430,217 Â Â Â Equity Warrants [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â Â Â Â Â 18,114 Â Â Â Class of Warrant or Right, Outstanding (in shares) Â Â Â 18,114 18,114 Â Â Â Â Â Securities Purchase Agreement [Member] Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) Â 1,743,695 Â Â Â Â Â Â Â Â Proceeds from Issuance or Sale of Equity | $ Â $ 4,000 Â Â Â Â Â Â Â Â Â Payment of Financing and Stock Issuance Costs | $ Â 3,400 Â Â Â Â Â Â Â Â Securities Purchase Agreement Warrants [Member] Â Â Â Â Â Â Â Â Â Warrants and Rights Outstanding | $ Â 5,000 Â Â Â Â Â Â Â Â Â Payments of Stock Issuance Costs | $ Â $ 600 Â Â Â Â Â Â Â Â [1] The number of warrants outstanding as of September 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,630,424 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. [2] The number of warrants outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,806,434 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. [3] The warrants exercised during the three months ended September 30, 2024, were 176,000 of the Tranche B Warrants, which were exercised at a price of $0.0001 per share. X - DefinitionRepresents the exercise price of warrants or rights exercised during the period. + ReferencesNo definition available. + Details Name: aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod Namespace Prefix: aytu_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of warrants or rights exercised during period. + ReferencesNo definition available. + Details Name: aytu_ClassOfWarrantOrRightExercisedDuringPeriod Namespace Prefix: aytu_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares issued for the warrants exercised. + ReferencesNo definition available. + Details Name: aytu_StockIssuedDuringPeriodSharesWarrantsExercised Namespace Prefix: aytu_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities. + ReferencesReference 1:

http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentOfFinancingAndStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_NonmonetaryTransactionTypeAxis=aytu_ReverseStockSplitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheACommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBCommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_CommonWarrantsExchangedForPrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_TrancheBPrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_August2022CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_LiabilityWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_LiabilityPrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aytu_EquityWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreementWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 88 R77.htm IDEA: XBRL DOCUMENT v3.24.3 Note 16 - Warrants - Schedule of Warrants Outstanding (Details) - $ / shares 3 Months Ended 12 Months Ended Sep. 30, 2024 Jun. 30, 2024 [1] Outstanding, balance (in shares) [1] 6,075,880 Â Outstanding, weighted average remaining contractual term (Year) [2] 3 years 3 months 18 days [3] 3 years 7 months 6 days Warrants exercised (2) (in shares) [4] (176,000) Â Outstanding, balance (in shares) 5,899,880 [3] 6,075,880 Weighted Average [Member] Â Â Outstanding, weighted average exercise price (in dollars per share) [1] $ 3.71 Â Warrants exercised, weighted average exercise price (in dollars per share) [4] 0.0001 Â Outstanding, weighted average exercise price (in dollars per share) $ 3.22 [3] $ 3.71 [1] The number of warrants outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,806,434 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. [2] As pre-funded warrants do not have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years. [3] The number of warrants outstanding as of September 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,630,424 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. [4] The warrants exercised during the three months ended September 30, 2024, were 176,000 of the Tranche B Warrants, which were exercised at a price of $0.0001 per share. X - DefinitionRepresents the exercise price of warrants or rights exercised during the period. + ReferencesNo definition available. + Details Name: aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod Namespace Prefix: aytu_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of warrants or rights exercised during period. + ReferencesNo definition available. + Details Name: aytu_ClassOfWarrantOrRightExercisedDuringPeriod Namespace Prefix: aytu_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average period of remaining contractual life of warrants or rights. + ReferencesNo definition available. + Details Name: aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife Namespace Prefix: aytu_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: srt_RangeAxis=srt_WeightedAverageMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 89 R78.htm IDEA: XBRL DOCUMENT v3.24.3 Note 17 - Earnings Per Share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Net income (loss) from continuing operations $ 1,093 $ (7,473) Â Â Net income (loss) from discontinued operations, net of tax 381 (647) Â Â Net income (loss) $ 1,474 $ (8,120) Â Â Basic weighted-average common shares outstanding (note 17) (in shares) 6,068,019 5,482,037 Â Â Basic - continuing operations (in dollars per share) $ 0.18 $ (1.36) Â Â Basic - discontinued operations, net of tax (in dollars per share) 0.06 (0.12) Â Â Net income (loss) per share (in dollars per share) $ 0.24 $ (1.48) Â Â Adjustment for change in fair value of warrant liabilities $ (2,880) $ 0 Â Â Adjusted numerator - net loss from continuing operations $ (1,787) $ (7,473) Â Â Dilutive effect of warrants to purchase common stock (in shares) 3,028,862 0 Â Â Dilutive effect of unvested restricted stock and restricted stock units (in shares) 2,720 0 Â Â Diluted weighted-average common shares outstanding (in shares) 9,099,601 5,482,037 Â Â Diluted - continuing operations (in dollars per share) $ (0.2) $ (1.36) Â Â Diluted - discontinued operations, net of tax (in dollars per share) $ 0.04 $ (0.12) Â Â Net income (loss) $ 1,474 $ (8,120) $ 1,474 $ (8,120) Adjusted numerator - net loss $ (1,406) $ (8,120) Â Â Diluted - net loss (in dollars per share) $ (0.15) $ (1.48) Â Â X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the parent for diluted calculation. + ReferencesNo definition available. + Details Name: aytu_AdjustedIncomeLossFromContinuingOperationsDiluted Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_DilutiveSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-18 + Details Name: us-gaap_IncomeLossFromContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPer basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPer diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 5.E) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479836/810-10-S99-5 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-26 + Details Name: us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 90 R79.htm IDEA: XBRL DOCUMENT v3.24.3 Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details) - shares 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive securities (in shares) 626,800 6,750,854 Liability Warrants [Member] Â Â Antidilutive securities (in shares) 455,392 6,498,980 Equity-based Warrants [Member] Â Â Antidilutive securities (in shares) 18,114 39,072 Restricted Stock [Member] Â Â Antidilutive securities (in shares) 10,644 46,656 Restricted Stock Units (RSUs) [Member] Â Â Antidilutive securities (in shares) 1,211 3,463 Share-Based Payment Arrangement, Option [Member] Â Â Antidilutive securities (in shares) 141,439 162,683 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_LiabilityWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_EquityBasedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-

gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 91 R80.htm IDEA: XBRL DOCUMENT v3.24.3 Note 20 - Discontinued Operations - Schedule of Discontinued Operations (Details) - USD ($) $ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2024 Net income (loss) from discontinued operations, net of tax $ 381 $ (647) Â Current assets of discontinued operations: Â Â Â Total current assets of discontinued operations 0 Â $ 1,121 LIABILITIES Â Â Â Total current liabilities of discontinued operations 0 Â 557 Consumer Health Divesture [Member] Â Â Â Net revenue 717 4,282 Â Cost of sales (359) (2,536) Â Selling and marketing (155) (1,331) Â General and administrative (2) (670) Â Amortization of intangible assets 0 (382) Â Non-operating other expense, net (4) (10) Â Recognized contingent consideration 412 0 Â Loss on divestiture (254) 0 Â Income (loss) from discontinued operations before income taxes 355 (647) Â Income tax benefit 26 0 Â Net income (loss) from discontinued operations, net of tax $ 381 $ (647) Â Current assets of discontinued operations: Â Â Â Accounts receivable, net Â Â Â 91 Inventories Â Â Â 492 Prepaid expenses and other current assets Â Â Â 538 Total current assets of discontinued operations Â Â Â 1,121 Non-current assets of discontinued operations: Â Â Â Other non-current assets Â Â Â 44 Total current and non-current assets of discontinued operations Â Â Â 1,165 LIABILITIES Â Â Â Accounts payable Â Â Â 126 Accrued liabilities Â Â Â 431 Total current liabilities of discontinued operations Â Â Â $ 557 X - DefinitionAmount of recognized contingent consideration attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesNo definition available. + Details Name: aytu_DisposalGroupIncludingDiscontinuedOperationRecognizedContingentConsideration Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of selling and marketing expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesNo definition available. + Details Name: aytu_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense Namespace Prefix: aytu_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of other expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-

gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of revenue attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=aytu_ConsumerHealthDivestureMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 92 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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}:(1MQ7G%6]W0DC12,[?%]&PO=&AE M;64O=&AE64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2 ;UKNW+][@5S(D4P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8(`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

+$)VPE^RX"B'76KO#Q.GLCQ2&"549ST/*PZZ0B\)K@$NW.$F2+BO[Q/!T$GA!2%IF)G%FCIK S'09 M!>_2,$[2I#NJ>\32Z704RIN6K\DHRG8/V\VFM V/EG9B*(7:2F8PY\]$"!E5 MGTO"^.
_&8GN"=Y\-'(F;;<>:?F?Q ?MP^Z0%W9GR"O-X"G>:9!XQNV1DW6> M%]=D. W$K>5G$N?G+DI[*J+I8Z UN62:90Y25PB'W@N0EG#)-)I@S2O(HZT? MU,2K=U4DRN=OSJTS:3L]=VL9/(LS>.?
%\WM7'^ZV:^M<&7ZF$#JY0R1:@ M,ODXAN22]0%^?:'%QIZ!SX768FT_KAAL&*01@.\70NCG"_. YF<4L_\!4$L# M!!0 ((N*;5G"%57DYP0 *8* 8 >&PO=V]R:W-
H965T&ULC59M;]LV$/XK!PTH.L#U6Y(V:Q(#<;JB'= V:+KMP[/M'22B%"D M2E)QTE^_YRA9=0HWV!>;.O*.SSWWPCO?.G\;:N9(]XVQX2*K8VQ?SV8AK[E1
M8>I:MM@IG6]4Q*>O9J'UK(JDU)C9K<==%HR]>>0M9%=+EZO MC^5\.O"7YFW86Y-XLG'N5C[>%Q?97 "QX3R*!86_.[YB8\008'P=;&;CE:*X MO]Y9?YM\AR\;%?C*F;]U$>N+[#2C@DO5F?
C9;= QX,^)V,N="> F7ML/9>49Y M%Z)K!F4@:+3M_]7]P,/ 45@."LN$N[\HH7RCHEJ=>[<#NEH_F$EO/E\1/VCD9OCY*]HR>\#10=
MO=56V5PK0S=114:6Q8/^]N:.#YN3@G0=6I7S18:#'.SO.%L]^V7QSQ4]97GWREK/ZF')LG=.5L<$87JD6]"U7&EC+T#<#OE$;W3(C0L2VG^^ M\'VDM7'Y[;^'?"T:S9
HEP^QH[5VU[5"34SHO,L_2KHP2IS?"5WG!^&O$]*!%+7\IR[J'.XF_?FJ70H M&*X(=$#4L!Y\ZSQH M+ A;GUW@K0;G5X,X46[ILJM0HO2;).A\.:$_.LMT*E^+DRE]4#ZO)747]'S_M-
O%F\>HL4(AR0_4@7B$I-PS8#/\,NJN@_HF?L5:1=--Z.!42ST;+"CG0 IK$ M_;%W8$5HV_&C6J@J0(."MB^,SJ7)VFJ"'OFUTSXM"P9CKNW%\/PPHY+VN==M M(F2?7A@&H05[<2Q'5]"V8]ITVB3/-%
(31,82*>T$A\=U./&8%LO"KWCO7='E M."C7&^Q[5>UTOZ.AR*H9&>7[EGW4@1.?4KWD>,INIO M^0?F1KNMU_)F]11*N [DF+;@1,DC\YB6T8\4-U44V!0/;*%E/U#!^6N']"Q
M!M8EB3T56E762<0 .*_A3.U<<1C@9FC:,;::'>&"'"L;Z?$VP]THDA> 1SL?9 M-L)&VRD& K21[/.NJVK\;U]0W#HJM4<1R"JPN+4G^-3NHAFXZCN20BO2!9:Z MU'UU25X[FS:1"5IVP\HXHCT
MB#NEC=H8" &1?*=,U^]M'E+!@$TN=]P 7<&Y3G-&HVZ1L[N&=O7IS8==[YG2 M91DEG^L4WSOMN@ Z%*+>V1R>A"[$8&RDS<<+!NVS?J0JHSZMW[&E/X+,8@ M6'0'RL3Z>_A2CK@\
[[R'R:*38DP:/:=H)B<32KUX.4?S1</[\?["0[] M#@4:4'$E5.?35R<9^7XJZC^B:],DLG$1]C@D(J% & 'AL+W=O6;(DXWS=V%-%-5#6=AP.EC' M6+T;CT.VIE*'D:O(8F7I?
*DC;OUJ'"I'.I=#93&>329OQZ4V=G!V(L]N_-F) MJV-A+-UX%>JRU/[QG JW.1U,!^V#SV:UCOQ@?'92Z17=4OQ:W7C;]L^+>A3>C]5NS)PKD[OKG*3P<3-H@*RB)+T+CS@.3!K#LS$[J1(K/R@
MHSX[\6ZC/.^&-/XAKLII&&JP:G(MGURZ2FJG7ZC9E1;FENC4K:Y8F MTS:J>9:YVD9C5^K&%28S%$[&$8KY^#AKED)PG);-GE!RHWYV-ZZ N;4[Y[ODQ M#.ZLGK56G\)>%'A+U4@=3(9J-
ID=OB#OH(O"@<@[>"$*046G/AJK;69TH6ZC MC@3TQ;W^)G&'^\5Q(;T+E<[H=(!*">3O:7#VXP_3MY/W+QA[V!E[^)+TL[)) MC_K/%WJ(ZKQPV=U_]]G^LO0&$#?>(Z5+@(CXL+9
/&YEDKZLB8*2MM'W_\ MX7@V/7H?5&UUG9M(N)K\H2P0U=1Y\3WJ%-Q2?0: M7#9K5Q3 Y<9"7J@7P>1&>W9T_AAK-L;KBNIHLC!4O_UV(>*OR84G2UX)>MK;QQGC'&3N;0 M&Z*)M2?
V\V79"/FO-80>3!/@1^I7Q:85:A, %^=W'7X-X=@DOP9TDV4 ,J-(^68O%9ZU:.A>3 M99Z^U<8G$U6=9);:HE_P;D6M^*'ZL\Y76PDZH,U4K"B,4"6QAA*(5<'G'\4 M$_EZ(UFY(5QR]9FR
@>EN,3&" _(S(G?P_VI70W M[W]H[S6[T*.";>'"2+5I=Z!RR+!OBC,9'U_W?,*^PNB%*9X\-S9$7Z<@_W&!4MP.;:YT&=.US4*U8SF[S_.+\]EY_3]S_MWW_A\BV(VF/SVXON MU!=7P! C:[E
:+EL*)%/>!$HX4OXO-/9FBM!;S'X5.8(-L/*1.;MF2'/K03V MR'?U8R#F:3F1$C0R"A(FI-D@V)7S# "@&^<)Q8,"I;BAE% T?M'-J-E23:. MC0\[UG,[9$.WK(B^X+PX4-4>
(:X$WL0I)BX<0CL.A^KY]+U;9PXEHC9\ U/?"@D4J(J^FQ M)? J=9VV')HT&\Z#+J12>&# PC;K6,2>6% NL\F6VX;;LN[5+L=<;[IFU9MY M>-.?M37(2 M0:PSZE#4#VSCH[ALQ-?
2>7;PCC@N*#/I3_R_3W =>:0Y(&%2!\L0>%EPPJ> MYZ[B+/7G?N\L?F?-4/&!%A&OJ#YVHWDEYK !'Q?\D)ZM5MO8BIIQWQL,B[H]=9&I0N82G &]0G](9+&0-Z M0]#;U.&D[Q)7>5(7#1/K56\>8-
T[PO5^^8ATER)NGJDQR!P];9L%YSZ%]H6 M7LN,*Z,E-K\G>U)MC3!/E"3 MH^$>#:_2C# [GK2[MIB1V^ZZQ\^GCX A&*-7*T^K;OQNYHGN35==@JEL^-[8 MP\[80S4Y&'Y_<&LU5ZRG-
7^UN:=V8R/WJ0G]\&A@%&)X= HZ_G,M]WUJ8-O MO_?Y:"3=%V\P2LLL4]"ZF3Y;@GO:_4/OQ;K74JOFQ7K{_9&Z5[BGI]LW) !/ M_NU],YI.]GT &/>^WY3D5_*5BN /6^=6KO6$%W>?!L_\!4$L#
M!!0 ((N*;5FO<[2=@ 0 -() 8 >&PO=V]R:W-H965T&UL?5;;;N,V$/V5@;98= '%%]E.LKD8R*7;%.AN@R3;/A1]H*611$0B MM21EQ_WZ'E*RXQ2.'^)0Y,R9,U?R8J7-LRV9';W4E;*74>E<F%@Z?
IAC:QK#(@E)=#9/1Z'A8"ZFB^478NS?S"]VZ2BJ^-V3;NA9F M?W!M\#;!/R6O[,Z:O"<+K9_]QV_9933RA+CBU'D$@7]+ON&J\D"@\:/'C+8FO>+N M>H/^)?
@.7Q;"\HVN_I*9*R^CTX@RSD5;N0>]NN/>GYG'2W5EPR^M.MGIYXC2 MUCI=]\@4$O5_1'>& LM;X<3)PN@5&2\--+(K@9M MD)/*)^71&9Q*Z+GY-^V8)G1$#[QDU?+%T
'5GPW3'N&Z0TC>09C05ZU<:>D7 ME7'V5G\(-EM*R8;2=7(0\)&; 4U&,26C9'H ;[)U<1+P)@=='1^@.QT2W9Z"'W> MIX%RHVNZ06 -ZA8UX4JZ"=7 AOY^XA='UY5.G__9Q_^PA3[CW]#P9M=8"F-2
MM5(5A)8WPC>-];M66F=)YV1%Q6'A_4Z-;$)?-:5 =Z3<.IDBM(W169M"(8"Z MDN%%W0BU_OCA-!F?G%NZNKV[I7MM7*XKJ4FHC.XYD\(9F;[NQT"2R%8CJFKM MLR>HDK5TG)%JZP7"
"*K4H,2:%$&DD8N6J>-#9]+0G&4@4>WU70#KFW@S!!3VR"H&5<85F;]#::"%;+A M=7T$D]%Y;IB/M#I::&&RL#<^AX)%]D+28)-5!PYG,O"PKK?NS>Z+1KS),UJB MXY;VI=@!["%$F1]
7A78T1LT>GZ<&\S82A%Y N#S02CQ6KN^\2\ M5MENME$KHH#A0O@(0-PB)S)'C.#])J?-5A4W7\?_')0E:A Z?>WETECG(S&C,(V2T6[R M?F5=&-&@&NAWG78E_;1GCJBW#8RAA%KW/<
'*SV4MU2[.4>?L^F:!Y$+8VZP M;Y8/=^Y9^%J$UX2?D:URW96[W=T^6*ZZ>_I5O'OM?$6/@ 15G$-U-#B9162Z M%T3WX703;NV%=A@E85GBT<7&"^ \UXA<_^$-;)]Q_\ 4$L#!!0 ((N* M;5D(-
!)RXP(%D& 9 >&PO=V]R:W-H965T)[<[VQMZY I'@OE3:S8."J)I&D S61MS MYST*H,"./(BSPRM4R@,QC5\=9M"'|[("@'}77,[Y[(6#]^,^BYS M*N;!RP!RW(A:T:W9O\SAR
M>!D_XI!T#DG#NPW4L+P6)!8S:_9@O36C>:%)M?%F">UT)D4"E8D"+F\Z&2^+=SP-)SO ME*FK1(;S@%O!H=UAL'CZ9#".7Y\A.^S)#L^A+PY/\1NNI>P^WQM< %3)*8UV0\AN__W5 :IN,41N$D
M&?FR.[HIF(3CT1C6X6 4/Z!Y 8-!.$E?>2$)!\,!G"JGZ*C=2[3;9JCY'&M- M;>?WVGYNOFG!3S=NA*G8KM0.%&W:-+R>C &P[R-H-F:H9'FM#/(H:L>#9 MC]8;\/G&&UL?55M;]LV$/XK!
[4H4L"U9+TX MCFL;J)L66]%L1K.U'X9]H*63180B59**T_[Z'BE97B\XV^O M](.I$"TU4*:95!9V\S#T.05ULR,58.2_I1*U\S24N]"TVADA7>J11A'T32L M&9?!:N%M&[U:J-8*+G&CP;1US?
2/-0JU7P:3X&#XPG>5=89PM6C8#N_1_MUL M-*W" :7@-4K#E02-Y3)X-YFO4[??;_C*<6^.YN"4;)5Z<(O?BV40.4(H,+<. M@='G$=^C$
Z(:'SO,8,AI',\GA_0/WKMI&7+#+Y7XALÖ;+4,9@$46+)6V"]J M_QOV>C*'ERMA_C[;F<8!"WQ]JZ=R8&-9?=ESWUYW#D,(O...2]0^QV=X$\
MRUMFV6JAU1ZTVTUH;N*E>F\BQZ5+RKW5])>3GUW]H2Q"!F]@HRG1VOX)@OX M\+WE#1V]7826@KBM8=X#KCO ^ Q@ G=*VLK !UE@\=P_)'(#P_C ,F@./%XR07%!JR"CUPRF7,FX-
XRBTZN..6W@TM/P[FBF9N& MY;@,J"H,ZD<,5J]>3*;1VPMDTX%L>@E]=D0-MD)@QJ UKU[,XLGU6T!C>>T]"5FJFN<@>(EC^(Q4 M9I42!?"ZT>3M4^-)L%H1OY\NV@'45&2BN2K]\@PJ*$T*7)?
B<@?"10#RJL?/ M+_X@>002:2 (4F /X*42U,4(80YT+>5):,"FPNYN?6E)[N*3=<,4E^:C6$*YY M#7=,MB7UH%8[BZ68-NC(WX)DU&:)OX[2V;P9UGR'(\)E:V6W+ID.W]#Y%?#3< M9%.X2;-
S1S;)9I!D9R7NM#(&XE&67=,XF\P(QY@YMY<)RD;7H3^S&!VXNX^$2O#J6HU*J&YB0D[)F!E]%X M0FU1B ,*&9+!0&^63YNM-.+_,N9RY,?D5)F&1QVU1WXS[X:AZ]!*VS77P3H\
M3>^ZCOS?]NY=NV-ZQZ6A.U>2:S2^S@+0W5O1+:QJ?'_>*DO=WD\K>EY1NPWT MOU14G?W"!1@>[-4O4$L#!!0 ((N*;5E>Z2,6$ 4 -,, 9 >&PO M=V]R:W-H965TQ,#2;9! MM]@C6*?
=AZ(/M#2RB$BDEJ3BI+^^0^JPE3@N\B+SF/GXS4GZ?"O5O4X1#3SF MF= 7O=288C$]Y;E; MNU7+(U99H&(QL\;L]<>:17WQPWZC;.=;%DSC=]8 MVS.V>)',M/O"MI(-Z<2HU$;FM3+-
:]HA#4"H'C71WD6'YD MABW/E=R"LM*$9@?.5*=-Y+BP05D91;N<],SRJS0($SB#STBVZ?.A(5"[-8QJ M@*L*('@%((0O4IA4PV\BQKBK/R0R+:.@8705' 5<83& T.M#X 6C(WAA:V'H M\,
(C%FHP$FZX8"+B+(.5808IL\Q!>RNXT6$X6R0+7; (+WI4!1K5 _:6[]_Y M$^_#$;*CENSH&/JRB@)\Y#K*I"X5PM]W^&C@*I/1_3^'V![%.\RVCOE=BG M M\X*))TB9!O('*HR!"W+6 U-
H^Y2AHDRHXDIE56G$,VXX6<9$#/BSY(7%Z+MIXN*"QP]H=0:6MZZE M-1%_0)"*;P@JDR&(,IZHWW##T^TZ[]03:BZ-2Z#@>U'"MAG5V1,XF4>$< M57.-I*8IHT<$W!&35(O2)J "\ ?48YJ9YRF
MZ&F*BK=I.KB8!=]*T&5*;&/BA-7$^@U59\)ES(\FL6>;8 M5K.>SC0;ITKG@9H-I%%*)^ M$(SI=Q:,7P@I>QV=R>ZLW&E\WGEJ =>E4F3OXGF)6^#1;$3?J1_ -Y.2,5$E
MVW'U5RG.HE/MJ7$U#]E24<1*832Y=6S$OO?2/UX?L;N^+W33FPKT:>O M!FDT"" 83%^B=2B^JN[[Q]^!=\;>/33R=*(Z102,N9M&?J&UO(L': _; Z-N MVK;-K&!/KG/OF]/2)
Y*YH>$R9_,7G2:YVJ=2\(J-95.ZLW-_C8U,0#2->). M[/NN<1_PR(:,[?0[AA.=LDQA]PY]]16T#RP^Q/J,7,[F$)(%4&##&82SB1W, M(1S/W#5"A#R;YO2T3BBUP)]WBJ/Q+03]\<2G!J[)S3PO2E-
=V56S.QD''IS6 MNP;)>&.%E'RH[@AFL!YY&1$S:^Y" Y5WJ'7S'#OH9FCVKCGM :7R-6;LUUM M7^R7U4-U)UX]][\P17>V)NL24O4&TW&OZEG-Q,C"/5O7TM CV U3^M>!R@K0 M?B+I&5-/[
'M_YCE?U!+ P04 " "+BFU9C5&%C(8& "5$ &0 'AL M+W=O:.G8)BJ)+DG%<7_JOD/)DIVXWC#L92\Q29WK=VYDSM?:?+%+ M(B<>\ZRP%YVEZ])EJJ!;(VR9Y])LKBC3ZXM.U-D>W*G%TO%!
[_)\)1?TF=RO MJUN#7:-1D]J<"JMT(0S-+SK3Z-75@.D]P6^*UG9G+=B3F=9?>/,QO>B$;!!E ME#B6(/'S0-)492P(9GRM978:EE:9[^KU"TO.I..2&DN MR\S=Z?
4'JOT9LKQ$9]; %>N*=CCLB*2T3N.%=]=PP3A4[&N/BK7%7 M\5&!GVG5%?TP$'$8#X[(ZS?.]KV_A%GK7!:O%.%+!(E, '924=(LL/^5N(& MA\5QO;RR*YG010<%8F7[[5.URK+A"S2Y]$1 M;Y1-
,FU+0^*/>WITXBK3R9<_#WEQ7$^= =-M70H]%VY)XEKG*UEL?OQA$D?C MUY93717*T6F&,D]%:BV2E472,BMB!D!G9)K B9_*@MK= 8+W1ELKKJ4Q&U4L MQ#379>'$-$G*O,P0GY2/C%/?
I*_D&_2JI\2_^ *C]'3Z0 ;=1-P1MR2F^$7- M29RH E[IT(@-^])O-R0-EM/D:ZD,=*R,3LO$*A?:$:%EO!"#*(A' M$RQ.HGYP-IF(EUC'XR">A"(*N\-6RG-
NN(D6*4Y&03P>@C&&A'@HHC[8[K5# M$C['\H481\&@TAB#?]3W&H*8>7=PMQ3"P-T8',]W_[MXA[E-M<9!B0;XR2+J:I1?>.&A<]DGEXZ*7N^&D1PQI2]S:9H19F>A% M =94:(32\Q?
<(N:H7/&VD?2NDK27&&]K24^"#3.'XL0T"7$F[-!.H48:MQ5W0]I6"%5Z@MVNWF*2T@-N9JO# MZ.#2Y[E:!+SG5B)!H6::?J-B8_W9-<9(OLIDM\YFX_N.]V\KQ=O;0,*08P-M M#/IL ^,=\-
NK_TI8F_MM B+%"YT#JXQ;4^6R]0)1G.1XCC5B%&I(61$-Q,_2 MS##Z,R_V&13L!JJWS'F-P;O-#1SK6:86M3M/8_FW*1'P:)18X5845)WAWL"@ M6_247
88[DE7G/"@CEOZO1=!D\8(0AN]O]5$.1N"#*5^";1H.]/MP4)R6I1-,9*[MQ#: "\ Z]5,!Z40/S,>RF<0W![1WE[6BGRG(_B>"CDW;8Y M'FB*=W>WN\?_KG.@**E!$/=?F,%25(+FT&0S-
#7N'BS.#2IBJ=#3D'!RCR0U MY0+MB:^;>PS[76//-!;AC$Q1E)08XL$K'>17ML]2@"L)3W\ M^3'.*:ZA%<;9Q> M^8?G3#L\8_UR20B.80)\GVNX66]80-?B,N _%!+ P04 " "+BFU9R+O# M'0H$
!B"0 &0 'AL+W=O@+#8TM(A2I):DX^?L>4K+B%(Z! MOD@D-7/FS)5:[+1YM!618\^U5'895Z(84O&VUJ[K UV\0V MAG@9E&J99&EZEM1W9K706]80?.?B,N_%!+ P04 " "+BFU9R+O# M'0H$
!B"0 &0 'AL+W=O@+#8TM(A2I):DX^?L>4K+B%(Z! MOD@D-7/FS)5:[+1YM!618\^U5'895Z(84O&VUJ[K UV\0V MAG@9E&J99&EZEM1W9K706]80?.?B,N MR\S=Z?
4'JOT9LKQ$9]; %>N*=CCLB*2T3N.%=]=PP3A4[&N/BK7%7 M\5&!GVG5%?TP$'$8#X[(ZS?.]KV\ A%GK7!:O%.%+!(E, '924=(LL/^5N(& MA\5QO;RR*YG010<%8F7[[5.URK+A"S2Y]$1 M;Y1-
,FU+0^*/>WITXBK3R9<_#WEQ7$^= =-M70H]%VY)XEKG*UEL?OQA$D?C MUY93717*T6F&,DJ%:BV2E472,BMB!D!G9)K B9_*@MK= 8+W1ELKKJ4Q&U4L MQ#379>'$-$G*O,P0GY2/C%/?
I*_D&_2JI\2_^ *C]'3Z0 ;=1-P1MR2F^$7- M29RH E[IT(@-^])O-R0-EM/D:ZD,=*R,3LO$*A?:$:%EO!"#*(A' M$RQ.HGYP-IF(EUC'XR">A"(*N\-6RG-
NN(D6*4Y&03P>@C&&A'@HHC[8[K5# M$C['\H481\&@TAB#?]3W&H*8>7=PMQ3"P-T8',]W_[MXA[E-M<9!B0;XR2+J:I1?>.&A<]DGEXZ*7N^&D1PQI2]S:9H19F>A% M =94:(32\Q?
<(N:H7/&VD?2NDK27&&]K24^"#3.'XL0T"7$F[-!.H48:MQ5W0]I6"%5Z@MVNWF*2T@-N9JO# MZ.#2Y[E:!+SG5B)!H6::?J-B8_W9-<9(OLIDM\YFX_N.]V\KQ=O;0,*08P-M M#/IL ^,=\-
NK_TI8F_MM B+%"YT#JXQ;4^6R]0)1G.1XCC5B%&I(61$-Q,_2 MS##Z,R_V&13L!JJWS'F-P;O-#1SK6:86M3M/8_FW*1'P:)18X5845)WAWL"@ M6_247
88[DE7G/"@CEOZO1=!D\8(0AN]O]5$.1N"#*5^";1H.]/MP4)R6I1-,9*[MQ#: "\ Z]5,!Z40/S,>RF<0W![1WE[6BGRG(_B>"CDW;8Y M'FB*=W>WN\?_KG.@**E!$/=?F,%25(+FT&0S-
#7N'BS.#2IBJ=#3D'!RCR0U MY0+MB:^;>PS[76//-!;AC$Q1E)08XL$K'>17ML]2@"L)3W\ M^3'.*:ZA%<;9Q> M^8?G3#L\8_UR20B.80)\GVNX66]80-?B,N _%!+ P04 " "+BFU9R+O# M'0H$
!B"0 &0 'AL+W=O@+#8TM(A2I):DX^?L>4K+B%(Z! MOD@D-7/FS)5:[+1YM!618\^U5'895Z(84O&VUJ[K UV\0V MAG@9E&J99&EZEM1W9K706]80?.?B,N_%!+ P04 " "+BFU9R+O# M'0H$
!B"0 &0 'AL+W=O@+#8TM(A2I):DX^?L>4K+B%(Z! MOD@D-7/FS)5:[+1YM!618\^U5'895Z(84O&VUJ[K UV\0V MAG@9E&J99&EZEM1W9K706]80?.?B,N MR\S=Z?
4'JOT9LKQ$9]; %>N*=CCLB*2T3N.%=]=PP3A4[&N/BK7%7 M\5&!GVG5%?TP$'$8#X[(ZS?.]KV_A%GK7!:O%.%+!(E, '924=(LL/^5N(& MA\5QO;RR*YG010<%8F7[[5.URK+A"S2Y]$1 M;Y1-
,FU+0^*/>WITXBK3R9<_#WEQ7$^= =-M70H]%VY)XEKG*UEL?OQA$D?C MUY93717*T6F&,DJ%:BV2E472,BMB!D!G9)K B9_*@MK= 8+W1ELKKJ4Q&U4L MQ#379>'$-$G*O,P0GY2/C%/?
I*_D&_2JI\2_^ *C]'3Z0 ;=1-P1MR2F^$7- M29RH E[IT(@-^])O-R0-EM/D:ZD,=*R,3LO$*A?:$:%EO!"#*(A' M$RQ.HGYP-IF(EUC'XR">A"(*N\-6RG-
NN(D6*4Y&03P>@C&&A'@HHC[8[K5# M$C['\H481\&@TAB#?]3W&H*8>7=PMQ3"P-T8',]W_[MXA[E-M<9!B0;XR2+J:I1?>.&A<]DGEXZ*7N^&D1PQI2]S:9H19F>A% M =94:(32\Q?
<(N:H7/&VD?2NDK27&&]K24^"#3.'XL0T"7$F[-!.H48:MQ5W0]I6"%5Z@MVNWF*2T@-N9JO# MZ.#2Y[E:!+SG5B)!H6::?J-B8_W9-<9(OLIDM\YFX_N.]V\KQ=O;0,*08P-M M#/IL ^,=\-
NK_TI8F_MM B+%"YT#JXQ;4^6R]0)1G.1XCC5B%&I(61$-Q,_2 MS##Z,R_V&13L!JJWS'F-P;O-#1SK6:86M3M/8_FW*1'P:)18X5845)WAWL"@ M6_247
88[DE7G/"@CEOZO1=!D\8(0AN]O]5$.1N"#*5^";1H.]/MP4)R6I1-,9*[MQ#: "\ Z]5,!Z40/S,>RF<0W![1WE[6BGRG(_B>"CDW;8Y M'FB*=W>WN\?_KG.@**E!$/=?F,%25(+FT&0S-
#7N'BS.#2IBJ=#3D'!RCR0U MY0+MB:^;>PS[76//-!;AC$Q1E)08XL$K'>17ML]2@"L)3W\ M^3'.*:ZA%<;9Q> M^8?G3#L\8_UR20B.80)\GVNX66]80-

3W_#<^@?!)S1X@P"UP'?]<,#>$$3 M=V#Q@@-Q*ZCBVQ=>Y1WN]S:51]YDWOP$T&8YZ)4H%7)0#M#'! U!6S MR35,RXQ*HH54YS#%=L/R1&0H,BZ4.H&%%!DD.#K+2PP8L.V@,1:N@M?@.6X_MP&N[YX2] $Y>\D^9JB&0_1;!@1SM,9N:/$(0>]"·PMY>%#-4V O-4+'C^2X: MC6@NL/ ,\?,Z]6M;ZS0]0\XQ)(B[RS#%F-C5H"]3VG,@PDC>;&A[)T%T=ZPOL(Y)DT&U8T,*J+[MWT UQGY840AC-/Z)8AI-WM_-QZ-SN+Z9SB?3N\GT%[BY'7^\FD]NIK.MROZY MR*[2/[$!XPJD 5<_2%8DQ[E&N@O")#P07MH271,I"=IP1NX99YJA!-J^$\=& M/6]>Q;[GOZVQ, WYAA^V7)-N0^PPK[;G]&(CUQUJ/UZ4MI7@ @ETL< 5UGF#(?T MG1Y6WS-4M/B-&/LXFWTG Z3Z?7-AS&TW] ,9B>');%G'?KW MNI%M..:+Z8_ >>O@?UQM7[6<2C3=35\QR^B!O62WV4MVC]Y+7J%ZTTVR9C0I M926\6/"2[-$6YU?BZPHM>6Y?P-ZY&[S(*_].^COV#5\^J903IL2>(*$$Z78 M@B%@.[:O MS'5U(&W>-L?YJ^H4NS6O_@OX0.22(6-.%^CJGO503+(Z7UV*DI1*8X#?%P)#K1_ ,V?'(._ %!+ P04 " "+BFU9AX.:%N$# 9 M"0 &0 'AL+W=OO?AYCX(>P%-;,F5Y)#VU]]*!H>TA,D76Y)WGWV> M74GKX5:J![U!-/!4Y$*/O(TQY<#W=;K!@ND+6:*@+RNI"F9HJM:^+A6RS#D5 MN1]V.EV_8%QXXZ%;NU/CH:O,S@7>*=!543#U8XJYW(Z\P-LOW//UQM@%?SPL MV1KG:+Z5=XIF?H.2\0*%YE* PM7(FP2#:6SMG<'?'+?Z8 Q6R5+*!SN992.O M8PEACJFQ"(Q>CWB%>6Z!B,;W':;7A+2.A^,]^A]..VE9,HU7,O^'9V8S\OH> M9+AB56[NY?9/W.E1+9)+%XJ<^V>L*UM>QT/TDH;6>RS ! C$ M=2]%X:+"#+Z6J)A-FX;6@BUSU.=#WU \Z^6G.^QIC1V^@AW!%P+<:+@6&68O M_7WBV9 -]V2GX4G .987$'7:1#B,3^!%C?C(X44GQ&NH]1V35WO'Q[WM<1GH MDJ4X\N@\:%2/Z(W?OPNZG8\GN,4-M_@4^IC*44K-UV"C$%\4$*H7!8HF]J8=]1-#B LQ&5IJ) M3)_#+5TK"A^1J,(9)((>/>-VV _A2FH#<@4DD6K0BI)+.(=6V$ZB+@WF=$RM M5$*AW:X>T-A9*T@2:Q6THRB@P6<4)#YW5BRCT\&ULAUZ30BK# M?[HLV9!<&";6W.:*:8U&P_MW_3 (/Q*-OO6[E>*#K/.*4:79D$Q\HGM08QL$ M26K%CH8%O\=4K@7_23FIB[)&8>Q0\VQ7&8B#L EQ([4&6LN(I3;<5,J232S@ MWH0J+0M:S+8XO WQZJ54_HLVAE$_8"}>SNA_50*?-\(O\>/>-VV RGU\OYG!5*653LTLY M ;T2: *3)-65(".%*?)'NZOKZ&=P&9 HVD]&*DY:X\L0[A26C&?["FWV">JB MI2]C)E$?%M+0CDG?2@:"=A &;D>\V6< 7UUT\;M3'/]*@+@>L3M!Z,Q2ZB9P M,YM,9S>SQ>SZ.;@@3TTE[2?EM00@R M27IP[";T#]I5@6KMFK(&1ZGN7,UJT_84+,<5N78N>HD' MJF[$]<3(TC6_I3342MUP0_\NJ*P!?5])Z@&[B0W0_ V- P=02P,$% @ MBXIM65>]Z@8T P)0L !D !X;"]W;W)K&UL MK59K3]LP%/TK5QF:F,1(FKX8:RM!6S2FP2H*[,.T#VYRTU@D=F8[+?S[V4G(MVI)F,.5+X]KJ&S^.1S'YA7:QU+/!2J7A<@'4&,67Y MESP6.FP -$\UP"T [BZ@LP?0+@#MUP(Z!:#S6D"W &2EVWGMF7 3HLAH(/@: MA%FMV4PC4S]#:[TH,^=DKH2>I1J G1M=<(;CP$>;Y00$>P)PN&0VH1YB",_C M*5.4+6'&(^I1E' X045H).$6'U5*H@\:?C>?P.'!!S@ RN VY*DDS)<#6^D< M323;*_(YS_-Q]^33ABO.5"AARGSTM_&VKJTLT"TN\-RM)9QC<@QMYPA&MO?#)ZZ.W*^#3>OC7E.U+?DN,=KG;[8ROLX=O&@28W4RX9!Z/ M$6{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

*(57QB7V-!Z@] :7Y4%H I5$H+832(A3-U&]M8GAV$^-':V6%;];*ACD_L[>B ML]:@?@641J&T$$J+4#13:[5?X=G]BHZUVVLENM7+<.G=J.&X6 M2ZC; J4%4!J%TD(H+4+13+'5;HMG=UNLQ?*:+W+!E^3JGHNT6*BG? 8N711/ MB)>S5 ^NK^C70WN!A#X6 J7Y4%H I5$H+832(A3-U&SMWW@=_9O.DU6]!]J&PO=V]R:W-H965T.*4Q]:7KZKR$BNH+68/ G:U4%34X53M7UPIHT9HJ M[@:>E[@59<+)TG;M1F6I; QG FX4T4U54?7G"KC<+QS?>5ZX9;O2V 4W2VNZ M@S68^_I&X$;: (=69O6BAJ:I4KWB;)JC&8';6U:-V;#A+W%M5&XNR]!GLA_2 /*] MG*+M?X|C)AU/R@3!!DK9 M:"H*G;H&Z>P9;MZ37'4DP1&2-=07)/3.2. %T81]^;;)6R..V5VLR5"88"A, MT,:+CL2[L\ER206I%1,YJRDGM)*-,%.I=;&2-I9]<1XS/XC#)'4?#S.84(6> MYPVJ%Z#A !J^"7H-6E^21B"<,NPO%/@4XQ453.>6EN!M$*9U0T4.))?:3-Y-M=T9\@'8>1!]'_%.B))G&CP;\Z.TZ2X.5MW@NW",-7Y='7|>CUG_IWK!F@RLR3N+>8MGZD'(%/ M 2>O'T&PO=V]R:W-H965T6V. M[?&&\6>1 $CTDJ543(Q$RGQDFB)*(,/BAN5 U9CED4A7)ASI$HL@GN}(VWCGNR2J3N,-.QCE?P M /2_4*&+W%M5&XNR]!GLA_2 /*] MG*+M?X|C)AU/R@3!!DK9 M:"H*G;H&Z>P9;MZ37'4DP1&2-=07)/3.2. %T81]^;;)6R..V5VLR5"88"A, MT,:+CL2[L\ER206I%1,YJRDGM)*-,%.I=;&2-I9]<1XS/XC#)'4?#S.84(6> MYPVJ%Z#A !J^"7H-6E^21B"<,NPO%/@4XQ453.>6EN!M$*9U0T4.))?:3-Y-M=T9\@'8>1!]'_%.B))G&CP;\Z.TZ2X.5MW@NW",-7Y='7|>CUG_IWK!F@RLR3N+>8MGZD'(%/ M 2>O'T&PO=V]R:W-H965T6V. M[?&&\6>1 $CTDJ543(Q$RGQDFB)*(,/BAN5 U9CED4A7)ASI$HL@GN}(VWCGNR2J3N,-.QCE?P M /2_4*&+W%M5&XNR]!GLA_2 /*] MG*+M?X|C)AU/R@3!!DK9 M:"H*G;H&Z>P9;MZ37'4DP1&2-=07)/3.2. %T81]^;;)6R..V5VLR5"88"A, MT,:+CL2[L\ER206I%1,YJRDGM)*-,%.I=;&2-I9]<1XS/XC#)'4?#S.84(6> MYPVJ%Z#A !J^"7H-6E^21B"<,NPO%/@4XQ453.>6EN!M$*9U0T4.))?:3-Y-M=T9\@'8>1!]'_%.B))G&CP;\Z.TZ2X.5MW@NW",-7Y='7|>CUG_IWK!F@RLR3N+>8MGZD'(%/ M 2>O'T&PO=V]R:W-H965T6V. M[?&&\6>1 $CTDJ543(Q$RGQDFB)*(,/BAN5 U9CED4A7)ASI$HL@GN}(VWCGNR2J3N,-.QCE?P M /2_4*&+W%M5&XNR]!GLA_2 /*] MG*+M?X|C)AU/R@3!!DK9 M:"H*G;H&Z>P9;MZ37'4DP1&2-=07)/3.2. %T81]^;;)6R..V5VLR5"88"A, MT,:+CL2[L\ER206I%1,YJRDGM)*-,%.I=;&2-I9]<1XS/XC#)'4?#S.84(6> MYPVJ%Z#A !J^"7H-6E^21B"<,NPO%/@4XQ453.>6EN!M$*9U0T4.))?:3-Y-M=T9\@'8>1!]'_%.B))G&CP;\Z.TZ2X.5MW@NW",-7Y='7|>CUG_IWK!F@RLR3N+>8MGZD'(%/ M 2>O'T&PO=V]R:W-H965T6V. M[?&&\6>1 $CTDJ543(Q$RGQDFB)*(,/BAN5 U9CED4A7)ASI$HL@GN}(VWCGNR2J3N,-.QCE?P M /2_4*&+W%M5&XNR]!GLA_2 /*] MG*+M?X|C)AU/R@3!!DK9 M:"H*G;H&Z>P9;MZ37'4DP1&2-=07)/3.2. %T81]^;;)6R..V5VLR5"88"A, MT,:+CL2[L\ER206I%1,YJRDGM)*-,%.I=;&2-I9]<1XS/XC#)'4?#S.84(6> MYPVJ%Z#A !J^"7H-6E^21B"<,NPO%/@4XQ453.>6EN!M$*9U0T4.))?:3-Y-M=T9\@'8>1!]'_%.B))G&CP;\Z.TZ2X.5MW@NW",-7Y='7|>CUG_IWK!F@RLR3N+>8MGZD'(%/ M 2>O'T&PO=V]R:W-H965T6V. M[?&&\6>1 $CTDJ543(Q$RGQDFB)*(,/BAN5 U9CED4A7)ASI$HL@GN}(VWCGNR2J3N,-.QCE?P M /2_4*&+W%M5&XNR]!GLA_2 /*] MG*+M?X|C)AU/R@3!!DK9 M:"H*G;H&Z>P9;MZ37'4DP1&2-=07)/3.2. %T81]^;;)6R..V5VLR5"88"A, MT,:+CL2[L\ER206I%1,YJRDGM)*-,%.I=;&2-I9]<1XS/XC#)'4?#S.84(6> MYPVJ%Z#A !J^"7H-6E^21B"<,NPO%/@4XQ453.>6EN!M$*9U0T4.))?:3-Y-M=T9\@'8>1!]'_%.B))G&CP;\Z.TZ2X.5MW@NW",-7Y='7|>CUG_IWK!F@RLR3N+>8MGZD'(%/ M 2>O'T&PO=V]R:W-H965T6V. M[?&&\6>1 $CTDJ543(Q$RGQDFB)*(,/BAN5 U9CED4A7)ASI$HL@GN}(VWCGNR2J3N,-.QCE?P M /2_4*&+W%M5&XNR]!GLA_2 /*] MG*+M?X|C)AU/R@3!!DK9 M:"H*G;H&Z>P9;MZ37'4DP1&2-=07)/3.2. %T81]^;;)6R..V5VLR5"88"A, MT,:+CL2[L\ER206I%1,YJRDGM)*-,%.I=;&2-I9]<1XS/XC#)'4?#S.84(6> MYPVJ%Z#A !J^"7H-6E^21B"<,NPO%/@4XQ453.>6EN!M$*9U0T4.))?:3-Y-M=T9\@'8>1!]'_%.B))G&CP;\Z.TZ2X.5MW@NW",-7Y='7|>CUG_IWK!F@RLR3N+>8MGZD'(%/ M 2>O'T&PO=V]R:W-H965T6V. M[?&&\6>1 $CTDJ543(Q$RGQDFB)*(,/BAN5 U9CED4A7)ASI$HL@GN}(VWCGNR2J3N,-.QCE?P M /2_4*&+W%M5&XNR]!GLA_2 /*] MG*+M?X|C)AU/R@3!!DK9 M:"H*G;H&Z>P9;MZ37'4DP1&2-=07)/3.2. %T81]^;;)6R..V5VLR5"88"A, MT,:+CL2[L\ER206I%1,YJRDGM)*-,%.I=;&2-I9]<1XS/XC#)'4?#S.84(6> MYPVJ%Z#A !J^"7H-6E^21B"<,NPO%/@4XQ453.>6EN!M$*9U0T4.))?:3-Y-M=T9\@'8>1!]'_%.B))G&CP;\Z.TZ2X.5MW@NW",-7Y='7|>CUG_IWK!F@RLR3N+>8MGZD'(%/ M 2>O'T&PO=V]R:W-H965TZRG;4-)&Z*;8&V08)VL8^,-+:)4*1*4G;R M]TM2LB([LIH8!O;%%J69,W/.D$-RLN'B0:X %'K,*9-39Z54<>&Z,EU!CN6 M%\#TEP47.59Z*):N+ 3@S#KEU T\+W%S3)@SF]AW-V(VX:6BA,&-0++, MKH#RS=3QG>V+6[)<*?/"G4T*O(0[4#^*&Z%';H.2D1R8))PA 8NI<^E?S/W M.%B+GP0VLO6,#)5[SA_,X',V=3R3$5!(E8' ^F|-RJFTOVA3VWH.2DNI M>%X[ZPQRPJI_ %@+T7((X@,.0>T0O-8AK!U"2[3*$-+ZB:603?(&&L-9IY ML-I8;\V&,%/&.R7T5Z+]U.P;5X#\&'U U[]*HI[09Y8",]*B&XJ9U!_N%$\?MT/?"RGYI9#=V9QJ!84+E>VWQ#KE(KK .7&53LI NVF=P%650' @@1!]Y4RM M)+IF&60=_O-^?S_H 7"U&HTDP5:2JZ 7\0Z* 0J]]U))A5E&V/(<<5L%BS/X/L>]Y>[7OC7]D[8<-MN^'1[$ZY"(8O%0'TJE=5SGC>PJOKD4-V58Y";UXOQ;]D8^< M8W|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|\>?#89AP QV^DVW;]H$/)\9'KX9/_QL M7SXFZ>=LRGE.OLYG:SGM[O#WKS,(H[5Y>KQV[3]\MDF<^BF-^7#/9.YV'Z[0V?)8^O.XG DH]\#[Z&&-EP_TKBX7X0. X_GOBJNT^*VW52;1G,=9E,0DY?>O.J^UB\ :E@U6 M2_PGXH_9SL^D?"F?DN1S^Z,[JQ1MD]DO.J,.F?#[<#G+WR>/+]>D%5ZXV26 MK?XEC]6R_0X9+[,\F5>-BQ',HWC]?_BU>B-V&FC&D09ZU4#?:V >Z\&H&AA- M&YA5 W-*

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{QA9Z(PB M,8;$ A F16JTC=1(O02]RD7TZ2,Q%8AX2\Y$816(,B04@3{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|^K@_>$/?3J@;4.)%*SH9I3:::=JPUQHKQY4\Z$:A6H,J@4H30ZD M*!/1U64B;788]JG6$8(6AT U!ZJY4,V#:CY4HU"-0;4 I@GBD3V MCW]ZW@:Q@_%]N9]$;C;E+E++;;>>H)H-U1RHYD(U#ZKY4(U"-0;5 I0FYTZ4E!C/ M=:61]EM/ZJ&T#BJTB 2J.5#-A6H>5/.A&H5J#*H%QN%E;4;#W4)[.8&BAL0X M44/RJVR'J4?5.HS0N49>9[*Z% MMJGM4K.MPX2]=PWVYC78N]= ZTF@F_5*%1C4"U :7+H1#V)<:*>Y$>N@D++ M3:"::#=4 M*=;Y:!1'|^5LL;J&9#-0>JN5#-@VH^5*-0C4&U *7).12%)\:3[W[S MK%MKT#OA0#4;JCE0S85J'E3SH1J%:@RJ!95V=$M2OJNW*%PQFQ>NJ.;$\.O) M.5'=4]M\034;JCE0S85J'E3SH1J%:@RJ!2A-SJ$H9#%_GD(6]5!:!Q5:R +5 M'*CF0C4/JOE0C4(U!M4"|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|(\O+J<[2!7 _/9K/R@E6A1B_(@=U_91DO+[(CC: MQ1N]TSMXW-$N?M-[`G>U"Z_N<5^[>%?WN*-?_%;GN_K%VIK'?2%WEB=WCKZW! M!2O^ M0],RR>&9/,]_1+OXI&$I^4"Q?/W29)O?BD[>$S2SZNW^.K_4$L#!!0 (M (N*;5F<[]4M^00 ,3 9 >&PO=V]R:W-H965TZRHSH&$B=&6R!ML-EV401]8*1Q1*PD>DDJ3OZ^ M0TF6;[3BIBGV)9&&/#.<,Q>/.%YR\56F(H\YUDASWNI4HO(LF2<0D[E@"^@ MP)4Y%SE5^"H>+;D00),*E&>6:]NAE5-6]";C2G8K)F->JHP5<"N(+/.@_EC<"GRS6BT)RZ&0C!=$P/R\=^%$,|?5 M@&K'GPR6./^J7WY)SGNV/A%D$"NM@N*_)YA"EFE->(YOC=)>:U,# M-Y]7VF>5|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|=Z8![+6Q.S5F#TKYC6+,_W] -'-AH;J)&XE4ASM,P'A+>N: M0_'PRWO%13EEHP1V(:1G7AMX5[3TU;W>\,>R%H3=MV[87OS9H"=I0>:ASG, MIP0+]64!&4JZ[F"F>_QW^4\Z6+UYNTI>&:0Z\ =M\8:RUH1?-WG8WN7E\ %D MGW+Z'<[=-F[A+A8SM]WN&03-9;1]";V!_XBF#]==']:W?6_ O[^8+B?"7K-Z MZZ23Z5GUM-WMWI!_1(.(ZPX1VUO$&O*P574Y;;/T<]NEGT'*5%7;U]";^(_H M#W'=(&)[AWC6UXS2QCN?,PQ2IN\99QE[?-=8<[UUTX;M?79NU$#.N/3!46WZG M(S.)F18_:$LVE+4FR[HIP_:NK'Y;]TJVQRMI:+3@99NVN9[7C]D][*)_GECI^(BT SS>NKQ-,Q!\"" [$Q1KJ4,6//>O(CZ5F.9@0IQ%)#8'69PPVDJ492/%Y* M4*MZID[<'*_0OYGB53%C+,"&I4\DD;.>U;90 A-2@$!GMR Q2<6Y2A Z471MJ;CI M)]AQR6.PY.&]P\-']XS*F4!W-(%D.]]6-56%>:O"!EXCX CR2^0[7Y#G>$$- MGYN/I_L-=/RJS[!"]|!T\U+5KT3&[TCM.S9>5W3EJ"A =5OY+P?>5'|<;KV M?+.6FK!6Z+3#H(K;(AU4I(-&TC\)'I.4R#?TA#G'5 KT]QZR,?!_=60;P?1^ M='5R'$//4AN. #X'J_ YDQLY7^OD.1+85MUA57=X"K"/16",/0[WHY8^V%1 MT&EWVDZ]6%%%.FHD??=2**4N)ZG?$RO1KQ#]3H2V%;IK:KTUBGT:NT)X;9=M-]B1:S_*[S@MKUZL=L6XWIU<9_U]= Y3ZI$2)5Z=/8P>U0>O2;9FX$-U.Q;: M=ALV;()["NE*U"WM/-?=D:XFR@\B_QWIO#5GKY&S,3$7 [,A#O&;,I\27>M] M<0IZ_ 7]SHV5;!2Q\1$'BW@DM.V&K#V(>Q(3XN[;"S=P [^S*V--G+8KNT+: M&W8U SXU+EZ@F!54+@U>M5J=%*Z-/]Y9'^@3A+'!:YCE|>,>|RFA J4P49#. M94N1XDM'OYQ(EAM3/&9266PSG*E3$' =H.Y/F#+&Y40_H#I7]?\#4$L#!!0 M ((N*;5DP&GKK,P8 +8D 9 >&PO=V]R:W-H965T4Q=:M;,%-[DB1(&'+&7RLK-2:GW1[+3&2S(CZNOZ5NB[;ATEH1EADG(& M!%E<=J[@11P4#H7%GY38.2S+AZ5\T4:O+SK #$K+ FU1]YO2J+O^"^LNUUP'PC%<\J9YU!1EGY'S]41.PXZ#AV!U0YH$.'L,4AJ!R" MYSJ$E4-8,%-"*7B(L<+CD>#W0.36.EI^49!9>&OXE.7]/E-"_TJUGQK_P14! MJ ?.0$SEG#-%V88DX-.:")QWC-2_S'2Q)9N4 +YHM7H=$X5I*M]H^Z^S&+Q^ M]0:|I2!+RN^D9@EZ\RNVZS VUY!: C[JIE03O64*2??^NQEF# M18]@KY$SX(RLWX&@]U8#1]$EG\GSW0.+>^QV_WW#VEK?0Q/471<4|<*VKM.C M F5SGA'P.N524[\0/ /);@_QNH?>J;M=0\J_&#KBK*M?M%6/EALQ\0CKK; M77I,F[-^.-@WBIU)Y\/8A5SC.;GLZ'%*KEG?'//\%^[Q<')6%-25A$#UHH MF6R$($P!+"51,D?;PL:%C8+03^8E5SZ#Q9Z"[7$:U9Q&SC+[PA5.]5#T3&9M MQ)8-1#MUTSNH+&<*Q|(5&64*(6IJ>8^%?LU"WUE9-].KZ^G-],OT_"4[72T^B62+41!/S]D61W1/QCP^V,>6Q5^0P6>PJVQ^5YS>7Y MD_.>(%NB"|=&VKG1>P-X,$=-3)L0#='!1.:,XD2,L-?HLMX3%2.+Z5KBE-BU M4|| <19$YP=(;58H"OH'6-W)G IV1X1")B9UOV4+8'6B5KBE!6B<:&U/I>[LN)?YFK GTI:5+-_E;XIGH,H5'Y3TK, MV)W=J>@;_0B=2FM\HU=H0%=\4LS\-)_[K6C[MO':Z&[3RH#[$L(/-LH/NJ?? M]-D+4W!"%EP+H6HIJY>G+?.=*U&K-O[:#Y\1HN1J6W#<]1"2"-&D5N,W@JR MQC1YU&"R$..E+-O?\;+2Y4E+5G3YC!8C4PU'P;'%KD:^(K=\|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|)0(U&43'[|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|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|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|>3<[EA.GSRD_/G,L<"R\|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end XML 93 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}if(e).style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p,;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 94 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px

solid #acf; } / Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 96 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html2043531true850false6 falsefalseR1.htm000 - Document - Document And Entity InformationSheethttp://aytubio.com/20240930/role/statement-document-and-entity-informationDocument And Entity InformationCover1 falsefalseR2.htm001 - Statement - Unaudited Consolidated Balance SheetsSheethttp://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheetsUnaudited Consolidated Balance SheetsStatements2 falsefalseR3.htm002 - Statement - Unaudited Consolidated Balance Sheets (Parentheticals)Sheethttp://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets-parentheticalsUnaudited Consolidated Balance Sheets (Parentheticals)Statements3 falsefalseR4.htm003 - Statement - Unaudited Consolidated Statements of OperationsSheethttp://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operationsUnaudited Consolidated Statements of OperationsStatements4 falsefalseR5.htm004 - Statement - Unaudited Consolidated Statements of Stockholders' EquitySheethttp://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-stockholders-equityUnaudited Consolidated Statements of Stockholders' EquityStatements5 falsefalseR6.htm005 - Statement - Unaudited Consolidated Statements of Cash FlowsSheethttp://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flowsUnaudited Consolidated Statements of Cash FlowsStatements6 falsefalseR7.htm006 - Disclosure - Note 1 - Nature of BusinessSheethttp://aytubio.com/20240930/role/statement-note-1-nature-of-businessNote 1 - Nature of BusinessNotes7 falsefalseR8.htm007 - Disclosure - Note 2 - Summary of Significant Accounting PoliciesSheethttp://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policiesNote 2 - Summary of Significant Accounting PoliciesNotes8 falsefalseR9.htm008 - Disclosure - Note 3 - RevenueSheethttp://aytubio.com/20240930/role/statement-note-3-revenueNote 3 - RevenueNotes9 falsefalseR10.htm009 - Disclosure - Note 4 - InventoriesSheethttp://aytubio.com/20240930/role/statement-note-4-inventoriesNote 4 - InventoriesNotes10 falsefalseR11.htm010 - Disclosure - Note 5 - Property and EquipmentSheethttp://aytubio.com/20240930/role/statement-note-5-property-and-equipmentNote 5 - Property and EquipmentNotes11 falsefalseR12.htm011 - Disclosure - Note 6 - LeasesSheethttp://aytubio.com/20240930/role/statement-note-6-leasesNote 6 - LeasesNotes12 falsefalseR13.htm012 - Disclosure - Note 7 - Intangible AssetsSheethttp://aytubio.com/20240930/role/statement-note-7-intangible-assetsNote 7 - Intangible AssetsNotes13 falsefalseR14.htm013 - Disclosure - Note 8 - Accrued LiabilitiesSheethttp://aytubio.com/20240930/role/statement-note-8-accrued-liabilitiesNote 8 - Accrued LiabilitiesNotes14 falsefalseR15.htm014 - Disclosure - Note 9 - Other LiabilitiesSheethttp://aytubio.com/20240930/role/statement-note-9-other-liabilitiesNote 9 - Other LiabilitiesNotes15 falsefalseR16.htm015 - Disclosure - Note 10 - Revolving Credit FacilitySheethttp://aytubio.com/20240930/role/statement-note-10-revolving-credit-facilityNote 10 - Revolving Credit FacilityNotes16 falsefalseR17.htm016 - Disclosure - Note 11 - Long-term DebtSheethttp://aytubio.com/20240930/role/statement-note-11-longterm-debtNote 11 - Long-term DebtNotes17 falsefalseR18.htm017 - Disclosure - Note 12 - Fair Value MeasurementsSheethttp://aytubio.com/20240930/role/statement-note-12-fair-value-measurementsNote 12 - Fair Value MeasurementsNotes18 falsefalseR19.htm018 - Disclosure - Note 13 - Commitments and ContingenciesSheethttp://aytubio.com/20240930/role/statement-note-13-commitments-and-contingenciesNote 13 - Commitments and ContingenciesNotes19 falsefalseR20.htm019 - Disclosure - Note 14 - Stockholders' EquitySheethttp://aytubio.com/20240930/role/statement-note-14-stockholders-equityNote 14 - Stockholders' EquityNotes20 falsefalseR21.htm020 - Disclosure - Note 15 - Equity Incentive PlansSheethttp://aytubio.com/20240930/role/statement-note-15-equity-incentive-plansNote 15 - Equity Incentive PlansNotes21 falsefalseR22.htm021 - Disclosure - Note 16 - WarrantsSheethttp://aytubio.com/20240930/role/statement-note-16-warrantsNote 16 - WarrantsNotes22 falsefalseR23.htm022 - Disclosure - Note 17 - Earnings Per ShareSheethttp://aytubio.com/20240930/role/statement-note-17-earnings-per-shareNote 17 - Earnings Per ShareNotes23 falsefalseR24.htm023 - Disclosure - Note 18 - License AgreementsSheethttp://aytubio.com/20240930/role/statement-note-18-license-agreementsNote 18 - License AgreementsNotes24 falsefalseR25.htm024 - Disclosure - Note 19 - Restructuring CostsSheethttp://aytubio.com/20240930/role/statement-note-19-restructuring-costs-Note 19 - Restructuring CostsNotes25 falsefalseR26.htm025 - Disclosure - Note 20 - Discontinued OperationsSheethttp://aytubio.com/20240930/role/statement-note-20-discontinued-operationsNote 20 - Discontinued OperationsNotes26 falsefalseR27.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes27 falsefalseR28.htm995472 - Disclosure - Significant Accounting Policies (Policies)Sheethttp://aytubio.com/20240930/role/statement-significant-accounting-policies-policiesSignificant Accounting Policies (Policies)Policieshttp://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies28 falsefalseR29.htm995473 - Disclosure - Note 3 - Revenue (Tables)Sheethttp://aytubio.com/20240930/role/statement-note-3-revenue-tablesNote 3 - Revenue (Tables)Tableshttp://aytubio.com/20240930/role/statement-note-3-revenue29 falsefalseR30.htm995474 - Disclosure - Note 4 - Inventories (Tables)Sheethttp://aytubio.com/20240930/role/statement-note-4-inventories-tablesNote 4 - Inventories (Tables)Tableshttp://aytubio.com/20240930/role/statement-note-4-inventories30 falsefalseR31.htm995475 - Disclosure - Note 5 - Property and Equipment (Tables)Sheethttp://aytubio.com/20240930/role/statement-note-5-property-and-equipment-tablesNote 5 - Property and Equipment (Tables)Tableshttp://aytubio.com/20240930/role/statement-note-5-property-and-equipment31 falsefalseR32.htm995476 - Disclosure - Note 6 - Leases (Tables)Sheethttp://aytubio.com/20240930/role/statement-note-6-leases-tablesNote 6 - Leases (Tables)Tableshttp://aytubio.com/20240930/role/statement-note-6-leases32 falsefalseR33.htm995477 - Disclosure - Note 7 - Intangible Assets (Tables)Sheethttp://aytubio.com/20240930/role/statement-note-7-intangible-assets-tablesNote 7 - Intangible Assets (Tables)Tableshttp://aytubio.com/20240930/role/statement-note-7-intangible-assets33 falsefalseR34.htm995478 - Disclosure - Note 8 - Accrued Liabilities (Tables)Sheethttp://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-tablesNote 8 - Accrued Liabilities (Tables)Tableshttp://aytubio.com/20240930/role/statement-note-8-accrued-liabilities34 falsefalseR35.htm995479 - Disclosure - Note 9 - Other Liabilities (Tables)Sheethttp://aytubio.com/20240930/role/statement-note-9-other-liabilities-tablesNote 9 - Other Liabilities (Tables)Tableshttp://aytubio.com/20240930/role/statement-note-9-other-liabilities35 falsefalseR36.htm995480 - Disclosure - Note 11 - Long-term Debt (Tables)Sheethttp://aytubio.com/20240930/role/statement-note-11-longterm-debt-tablesNote 11 - Long-term Debt (Tables)Tableshttp://aytubio.com/20240930/role/statement-note-11-longterm-debt36 falsefalseR37.htm995481 - Disclosure - Note 12 - Fair Value Measurements (Tables)Sheethttp://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-tablesNote 12 - Fair Value Measurements (Tables)Tableshttp://aytubio.com/20240930/role/statement-note-12-fair-value-measurements37 falsefalseR38.htm995482 - Disclosure - Note 15 - Equity Incentive Plans (Tables)Sheethttp://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-tablesNote 15 - Equity Incentive Plans (Tables)Tableshttp://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans38 falsefalseR39.htm995483 - Disclosure - Note 16 - Warrants (Tables)Sheethttp://aytubio.com/20240930/role/statement-note-16-warrants-tablesNote 16 - Warrants (Tables)Tableshttp://aytubio.com/20240930/role/statement-note-16-warrants39 falsefalseR40.htm995484 - Disclosure - Note 17 - Earnings Per Share (Tables)Sheethttp://aytubio.com/20240930/role/statement-note-17-earnings-per-share-tablesNote 17 - Earnings Per Share (Tables)Tableshttp://aytubio.com/20240930/role/statement-note-17-earnings-per-share40 falsefalseR41.htm995485 - Disclosure - Note 20 - Discontinued Operations (Tables)Sheethttp://aytubio.com/20240930/role/statement-note-20-discontinued-operations-tablesNote 20 - Discontinued Operations (Tables)Tableshttp://aytubio.com/20240930/role/statement-note-20-discontinued-operations41 falsefalseR42.htm995486 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)Sheethttp://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textualNote 2 - Summary of Significant Accounting Policies (Details Textual)Details42 falsefalseR43.htm995487 - Disclosure - Note 3 - Revenue (Details Textual)Sheethttp://aytubio.com/20240930/role/statement-note-3-revenue-details-textualNote 3 - Revenue (Details Textual)Detailshttp://aytubio.com/20240930/role/statement-note-3-revenue-tables43 falsefalseR44.htm995488 - Disclosure - Note 3 - Revenue - Disaggregation of Revenue (Details)Sheethttp://aytubio.com/20240930/role/statement-note-3-revenue-disaggregation-of-revenue-detailsNote 3 - Revenue - Disaggregation of Revenue (Details)Details44 falsefalseR45.htm995489 - Disclosure - Note 4 - Inventories (Details Textual)Sheethttp://aytubio.com/20240930/role/statement-note-4-inventories-details-textualNote 4 - Inventories (Details Textual)Detailshttp://aytubio.com/20240930/role/statement-note-4-inventories-tables45 falsefalseR46.htm995490 - Disclosure - Note 4 - Inventories - Schedule of Inventories (Details)Sheethttp://aytubio.com/20240930/role/statement-note-4-inventories-schedule-of-inventories-detailsNote 4 - Inventories - Schedule of Inventories (Details)Details46 falsefalseR47.htm995491 - Disclosure - Note 5 - Property and Equipment (Details Textual)Sheethttp://aytubio.com/20240930/role/statement-note-5-property-and-equipment-details-textualNote 5 - Property and Equipment (Details Textual)Detailshttp://aytubio.com/20240930/role/statement-note-5-property-and-equipment-tables47 falsefalseR48.htm995492 - Disclosure - Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)Sheethttp://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-detailsNote 5 - Property and Equipment - Schedule of Property and Equipment (Details)Details48 falsefalseR49.htm995493 - Disclosure - Note 6 - Leases (Details Textual)Sheethttp://aytubio.com/20240930/role/statement-note-6-leases-details-textualNote 6 - Leases (Details Textual)Detailshttp://aytubio.com/20240930/role/statement-note-6-leases-tables49 falsefalseR50.htm995494 - Disclosure - Note 6 - Leases - Lease Cost (Details)Sheethttp://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-detailsNote 6 - Leases - Lease Cost (Details)Details50 falsefalseR51.htm995495 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details)Sheethttp://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-detailsNote 6 - Leases - Lease Balance Sheet Information (Details)Details51 falsefalseR52.htm995496 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals)Sheethttp://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticalsNote 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals)Details52 falsefalseR53.htm995497 - Disclosure - Note 6 - Leases - Schedule of Lease Liability Maturity (Details)Sheethttp://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-detailsNote 6 - Leases - Schedule of Lease Liability Maturity (Details)Details53 falsefalseR54.htm995498 - Disclosure - Note 7 - Intangible Assets (Details Textual)Sheethttp://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textualNote 7 - Intangible Assets (Details Textual)Detailshttp://aytubio.com/20240930/role/statement-note-7-intangible-assets-tables54 falsefalseR55.htm995499 - Disclosure - Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)Sheethttp://aytubio.com/20240930/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-detailsNote 7 - Intangible Assets - Schedule of Intangible Assets (Details)Details55 falsefalseR56.htm995500 - Disclosure - Note 7 - Intangible Assets - Future Amortization Expense (Details)Sheethttp://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-detailsNote 7 - Intangible Assets - Future Amortization Expense (Details)Details56 falsefalseR57.htm995501 - Disclosure - Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)Sheethttp://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-detailsNote 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)Details57 falsefalseR58.htm995502 - Disclosure - Note 9 - Other Liabilities (Details Textual)Sheethttp://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textualNote 9 - Other Liabilities (Details Textual)Detailshttp://aytubio.com/20240930/role/statement-note-9-other-liabilities-tables58 falsefalseR59.htm995503 - Disclosure - Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)Sheethttp://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-detailsNote 9 - Other Liabilities - Schedule of Other Liabilities (Details)Details59 falsefalseR60.htm995504 - Disclosure - Note 10 - Revolving Credit Facility (Details Textual)Sheethttp://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textualNote 10 - Revolving Credit Facility (Details Textual)Detailshttp://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility60 falsefalseR61.htm995505 - Disclosure - Note 11 - Long-term Debt (Details Textual)Sheethttp://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textualNote 11 - Long-term Debt (Details Textual)Detailshttp://aytubio.com/20240930/role/statement-note-11-longterm-debt-tables61 falsefalseR62.htm995506 - Disclosure - Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)Sheethttp://aytubio.com/20240930/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-detailsNote 11 - Long-term Debt - Schedule of Long-term Debt (Details)Details62 falsefalseR63.htm995507 - Disclosure - Note 11 - Long-term Debt - Future Principal Payments (Details)Sheethttp://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-detailsNote 11 - Long-term Debt - Future Principal Payments (Details)Details63 falsefalseR64.htm995508 - Disclosure - Note 12 - Fair Value Measurements (Details Textual)Sheethttp://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-details-textualNote 12 - Fair Value Measurements (Details Textual)Detailshttp://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-tables64 falsefalseR65.htm995509 - Disclosure - Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details)Sheethttp://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-detailsNote 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details)Details65 falsefalseR66.htm995510 - Disclosure - Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details)Sheethttp://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-detailsNote 12 - Fair Value Measurements - Summary of Level 3 Changes (Details)Details66 falsefalseR67.htm995511 - Disclosure - Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals)Sheethttp://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticalsNote 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals)Details67 falsefalseR68.htm995512 - Disclosure - Note 12 - Fair Value Measurements - Valuation*

Assumptions (Details)Sheethttp://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-detailsNote 12 - Fair Value Measurements - Valuation Assumptions (Details)Details68 falsefalseR69.htm995513 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual)Sheethttp://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textualNote 13 - Commitments and Contingencies (Details Textual)Detailshttp://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies69 falsefalseR70.htm995514 - Disclosure - Note 14 - Stockholders' Equity (Details Textual)Sheethttp://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textualNote 14 - Stockholders' Equity (Details Textual)Detailshttp://aytubio.com/20240930/role/statement-note-14-stockholders-equity70 falsefalseR71.htm995515 - Disclosure - Note 15 - Equity Incentive Plans (Details Textual)Sheethttp://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textualNote 15 - Equity Incentive Plans (Details Textual)Detailshttp://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-tables71 falsefalseR72.htm995516 - Disclosure - Note 15 - Equity Incentive Plans - Stock Option Activity (Details)Sheethttp://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-option-activity-detailsNote 15 - Equity Incentive Plans - Stock Option Activity (Details)Details72 falsefalseR73.htm995517 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)Sheethttp://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-detailsNote 15 - Equity Incentive Plans - Restricted Stock Activity (Details)Details73 falsefalseR74.htm995518 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)Sheethttp://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-detailsNote 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)Details74 falsefalseR75.htm995519 - Disclosure - Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)Sheethttp://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-detailsNote 15 - Equity Incentive Plans - Stock Compensation Expense (Details)Details75 falsefalseR76.htm995520 - Disclosure - Note 16 - Warrants (Details Textual)Sheethttp://aytubio.com/20240930/role/statement-note-16-warrants-details-textualNote 16 - Warrants (Details Textual)Detailshttp://aytubio.com/20240930/role/statement-note-16-warrants-tables76 falsefalseR77.htm995521 - Disclosure - Note 16 - Warrants - Schedule of Warrants Outstanding (Details)Sheethttp://aytubio.com/20240930/role/statement-note-16-warrants-schedule-of-warrants-outstanding-detailsNote 16 - Warrants - Schedule of Warrants Outstanding (Details)Details77 falsefalseR78.htm995522 - Disclosure - Note 17 - Earnings Per Share - Schedule of Earnings Per Share (Details)Sheethttp://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-detailsNote 17 - Earnings Per Share - Schedule of Earnings Per Share (Details)Details78 falsefalseR79.htm995523 - Disclosure - Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details)Sheethttp://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-detailsNote 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details)Details79 falsefalseR80.htm995524 - Disclosure - Note 20 - Discontinued Operations - Schedule of Discontinued Operations (Details)Sheethttp://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-detailsNote 20 - Discontinued Operations - Schedule of Discontinued Operations (Details)Details80 falsefalseAll ReportsBookAll Reports aytu-20240930.xsdaytu-20240930_cal.xmlaytu-20240930_def.xmlaytu-20240930_lab.xmlaytu-20240930_pre.xmlaytu20240930_10q.htm aytu20231231_10qimg001.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 99 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "aytu20240930_10q.htm": { "nsprefix": "aytu", "nsuri": "http://aytubio.com/20240930", "dts": { "schema": { "local": ["aytu-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["aytu-20240930_cal.xml"] }, "definitionLink": { "local": ["aytu-20240930_def.xml"] }, "labelLink": { "local": ["aytu-20240930_lab.xml"] }, "presentationLink": { "local": ["aytu-20240930_pre.xml"] }, "inline": { "local": ["aytu20240930_10q.htm"] } }, "keyStandard": 304, "keyCustom": 49, "axisStandard": 25, "axisCustom": 0, "memberStandard": 32, "memberCustom": 47, "hidden": { "total": 51, "http://xbrl.sec.gov/dei/2024": 6, "http://fasb.org/us-gaap/2024": 40, "http://xbrl.sec.gov/ecd/2024": 4, "http://aytubio.com/20240930": 1 }, "contextCount": 204, "entityCount": 1, "segmentCount": 85, "elementCount": 557, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 713, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://aytubio.com/20240930/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets", "longName": "001 - Statement - Unaudited Consolidated Balance Sheets", "shortName": "Unaudited Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets-parentheticals", "longName": "002 - Statement - Unaudited Consolidated Balance Sheets (Parentheticals)", "shortName": "Unaudited Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": null, "uniqueAnchor": null }, "R4": { "role": "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations", "longName": "003 - Statement - Unaudited Consolidated Statements of Operations", "shortName": "Unaudited Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R5": { "role": "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-stockholders-equity", "longName": "004 - Statement - Unaudited Consolidated Statements of Stockholders' Equity", "shortName": "Unaudited Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-06-30_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows", "longName": "005 - Statement - Unaudited Consolidated Statements of Cash Flows", "shortName": "Unaudited Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R7": { "role": "http://aytubio.com/20240930/role/statement-note-1-nature-of-business", "longName": "006 - Disclosure - Note 1 - Nature of Business", "shortName": "Note 1 - Nature of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "007 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://aytubio.com/20240930/role/statement-note-3-revenue", "longName": "008 - Disclosure - Note 3 - Revenue", "shortName": "Note 3 - Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://aytubio.com/20240930/role/statement-note-4-inventories", "longName": "009 - Disclosure - Note 4 - Inventories", "shortName": "Note 4 - Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment", "longName": "010 - Disclosure - Note 5 - Property and Equipment", "shortName": "Note 5 - Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://aytubio.com/20240930/role/statement-note-6-leases", "longName": "011 - Disclosure - Note 6 - Leases", "shortName": "Note 6 - Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "aytu:LeasesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "aytu:LeasesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://aytubio.com/20240930/role/statement-note-7-intangible-assets", "longName": "012 - Disclosure - Note 7 - Intangible Assets", "shortName": "Note 7 - Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities", "longName": "013 - Disclosure - Note 8 - Accrued Liabilities", "shortName": "Note 8 - Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30",

```
"name": "aytu:AccruedLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "aytu:AccruedLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://aytubio.com/20240930/role/statement-note-9-other-liabilities", "longName": "014 - Disclosure - Note 9 - Other Liabilities", "shortName": "Note 9 - Other Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility", "longName": "015 - Disclosure - Note 10 - Revolving Credit Facility", "shortName": "Note 10 - Revolving Credit Facility", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "longName": "016 - Disclosure - Note 11 - Long-term Debt", "shortName": "Note 11 - Long-term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements", "longName": "017 - Disclosure - Note 12 - Fair Value Measurements", "shortName": "Note 12 - Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies", "longName": "018 - Disclosure - Note 13 - Commitments and Contingencies", "shortName": "Note 13 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "longName": "019 - Disclosure - Note 14 - Stockholders' Equity", "shortName": "Note 14 - Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "longName": "020 - Disclosure - Note 15 - Equity Incentive Plans", "shortName": "Note 15 - Equity Incentive Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://aytubio.com/20240930/role/statement-note-16-warrants", "longName": "021 - Disclosure - Note 16 - Warrants", "shortName": "Note 16 - Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "aytu:WarrantsOrRightsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "aytu:WarrantsOrRightsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share", "longName": "022 - Disclosure - Note 17 - Earnings Per Share", "shortName": "Note 17 - Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://aytubio.com/20240930/role/statement-note-18-license-agreements", "longName": "023 - Disclosure - Note 18 - License Agreements", "shortName": "Note 18 - License Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "aytu:LicensingAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "aytu:LicensingAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://aytubio.com/20240930/role/statement-note-19-restructuring-costs-", "longName": "024 - Disclosure - Note 19 - Restructuring Costs", "shortName": "Note 19 - Restructuring Costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations", "longName": "025 - Disclosure - Note 20 - Discontinued Operations", "shortName": "Note 20 - Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": null, "uniqueAnchor": null }, "R28": { "role": "http://aytubio.com/20240930/role/statement-significant-accounting-policies-policies", "longName": "995472 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://aytubio.com/20240930/role/statement-note-3-revenue-tables", "longName": "995473 - Disclosure - Note 3 - Revenue (Tables)", "shortName": "Note 3 - Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://aytubio.com/20240930/role/statement-note-4-inventories-tables", "longName": "995474 - Disclosure - Note 4 - Inventories (Tables)", "shortName": "Note 4 - Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-tables", "longName": "995475 - Disclosure - Note 5 - Property and Equipment (Tables)", "shortName": "Note 5 - Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://aytubio.com/20240930/role/statement-note-6-leases-tables", "longName": "995476 - Disclosure - Note 6 - Leases (Tables)", "shortName": "Note 6 - Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "aytu:LeasesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "aytu:LeasesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-tables", "longName": "995477 - Disclosure - Note 7 - Intangible Assets (Tables)", "shortName": "Note 7 - Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-tables", "longName": "995478 - Disclosure - Note 8 - Accrued Liabilities (Tables)", "shortName": "Note 8 - Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "aytu:AccruedLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "aytu:AccruedLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://aytubio.com/20240930/role/statement-note-9-
```

other-liabilities-tables", "longName": "995479 - Disclosure - Note 9 - Other Liabilities (Tables)", "shortName": "Note 9 - Other Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-tables", "longName": "995480 - Disclosure - Note 11 - Long-term Debt (Tables)", "shortName": "Note 11 - Long-term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-tables", "longName": "995481 - Disclosure - Note 12 - Fair Value Measurements (Tables)", "shortName": "Note 12 - Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-tables", "longName": "995482 - Disclosure - Note 15 - Equity Incentive Plans (Tables)", "shortName": "Note 15 - Equity Incentive Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://aytubio.com/20240930/role/statement-note-16-warrants-tables", "longName": "995483 - Disclosure - Note 16 - Warrants (Tables)", "shortName": "Note 16 - Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["aytu:WarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["aytu:WarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-tables", "longName": "995484 - Disclosure - Note 17 - Earnings Per Share (Tables)", "shortName": "Note 17 - Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-tables", "longName": "995485 - Disclosure - Note 20 - Discontinued Operations (Tables)", "shortName": "Note 20 - Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "longName": "995486 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://aytubio.com/20240930/role/statement-note-3-revenue-details-textual", "longName": "995487 - Disclosure - Note 3 - Revenue (Details Textual)", "shortName": "Note 3 - Revenue (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://aytubio.com/20240930/role/statement-note-3-revenue-disaggregation-of-revenue-details", "longName": "995488 - Disclosure - Note 3 - Revenue - Disaggregation of Revenue (Details)", "shortName": "Note 3 - Revenue - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_StatementBusinessSegmentsAxis-RxSegmentMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R45": { "role": "http://aytubio.com/20240930/role/statement-note-4-inventories-details-textual", "longName": "995489 - Disclosure - Note 4 - Inventories (Details Textual)", "shortName": "Note 4 - Inventories (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:InventoryWriteDown", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R46": { "role": "http://aytubio.com/20240930/role/statement-note-4-inventories-schedule-of-inventories-details", "longName": "995490 - Disclosure - Note 4 - Inventories - Schedule of Inventories (Details)", "shortName": "Note 4 - Inventories - Schedule of Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-details-textual", "longName": "995491 - Disclosure - Note 5 - Property and Equipment (Details Textual)", "shortName": "Note 5 - Property and Equipment (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "longName": "995492 - Disclosure - Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)", "shortName": "Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://aytubio.com/20240930/role/statement-note-6-leases-details-textual", "longName": "995493 - Disclosure - Note 6 - Leases (Details Textual)", "shortName": "Note 6 - Leases (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FinanceLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "aytu:LeasesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FinanceLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "aytu:LeasesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R50": { "role": "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details", "longName": "995494 - Disclosure - Note 6 - Leases - Lease Cost (Details)", "shortName": "Note 6 - Leases - Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:LeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "aytu:LeasesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:LeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "aytu:LeasesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details", "longName": "995495 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details)", "shortName": "Note 6 - Leases - Lease Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "aytu:ScheduleOfLeaseByBalanceSheetInformationTableTextBlock", "aytu:LeasesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R52": { "role": "http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-

information-details-parentheticals", "longName": "995496 - Disclosure - Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals)", "shortName": "Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "52", "firstAnchor": null, "uniqueAnchor": null }, "R53": { "role": "http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "longName": "995497 - Disclosure - Note 6 - Leases - Schedule of Lease Liability Maturity (Details)", "shortName": "Note 6 - Leases - Schedule of Lease Liability Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "aytu:LesseeLiabilityMaturityTableTextBlock", "aytu:LeasesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "aytu:LesseeLiabilityMaturityTableTextBlock", "aytu:LeasesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textual", "longName": "995498 - Disclosure - Note 7 - Intangible Assets (Details Textual)", "shortName": "Note 7 - Intangible Assets (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "aytu:AmortizationExpenseOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "aytu:AmortizationExpenseOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "longName": "995499 - Disclosure - Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)", "shortName": "Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R56": { "role": "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details", "longName": "995500 - Disclosure - Note 7 - Intangible Assets - Future Amortization Expense (Details)", "shortName": "Note 7 - Intangible Assets - Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details", "longName": "995501 - Disclosure - Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)", "shortName": "Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "aytu:AccruedSavingOffers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "aytu:AccruedLiabilitiesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "aytu:AccruedSavingOffers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "aytu:AccruedLiabilitiesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual", "longName": "995502 - Disclosure - Note 9 - Other Liabilities (Details Textual)", "shortName": "Note 9 - Other Liabilities (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "aytu:FixedPaymentArrangements", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember", "name": "aytu:SupplyAndDistributionAgreementMaximumYearlyMakewholePayment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R59": { "role": "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "longName": "995503 - Disclosure - Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)", "shortName": "Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "aytu:FixedPaymentArrangements", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:OtherSundryLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R60": { "role": "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual", "longName": "995504 - Disclosure - Note 10 - Revolving Credit Facility (Details Textual)", "shortName": "Note 10 - Revolving Credit Facility (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "i_2024-06-12_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:ShortTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-12_LineOfCreditFacilityAxis-EclipseBusinessCapitalLlcLoanAgreementMember_LongtermDebtTypeAxis-SecuredDebtMember", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:ShortTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R61": { "role": "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual", "longName": "995505 - Disclosure - Note 11 - Long-term Debt (Details Textual)", "shortName": "Note 11 - Long-term Debt (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "i_2022-03-07_SubsidiarySaleOfStockAxis-AvenueCapitalIssuanceMember", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-03-07_SubsidiarySaleOfStockAxis-AvenueCapitalIssuanceMember", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R62": { "role": "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "longName": "995506 - Disclosure - Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)", "shortName": "Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R63": { "role": "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details", "longName": "995507 - Disclosure - Note 11 - Long-term Debt - Future Principal Payments (Details)", "shortName": "Note 11 - Long-term Debt - Future Principal Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R64": { "role": "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-details-textual", "longName": "995508 - Disclosure - Note 12 - Fair Value Measurements (Details Textual)", "shortName": "Note 12 - Fair Value Measurements (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "i_2024-09-30_ClassOfWarrantOrRightAxis-TrancheBPrefundedWarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "tbody", "table", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R65": { "role": "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details", "longName": "995509 - Disclosure - Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details)", "shortName": "Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:DerivativeLiabilitiesNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R66": { "role": "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details", "longName": "995510 - Disclosure - Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details)", "shortName": "Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R67": { "role": "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals", "longName": "995511 - Disclosure - Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals)", "shortName": "Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R68": { "role": "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details", "longName": "995512 - Disclosure - Note 12 - Fair Value Measurements - Valuation Assumptions (Details)", "shortName": "Note 12 - Fair Value Measurements - Valuation Assumptions (Details)", "isDefault": "false", "groupType":

"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "i_2024-09-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember", "name": "us-gaap:DerivativeLiability MeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_ClassOfWarrantOrRightAxis-June2023WarrantsTrancheAMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember", "name": "us-gaap:DerivativeLiability MeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R69": { "role": "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "longName": "995513 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual)", "shortName": "Note 13 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30_TypeOfArrangementAxis-TrisKarbinalAgreementMember", "name": "aytu:SupplyAndDistributionCommitmentPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_RangeAxis-MaximumMember_TypeOfArrangementAxis-TrisKarbinalAgreementMember", "name": "aytu:SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-2", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R70": { "role": "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "longName": "995514 - Disclosure - Note 14 - Stockholders' Equity (Details Textual)", "shortName": "Note 14 - Stockholders' Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2022-08-11_ClassOfWarrantOrRightAxis-August2022CommonAndPrefundedWarrantsMember", "name": "us-gaap:SaleOfStockPricePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R71": { "role": "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual", "longName": "995515 - Disclosure - Note 15 - Equity Incentive Plans (Details Textual)", "shortName": "Note 15 - Equity Incentive Plans (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R72": { "role": "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "longName": "995516 - Disclosure - Note 15 - Equity Incentive Plans - Stock Option Activity (Details)", "shortName": "Note 15 - Equity Incentive Plans - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R73": { "role": "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "longName": "995517 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)", "shortName": "Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "i_2024-06-30_AwardTypeAxis-RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30_AwardTypeAxis-RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R74": { "role": "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "longName": "995518 - Disclosure - Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)", "shortName": "Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "i_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R75": { "role": "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "longName": "995519 - Disclosure - Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)", "shortName": "Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R76": { "role": "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual", "longName": "995520 - Disclosure - Note 16 - Warrants (Details Textual)", "shortName": "Note 16 - Warrants (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-06_2023-01-06_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember", "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "aytu:WarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R77": { "role": "http://aytubio.com/20240930/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "longName": "995521 - Disclosure - Note 16 - Warrants - Schedule of Warrants Outstanding (Details)", "shortName": "Note 16 - Warrants - Schedule of Warrants Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "aytu:WarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "aytu:WarrantsOrRightsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R78": { "role": "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "longName": "995522 - Disclosure - Note 17 - Earnings Per Share - Schedule of Earnings Per Share (Details)", "shortName": "Note 17 - Earnings Per Share - Schedule of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } }, "R79": { "role": "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "longName": "995523 - Disclosure - Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details)", "shortName": "Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true, "unique": true } }, "R80": { "role": "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "longName": "995524 - Disclosure - Note 20 - Discontinued Operations - Schedule of Discontinued Operations (Details)", "shortName": "Note 20 - Discontinued Operations - Schedule of Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-ConsumerHealthDivestureMember", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "aytu20240930_10q.htm", "unique": true } } },

```
"tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": [ "http://aytubio.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r63", "r680" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r728" ] }, "aytu_AccruedCustomerAndProductRelatedFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AccruedCustomerAndProductRelatedFeesCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Accrued customer and product related fees", "documentation": "Represents the amount of accrued customer and product related fees classified as current." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accrued liabilities", "totalLabel": "Total accrued liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r66" ] }, "aytu_AccruedLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AccruedLiabilitiesTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities [Text Block]", "documentation": "The entire disclosure regarding accrued liabilities." } } }, "auth_ref": [] }, "aytu_AccruedProgramRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AccruedProgramRelatedLiabilities", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Accrued program liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for program related liabilities." } } }, "auth_ref": [] }, "aytu_AccruedSavingOffers": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AccruedSavingOffers", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Accrued savings offers", "documentation": "Represents information related to accrued saving offers." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less: accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r27", "r154", "r518" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r76", "r680", "r854" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r561", "r717", "r718", "r719", "r721", "r792", "r855" ] }, "aytu_AdhdPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AdhdPortfolioMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-3-revenue-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "ADHD Portfolio [Member]", "documentation": "Relating to the ADHS Portfolio." } } }, "auth_ref": [] }, "aytu_AdjustedIncomeLossFromContinuingOperationsDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AdjustedIncomeLossFromContinuingOperationsDiluted", "crdr": "credit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Adjusted numerator - net loss from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent for diluted calculation." } } }, "auth_ref": [] }, "aytu_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInDiscontinuedOperations", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Non-cash adjustments from discontinued operations", "documentation": "The amount of adjustments to net income or loss from discontinued operations." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to cash used in operating activities:" } } }, "auth_ref": [] }, "aytu_AfterJanuary262023ButBeforeJanuary262024Member": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AfterJanuary262023ButBeforeJanuary262024Member", "presentation": [ "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual" ], "lang": { "en-us": { "role": { "label": "After January 26, 2023 But Before January 26, 2024 [Member]", "documentation": "Relating to after January 26, 2023 but before January 26, 2024." } } }, "auth_ref": [] }, "aytu_AfterJanuary262024ButBeforeJanuary262025Member": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AfterJanuary262024ButBeforeJanuary262025Member", "presentation": [ "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "After January 26, 2024 But Before January 26, 2025 [Member]", "documentation": "Relating to after January 26, 2024 but before January 26, 2025." } } }, "auth_ref": [] }, "aytu_AfterJune122025ButOnOrBeforeJune122026Member": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AfterJune122025ButOnOrBeforeJune122026Member", "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "After June 12, 2025, but on or before June 12, 2026 [Member]", "documentation": "Represents the termination fee if the termination is after June 12, 2025, but on or before June 12, 2026." } } }, "auth_ref": [] }, "aytu_AfterJune122026ButOnOrBeforeJune122027Member": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AfterJune122026ButOnOrBeforeJune122027Member", "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "After June 12, 2026, but on or before June 12, 2027 [Member]", "documentation": "Represents the termination fee if the termination is after June 12, 2026, but on or before June 12, 2027" } } }, "auth_ref": [] }, "aytu_AfterJune122026ButOnOrBeforeJune122028Member": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AfterJune122026ButOnOrBeforeJune122028Member", "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "After June 12, 2026, but on or before June 12, 2028 [Member]", "documentation": "Represents the termination fee if the termination is after June 12, 2026, but on or before June 12, 2028." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Total stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r396", "r401" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://aytubio.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "aytu_AmortizationExpenseOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AmortizationExpenseOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_AmortizationExpenseOfIntangibleAssets", "terseLabel": "Amortization Expense of Intangible Assets", "documentation": "The value of amortization expense of intangible assets." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Amortization of debt discount and issuance costs", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r326", "r648", "r649", "r713", "r801" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Amortization of intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r5", "r270", "r276", "r644" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive securities (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r218" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri":
```

"http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r23"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r23"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r427"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r123", "r135", "r157", "r180", "r222", "r225", "r242", "r245", "r252", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r428", "r430", "r462", "r510", "r584", "r640", "r641", "r680", "r696", "r755", "r756", "r805"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsNoncurrent", "totalLabel": "Total non-current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r180", "r252", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r428", "r430", "r462", "r755", "r756", "r805"] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Non-current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "totalLabel": "Total current and non-current assets of discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r1", "r45", "r58", "r106", "r149", "r150"] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 }, "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Current assets of discontinued operations", "totalLabel": "Total current assets of discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r1", "r45", "r58", "r104", "r106", "r149", "r150"] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "presentation": ["http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details"], "lang": { "en-us": { "role": { "label": "Current assets of discontinued operations:" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract", "presentation": ["http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details"], "lang": { "en-us": { "role": { "label": "Non-current assets of discontinued operations:" } } }, "auth_ref": [] }, "aytu_August2022CommonAndPrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "August2022CommonAndPrefundedWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "August 2022 Common and Prefunded Warrants [Member]", "documentation": "Relating to the August 2022 Common and Prefunded Warrants." } } }, "auth_ref": [] }, "aytu_August2022CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "August2022CommonWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "August 2022 Common Warrants [Member]", "documentation": "Relating to the August 2022 Common Warrants." } } }, "auth_ref": [] }, "aytu_August2022PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "August2022PrefundedWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "August 2022 Prefunded Warrants [Member]", "documentation": "Relating to August 2022 prefunded warrants." } } }, "auth_ref": [] }, "aytu_AvenueCapitalIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AvenueCapitalIssuanceMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Avenue Capital Issuance [Member]", "documentation": "Relating to Avenue Capital Issuance." } } }, "auth_ref": [] }, "aytu_AvenueCapitalLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AvenueCapitalLoanMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Avenue Capital Loan [Member]", "documentation": "Relating to the Avenue Capital Loan." } } }, "auth_ref": [] }, "aytu_AvenueCapitalWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "AvenueCapitalWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Avenue Capital Warrants [Member]", "documentation": "Relating to the Avenue Capital Warrants." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r284", "r821", "r822"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r40", "r41", "r284", "r821", "r822"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationContingentConsiderationLiability", "terseLabel": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r37", "r119", "r424", "r444", "r445", "r446"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r20", "r152", "r627"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r20", "r97", "r177"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net change in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including

effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r97"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-details-textual", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r33"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-details-textual", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "aytu_ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod": { "xbrltype": "perShareItemType", "nsuri": "http://aytubio.com/20240930", "localname": "ClassOfWarrantOrRightExercisePriceExercisedDuringPeriod", "presentation": ["http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "Warrants exercised, weighted average exercise price (in dollars per share)", "terseLabel": "Class of Warrant or Right, Exercise Price, Exercised During Period (in dollars per share)", "documentation": "Represents the exercise price of warrants or rights exercised during the period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-details-textual", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r345"] }, "aytu_ClassOfWarrantOrRightExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://aytubio.com/20240930", "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "presentation": ["http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "aytu_ClassOfWarrantOrRightExercisedDuringPeriod", "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)", "negatedLabel": "Warrants exercised (2) (in shares)", "documentation": "The number of warrants or rights exercised during period." } } }, "auth_ref": [] }, "aytu_ClassOfWarrantOrRightIssuedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://aytubio.com/20240930", "localname": "ClassOfWarrantOrRightIssuedDuringPeriod", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_ClassOfWarrantOrRightIssuedDuringPeriod", "terseLabel": "Class of Warrant or Right, Issued During Period (in shares)", "documentation": "The number of warrants or rights issued during period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-details-textual", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r345"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "terseLabel": "Class of Warrant or Right, Outstanding (in shares)", "periodStartLabel": "Outstanding, balance (in shares)", "periodEndLabel": "Outstanding, balance (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://aytubio.com/20240930", "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLife", "presentation": ["http://aytubio.com/20240930/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "Outstanding, weighted average remaining contractual term (Year)", "documentation": "The weighted average period of remaining contractual life of warrants or rights." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (note 13)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r72", "r127", "r513", "r571"] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r108", "r295", "r296", "r622", "r744", "r750"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r687", "r688", "r689", "r691", "r692", "r693", "r694", "r717", "r718", "r721", "r792", "r852", "r855"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r75"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r75", "r572"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r75"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, outstanding (in shares)", "terseLabel": "Common Stock, Shares, Outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r9", "r75", "r572", "r590", "r855", "r856"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Common stock, par value $.0001; 200,000,000 shares authorized; 6,149,202, and 5,972,638 shares issued and outstanding, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r75", "r515", "r680"] }, "aytu_CommonWarrantsExchangedForPrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "CommonWarrantsExchangedForPrefundedWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Common Warrants Exchanged for PreFunded Warrants [Member]", "documentation": "Relating to Common Warrants exchanged for Pre-Funded Warrants." } } }, "auth_ref": [] }, "aytu_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "CommonWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Common Warrants [Member]", "documentation": "Relating to the Common Warrants." } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r39", "r636"] }, "aytu_ConsumerHealthDivestureMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "ConsumerHealthDivestureMember", "presentation": [

```
"http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "Consumer Health Divesture [Member]", "documentation": "Relating to Consumer Health Divesture." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "crdr": "credit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-3-revenue-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "terseLabel": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price", "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained." } } }, "auth_ref": [ "r651" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Cost of sales", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r88", "r89", "r502" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://aytubio.com/20240930/role/statement-note-7-intangible-assets", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r181", "r182", "r314", "r334", "r494", "r500", "r509", "r633", "r635" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://aytubio.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "aytu_DebtInstrumentAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://aytubio.com/20240930", "localname": "DebtInstrumentAmortizationPeriod", "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_DebtInstrumentAmortizationPeriod", "terseLabel": "Debt Instrument, Amortization Period (Year)", "documentation": "The duration in which the debt will amortize." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r16", "r65", "r66", "r124", "r126", "r183", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r645", "r646", "r647", "r648", "r649", "r669", "r714", "r745", "r746", "r747", "r800", "r802" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "label": "Term loan principal amount", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r16", "r126", "r327" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r311", "r470", "r471", "r646", "r647", "r669" ] }, "aytu_DebtInstrumentFinalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "DebtInstrumentFinalPayment", "crdr": "credit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_DebtInstrumentFinalPayment", "terseLabel": "Debt Instrument, Final Payment", "documentation": "Represents the final payment of a debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateEffectivePercentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r68", "r329", "r470", "r471", "r669" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r68", "r312" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r16", "r183", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r645", "r646", "r647", "r648", "r649", "r669", "r714", "r745", "r746", "r747", "r800", "r802" ] }, "aytu_DebtInstrumentPrepaymentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "DebtInstrumentPrepaymentFeeAmount", "crdr": "debit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_DebtInstrumentPrepaymentFeeAmount", "terseLabel": "Debt Instrument, Prepayment Fee, Amount", "documentation": "The prepayment fee amount." } } }, "auth_ref": [] }, "aytu_DebtInstrumentPrepaymentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://aytubio.com/20240930", "localname": "DebtInstrumentPrepaymentFeePercentage", "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_DebtInstrumentPrepaymentFeePercentage", "terseLabel": "Debt Instrument, Prepayment Fee, Percentage", "documentation": "Represents the percentage of loan that is payable as a prepayment fee." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentTerm", "terseLabel": "Debt Instrument, Term (Year)", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "aytu_DebtInstrumentTerminationFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://aytubio.com/20240930", "localname": "DebtInstrumentTerminationFeePercentage", "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_DebtInstrumentTerminationFeePercentage", "terseLabel": "Debt Instrument, Termination Fee, Percentage", "documentation": "The termination fee if the debt is terminated before or on a certain date." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "negatedLabel": "Less: unamortized debt discount and issuance costs", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r317", "r328", "r469", "r470", "r471", "r646", "r647", "r669" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Depreciation, amortization and accretion", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r5", "r222", "r230", "r245", "r640", "r641" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 }, "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Derivative, Gain (Loss) on Derivative, Net", "negatedLabel": "Derivative warrant liabilities (gain) loss", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r790" ] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Derivative warrant liabilities", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r163" ] }, "us-gaap_DerivativeLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityMeasurementInput", "presentation": [ "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Derivative liability, measurement input", "documentation": "Value of input used to measure derivative liability." } } }, "auth_ref": [ "r444", "r445", "r446" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r118", "r732", "r733", "r734", "r735", "r736", "r738", "r741", "r742" ] }, "us-gaap_DilutiveSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DilutiveSecurities", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Adjustment for change in fair value of warrant liabilities", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities." } } }, "auth_ref": [ "r22" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-note-3-revenue-tables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r758" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r367", "r369", "r397", "r398", "r400", "r659" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://aytubio.com/20240930/role/statement-note-1-nature-of-business", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share", "http://aytubio.com/20240930/role/statement-note-18-license-agreements", "http://aytubio.com/20240930/role/statement-note-19-restructuring-costs-", "http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations", "http://aytubio.com/20240930/role/statement-note-3-revenue", "http://aytubio.com/20240930/role/statement-note-4-inventories", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment", "http://aytubio.com/20240930/role/statement-note-6-leases", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets", "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "terseLabel": "Income (loss) from discontinued operations before income taxes", "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r46", "r47", "r48", "r49", "r50", "r56", "r87", "r818" ] }, "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax", "crdr": "debit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax", "negatedTerseLabel": "Loss on divestiture", "documentation": "Amount before tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation." } } }, "auth_ref": [ "r46", "r48", "r50" ] }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "terseLabel": "Income tax benefit", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r47", "r48", "r49", "r50", "r56", "r60", "r406", "r416", "r417" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "terseLabel": "Accounts receivable, net", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r45", "r58", "r106" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "terseLabel": "Accounts payable", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r45", "r58", "r104", "r106" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "terseLabel": "Accrued liabilities", "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r45", "r58", "r104", "r106" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Non-current assets of discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r2", "r45", "r58", "r106", "r149", "r150" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "negatedTerseLabel": "Cost of sales", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r57", "r150" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "negatedTerseLabel": "Amortization of intangible assets", "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r57" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "negatedTerseLabel": "General and administrative", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r57" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "terseLabel": "Inventories", "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r45", "r58", "r104", "r106" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense", "crdr": "debit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense", "negatedTerseLabel": "Non-operating other expense, net", "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r57" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "terseLabel": "Other non-current assets", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r2", "r45", "r58", "r106" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r45", "r58", "r104", "r106" ] }, "aytu_DisposalGroupIncludingDiscontinuedOperationRecognizedContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationRecognizedContingentConsideration", "crdr": "credit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "aytu_DisposalGroupIncludingDiscontinuedOperationRecognizedContingentConsideration", "terseLabel": "Recognized contingent consideration", "documentation": "Amount of recognized contingent consideration attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue", "terseLabel": "Net revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r57", "r150" ] }, "aytu_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense", "crdr": "debit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "aytu_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense", "negatedTerseLabel": "Selling and marketing", "documentation": "Amount of selling and marketing expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

"DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-20-discontinued-operations"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r44", "r103"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r656", "r657"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r700"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r701"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Net income (loss) per share (note 17):" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "calculation": { "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Basic - net income (loss) (in dollars per share)", "totalLabel": "Net income (loss) per share (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r170", "r189", "r190", "r191", "r192", "r193", "r194", "r200", "r203", "r215", "r216", "r217", "r221", "r422", "r426", "r440", "r441", "r506", "r524", "r637"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Diluted - net loss (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r170", "r189", "r190", "r191", "r192", "r193", "r194", "r203", "r215", "r216", "r217", "r221", "r422", "r426", "r440", "r441", "r506", "r524", "r637"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-17-earnings-per-share"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r199", "r218", "r219", "r220"] }, "aytu_EclipseBusinessCapitalLlcLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "EclipseBusinessCapitalLlcLoanAgreementMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual"], "lang": { "en-us": { "role": { "label": "Eclipse Business Capital LLC Loan Agreement [Member]", "documentation": "Relating to Eclipse Business Capital LLC Loan Agreement." } } }, "auth_ref": [] }, "aytu_EclipseTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "EclipseTermLoanMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Eclipse Term loan [Member]", "documentation": "Represents the Eclipse Term loan" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r407", "r662"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Accrued employee compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r66"] }, "aytu_EmployeeRetentionCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "EmployeeRetentionCredit", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": { "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details"], "lang": { "en-us": { "role": { "label": "Employee retention credit", "terseLabel": "Employee Retention Credit", "documentation": "Represents the amount of employee retention credit." } } }, "auth_ref": [] }, "aytu_EmployeeRetentionCreditPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20240930", "localname": "EmployeeRetentionCreditPolicyTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Employee Retention Credit [Policy Text Block]", "documentation": "Represents the accounting policy for employee retention credits." } } }, "auth_ref": [] }, "aytu_EmployeeRetentionCreditVendorFee": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "EmployeeRetentionCreditVendorFee", "crdr": "debit", "presentation": ["http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_EmployeeRetentionCreditVendorFee", "terseLabel": "Employee Retention Credit, Vendor Fee", "documentation": "Represents the amount of vendor fee from employee retention credit during the period." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r399"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r786"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r786"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities

{ "that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r698"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information", "http://aytubio.com/20240930/role/statement-note-1-nature-of-business", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-tables", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-details-textual", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-tables", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-tables", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "http://aytubio.com/20240930/role/statement-note-16-warrants-tables", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-tables", "http://aytubio.com/20240930/role/statement-note-18-license-agreements", "http://aytubio.com/20240930/role/statement-note-19-restructuring-costs-", "http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations", "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-tables", "http://aytubio.com/20240930/role/statement-note-3-revenue", "http://aytubio.com/20240930/role/statement-note-3-revenue-details-textual", "http://aytubio.com/20240930/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://aytubio.com/20240930/role/statement-note-3-revenue-tables", "http://aytubio.com/20240930/role/statement-note-4-inventories", "http://aytubio.com/20240930/role/statement-note-4-inventories-details-textual", "http://aytubio.com/20240930/role/statement-note-4-inventories-schedule-of-inventories-details", "http://aytubio.com/20240930/role/statement-note-4-inventories-tables", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-details-textual", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-tables", "http://aytubio.com/20240930/role/statement-note-6-leases", "http://aytubio.com/20240930/role/statement-note-6-leases-details-textual", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details", "http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "http://aytubio.com/20240930/role/statement-note-6-leases-tables", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textual", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-tables", "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities", "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details", "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-tables", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-tables", "http://aytubio.com/20240930/role/statement-significant-accounting-policies-policies", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets-parentheticals", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r698"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r698"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r704"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r698"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r698"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r698"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r698"] }, "aytu_EquityBasedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "EquityBasedWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Equity-based Warrants [Member]", "documentation": "Represents equity-based warrants." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r9", "r147", "r167", "r168", "r169", "r184", "r185", "r186", "r188", "r193", "r195", "r197", "r223", "r253", "r254", "r281", "r346", "r414", "r415", "r419", "r420", "r421", "r423", "r425", "r426", "r432", "r433", "r434", "r435", "r436", "r437", "r439", "r463", "r464", "r465", "r466", "r467", "r468", "r472", "r473", "r493", "r523", "r548", "r549", "r550", "r561", "r610"] }, "aytu_EquityWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "EquityWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Equity Warrants [Member]", "documentation": "Relating to Equity Warrants." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-tables"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r444", "r445", "r665"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r319", "r359", "r360", "r361", "r362", "r363", "r364", "r442", "r443", "r444", "r445", "r446", "r454", "r455", "r457", "r495", "r496", "r497", "r646", "r647", "r653", "r654", "r655", "r663", "r665"] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of

credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r450", "r452", "r453", "r454", "r457", "r458", "r459", "r460", "r461", "r505", "r663", "r666"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r319", "r359", "r364", "r443", "r455", "r495", "r653", "r654", "r655", "r663"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r319", "r359", "r364", "r443", "r444", "r455", "r496", "r646", "r647", "r653", "r654", "r655", "r663"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r319", "r359", "r360", "r361", "r362", "r363", "r364", "r443", "r444", "r445", "r446", "r455", "r497", "r646", "r647", "r653", "r654", "r655", "r663", "r665"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-tables"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r447", "r451", "r456"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details"], "lang": { "en-us": { "role": { "label": "Included in earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": ["r448", "r456"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details"], "lang": { "en-us": { "role": { "label": "Settlements (1)", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r449", "r456"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r447", "r456"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r319", "r359", "r360", "r361", "r362", "r363", "r364", "r442", "r443", "r444", "r445", "r446", "r454", "r455", "r457", "r495", "r496", "r497", "r646", "r647", "r653", "r654", "r655", "r663", "r665"] }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals"], "lang": { "en-us": { "role": { "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)." } } }, "auth_ref": ["r448", "r456"] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details"], "lang": { "en-us": { "role": { "label": "Interest on lease liabilities", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": ["r477", "r482", "r671"] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details"], "lang": { "en-us": { "role": { "label": "Operating cash flows from finance leases", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": ["r479", "r485"] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-6-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiability", "terseLabel": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": ["r475", "r488"] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details"], "lang": { "en-us": { "role": { "label": "Financing cash flows from finance leases", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": ["r478", "r485"] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details"], "lang": { "en-us": { "role": { "label": "Amortization of leased assets", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": ["r477", "r482", "r671"] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details"], "lang": { "en-us": { "role": { "label": "Financial liabilities, fair value", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": ["r793", "r794", "r798"] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Finite-lived intangible assets, amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r155", "r259", "r275", "r644"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "Thereafter, future amortization expense", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r739", "r857"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "2026, future amortization expense", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r277", "r625", "r644"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "2025 (remaining 9 months), future amortization expense", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": ["r857"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "2030, future amortization expense", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r277", "r625", "r644"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "2029, future amortization expense", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r277", "r625", "r644"] }, "us-

gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "2028, future amortization expense", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r277", "r625", "r644"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "2027, future amortization expense", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r277", "r625", "r644"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r269", "r271", "r272", "r273", "r274", "r275", "r278", "r279", "r503", "r504", "r625"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Finite-lived intangible assets, gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r259", "r275", "r504", "r644"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r269", "r271", "r272", "r273", "r274", "r275", "r278", "r279", "r625"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Finite-lived intangible assets, net", "totalLabel": "Total future amortization expense", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r503", "r738"] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Finite-lived intangible assets, remaining life (Year)", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r503"] }, "aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod": { "xbrltype": "durationItemType", "nsuri": "http://aytubio.com/20240930", "localname": "FinitelivedIntangibleAssetUsefulLifeRenewablePeriod", "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_FinitelivedIntangibleAssetUsefulLifeRenewablePeriod", "terseLabel": "Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year)", "documentation": "Represents the renewable period for a finite-lived intangible asset." } } }, "auth_ref": [] }, "aytu_FixedPaymentArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "FixedPaymentArrangements", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": { "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details"], "lang": { "en-us": { "role": { "label": "Fixed payment arrangements", "terseLabel": "Fixed Payment Arrangements", "documentation": "Represents the amount of fixed payment arrangements." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment", "terseLabel": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": ["r5"] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_GainsLossesOnExtinguishmentOfDebt", "terseLabel": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r5", "r29", "r30"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r92", "r594"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r92"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": ["r730", "r731"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r84", "r90", "r134", "r180", "r252", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r462", "r638", "r640", "r723", "r724", "r725", "r726", "r727", "r755"] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Net income (loss) from continuing operations", "totalLabel": "Net income (loss) from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": ["r38", "r86", "r99", "r189", "r190", "r191", "r192", "r193", "r213", "r217", "r426"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Income (loss) from continuing operations before income tax expense", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r85", "r129", "r134", "r507", "r520", "r638", "r640", "r723", "r724", "r725", "r726", "r727"] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r121", "r134", "r180", "r187", "r193", "r252", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r422", "r426", "r441", "r462", "r520", "r638", "r723", "r724", "r725", "r726", "r727", "r755"] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "calculation": { "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Basic - continuing operations (in dollars per share)", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r86", "r130", "r170", "r187", "r189", "r190", "r191", "r192", "r193", "r203", "r215", "r216", "r422", "r426", "r441", "r506", "r819"] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": ["http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Diluted - continuing operations (in dollars per share)", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r86", "r170", "r187", "r189", "r190", "r191", "r192", "r193", "r203", "r215", "r216", "r217", "r426", "r441", "r506", "r819"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Net income (loss) from discontinued operations, net of tax", "terseLabel": "Net income (loss) from discontinued operations, net of tax", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": ["r46", "r47", "r48", "r49", "r50", "r60", "r150", "r418", "r521"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "terseLabel": "Net income (loss) from discontinued operations, net of tax",

```
"documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r46", "r47", "r48", "r49", "r50", "r56", "r60", "r121" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "calculation": { "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Basic - discontinued operations, net of tax (in dollars per share)", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r87", "r170", "r208", "r215", "r216", "r814", "r819" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "presentation": [ "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Diluted - discontinued operations, net of tax (in dollars per share)", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r122", "r208", "r215", "r216" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "presentation": [ "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r656", "r657" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r282", "r284", "r288", "r448", "r451", "r456", "r545", "r547", "r595", "r625", "r664", "r823" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r284", "r288", "r448", "r451", "r456", "r545", "r547", "r595", "r625", "r664", "r823" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxExpenseBenefit", "negatedLabel": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r137", "r145", "r196", "r197", "r222", "r233", "r245", "r406", "r407", "r416", "r525", "r662" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r166", "r404", "r405", "r408", "r409", "r410", "r413", "r557" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r21", "r176", "r411", "r412" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable, net", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued liabilities", "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "aytu_IncreaseDecreaseInOperatingCapitalAttributableToDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "IncreaseDecreaseInOperatingCapitalAttributableToDiscontinuedOperations", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "aytu_IncreaseDecreaseInOperatingCapitalAttributableToDiscontinuedOperations", "negatedLabel": "Changes in operating assets and liabilities from discontinued operations", "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities of discontinued operations." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet", "negatedLabel": "Other operating assets and liabilities, net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "calculation": { "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Dilutive effect of warrants to purchase common stock (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method." } } }, "auth_ref": [ "r204", "r205", "r206", "r217" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Dilutive effect of unvested restricted stock and restricted stock units (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r204", "r205", "r207", "r217", "r368" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r702" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r269", "r738", "r740" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseDebt", "terseLabel": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r93", "r324", "r330", "r648", "r649" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseNonoperating", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r229", "r710" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r172", "r174", "r175" ] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType",
```

```
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-note-4-inventories" ], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r255" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-4-inventories-schedule-of-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-4-inventories-schedule-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r102", "r630" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 0.0 }, "http://aytubio.com/20240930/role/statement-note-4-inventories-schedule-of-inventories-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-4-inventories-schedule-of-inventories-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Inventories", "totalLabel": "Inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r160", "r628", "r680" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-4-inventories-schedule-of-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-4-inventories-schedule-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r102", "r632" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-4-inventories-schedule-of-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-4-inventories-schedule-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "Work in process", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r102", "r631" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-4-inventories-details-textual", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Inventory write-down", "terseLabel": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r256" ] }, "aytu_June2023WarrantsTrancheAMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "June2023WarrantsTrancheAMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "June 2023 Warrants Tranche A [Member]", "documentation": "Represents the June 2023 Warrants Tranche A." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases", "http://aytubio.com/20240930/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r490", "r708" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases", "http://aytubio.com/20240930/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r490", "r708" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LeaseCost", "totalLabel": "Total lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r481", "r671" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-tables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r803" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r105", "r489" ] }, "aytu_LeasesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20240930", "localname": "LeasesDisclosureTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases" ], "lang": { "en-us": { "role": { "label": "Leases Disclosure [Text Block]", "documentation": "The entire disclosure for leases." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://aytubio.com/20240930/role/statement-document-and-entity-information",
"http://aytubio.com/20240930/role/statement-note-1-nature-of-business", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility",
"http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt",
"http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-tables", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-details-textual", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details",
"http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-tables",
"http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual",
"http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual",
"http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual",
"http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details",
"http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-tables", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual",
"http://aytubio.com/20240930/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "http://aytubio.com/20240930/role/statement-note-16-warrants-tables", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details",
"http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-tables", "http://aytubio.com/20240930/role/statement-note-18-license-agreements",
"http://aytubio.com/20240930/role/statement-note-19-restructuring-costs-", "http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies",
"http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations", "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details",
"http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-tables", "http://aytubio.com/20240930/role/statement-note-3-revenue",
"http://aytubio.com/20240930/role/statement-note-3-revenue-details-textual", "http://aytubio.com/20240930/role/statement-note-3-revenue-disaggregation-of-revenue-details",
"http://aytubio.com/20240930/role/statement-note-3-revenue-tables", "http://aytubio.com/20240930/role/statement-note-4-inventories",
"http://aytubio.com/20240930/role/statement-note-4-inventories-details-textual", "http://aytubio.com/20240930/role/statement-note-4-inventories-schedule-of-inventories-details", "http://aytubio.com/20240930/role/statement-note-4-inventories-tables", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment",
"http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-details-textual", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-tables",
"http://aytubio.com/20240930/role/statement-note-6-leases", "http://aytubio.com/20240930/role/statement-note-6-leases-details-textual",
"http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details",
"http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "http://aytubio.com/20240930/role/statement-note-6-leases-tables",
"http://aytubio.com/20240930/role/statement-note-7-intangible-assets", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textual",
"http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-tables", "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities", "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details",
"http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-tables", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities",
"http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-tables", "http://aytubio.com/20240930/role/statement-significant-accounting-policies-policies", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets-parentheticals", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "aytu_LesseeLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20240930", "localname": "LesseeLiabilityMaturityTableTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-tables" ], "lang": { "en-us": { "role": { "label": "Lessee, Liability, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to lease liability recognized in statement of financial position." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseDiscountRate", "terseLabel": "Lessee, Operating Lease, Discount Rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": [ "r670" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r488" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes
```

interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r488"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"], "lang": { "en-us": { "role": { "label": "2030", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r488"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"], "lang": { "en-us": { "role": { "label": "2029", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r488"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r488"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r488"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"], "lang": { "en-us": { "role": { "label": "2025 (remaining 9 months)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r804"] }, "aytu_LesseeOperatingLeaseLiabilityTenantImprovementAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "LesseeOperatingLeaseLiabilityTenantImprovementAllowance", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"], "lang": { "en-us": { "role": { "verboseLabel": "Less: tenant improvement allowance", "label": "aytu_LesseeOperatingLeaseLiabilityTenantImprovementAllowance", "documentation": "The amount of tenant improvement allowance for operating lease liability of lessee." } } }, "auth_ref": [] }, "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"], "lang": { "en-us": { "role": { "label": "aytu_LesseeOperatingLeaseLiabilityToBePaidIncludingLeaseNotYetCommenced", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease, including lease not yet commenced." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r488"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r80", "r128", "r517", "r680", "r715", "r729", "r799"] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r67", "r151", "r180", "r252", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r429", "r430", "r431", "r462", "r680", "r755", "r805", "r806"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent", "totalLabel": "Total non-current liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r16", "r70", "r71", "r72", "r73", "r180", "r252", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r429", "r430", "r431", "r462", "r755", "r805", "r806"] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract", "presentation": ["http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details"], "lang": { "en-us": { "role": { "label": "LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Current liabilities of discontinued operations", "totalLabel": "Total current liabilities of discontinued operations", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r1", "r45", "r58", "r104", "r106", "r149", "r150"] }, "aytu_LiabilityPrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "LiabilityPrefundedWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Liability Pre-Funded Warrants [Member]", "documentation": "Represents information pertaining to pre-funded warrants classified as liabilities." } } }, "auth_ref": [] }, "aytu_LiabilityWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "LiabilityWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Liability Warrants [Member]", "documentation": "Represents liability warrants." } } }, "auth_ref": [] }, "aytu_LicensingAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20240930", "localname": "LicensingAgreementsTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-18-license-agreements"], "lang": { "en-us": { "role": { "label": "Licensing Agreements [Text Block]", "documentation": "The entire disclosure for licensing agreements." } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCredit", "terseLabel": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r16", "r126", "r816"] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual"], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": ["r64", "r69", "r714", "r753", "r754"] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": ["r64", "r69", "r714", "r753"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r64", "r69"] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity", "terseLabel": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": ["r64", "r69", "r301"] }, "aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment": { "xbrltype": "percentItemType", "nsuri": "http://aytubio.com/20240930", "localname": "LineOfCreditFacilityTerminationFeePercentageOfCommitment", "presentation": ["http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_LineOfCreditFacilityTerminationFeePercentageOfCommitment", "terseLabel": "Line of Credit Facility, Termination, Fee, Percentage of Commitment", "documentation": "Represents the percentage of commitment used as a termination fee of a line of credit facility." } } }, "auth_ref": [] }, "us-

gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": ["http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LoanProcessingFee": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoanProcessingFee", "crdr": "debit", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LoanProcessingFee", "terseLabel": "Loan Processing Fee", "documentation": "Expenses paid for obtaining loans which includes expenses such as application and origination fees." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "Total debt, net of current portion", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": ["r16", "r512"] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent", "negatedLabel": "Less: current portion of debt", "documentation": "Amount of long-term debt and lease obligation, classified as current." } } }, "auth_ref": ["r66"] }, "aytu_LongTermDebtAndCapitalLeaseObligationsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "LongTermDebtAndCapitalLeaseObligationsGross", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details"], "lang": { "en-us": { "role": { "label": "aytu_LongTermDebtAndCapitalLeaseObligationsGross", "totalLabel": "Total future principal payments", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt and capital lease obligations." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "totalLabel": "Total debt", "documentation": "Amount of long-term debt and lease obligation, including portion classified as current." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Current portion of debt", "negatedLabel": "Less: current portion of debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": ["r158"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details": { "parentTag": "aytu_LongTermDebtAndCapitalLeaseObligationsGross", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r7", "r183", "r322"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "terseLabel": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r7", "r183", "r322"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details": { "parentTag": "aytu_LongTermDebtAndCapitalLeaseObligationsGross", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "terseLabel": "2028", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r7", "r183", "r322"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details": { "parentTag": "aytu_LongTermDebtAndCapitalLeaseObligationsGross", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "terseLabel": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r7", "r183", "r322"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details": { "parentTag": "aytu_LongTermDebtAndCapitalLeaseObligationsGross", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "terseLabel": "2025 (remaining 9 months)", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": ["r716"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Debt, net of current portion", "terseLabel": "Total debt, net of current portion", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r159"] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt"], "lang": { "en-us": { "role": { "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": ["r109"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r16", "r745", "r746", "r747"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r16", "r28", "r745", "r746", "r747"] }, "aytu_ManufacturingEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "ManufacturingEquipmentMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details"], "lang": { "en-us": { "role": { "label": "Manufacturing Equipment [Member]", "documentation": "Represents manufacturing equipment." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": ["r297", "r298", "r299", "r300", "r365", "r402", "r446", "r501", "r544", "r546", "r553", "r563", "r564", "r615", "r616", "r617", "r618", "r619", "r623", "r624", "r642", "r650", "r658", "r665", "r666", "r667", "r668", "r682", "r757", "r807", "r808", "r809", "r810", "r811", "r812"] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": ["r795", "r796", "r797"] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": ["r795", "r796", "r797"] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": ["r665", "r795", "r796", "r797"] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": ["r795", "r796", "r797"] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputSharePriceMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": ["r795", "r796", "r797"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r444", "r445", "r446", "r665"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } }

```
}, "auth_ref": [ "r444", "r445", "r446", "r665" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"MinimumMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details",
"http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual",
"http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual",
"http://aytubio.com/20240930/role/statement-note-7-intangible-assets", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-
us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r365", "r402", "r446", "r501", "r544", "r546", "r553", "r563", "r564", "r615",
"r616", "r617", "r618", "r619", "r623", "r624", "r642", "r650", "r658", "r665", "r666", "r667", "r682", "r757", "r807", "r808", "r809", "r810", "r811", "r812" ] },
"ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [
"r703" ] }, "aytu_Neos2015PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "Neos2015PlanMember", "presentation": [
"http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual" ],
"lang": { "en-us": { "role": { "label": "Neos 2015 Plan [Member]", "documentation": "Represents Neos 2015 plan." } } }, "auth_ref": [] }, "us-
gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-
flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0,
"order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-
gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow)
from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a
return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors
on long-term credit." } } }, "auth_ref": [ "r173" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://aytubio.com/20240930/role/statement-
unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-
gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-
flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0,
"order": 2.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-
gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow)
from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity
instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r173" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" }
} }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": {
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 }
}, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating
activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing
activities." } } }, "auth_ref": [ "r97", "r98", "r99" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://aytubio.com/20240930/role/statement-
unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-
gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": {
"http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": "us-
gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 0.0 }, "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-
of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://aytubio.com/20240930/role/statement-unaudited-
consolidated-statements-of-operations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-
17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows",
"http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-
statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Net income (loss)", "totalLabel": "Net income (loss)", "terseLabel": "Net income (loss)",
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r91", "r99", "r131", "r150", "r164",
"r165", "r169", "r180", "r187", "r189", "r190", "r191", "r192", "r193", "r196", "r197", "r213", "r252", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310",
"r422", "r426", "r441", "r462", "r522", "r592", "r608", "r609", "r695", "r755" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": {
"http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": null, "weight": null, "order": null, "root": true
} }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label":
"us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "totalLabel": "Net income (loss)", "documentation": "Amount, after deduction of tax, noncontrolling
interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r171", "r189", "r190", "r191",
"r192", "r200", "r201", "r214", "r217", "r426" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": {
"http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": null, "weight": null, "order": null, "root": true
} }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label":
"us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "totalLabel": "Adjusted numerator - net loss", "documentation": "Amount, after deduction of tax,
noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common
shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r171", "r202", "r209", "r210", "r211", "r212", "r214", "r217" ] },
"aytu_NetLossFromDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname":
"NetLossFromDiscontinuedOperationsMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-
details" ], "lang": { "en-us": { "role": { "label": "Net Loss From Discontinued Operations [Member]", "documentation": "Relating to net loss from discontinued operations." } }
}, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": {
"en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting
pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] },
"ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1
Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r703" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label":
"ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r703" ] }, "us-
gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": {
"en-us": { "role": { "label": "Non-cash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_NonmonetaryTransactionTypeAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonmonetaryTransactionTypeAxis", "presentation": [ "http://aytubio.com/20240930/role/statement-note-16-warrants",
"http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Axis]",
"documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": [ "r491", "r492",
"r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679" ] }, "us-gaap_NonmonetaryTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "NonmonetaryTransactionTypeDomain", "presentation": [ "http://aytubio.com/20240930/role/statement-note-16-warrants",
"http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Domain]",
"documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": [ "r491", "r492",
"r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679" ] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-
note-15-equity-incentive-plans-tables" ], "lang": { "en-us": { "role": { "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular
disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r14" ] }, "aytu_NoteToFinancialStatementDetailsTextual": { "xbrltype":
"stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial
Statement Details Textual" } } }, "auth_ref": [] }, "aytu_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930",
"localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] },
"aytu_OfficeEquipmentFurnitureAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname":
"OfficeEquipmentFurnitureAndOtherMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-
equipment-details" ], "lang": { "en-us": { "role": { "label": "Office Equipment, Furniture and Other [Member]", "documentation": "Represents office equipment, furniture and
other." } } }, "auth_ref": [] }, "aytu_OfficeSpaceInBerwynPennsylvaniaMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname":
"OfficeSpaceInBerwynPennsylvaniaMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases", "http://aytubio.com/20240930/role/statement-note-
6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Office Space in Berwyn, Pennsylvania [Member]", "documentation": "Relating to an office space in Berwyn,
Pennsylvania." } } }, "auth_ref": [] }, "aytu_OnOrBeforeJanuary262023Member": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname":
"OnOrBeforeJanuary262023Member", "presentation": [ "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility",
"http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual" ], "lang": { "en-us": { "role": { "label": "On or Before January 26, 2023
[Member]", "documentation": "Relating to on or before January 26, 2023." } } }, "auth_ref": [] }, "aytu_OnOrBeforeJune122025Member": { "xbrltype": "domainItemType",
"nsuri": "http://aytubio.com/20240930", "localname": "OnOrBeforeJune122025Member", "presentation": [ "http://aytubio.com/20240930/role/statement-note-11-longterm-
debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "On or Before June 12 2025 [Member]",
"documentation": "Termination is on or before the date of June 12 2025" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenseMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingExpenseMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details" ],
"lang": { "en-us": { "role": { "label": "Operating Expense [Member]", "documentation": "Primary financial statement caption encompassing expenses associated with normal
operations." } } }, "auth_ref": [ "r13" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingExpenses", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-
gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations"
], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with
normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and
administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingExpensesAbstract", "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": {
```

```
"label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r134", "r638", "r723", "r724", "r725", "r726", "r727" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r483", "r671" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": { "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-details-textual", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total lease liabilities", "label": "us-gaap_OperatingLeaseLiability", "terseLabel": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r475" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details" ], "lang": { "en-us": { "role": { "label": "Current: operating leases", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r475" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r476" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseLiabilityNoncurrent", "terseLabel": "Non-current: operating leases", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r475" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r476" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r480", "r485" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-details-textual", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "terseLabel": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r474" ] }, "aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "OperatingLeaseUndiscountedMinimumMonthlyPayment", "crdr": "credit", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "aytu_OperatingLeaseUndiscountedMinimumMonthlyPayment", "terseLabel": "Operating Lease, Undiscounted Minimum Monthly Payment", "documentation": "Represents the undiscounted minimum monthly payment on an operating lease." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Operating lease assets", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r487", "r671" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Operating lease assets (Year)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r486", "r671" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-note-1-nature-of-business" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r43", "r120", "r554", "r555" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Other accrued liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r66" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherAssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r162", "r680" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Other non-current assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r156" ] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-9-other-liabilities", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenseMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Other Expense [Member]", "documentation": "Primary financial statement caption encompassing other expense." } } }, "auth_ref": [ "r13" ] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherLiabilities", "totalLabel": "Total other liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r125", "r511", "r567", "r568", "r696", "r817", "r853" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "negatedLabel": "Less: current portion of other liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r66", "r680" ] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-note-9-other-liabilities" ], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r66", "r71", "r743" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Total non-current portion of other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r71" ] }, "us-gaap_OtherLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesTableTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "Other Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherNoncashIncomeExpense", "negatedLabel": "Other non-cash adjustments", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r99" ] }, "aytu_OtherNoncashInvestingAndFinancingItems": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "OtherNoncashInvestingAndFinancingItems", "crdr": "credit", "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Other non-cash investing and financing activities", "documentation": "Represents the amount of other noncash investing and financing items." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual" ], "lang": { "en-us": { "role": { "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Other income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r94" ] }, "us-gaap_OtherSundryLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherSundryLiabilities", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details": { "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherSundryLiabilities", "terseLabel": "Other", "documentation": "The aggregate carrying amount, as of the balance sheets date, of obligations not otherwise itemized or
```

categorized in the footnotes to the financial statements." } } }, "auth_ref": ["r66", "r71", "r125"] }, "aytu_OtherWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "OtherWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details"], "lang": { "en-us": { "role": { "label": "Other Warrants [Member]", "documentation": "Relating to other warrants." } } }, "auth_ref": [] }, "aytu_OutsideEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "OutsideEquityIncentivePlanMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "Outside Equity Incentive Plan [Member]", "documentation": "Relating to outside the equity incentive plan." } } }, "auth_ref": [] }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentOfFinancingAndStockIssuanceCosts", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentOfFinancingAndStockIssuanceCosts", "terseLabel": "Payment of Financing and Stock Issuance Costs", "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities." } } }, "auth_ref": ["r19"] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities", "negatedLabel": "Other investing activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": ["r707", "r711"] }, "aytu_PaymentsOfFixedPaymentArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "PaymentsOfFixedPaymentArrangements", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "aytu_PaymentsOfFixedPaymentArrangements", "negatedLabel": "Payment made to fixed payment arrangements", "documentation": "The cash outflow for fixed payments arrangements." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfStockIssuanceCosts", "terseLabel": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of stock issuance costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r19"] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireProductiveAssets", "negatedLabel": "Cash payments for fixed asset purchases", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": ["r136", "r787", "r788", "r789"] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785"] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": ["http://aytubio.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r74", "r332"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred stock, authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r74", "r572"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred stock, issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r74", "r332"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred stock, outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r74", "r572", "r590", "r855", "r856"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r74", "r514", "r680"] }, "aytu_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "PrefundedWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Pre-Funded Warrants [Member]", "documentation": "Relating to the Pre-Funded Warrants." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r161", "r257", "r258", "r629"] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrimeRateMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": ["http://aytubio.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": ["r709"] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity", "terseLabel": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": ["r3", "r558"] }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Net proceeds received from (payments made on) revolving credit facility", "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Cash received from sales of fixed assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": ["r95"] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromWarrantExercises", "terseLabel": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r712"] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductAndServiceOtherMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": ["r759"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r248", "r502", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r626", "r652", "r681", "r682", "r683", "r685", "r686", "r751", "r752", "r758", "r820", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r248", "r502", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r626", "r652", "r681", "r682", "r683", "r685", "r686", "r751", "r752", "r758", "r820", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis",

```
"presentation": [ "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6", "r489" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r103", "r140", "r143", "r144" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r105", "r153", "r519" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 4.0 }, "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r489", "r508", "r519", "r680" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-tables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r105", "r489" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r358", "r365", "r392", "r393", "r394", "r402", "r446", "r498", "r499", "r501", "r544", "r546", "r553", "r563", "r564", "r615", "r616", "r617", "r618", "r619", "r623", "r624", "r642", "r650", "r658", "r665", "r666", "r667", "r668", "r682", "r689", "r748", "r757", "r796", "r808", "r809", "r810", "r811", "r812" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r358", "r365", "r392", "r393", "r394", "r402", "r446", "r498", "r499", "r501", "r544", "r546", "r553", "r563", "r564", "r615", "r616", "r617", "r618", "r619", "r623", "r624", "r642", "r650", "r658", "r665", "r666", "r667", "r668", "r682", "r689", "r748", "r757", "r796", "r808", "r809", "r810", "r811", "r812" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfLongTermDebt", "negatedLabel": "Payments made to borrowings", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r96", "r559" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://aytubio.com/20240930/role/statement-note-7-intangible-assets", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r181", "r182", "r314", "r334", "r494", "r500", "r509", "r634", "r635" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r403", "r625", "r640", "r813" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "aytu_RestrictedStockAndRestrictedStockUnitsRsusMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "RestrictedStockAndRestrictedStockUnitsRsusMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Restricted Stock and Restricted Stock Units (RSUs) [Member]", "documentation": "Share instruments in which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r23" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-note-19-restructuring-costs-" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r285", "r286", "r287", "r290", "r294" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Restructuring costs", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r5", "r291", "r292", "r749" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r77", "r113", "r516", "r551", "r552", "r560", "r573", "r680" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r147", "r184", "r185", "r186", "r188", "r193", "r195", "r197", "r253", "r254", "r281", "r414", "r415", "r419", "r420", "r421", "r423", "r425", "r426", "r432", "r434", "r435", "r437", "r439", "r472", "r473", "r548", "r550", "r561", "r855" ] }, "aytu_ReturnReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "ReturnReserveCurrent", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Return reserve", "documentation": "Represents the amount of return reserve classified as current." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenue", "label": "Net revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r132", "r133", "r222", "r226", "r227", "r240", "r245", "r248", "r249", "r250", "r355", "r356", "r502" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://aytubio.com/20240930/role/statement-note-3-revenue" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer,
```

judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r146", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r357"] }, "aytu_ReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "ReverseStockSplitMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Reverse Stock Split [Member]", "documentation": "The conversion of a reverse stock split where there is a reduction in the shares outstanding." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r703"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r703"] }, "aytu_RxSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "RxSegmentMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Rx Segment [Member]", "documentation": "Relating to the Rx Segment." } } }, "auth_ref": [] }, "aytu_SaleOfStockMaximumAmountOfEquityIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "SaleOfStockMaximumAmountOfEquityIssuable", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_SaleOfStockMaximumAmountOfEquityIssuable", "terseLabel": "Sale of Stock, Maximum Amount of Equity Issuable", "documentation": "Represents the maximum monetary amount of equity issuable." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] } }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SaleOfStockPricePerShare", "terseLabel": "Sale of Stock, Price Per Share (in dollars per share)", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r198", "r366", "r705", "r720"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r23"] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": ["r36"] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": ["r16", "r31", "r32", "r42", "r111", "r112", "r646", "r648", "r716", "r800"] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-tables"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r8", "r12", "r17", "r45", "r51", "r52", "r53", "r54", "r55", "r59", "r61", "r62", "r107"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r722"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r793", "r794"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r644", "r737"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-4-inventories-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r18", "r81", "r82", "r83"] }, "aytu_ScheduleOfLeaseByBalanceSheetInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20240930", "localname": "ScheduleOfLeaseByBalanceSheetInformationTableTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-6-leases-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Lease by Balance Sheet Information [Table Text Block]", "documentation": "Tabular disclosure of leases by balance sheet information." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r7"] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": ["r116"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r10", "r11", "r115"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-16-warrants-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r33"] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": ["r644", "r739"] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual"], "lang": { "en-us": { "role": { "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": ["r791"] }, "aytu_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]", "documentation": "Relating to the Securities Purchase Agreement." } } }, "auth_ref": [] }, "aytu_SecuritiesPurchaseAgreementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "SecuritiesPurchaseAgreementWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity",

"http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement Warrants [Member]", "documentation": "Relating to the Securities Purchase Agreement Warrants." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r697"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r699"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r132", "r133", "r134", "r135", "r222", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r250", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r280", "r289", "r293", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r639", "r640", "r641", "r643", "r684", "r820", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851"] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Selling and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details"], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": ["r92"] }, "us-gaap_SettlementLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SettlementLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SettlementLiabilitiesCurrent", "terseLabel": "Settlement Liabilities, Current", "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation expense", "label": "us-gaap_ShareBasedCompensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r4"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r659"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r384"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)", "periodStartLabel": "Unvested, shares (in shares)", "periodEndLabel": "Unvested, shares (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r381", "r382"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodStartLabel": "Unvested, weighted average grant date fair value (in dollars per share)", "periodEndLabel": "Unvested, weighted average grant date fair value (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r381", "r382"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Vested, shares (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r385"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details"], "lang": { "en-us": { "role": { "label": "Vested, weighted average grant date fair value (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r385"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r661"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r34"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Exercisable, options (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r375"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Exercisable, options, weighted average exercise price (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r375"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited/Cancelled, options (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r379"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } },

"auth_ref": ["r377"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)", "periodStartLabel": "Outstanding, options (in shares)", "periodEndLabel": "Outstanding, options (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r373", "r374"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Outstanding, options, weighted average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, options, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r373", "r374"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details"], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Forfeited/Cancelled, options, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r379"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r660"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Exercisable, options, weighted average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r34"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Outstanding, options, weighted average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r117"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-stockholders-equity"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Revolving credit facility", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r63", "r124", "r680", "r815"] }, "us-gaap_ShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility"], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Text Block]", "documentation": "The entire disclosure for short-term debt." } } }, "auth_ref": ["r109"] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details"], "lang": { "en-us": { "role": { "label": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": ["r484", "r671"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r100", "r178"] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r132", "r133", "r134", "r135", "r148", "r222", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r250", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r280", "r283", "r289", "r293", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r639", "r640", "r641", "r643", "r684", "r820", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r9", "r75", "r78", "r79", "r147", "r167", "r168", "r169", "r184", "r185", "r186", "r188", "r193", "r195", "r197", "r223", "r253", "r254", "r281", "r346", "r414", "r415", "r419", "r420", "r421", "r423", "r425", "r426", "r432", "r433", "r434", "r435", "r436", "r437", "r439", "r463", "r464", "r465", "r466", "r467", "r468", "r472", "r473", "r493", "r523", "r548", "r549", "r550", "r561", "r610"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://aytubio.com/20240930/role/statement-note-1-nature-of-business", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-tables", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-details-textual", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-tables", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-tables", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "http://aytubio.com/20240930/role/statement-note-16-warrants-tables", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-tables", "http://aytubio.com/20240930/role/statement-note-18-license-agreements", "http://aytubio.com/20240930/role/statement-note-19-restructuring-costs-", "http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations", "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-tables", "http://aytubio.com/20240930/role/statement-note-3-revenue", "http://aytubio.com/20240930/role/statement-note-3-revenue-details-textual", "http://aytubio.com/20240930/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://aytubio.com/20240930/role/statement-note-3-revenue-tables", "http://aytubio.com/20240930/role/statement-note-4-inventories", "http://aytubio.com/20240930/role/statement-note-4-inventories-details-textual", "http://aytubio.com/20240930/role/statement-note-4-inventories-schedule-of-inventories-details", "http://aytubio.com/20240930/role/statement-note-4-inventories-tables", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-details-textual", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-tables", "http://aytubio.com/20240930/role/statement-note-6-leases", "http://aytubio.com/20240930/role/statement-note-6-leases-details-textual", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details", "http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "http://aytubio.com/20240930/role/statement-note-6-leases-tables", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textual", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-tables", "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities", "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details",

"http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-tables", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-tables", "http://aytubio.com/20240930/role/statement-significant-accounting-policies-policies", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets-parentheticals", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r184", "r185", "r186", "r223", "r473", "r502", "r556", "r562", "r565", "r566", "r567", "r568", "r569", "r570", "r572", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r585", "r586", "r587", "r588", "r589", "r591", "r593", "r594", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r610", "r690"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r198", "r366", "r705", "r706", "r720"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://aytubio.com/20240930/role/statement-note-1-nature-of-business", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility", "http://aytubio.com/20240930/role/statement-note-10-revolving-credit-facility-details-textual", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-future-principal-payments-details", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-tables", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-details-textual", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-tables", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-valuation-assumptions-details", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-stock-option-activity-details", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-tables", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details", "http://aytubio.com/20240930/role/statement-note-16-warrants-tables", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-tables", "http://aytubio.com/20240930/role/statement-note-18-license-agreements", "http://aytubio.com/20240930/role/statement-note-19-restructuring-costs-", "http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://aytubio.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations", "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-tables", "http://aytubio.com/20240930/role/statement-note-3-revenue", "http://aytubio.com/20240930/role/statement-note-3-revenue-details-textual", "http://aytubio.com/20240930/role/statement-note-3-revenue-disaggregation-of-revenue-details", "http://aytubio.com/20240930/role/statement-note-3-revenue-tables", "http://aytubio.com/20240930/role/statement-note-4-inventories", "http://aytubio.com/20240930/role/statement-note-4-inventories-details-textual", "http://aytubio.com/20240930/role/statement-note-4-inventories-schedule-of-inventories-details", "http://aytubio.com/20240930/role/statement-note-4-inventories-tables", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-details-textual", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-tables", "http://aytubio.com/20240930/role/statement-note-6-leases", "http://aytubio.com/20240930/role/statement-note-6-leases-details-textual", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-balance-sheet-information-details-parentheticals", "http://aytubio.com/20240930/role/statement-note-6-leases-lease-cost-details", "http://aytubio.com/20240930/role/statement-note-6-leases-schedule-of-lease-liability-maturity-details", "http://aytubio.com/20240930/role/statement-note-6-leases-tables", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textual", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-future-amortization-expense-details", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-tables", "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities", "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details", "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-tables", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-tables", "http://aytubio.com/20240930/role/statement-significant-accounting-policies-policies", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets-parentheticals", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r184", "r185", "r186", "r223", "r251", "r473", "r502", "r556", "r562", "r565", "r566", "r567", "r568", "r569", "r570", "r572", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r585", "r586", "r587", "r588", "r589", "r591", "r593", "r594", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r610", "r690"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockIssuedDuringPeriodSharesNewIssues", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r9", "r74", "r75", "r113", "r558", "r610", "r620"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r9", "r74", "r75", "r113"] }, "aytu_StockIssuedDuringPeriodSharesWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://aytubio.com/20240930", "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Issuance of common stock from exercise of warrants (in shares)", "terseLabel": "Stock Issued During Period, Shares, Warrants Exercised (in shares)", "documentation": "The number of shares issued for the warrants exercised." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r35", "r74", "r75", "r113"] }, "aytu_StockIssuedDuringPeriodValueWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Issuance of common stock from exercise of warrants", "documentation": "The value of stock issued for warrants exercised" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-stockholders-equity"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r75", "r78", "r79", "r101", "r574", "r590", "r611", "r612", "r680", "r696", "r715", "r729", "r799", "r855"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-balance-sheets"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r110", "r179", "r331", "r333", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r346", "r438", "r613", "r614", "r621"] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": ["http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": ["r114"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionAgreementExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://aytubio.com/20240930", "localname": "SupplyAndDistributionAgreementExtensionTerm", "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionAgreementExtensionTerm", "terseLabel": "Supply and Distribution Agreement, Extension Term (Year)", "documentation": "Represents the

extension term of a supply and distribution agreement." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionAgreementFirstMilestoneMinimumNetRevenues", "terseLabel": "Supply and Distribution Agreement, First Milestone, Minimum Net Revenues", "documentation": "The amount of net revenues to be reached to trigger the first milestone obligation of the supply and distribution agreement." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "SupplyAndDistributionAgreementMaximumMilestoneObligations", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionAgreementMaximumMilestoneObligations", "terseLabel": "Supply and Distribution Agreement, Maximum Milestone Obligations", "documentation": "The maximum amount of milestone obligations of the supply and distribution agreement." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "SupplyAndDistributionAgreementMaximumYearlyMakewholePayment", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionAgreementMaximumYearlyMakewholePayment", "terseLabel": "Supply and Distribution Agreement, Maximum Yearly Make-whole Payment", "documentation": "The maximum amount of make-whole payment per year under supply and distribution agreement." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionAgreementMinimumSalesPerYear": { "xbrltype": "decimalItemType", "nsuri": "http://aytubio.com/20240930", "localname": "SupplyAndDistributionAgreementMinimumSalesPerYear", "presentation": ["http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionAgreementMinimumSalesPerYear", "terseLabel": "Supply and Distribution Agreement, Minimum Sales Per Year", "documentation": "Th minimum amount of units to be sold per year under supply and distribution agreement." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit": { "xbrltype": "monetaryItemType", "nsuri": "http://aytubio.com/20240930", "localname": "SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionAgreementRoyaltyMakeWholePaymentUnderMinimumSalesCommitmentPerUnit", "terseLabel": "Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit", "documentation": "The amount of royalty make-whole payment per unit for sales under the minimum units for the supply and distribution agreement." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionCommitmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://aytubio.com/20240930", "localname": "SupplyAndDistributionCommitmentPeriod", "presentation": ["http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionCommitmentPeriod", "terseLabel": "Supply and Distribution Commitment, Period (Year)", "documentation": "Period covered by the supply and distribution commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales": { "xbrltype": "percentItemType", "nsuri": "http://aytubio.com/20240930", "localname": "SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales", "presentation": ["http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "aytu_SupplyAndDistributionCommitmentRoyaltyPercentageOfNetSales", "terseLabel": "Supply and Distribution Commitment, Royalty, Percentage of Net Sales", "documentation": "The percentage of net sales to be paid for royalties under supply and distribution agreement." } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-tables", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-tables", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-tables", "http://aytubio.com/20240930/role/statement-note-16-warrants-tables", "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-tables", "http://aytubio.com/20240930/role/statement-note-20-discontinued-operations-tables", "http://aytubio.com/20240930/role/statement-note-3-revenue-tables", "http://aytubio.com/20240930/role/statement-note-4-inventories-tables", "http://aytubio.com/20240930/role/statement-note-5-property-and-equipment-tables", "http://aytubio.com/20240930/role/statement-note-6-leases-tables", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-tables", "http://aytubio.com/20240930/role/statement-note-8-accrued-liabilities-tables", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-tables"], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-7-intangible-assets-schedule-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": ["r15", "r732", "r733", "r734", "r735", "r736", "r738", "r741", "r742"] }, "aytu_The2015PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "The2015PlanMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "The 2015 Plan [Member]", "documentation": "Represents the Aytu BioScience 2015 Stock Option and Incentive Plan (the \u201c2015 Plan\u201d)." } } }, "auth_ref": [] }, "aytu_The2020ShelfMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "The2020ShelfMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "The 2020 Shelf [Member]", "documentation": "Relating to the 2020 Shelf." } } }, "auth_ref": [] }, "aytu_The2023EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "The2023EquityIncentivePlanMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans", "http://aytubio.com/20240930/role/statement-note-15-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "The 2023 Equity Incentive Plan [Member]", "documentation": "Relating to the 2023 Equity Incentive Plan." } } }, "auth_ref": [] }, "aytu_The2024ShelfMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "The2024ShelfMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "The 2024 Shelf [Member]", "documentation": "Represents the The 2021 Shelf registration." } } }, "auth_ref": [] }, "aytu_TheAugust2022OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "TheAugust2022OfferingMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "The August 2022 Offering [Member]", "documentation": "Relating to the August 2022 Offering." } } }, "auth_ref": [] }, "aytu_ThePediatricPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "ThePediatricPortfolioMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-3-revenue-disaggregation-of-revenue-details"], "lang": { "en-us": { "role": { "label": "The Pediatric Portfolio [Member]", "documentation": "Represents the Pediatric Portfolio." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://aytubio.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "aytu_TrancheACommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "TrancheACommonWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Tranche A Common Warrants [Member]", "documentation": "Relating to Tranche A Common Warrants." } } }, "auth_ref": [] }, "aytu_TrancheBCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "TrancheBCommonWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Tranche B Common Warrants [Member]", "documentation": "Relating to the Tranche B Common Warrants." } } }, "auth_ref": [] }, "aytu_TrancheBPrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "TrancheBPrefundedWarrantsMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements", "http://aytubio.com/20240930/role/statement-note-12-fair-value-measurements-details-textual", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Tranche B Pre-Funded Warrants [Member]", "documentation": "Represents the Tranche B Pre-Funded Warrants" } } }, "auth_ref": [] }, "aytu_TrisKarbinalAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aytubio.com/20240930", "localname": "TrisKarbinalAgreementMember", "presentation": ["http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets", "http://aytubio.com/20240930/role/statement-note-7-intangible-assets-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "Tris Karbinal Agreement [Member]", "documentation": "Relating to Tris Karbinal Agreement." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies", "http://aytubio.com/20240930/role/statement-note-13-commitments-and-contingencies-details-textual", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities", "http://aytubio.com/20240930/role/statement-note-9-other-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r427"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://aytubio.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r24", "r25", "r26", "r138", "r139", "r141", "r142"] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt", "http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": ["http://aytubio.com/20240930/role/statement-note-11-longterm-debt-details-textual", "http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstanding", "terseLabel": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": ["r795", "r796", "r797"] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://aytubio.com/20240930/role/statement-note-14-stockholders-equity-details-textual", "http://aytubio.com/20240930/role/statement-note-16-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term (Year)", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r795", "r796", "r797"] }, "aytu_WarrantsOrRightsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20240930", "localname": "WarrantsOrRightsDisclosureTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-note-16-warrants"], "lang": { "en-us": { "role": { "label": "Warrants or Rights Disclosure [Text Block]", "documentation": "The entire disclosure for warrants or rights." } } }, "auth_ref": [] }, "aytu_WarrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aytubio.com/20240930", "localname": "WarrantsPolicyTextBlock", "presentation": ["http://aytubio.com/20240930/role/statement-

```
significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Warrants [Policy Text Block]", "documentation": "Disclosure of the company's accounting policy regarding warrants." } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "WeightedAverageMember", "presentation": [ "http://aytubio.com/20240930/role/statement-note-16-warrants-schedule-of-warrants-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r446", "r499", "r623", "r624", "r665", "r807", "r809", "r812" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Diluted weighted-average common shares outstanding (note 17) (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r202", "r217" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aytubio.com/20240930/role/statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "http://aytubio.com/20240930/role/statement-unaudited-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Basic weighted-average common shares outstanding (note 17) (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r200", "r217" ] }, "aytu_statement-statement-note-11-longterm-debt-future-principal-payments-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-11-longterm-debt-future-principal-payments-details", "lang": { "en-us": { "role": { "label": "Note 11 - Long-term Debt - Future Principal Payments (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-11-longterm-debt-schedule-of-longterm-debt-details", "lang": { "en-us": { "role": { "label": "Note 11 - Long-term Debt - Schedule of Long-term Debt (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-11-longterm-debt-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-11-longterm-debt-tables", "lang": { "en-us": { "role": { "label": "Note 11 - Long-term Debt" } } }, "auth_ref": [] }, "aytu_statement-statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-12-fair-value-measurements-recurring-fair-value-measurements-details", "lang": { "en-us": { "role": { "label": "Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details", "lang": { "en-us": { "role": { "label": "Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-12-fair-value-measurements-summary-of-level-3-changes-details-parentheticals", "lang": { "en-us": { "role": { "label": "Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-12-fair-value-measurements-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-12-fair-value-measurements-tables", "lang": { "en-us": { "role": { "label": "Note 12 - Fair Value Measurements" } } }, "auth_ref": [] }, "aytu_statement-statement-note-12-fair-value-measurements-valuation-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-12-fair-value-measurements-valuation-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 12 - Fair Value Measurements - Valuation Assumptions (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-15-equity-incentive-plans-restricted-stock-activity-details", "lang": { "en-us": { "role": { "label": "Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-15-equity-incentive-plans-restricted-stock-unit-activity-details", "lang": { "en-us": { "role": { "label": "Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-15-equity-incentive-plans-stock-compensation-expense-details", "lang": { "en-us": { "role": { "label": "Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-15-equity-incentive-plans-stock-option-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-15-equity-incentive-plans-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Note 15 - Equity Incentive Plans - Stock Option Activity (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-15-equity-incentive-plans-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-15-equity-incentive-plans-tables", "lang": { "en-us": { "role": { "label": "Note 15 - Equity Incentive Plans" } } }, "auth_ref": [] }, "aytu_statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-16-warrants-schedule-of-warrants-outstanding-details", "lang": { "en-us": { "role": { "label": "Note 16 - Warrants - Schedule of Warrants Outstanding (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-16-warrants-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-16-warrants-tables", "lang": { "en-us": { "role": { "label": "Note 16 - Warrants" } } }, "auth_ref": [] }, "aytu_statement-statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-17-earnings-per-share-schedule-of-antidilutive-securities-details", "lang": { "en-us": { "role": { "label": "Note 17 - Earnings Per Share - Schedule of Anti-Dilutive Securities (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-17-earnings-per-share-schedule-of-earnings-per-share-details", "lang": { "en-us": { "role": { "label": "Note 17 - Earnings Per Share - Schedule of Earnings Per Share (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-17-earnings-per-share-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-17-earnings-per-share-tables", "lang": { "en-us": { "role": { "label": "Note 17 - Earnings Per Share" } } }, "auth_ref": [] }, "aytu_statement-statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-20-discontinued-operations-schedule-of-discontinued-operations-details", "lang": { "en-us": { "role": { "label": "Note 20 - Discontinued Operations - Schedule of Discontinued Operations (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-20-discontinued-operations-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-20-discontinued-operations-tables", "lang": { "en-us": { "role": { "label": "Note 20 - Discontinued Operations" } } }, "auth_ref": [] }, "aytu_statement-statement-note-3-revenue-disaggregation-of-revenue-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-3-revenue-disaggregation-of-revenue-details", "lang": { "en-us": { "role": { "label": "Note 3 - Revenue - Disaggregation of Revenue (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-3-revenue-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-3-revenue-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Revenue" } } }, "auth_ref": [] }, "aytu_statement-statement-note-4-inventories-schedule-of-inventories-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-4-inventories-schedule-of-inventories-details", "lang": { "en-us": { "role": { "label": "Note 4 - Inventories - Schedule of Inventories (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-4-inventories-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-4-inventories-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Inventories" } } }, "auth_ref": [] }, "aytu_statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details", "lang": { "en-us": { "role": { "label": "Note 5 - Property and Equipment - Schedule of Property and Equipment (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-5-property-and-equipment-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-5-property-and-equipment-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Property and Equipment" } } }, "auth_ref": [] }, "aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-6-leases-lease-balance-sheet-information-details", "lang": { "en-us": { "role": { "label": "Note 6 - Leases - Lease Balance Sheet Information (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-6-leases-lease-balance-sheet-information-details-parentheticals", "lang": { "en-us": { "role": { "label": "Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-6-leases-lease-cost-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-6-leases-lease-cost-details", "lang": { "en-us": { "role": { "label": "Note 6 - Leases - Lease Cost (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-6-leases-schedule-of-lease-liability-maturity-details", "lang": { "en-us": { "role": { "label": "Note 6 - Leases - Schedule of Lease Liability Maturity (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-6-leases-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-6-leases-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Leases" } } }, "auth_ref": [] }, "aytu_statement-statement-note-7-intangible-assets-future-amortization-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-7-intangible-assets-future-amortization-expense-details", "lang": { "en-us": { "role": { "label": "Note 7 - Intangible Assets - Future Amortization Expense (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-7-intangible-assets-schedule-of-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Note 7 - Intangible Assets - Schedule of Intangible Assets (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-7-intangible-assets-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-7-intangible-assets-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Intangible Assets" } } }, "auth_ref": [] }, "aytu_statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-8-accrued-liabilities-schedule-of-accrued-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-8-accrued-liabilities-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-8-accrued-liabilities-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Accrued Liabilities" } } }, "auth_ref": [] }, "aytu_statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-9-other-liabilities-schedule-of-other-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 9 - Other Liabilities - Schedule of Other Liabilities (Details)" } } }, "auth_ref": [] }, "aytu_statement-statement-note-9-other-liabilities-tables": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-note-9-other-liabilities-tables", "lang": { "en-us": { "role": { "label": "Note 9 - Other Liabilities" } } }, "auth_ref": [] }, "aytu_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://aytubio.com/20240930", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-11" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r9":
```

{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-13" }, r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 5.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479836/810-10-S99-5" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r144": { "role":
```

"http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r210": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r399": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55",

"Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-5" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r705": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r706": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",

"Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405/tableOfContent" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r838": { "role":

```
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 100 0001437749-24-034970-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-034970-xbrl.zip M4$L#!!0 ( (N*;5FD=+[:/!< *([ 0 1 87ET=2TR,#(T,#DS,"YX M]:\>9]"24C"-@5] M -"QYMT\+B+L0W(1+]'SM[/[:|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|CWN6^(CU4VFSQY*@-3QYR!OVG M|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|=*IEHM$:DXZEZ$E='I$MIG':.,\[Y&ALWTJAR1WZ^A5"]|TZF M;GHM4DH]\:L[*E!LG92'"49B:3?^VXMZ3*1;)(EZ/E=SOF",>FJARM=S+9"6MZ6&FTR)IU/.]:M(4VQ4]J7:=3%77R%IL7AJIL4@9S;,8R@MLQP:G[AR215[4 MB;;(!=).S:"1.27(DO'MBB#L MH14(W!58QT?<7H$Y](J,T=T)7,4K$OXFEM:P;V:8%,W>* M)X#/,'/76\!|-S*H+N;7GO\TGPFK89?N0-$U\)$Y] YCTTL>&=:T[^,\$1LQ;>)1[:36(K,T4]P&O>!YSL)QMVK% M]8,6P^L*J?8XH?M,8O%VPS&$UD*3WUB1/0PCQK-@7RQA66@^VJBS2!&#[R^6 M-G)DCV\WEHW-1>5MEGE@%:\ML*B+6HML:O3UQQ*O5+=PCJPRA)=72.2C()+A M!Q4+U[8V-G?7;9%?FFEE(WZ=;AU:;I3S9(!%OFF MGJJNO#:V2#KMY;([P+G/>R_4_P16*W$S@7R6/,$<;9#Y^ED\@X'D@:2EX,L_ MDH-.YQ$?12TA.<7^'0G]R&/WD/L/_4L(Z7E$Q"+UQ,%@";],FF5!02#N]_TR M83S3Q*'1$V6(1<*LOY(P6GV9"&:@3X@S=.(P[E;Z9!EB#AY97_$WPMV)$S]/ MKF/X,HFW[Z>/.>@HJ!^E (1%Q,0F>_6>Y\YBB,C\+.!#M9*GFB1M//,9<<4O M^HFEDLKNY?WPHYC()HYP$.8$+!,0P'H X)W$[FT%2=JOTJF^> M*Z? (^E!FT\|Q?^74C8+ Q0> .73Y!DGBE?=:.='RX!PMTYY_!?K_[0O\*\ MMX'7(:67)%S&2|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|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|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|^4D M7XWEY/R_&9B36"VFW;3G"S$'AO_EQYEN7U>IKUM4?#KER6W*@^]& )IF3GD] M8P)$ET8/;T@EDX>9"^W2/JCS01%B@ZE<*T6N.OY4\'U%\[#QRC6+2Q5NCK& M] #BY&*NSZEN:^(VA/$\!| @Y1-ZPF/8UTAEF-*Y+D2![-86%O-*0\1_JF*U MZ-BJ-4XL+OZ6J+86_BM!IV_9&L?E*F=L()3OS2+@@0JV!$?WRC^KA% MD4ZB6*Q19G71-VR+WU)E.;9USS5Z*2AIW2KG.*'361EN@ R#X'+/SHI 9K(8%89HH)/:J@:H1(Z.0L:L&$I^1H%0_B<1F*9Z+1>[" MMF@]7%[)%:9D8C"0K$43*9DAU+/$;R(I&1\,M.IA4THF"(,0[_32,S%Z@[H_ M-J7$.)(W]H:P@*:\IA$D%P|&!PD5%*%DRG&PD-43E PY#ECIEI*2Y48_J])" M(TIG:)"VPF:6@ZBI1#C'B) E4:-I!H?)F! UFR7^2Y6:"4IZ:8A=K8<:C-4L ME%01AP=5:D=)$7&PJH9^*2WD.(2E>1%*DC<,"JP927<|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
```

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|$Y8G M-/O;CV=_ ^?G''T@6T3C)IG_[\>M#,'JXN+GY\8>|"+,X3&E&_O9C1G_\W__K MO_^W?_L?02")9(2%!8E_>%K^\#@KLYBP2SHG/_S? _O;'X(??O[MK^]^N_O\ MP]?'BQ_>_?SNE^#L+#A['P3_Z]_2)/OSK^)_GL*<_,"%R/+JGW_[<584B[_^ MJ-/W[]_\O+$TK]0-OWIW<_O_IIT_K'=7/Q:UQL.^PW_O#3ZL=MTZ.AO[^O MVI[]_OOO/U6_;IOF25U#/NC93__W\^U#-"/S,$@R,2.1D"5/_II7?[RE45A4 MT]@(X0=I"_&O8-,L$'*$MX%[_^\I+'/_)9_^&'U=2%+&(T)?=D\L/Z/[_> MWQS/19(5/\7)_*=UFY_"-.4B5R/,&)E(1=U,H)#@@WCV_]SK62P7?!GDR7R1 MDA]_:B]43.=AD@5S,G\BS%"|VC&L"YK,22:^E&#U.%-9)4!#^F"+ (;"&^5CX]>42S(LE*$@=T(39'+D+^&H,8,-B,5 FK/9 4! >; M9(EH>\O_N6XMA:T"SDH*\(0OO&OMZ>-("F-CEY3O5_RIQ?+RU?>1AD\D_=N/LI]7TJ1B%Z9L/2GNI:E?;IU(=4NF M8;IZ]N@ER6L$D[0PEFD2YD_5)U?FP30,%RO!2%KDF[_L)%S_X>^7? VE-"|9 M>>0KY9R/_^2H*2]8&!4'$FOT<(U@0?,P_<1HNQ_ I)4VROFJDDG.WS8Y8] -EG/?^ M[4?.G5>GT%_%JR+QWWXL6+D=;GW &=*A":-ST.12@^^(/]DE/@G]64%4;5NT M:?-W"T3!BB2OZ_7ZHH!-&HCHS/JK>7V*&;V;^J.P+:+U'_D6R1?U55K-*Z=" M9"K^0QOOGEIC\HFI=@['7U7SK@'9#VA7Y]-N-O[MIQJF:I.'G_T>,,)QE5%1 M,BYQ$-&\R --$MXPB@L&#A+!TV]/OT^:?M_O?P*C++XGJ3 YCJ(B>>;?&=&@ MW&V&\C3;TVQ/LSW-]C3;TVR;-+O]F>226O\6IG%R\)PBDCU2^ZUFWE&$YH M=;, ,%)]#%7|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|%!4SBS@)A^08<)YG<"PON #A[07P7$]Q$Y M/HFG"XCN5[3HC@W^0$B_H86= $!T?V.%IW"!0<]M+N/@S%>C4K'&!0?5E8B M,RA"<6%E)!HV/BA4? Q%PRP#!8F/L@!]K5" ^$@+R$T+A8>/L\!=IE", ^)@+ MU(4-18B/R,A#Z:"8\-$7M7D6JI+C8RYJ R\4%S[&HK##0D'AHRO--F\H-JS\ M!!(E <6(E9Y O+-0C%@9BL+%#X6&E9TH_*]0:%A)"2"D!0H1'RMI'C M)KI! <3ND72;4E%E8QDE!XB#:I@3Q?SR%];BZ.LAGA!1YL C%YCBU=XU M*HL99PJ5_W;I?R>41V#I=G&*XX\,03J-CDX]"KW./ MN("?!JQ3[SB4'TASA][E;_Y,@+U\58X3J\KQ9J+N? -6*X<?;.:]:T;UM6 ^2 MR7$/M0V@AJIF D"(W1N.VT.L(PI >-W;C-O#)AU>@[%T\-M6>&; M:>53[-Z*W!)?B^^P>_ - Q2VP]&U>K@ISO@KRN;YRCK_((SS(M:CVH^.Q84V[UWV MVE4 [S!4^:VMZS=:W[:8$?:%9M$])F&O@O;G5T?H8;U:8#>WEJ/=Z3#:'@YW MZ[.AJ0*O7F=OP3LQ"YZOJSL,"Z4:"/BPIOI'X^ LL7K,Q?%K;/[> .^%FAY(MJ&S0=A=M-X65G2]>[T;01G1J;@2TQ:I-J*)#(]'[@)%GDNVF"F@!.NKGPKPC M>:BWW7C;S4GKW?>K57_-]Z$+FE5R?$N*V469%W1.6).VJMO=ZZM>7_7ZZC#U M.$^%/17&2H7-SB&'9/B7(,FXB'QWUG>)UO9U08H5#_;$V!/CDR;&-^N5OX1? MG@CIX@FP)\"> 'L"[FP)\ V"3#\['% (>C\$"T;Y9UWLK \LB3_SY]5F8CJ:.5 ^6FS$ S7&$"W!)\S:, M%SDK]E0@_J^=9/P??ZJN-R-L5;+]B*:X0J1&0J5GG,GX.7Y)Y.:_] *2_=R\5 MVMTN44M7]WKE4]^(N&,E+//K-C332&:KY%8]$]@TH39*11.R&\$P*%$T+#^#%B3)!/L7IROH%\H5FX^\LC_Z]<7)=- M,W45:L-13AJIKR937UC?%];W9O>J(/&%057]IC[N4>R) O<8:/1TC^A4+CSP M+H].Y'SD#QM/]LY7B(M"%?.$OHURQ3RZJ M,_UZ?:2K2@(U-.]=]EM!/YBZL ZPVRE@Z=6=>TNS:2$J09"G0MC$5.M*T;17 MF=6SKVP\-+G[+2M%(KXGQD(BI4=6VLZMM#/*BL?-##;=,:]L[%W'/EO..V'1 M 0$=3%3O*$")KXG045/BA EMLJ9 M52WP3J38?P=G7D8O)H:Z,4*]J&%U\I M!E^G"9D;-W8GS^U#W2LOGSQR;!J?I;%_MC_6- MA8H-Z^]*[-]:BOV;?;&? 25:2M7'@)LJ+$?VID+*YN6VAA+D"*-!Q4]O"?*NB MTXOZE#EH^FLRO4.[W@]>##$W8V?"XQ\H9#D5=G#_31 MFSYZ$QC=]%!7]*YZ@!%?LT9/#=1GC$BE&S*%;X,8<36? CM2<&V,"[$-P@284 M?)[]INV1ZKBC4,6- 3A*/@%*TO*F0DYP9.;_CC4HQ2G,2 K +CO!V7-*\C6![M'V+M0ZR=(QE^R.PUW^S_$'O]3K"|*706U,>'!?H2>#Z("AV04PHR\BY)+9>D M%H5&I=^CWP1AIOI,%JI-'@"Z--->\#WF:>%)5%(PBS.!!K(Q_[-I3@DN9MF&T:\O<_AR_)O)S7+B[I M[YU+=2^N\Y14$CCZS8TTAFJ^16/1+T:;PSOLSW0TEO=7WS*2'M]MQ> [HY"+ M>K%_$"JN%3RT.AH-X@V0WG2'(*-75%^6WE=](*ZRK3H-CRQ2Q8TY$&\@) M)@2PK\3!\O@3,:$"-A%T1@W3-T5U55M4EKBN%_2)F%<5VAR:A2S;1&FC>HQJ M14((B1-)A/.&>VU$WG#OR'#?1NEU:-LI3'SQ47TP'HAE-8O=S]QK_ MU4LT$X=G?$V9AL#&@U@')71NA@:L]7]G%1)8GR_(?E=R?C+R G ZP;NU*V MS?.GW=F"P(\SPA_X\|_.I!.%XU+:RIH(OX!$]&ME1X3=WC2>3 CC1[U2EJ;F M-H1:12F-H!L!I+T]L:#1SJ2 M3O*I,DE]H0>"14]KJW:)6S>A\CX$!E@@$F]ID1=GGD8I^444A7??-UP MBX%%"@,".F=KIU\HU5+-4,40]+K%G4@\DB8=P?=MZ%>A;?+ H%SCF(K/NJWM M:?9V80ZEP05X:5J2T7VJ6I7.]<(;4'ZRIU18H+/7V^S*=/N==@P4&NL$!-U] MJ583T#81NGNM!F>-9C@,$'+W%6I-7BH\) ((TU)=VH[JV5B#^1$E3&OP?AT M/.U@0R#VWU!B-PQ] V+^'27F+JI0N3M;C758>0B?6XP^>\5GKYQP]HJAX]%E MXLJ'=9')'D&01_VOR3(%RC>1C430W)6F<9RDK\$:)7!H70_-W9D>QP*$35<> MU2IO92'=EP6>1*3U8*ZV2!5"P3M8T&\ V< 5UP/_O*5O^[\/8\|X|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|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

~~*M%(]Y#<@H[JT5 M!N,JRA;N+SV*UY]<^G1S?). Z$(2YY#P8T_\?4M/L5QMOL;_T8E&,#]+!B_M)V&:=_+%-KT(:HSW>'>R_N8V->VY,G-1,M:\ ]}H[.%UYU0U1QS))A&]HC7F5 M>;]\.*L)]";Y>5J@7VA6:2[QN1]>EUF.[& *^VXPT 6F^(%*-:;#&XS)5G_M7?R/*&S#__+_ 5!+ P04 " "+BFU96Y(CLX)Y "5Z@8 %0 &%Y=*4M M,C R-# Y,S\?;&%B+GAM;.R]:W/D.)(@^/W,[C]@>\ZFL\Q"5?GH>L[,KD4J MI1KM*E,Z2=FU?6EG;500H6 W@X@F&4JI?_W!P4~~

~~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|^KY_)FDO0*E!NB#5NEO1[--\&?_H";!APS<'M:ANE8@E#-6G' M/\#*N'1BY\5 A77: 4T =MC:M0ID9OJT"^&4N2W9XN\K?B)RK7'VCVU2/JM[M9|:_-7?3R&%X]==TT?@CJ1"9D.=&82?Z73BJY VJ\08JN8\-MZCM?-1OE^FZ M<-7<1PD\HN>FTQ1R1*-C#9ZWSR:U34?U6D6G8HT8575&''EG1X#JZ/;Q8K& MVY0>E.PNAF^;Q<$BZIZ;MRM*2Q$T$(MJ#E'ZH>V:)&V)-0%,L*>X?XS=9R)6 M"R'52F:D70OI+H;L5E/7@B+*K;Y<&0L!V8=-B">FZ.JYR."*> <#G6,7CA$=<(Z;GZ;NH^EC2)QG1DK=Z0KU.=|Y6S+=G*NQI03*/[!QU7#V6S$6ZE##7)JAGR3-=T= M66 1EN0!?-3'%?^%|U'=M:PZ@;%'> R0||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|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|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~~

,NH,WM4MNF6T": M6J!RO=KX6TC8S@)]_U\=$RKMYZM;M,3DT&8 :&F!QGL2%V7&9D])*^I#2KI M)T24[?ULW HX25-Z6Y>;_V&*
[\X1K$A2TM44GN^&FY![_X!LNN2UMT7B#J0B3 M___9DG-+RQO;HK018J?DAN"G;%VW6D@KI[EQ:L_HIB!Q?D7%N^?_1"LNF9QV
MYNG#BP4N[BHJ^3<1:^6TKIK:Z%G1)C3".YFG?"V6K4] ^F$VPZTB!Z3YT7@L MUI^[6"#R2$'XG> ?U9Q.YS(N^&M3V-HXK9=9CK[5BP=$N
2^;6*%*G)&SY1' M3/C(M;8R3MM5D6!"EWDC"C8'WQFNZ?&R$A[JH%X6:*?25\RJJB J(\;72L@ M6M3<.+6WZ#%CIIFB^A8O^-"V-S-.W=T$>
<,$34S2!U5,ID\=[=:/."\A:S6W_WQ9HJVC_>. M*9!9Z1C<4RI P"V&GBZ/M]QBL(KKZ4*10"(2#,&(O/,#8_"@S%>S^@@'F< MP*A|| ,5H(,+#,M''V'A>-3
H'SR"Y2W_@@P$K_YA830L04&Y;-?H C\D6!(MOO@%B=BW"!?3O!)=>09F.!Q>B:T*IF(X0IZ(L0I&03@VGLBU0%<\'!=/)%N0 M\Q^.BB>"+=Q_#X?
&$_$6&H8!!\83:9 MR+4"[PT<"T^$6KF##0Z)5U(L)&8*#HU70BPD| 0.C5=RK"#H"8Z(5S*L() % MCHA7HBL@I!".C">RZX4D'@L.B"
<2[(5BL+&M9,6ZB.LTJU :)2\)E_0?#W$> M4]4T*N<(566TQF&.JHS*X0HE:/J,;CRML3]Q1G(=+YR*L1Y'59B]?743DREI M+"SI'W%>HVWYV@/*._0$UV-
8#J[*LH93_[KUL)3S M\TA4NECEX69[9W;9%&J=!^0+N#5@G0;G0[A!Y!T&IU^^38"]0GTF"+U[53!N M\-K-
+2DDIM(UU)P:O'P,9)8&+SP5(MCM+XSCBUT/I96Z55_K(LEYMU84$!++ MAG"KE:_(M$F<8%0<=9KT1P5@Q1MG6+L:-,JV%#
\CGI0.LCZ9AQU(W2$Y9> M9XRC_I.>D SN)F@JN;^+RGJQB,F7<E7(OL\>BB0AE=0&3A,7,4NJB)J#6.9C*
M@UE9+'J&IPS"4P;!WMYE54BE+*PNT_B"C=P0#Y-1?3$VJZP5-9G%%X1L>*_& M8G<_>N^5XL,@761BJZ:Q]Q%!3ZC8@06T>[WI9\>HQ?
ELL%@%BU6PFHS):G*[MWL:7]']PT5#R9]9-3^KRPHO$)'9&E2[!VM#L#8$:T.P-@1KPSCUH]&JB$$_ M$NI'W>YQJQK2AR@K*)'T?
E./#FCM:T=3$GPZ:$M!6PK:TIBTI:O-5E[!GZ"' M= E:4="*@E84M**@%06M*&A%[FA%\+O;JB;T,5H2O$2D6JT?5/]GG2W9KXI*
MD6P8._H1C(J@*@55*:A*8U*5;C:[^B9G/OJ6GV*4B&JRQBG S M MV-0^)T-LL2=+>,$W15G"+R8U7L>@9 8ETUT.!E(R MFQ-H&[!0Q_D]
(@M!UK.L^>"T"[.>Y1V"\AN4WZ#\!N4W*+_Z5X7T[L#J)[4O MV,BU8MC-ZXN5 +)6NFH OF 4LCF#,4G5F*1B=;!J-OHMRNC(Q6-&YS&*RQ)5
MJA8DP0AVC$E2 KQQP7-(O"=9^9\Q>: ?RR>/!#4?XAMO ,V#R<:\R:8DU9[R
M1_^UHXS^XQ_-4]R(T!.H6K&7#%O(DS4S3N/7^#E;U(O6I<;]W3Q562&FJNUW MXU3=LB%.X(@$34?%6!XV"HX*M:C7/IJN50?&EPBSFK)1OBLEJ^C
$(Q@QX$A)2 X M,((#PST'AH*19T((D]#6ZZ=(O^$BWOWEGOY721<4W4KB!R\ZCC+XBS#A-9L1 MFJG'S\&0K]F<=7C*1M;'/A=[I,!]! H]PRM#P%5Q=
MPK;!-1-<,X=P!-?,OOG%7]<,6+8]XC>$Q(H^]ZNH]4K:!6'49G?S*W@##^1-[MP#ZA@&=5-(L31NM*T7<$&,"X#'KTO](2N 44_)V!M\+2M]
.@3WX^#Y4W<)HJIRAK\7Y1(EV2Q# M*3=_1-K6/+7;-;XEA9,I)&PW7E?5^#D8JHP0/<^GL[/FNK_JB8@48T!X*F@](L1EW8V*XS#5%%G)[0E!*A
MYY+;SBZU]P40F+>*N M4MG8$9*K8EA)LQP['G"#.4P#\<4)!]E!/0UTOD %6#I2QOTV%<'')0^']>QN[)[H*3@W!H[2C9C'CZ,%8(0\R",>8#8
M[NR&.9Q$^4:0B%)*DVIH Z>[I7 &X=?UAC",)PY@_>&Z0"?OV/CTJWL7_O;/ MGV2$J_773O:G]L_^!B4;UM\6V9]
[DOU9/]E/J*C11H6*LN:!3H*J)0WUTT4 M4VJ!!+UMJIN8/YN ^JH]"P[:7%^,#[M!Q/@(&QY=U,[+808*V>&T#O$Z(5[' M\WB=LSPNR^ELE=TK;#T^],&
!T,-NM!$58J*>A+6DKQ:?L,! MZ>667X8V'VJDU_@Y&"HVC>IOT, 785NK5-^0;(%NZ:DMC"WBM+(;\1+G:#]I MJRA2;+]-9WOIH,*]"N\X1%S7]
F1@AW6&U&R>&0XW^$9@41[07N'6"H/RE7< MU0]EEF8Q6>TM:<'5*FUOE?H_]#S(H&,+5$ TK]E@M K/%G[#$&47HNP.X0A1
M=EM$CB/*3J#;8%5=PA=,Y(HV[J#5^H(.]_;#\#O'%RSDX@ON+N2/':00DMG5 MGR\S.(T]>@IV^U A+.U (N_ \I#/';&AVO#1A"NX]
<00$X#A,#X@@9$.NGD^Q@[M0)V2(H3Q/V._FU6/F2YQH&._D[IBI!)T"L;HXU%@U!KA.G:,;&:,?!HK!'"%C M1)@Q
@AZL9LP\BZ:Q1F)GN*\1M$"Q8R3QJ6Y)0J:.B(=R%(2"9 ._]J7HQ^9 MH],;VJAFC,ICWH%=0N"T^<#I$.0[GB#?$'CJ0.#I)3WS_V!'_HZT4A: "NH3
M@@9# ;80&A9"PT)HV$" ^MJ,-@PJNVCUI:LL4N3N+*8EG^RJM>9#<%1.J]==/0P#ZA@&=5-(L31NM*T7<$&,"X#'KTO](2N 44_)V!M\+2M]
*7Q&"M3*TRH^6EK\@*SBEX4-S6AZZ5$ &<:N)-9 N7X*7?6X9B<(_K'7^_F M*)\)_)'<5MI(^ BH:V5'A)VQ^=T1@4M*I$(:9$UUY?D,(&>59#V&G,O%,D2
MM@\I(4?N:5?QV?Z(2AY]Y3- I%2=3>@\JQ;@*,$".%TA5+M0!<,B#L7&\DJ.2S^J2CH_\,X;P<="1HOKBR)DM'3+:.GHE;:;S/)Q
MD_81945"_YH]H6B9QX5RF2G9.)926F!D]"LLA7#Y[M>3C\PUQ@\CY;1 MMO#\]TK3"^T30JM#$;-VJK)"3%7;[Z&TFDNEU481IK\3T::S_>"96Y33&S,]
MPV55O@F=D=;>US3J>,/-Q_!0 'S%U1HQBN$&J%BNF2+1A@T+VUOE?IM")E@ MR[)R1,A(0),_2&UUU"4'X(R@]!^:%X M8DA%L
AEJR",82*H+QC(_4U\=<&7>$_>.NA@1_4%DI!B 3EJ@:J_+V& H8):MY>(X'+ZEB(;(S^K(^A'M$ M%K?BR\(0@J
6B.++N@BQCB'6L6NLHU;GMMT(R$_1CTUH]Y8*:,SCVYZ6HAQY M']9:K3N4OH83&$I?ZR%C?>/*R1"UTT#&=18_9#G]@L+L0?OH)$^!JE"MW)%J
MY;?HB;DK&VWC;DFG1A1@+&P:2J>[6#H]U.?N0-:PJ;DYQ&T'WJ0) I[$5>T6 M(MU#I'N(=/@^EWAWB8*#(]6^XH.(#JF*RVJL$*4D @75RA _AIH!V
MLQOCZELA^Q!C;(;.4+8\1$B'"&EMP(0(Z:.-D X5QD7H .4]W%6N\@6G4(D] M%-X>8^E.UP$*Q:;=J('K>&CIH"5>'0\=&[3$J^,Q98.4>/6F7+*M$J^.'SY:
M;O%0;+KM)-*[CKRI-VWJ(0EOBD\;>4C"]6,HY-L=\!SR[;P5:N6*H8JGH>/$\4T%!T@>^>Z+WFPC'XDT51 4G= MM;5"*1S2(?$$@]D'R7%=,|"3
ZOM7',JG\5X+C5H@.O:G&G$663@AZ@Y^XFS MX,!.&G.:C;/ @.\S'3(LI !!F3T6V2Q+J(=Q4F":ZJ"%8_1$N=9DJ'RY3}> MR[>B6@JJ(QJOL="-H%ZU%
[9E^VY1Q6K-X.*,KMRLNF%?6@FS#=5Z:LR*!- F M::J!F+U)ZSQ]^Q3K&"\D=9I/ZE1(8YB\3-G-9J(D653R#E;I/XW+C J:!U2M MQ-NO6V>[*8:X*"D9:7-
4QV'"4F('B0A?B_1='915MF"DL+#M+V1/]8I?:)I2$3D M)2("C\ZQ^]...@G1IF?9\8"#X%F&2GM873/T!1H O[B+=N;+)E+#IXLN/O80
MTFY(B>0Y7X)+U1#IIP/YA&PPQN>O8E3$QM+<&L4+[D RFLF2ZN%%_R@M26 M4#^CGRU795,K_7U$T!,J:A153-
)5K?'.ZVZGT+OXZ[T\CFWF!.$W96XR ,'! M)^:(3^P|*^/'1T(I8%]6D2"^VTR83 M0N$=@(5%"B7Z3P^!DT5>M*LI
==*NA209<*NE30I>2ZE*H\9%6+ ^A3E*"Z[NI4X MO>UH2<*/]]**KE%9(O12O/1K7+$:_ "NA!*'>44/!C)V:?LV@.%V=QG21)>AN
MCE!U5(1QTR*!#!ATRZ)!!AY3KD""AQY>%P8=#FZKB2R:V!*H. ^JA5Z\-O M449'+AXS2D\44UJKCH8(^4!V;!)0.LPX;>5?!VG-4";" NV(KT[$2^S(JOH
MAG]"Z=7+'$Z:*50,@54>:1".L8C.RYH>=VBRP*3*_M7L[XOG)2I*6&:DB4\$ MXT0P3KA,Y_$9)P!W7;!3!#M%L%,$.T6P4ZC$#7>4'WU9-
'"H],N75E7XSZQ4 M+04QC?*-F:%SDBID*#MJ/)P2,XH\Y/L@51[.2%#FG5/F)^NIN][-G*(.#QT@ MJ*5!+769SN-32T'G=E!,@V(:%-.@F
;%5$4Q51.*K.I27R)!^-E$LJ-#:CJ[I@ORGBY(1JJB MDTQMF* !@7093J/3P&474=!^PO:7]#^@O87M#\5+QE,YO-EC:@@TT5>M*LI
MOXMF<4:BISBO4;1 <5F3YN>.SD3P>):T9S5R#.G14")@&K4:2T&W=D2WOJ23 M]@>;LW6P]J38CRKXNI[&=%K:8-ON"#;?S9/B+/^ZW1UE,R+[)\U
MT%]I]=O#H"IFJ.'@>X$?2D2>&-57Q;*NZ, ^X2&BO#5] $ U\:J@,8,5UT?"F MFANL[QO!GA+L*2[3>83V%+ P$BPKP;
(2+"O!LA(L*TJ)L;J%)U^6DQQ$|^(Z M&,O1U@4;4'^T:P7[V+Q>4:VBK$CH7[,G%"WSN.AJ! ,.9\D&ID2-(1,8D :8 M!4R)H6 <\0 1D^$)U16*+VE_Y]D"?
VONXKN^[LY/:'*24+G458W7\=0 YE: MSO""U6)HMC2KS7F)24,M/1M1>A.OV/*>$!(7CVO]:9(W)#9OC.|:'HY2GC8O M12B:9
:@92#4>0OE>Y%5:DM.RY@#H= ^9PW1TR7[SZY0]!TX&/2"0<]E.H_0 MH
>5K8(]+]CS@CTOV/."/4_%GJ='8/)E#&HP&5&RK:J[+_[-4]S,L&4DX*]K8/IC=I\J*/C%#R> M';5?D1PSNC^8") !0)&E8 5PS@IPGI5+7,;Y[P37R_*J8,
<%/1?.JV9U^C*I M]&>|0"^7U6FM-C\::[AZ%,J:V*0G:=-"F7:;S M^+1I^'425.J@4@>5.JC40:56JAHZC(AE5XF,RGJQB,DJPK.HS!Z+;)8E,?TU M3A)<,RX?
HR7.LX2]1)2B*LYR>KM0PNLX5]4O-7S*DNJIC=)>6ND%Y1*O$)U@ M.D@3KTWW5%:UJ9RS&6+I.FA] M_=W'S[=TZYRMKT=Z3.[N1PX_|
&Z'16].6R>D/J&"U8IJ!&/]LH*+1X0X? % M[1:L*O:M*N.27+M<4(/K^T&]M:;12.\SK'Y[^(*-7. ^%20. ^V %4UHK:#>8+ M0C:,18XGH%Z=U8LZC]DM<197
MR?S["'>P,UF[WO1I'+71872KUF1+>K%5UQ4|WRU>=FCE62U(30(MAT$Q,"&.KK<':F;QQ9?%D4I;VPXD]C=$;!UR=!O?([(09%])F@].NS#S2M[!
M,OUEB=#K$^!\L_]9Z"F7"W&WH;*L7A$DVP.<+]C(M7N8Q.*+M0.R5KJJ2KY@%/+#@E&LBU$, MI+8=6RI83_O%$:6(==(;P/@H/Y([$GSZ;
[0/WB"CJOA;M*\#W)RO^,R0,%*G_Y'-^? M V@>W"#FW2 EJ?:,>?1?.\KH/_YQULA[A-YRU>I;O$ MY,F:&:?Q:_S<"*-M M2XW[NWFJ-
B(REZJVWXU3=FY>PDTGZB'R#?8VR5CT]7R+,Z@I'^:Z<<$]/C*(=CP]R@3Y]$C,9?:, MTHV_?D(($QS9?[;ZFGAM@U^F;0]?9J2LOF8Y*BMIK_!?
Z,:>'A2";I\=P-ME:+Q.6 MVL=>PV;T=&#F]2 66;C%]SBO&A#_W /Q.SV#R3YB9]KB<93&[T7[H6KH M4^;A>/5)CE,=U-
$FJ1L\Z8<3=E_4DF0'E@-A!WH%XP6/-='[[E6\"7M2R]T MM7W#1;S[RUYY2?&;41U'&?S!LO#8FB7ZZY+J?R6[+-C9L#[+FMWUV1]['/ARR-
RJ*KRC37BA9X-VCPONJ'+2'8<,EI! M.YWW]&/3V=Y-)K@.PA""SZ)"5,L? ER<.#%4,<1"F$@(0RD2T*FBE)\;"$?G?P.
M(>2CJW/CB!+%]3@GCRA_W*:3$PSKQV. 5"X3_?W]:5V=HADF:/^O'_BQ0MU& MT!#3].;#'UH__%&!=- (&DB_2/)L6:*7C1DOLRK.K_/D&L<%
(#ZK2W\-9+-3 M9CI;'ZR7F[7)XODWA|HE0ONZWD[8;F.AZUC'&IH]+:;D[=)\+WA- -(A1/$- M7G_FCB[RF&3X>U$N49+-,I1RZV]
(VJG=KO0MZ1P*JT(VUF-!SE'#]55036- MFI%S&I=9>4=O[CB=%G]0PIB]F%6?.SE@0K7[0%%$K\F[8DFR5'-B%%W,9BAA
M#Y'OSE$0BY(Q!N)S2]4F_8Z1S.&FI>50CU/L77$<8O>;.$#E]B(6/:$A:3XX M[==,&";BAS2 W0;G96-%.L6$X!]4,:""'OV%&U2K,H1#J^T6,= I;7WXY_B
M$*??B[I$Z9:PG5#[2MI58!HTWE#\X^*Q8O7[Z0',(F%$9XJ@Z: TBT\186/+ M$=%)31<&HT08SLUM%R*?0YVV$$,<8HA[/-
TA.L.QVJGI#28R61EWE4G'CI#< M1("5+!YCQP,>QP;3OWR)C87LH)X6<5^@ BP=J9CM"Q;0RT@B#_L?(PTU8Y]
M78"N&U6OR=A7!QR4/B[>L4>8]T!)P9I\=I1LIB(H1[2Z D%(1>"_ #=7#4,Z#' MZ6LW@/DDRC<6B"AEB[EGT#?P.$N!RDK4Z
U.'D^$[_K#=8%.WK'QZ5?W+ O; M/W^2$:[67SO9G]H_^QN4;%A_6V1_[DGV9_UD-RE-&UOU55G6K-"!@$IY<]U$ M,>LYD*"W3743\V=34*=JKU@';:Z!J-
=B\?[C /PZMK(^6L/:7W^,N>MS0=5G M?FN#1-T0M%Q_A K&%(X:0EM+)ULDG7AB M"N@Q/ <7S_1.R4IT0[($O?Q8;GXM>6DWG<9R(@='L.#X#4-
&E"'N+N.D7;R4 M-7>">G_SN?@T-O=)VH/)PP&X]}$ MY;2X>&;%+>]LG#.JIC-!MJ"T7U2A=X^DQ,LZO"E8%ZQ+7O-2:3F,-Q#>E9-'^06?
G'GDP'NWS@ 4*^X"%?&6(UP1<<(%>,T+8T]L1*^((M>J!]61D@T4PMD,__Q$E%PX@O:P4DG*F%Q?J?81K2^0_7AHV<;,>O(8"V5%^N(UV]*LV-J#
,BSM-YNB42JRSFC$L+XL%[!)*Q)@O$:.0'Q/* MF81R)L[P_:UF)\5TUH1&-,+869SG*#U='9*M@@!\U) 5&IXJ#%ESO:$)67,A M0ZQW^$&(6N=$K2O)V;[
8R-BQ]&0R1"QHSM\H+M >(2!/9H#,(8U9I7U8A&3 M5IG48Z>4!Z]IP#%Q2/:F7W6N,U1E25Q_H)(?W-7YT\/;A#K27DOD]F.2@OT M[ENSK'XXV,2*J6-
85_1D7[,6;S8$2/S2OWVQ9>;DMIK.K@AXG MZ(+MZS*CW:^SD@>)W8];KIW("&'47=)K]0S3-5O4E,'I$I&&BY*VR&L6<'?#
MO*]4/]@]DCW4%>/Z'G^C#*--.]#"F5#UNG6@<',U^; #<7F9T\E!6)$[$C'-; M!SM=L-,![1V;_-@YCL>,Y_L?,)VSW!?8)4;.T 7@R_F+X55IBB$^H)0,! Z M;2
<" FA96L(W<2N(8Q*+"\O)=17*11TMPZCXCR@WK'=G40%AR M$XR=:]CFQYIN$U_0DEL9 8>I+U9GZ=)1TQE\@45<.Y@CZHZ=>>$A*E X_'<_ MZ//
.%K#=0P>&.<"C+L;L8XH"ENSI9.IC$"ILUB#H9U_,5F M]#J/P,"-OJB, 6^B7>_[AZADSXG0C4)GI(S0/VLJ_/3UN2L-LG3WH&F7O[U M2
U8EQ7]^SMVT-#U4*0*=4K4>VOP,AU^5)U,"Z1U M$|=JT9:.O2K> M<^NBU[M#99W#QY5SY,["^.W>$'_+]":/"S8GXODS^*F0K^%!OH;0Y/P-
_6A^XF,- MZ3S4+JL?RBS-8K+:V_X"RXNTO57J12^)7S4 2[8DSP=.&E[9RQD"84L M(5^SA,2F[,/'=8U>]:Y &1X)$,8'2NJ!W%T_|
8D:!%R,=MQ.,_0#CXY+/ZI*.C_MPAO!QT(] M%=<71:BGTN'!1G@TZ1$54ND1-WQ$15.Z!2(>49&4?K&G1U3VI$M8^-$5-^F8
M;6U..W<.IW[Q7>94=6>!&NK!:V7%WA<$Y7EEYG1]9S&$ACD;U.Z=Q4;S@^HR MX/P1W55C,>$8^22XJ^;\)L+ENU]//K($ 7XI)7ZKXZI-R.
[K+$4;B])XDL380?MH(.\@ M,)N)&:__PLI'E[=E+:B:U74, 797B9$N1VTA;J;KW2M,+[1/*C)DO,S;*APPW ME;;Y5+7];IRJ-X^O[%'$>7/F>)]7'$7)N@LJO.
50G>(/&4):L\K_(:+)WK< MHW7R8'F/JSC?_YVI8O36_2_4/.3^6# /YEI0O,1D\R?6CE=KS2X1 Z5'&V-R M-]*ZT[2:(W(_CXOILNVI[<'I\0Y_)O\,A?7>MX?
&=4>*L%".M+W=0D6;%&C! M(=W69! :A<5?'"C;,LYR2:V*S-UW%>K;^[A59DA8#^ /RL^+<8=W2^O\A*O% MF'@L;!4Y.NWUVAA]
<*G]WA@2KXK6AS)L?]X[=%^NQG60@'5X#[X_-GRWH163 M-&U$X#@'5DLT^,6Q8F@+.<_P>HJSG 7:45VL.:L,PW;XN;&AUWJL_TYPR2UH MIO]+
(\5LSWMNYK;@?<=5O$*!R7;,'N1S__!&4GA>9J1I+!?T=(P_U)H*!3C9 M;^,J5Q6*"H:B@FW,MSMGL,1+,G:NQ2Z64$JQ Y2MAE ,,T'Z@H$\7Y9O+C:7
M'"K&.N@0^> +)*%$).2H!;I^S&4#N[(H!/$28U\,0FE#$+4R]DD7\\V/(1H[MW]+-KR%^T!>,Y!V.='=7W2!_EIS$J#;T)KP(9F[$=S&TE#HFKG;
MQ3\XH<$M8$S]R7(W'HX QM2?S/C! @+!6(_R]YB !(8U?$GXP^:. +&V9]J M6L-FH,$5AZ"7]8V%AV/MCY;F3*J?W3HAGZ(?FP(O?2N#R$>R5
L$2DBOZA^P M1Y3VRQVH/+O4JQ8#^ &L=NI]?Y[$2@O/?A2;&B_H$X;V1V'ZA8RVH6=?AP8 M)+KKPR&O:._W^HA&!J T:B=C?
=/*R1"UTT#&=18_9#G]@L+L0?OH)$^!*F/$ MC*AJDL)LFI_6_3A+=U$?4EG2)1*21A4PW$@%]9VR=+|6DV4P3*)[/C*T7] M'"%:J
MA*=:|Z@OWJ3P'>E'M5>PK\!IT.LH3/N;60!7C^30M9"L>+TFM0H597 MJ-45:G5Y5JM+^G+<02H9\(J(:D7)G(">@S/@:Q@OPIQJL7_A^1;Y2$,%0SZ
M/+#A)AZ'TZ@'#=F#+4-BL>?E56%64%'>$C??<$&E/JI+DA43M\HX809127E$ M6"='^! >N-!N=NN*P=YHX+#4\84'N[RU/AH@9@CTSH
M+J1OC?!X47ZD9 ". M#A\K / B>]_ 5KV!W>-++$Q[.MO;U.(*&N".H=Z#_7H/!NB$O*G'I;_+@WPV M.9OC/$6D7!\HS("\,XJ>,6\R*>FROF6N3VY-
0<5AAN)6]G3V(5O2I[9M4B]Z M8(C#@,J;1 YPP=XFZ\!)VY-FH1),J 03*L'XQ#7<:"=[0M+'-:&H:^.N.JTO

*M.,FO]O9'6D'BOC<@R3,581+2V*MA**V:+GY\;P"2KAB@S\470$"W%3PZQI<2 M&G!8X&$0OJ3(*V,#B,7P)7<>CHU&3)2S$\>!B7(PK"^'CY9;7 M0RCF:KJXL MI=@KBBR M.2NHNR!U"Z8W9Q!U%BF5R$1SYE!GX5%)8C"G\+L+CT(N@4'%WSE\--0X,&@& M< XN7>'K<,P\%]=U'.(GXQ?->U;-@D,U? @E<9XFT'6X6RA)^BG(4L^NF^9_H M(<[9!1V5,WF]<79'^&^X2,S"T^<+EM=/R-85R3:..>F'M'/4A MBP^>Q3?>F"";SMG1AP<-YYP=" FA]FU&./ EK*H7AOTEB&'TT#*9H[3.481G MF^LGW[(4T5N'N0%7VWNGJ_;9Y1N6=<[N)/;2-*]162+$65+WB*Z>ZFJQ)/BI MH7F2Y_@'$PW:%,F.0T7%R<| <4L+/_@4W<19>E4D>9UN?UZ_*L'BMQ$EI[7| M;O]1H_<:F93+<5U6DYI1H/MZ#:8 DR5L%10CX:K>>O+.:S2958C|%XK)9?;$ MTY]ZC>4DU]_HN7K_ ^5/Z"NFJ@Y/R>T(G).|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x;.4"R18N0=AJ)?'@/1UG9XW,$")*C/4%QH%"4UC3J>.,+!*>X8 M/C0(W:|+5JT? $I]]+}>7+X=\4!^[7%1S1%XIWCS2WS0E' :Z.SK%S=;[(U7F!"MH2R,LW23125>*<*VEJG&]'2K5C=Y7#!? M,1. ETRAYTO]D"Y6>;AE(8$%2B]B4M!3NIPD2;VH<^;|.4>S+,EXG, [V@T8 MG6-2L?OR%!."?S#*. P(6H:07 B]+:]M2L1HE:X^A!D;H!.HI3NCE[|E1+I& M9!W|">SNM"]"T'8(V@Y!VTX$;;M8L #@4O8%$#&K>YAT^37]0Z#15M(E8=7/ Q! M6=RPN:*"HP"F,QR.G]# -"]@8),O0@^ WQ;%7)2PXXO HXP,))? &E|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|+SRA2 MK_)55<-+S*W8)T0>L.U'SVT!#=.^#*1:? 5F#6]!KOMJT]0Y<]9@B7Q*W;"'< M+2C7E]1;6RC+?-|&RC,E8+Q:|':3:;R)P$9(B1W#2@S(/H.>3AT M@$$((B BU(!HZQ."HFA-SP17W=!UBB$T6/T&$=MZEJGMS(E9-R=Y#J*E&D!/ M$D?NF:BI&T!P#+0!B7)\.)K,/0<#_-L(ZF?T6Z;=PQE],8?T\FZ PUM],3+W MP.'U$R!*H3V>2=F:0%2.8_-,XM8+8]>@38,BM_W+1^ ^DW;,>?+'^JKI4P%DP MGE\|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|-N82/5Q"""6#N-Y?4,=## M*%UO^:ZOD\!S.4:!B]2:8RLHH, 5BCY$6?%$_X4)>_FJ3.8HK7/$?.'[?T^9 MUI,K%/[O/K;QO("'U/4* =B1H8.@?0>[W!$- OBUP$5XZZ%"PT82DL71F\L0MT:;0P8_L'V/Z;@L]R8NK"/Q!(4:94+C:ZA1YH#]V44%7?5" M]FZ=P-"!WN['98=6%J+-V9V=+=TFDM:M6C0^1DO"*F-4JR@NTB:*?[D6,_8D M"4Z3;G8.C5^T8_W03G OF\C7N*AG|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|=J+?A+&-FT<47QM[]VLP/W_K=_&[F,GO9 M?W,#C.J&PC1I96Y.VR]X3 M!]);:EH>P6;IB,URND2$'AS%8Y,TNSV:>8\Z3(FV:EF4=%PDZPZ6HSD3/ M40>K14|WWSW=? (PF2MI9O,R8",0$T^E#GCTVAQ[/\]76V4&^Q,9@I3';S=/7RG_\K0X0>/?/5-9M*43%AI<[#\'\55+.NJ;(AY+ZRV M">@Q# =?=QOMSZR:?R_P \LO89K$FM1;E. BR?+U@PST7_3"I3++:5QFY8L/ M^W>ZZJ]QN1%I6&&:BYBP0C32R;7U_3&C>X>J*F\-@[?WP5'@5W+X:<;2#)WP M6]&'@%LGW#XZ@UOY]M(15U+0,D8PD@2\CN1:A.=C+C|=>KBA58RT'G"_@ M 8I5=U!:?/%#:%A:,NW(%ZA"D66GO5;+IF0J_3ZI7+2,6U%9O-MJ1B!55:"] MV[TV485:>9%8W8_TDMNOB,@:;[IDFA=&_HQ9%ASG^2E88PV5.UZ6L9P< M25.3942T32',QZ9WP00_FR-^MLG>K-V]3-K%_J:O*1WR1E>T(._.7:FL^VM M>8/('5L!PCA^K6./"9735?L I>EA2\Z@*#T45%HMT'*;=]5./EKNF0S(/38 M2MM;I? X6E17)D@JE#3U"RH5MAZ3Z>Y%1V?/NNPKU[7V"WR3X37KY3;0)0L%W M ,%!3]>4V"[YSIWWG+OHA#=@P78G]:OQ<'1%P|+Q%3=L^SIRRE$L8M MO9J$_B[U 9S@CU4;Z,37VXZ#\G-#L@3]@7.ZM-9K2H$E8=]!N;K-RK\N"4)7 M186H[%TIKT+Y (/RUZAE#?Q*7/&Z#_'9="$N4DK%S#==B< >5P1=TI!^^)[Z MK!6Q\.D+0O(5 [2I^^((Z/!5]A'XXLF$HR/U6/@"29\S1F9D\04C_BDCL']/ M_401"K$"W\/8WD)UW,-]\3Y$LH7)|# 6"B]"6NK0],4'.G+Q%].NX8F8/"E^UG M(][,\:T5XLW4XLV4G956H\G>1P0]H:)&49J5\>,C0>OZX'SMZ>673@%D'4:V M$S/6F;!>86*3=)[>8%+-<)YA? BR6H)F&6*S;YSOTR)#@$\!IHN'C]W-T@](L M9A'@ "0 S4U&IW58):" M,ZK+\2@#1B#=D-P6B?5E-PA|D2E:$Z(E:B9+1K+ M29%N/E^V3BRHK57/YH::'3&-?4?HS8=TL9S>WNS==?QX49$X:>HMG=5EA1>(MK./+V=- "98GH_Z7W\3.'M0XC'3[G:\LCO;XIA$[_UC;#^,U/ZY(*:F6Y(4E4 MO /4)T0KA&B%/M$*742!$*!P' $*0DD"*UWB8X=#[4S&H*O'.TSDQACY339V MGXCR0I$KO-Y!TNHCDZLM8\6^T*TT@.WP_AH,QWI%]QJ,E(G2>BL?F?>,7#RO' MWL11/9#YE$/-YA5K-18..KG QS=<)%U8V?6+WCG 3Q.%.IU]+Q& [J&"|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|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|^_K7H M,+:.KMM2_8PW ;(A,NQC_2!? 20_*0LF+Y8T5:6()0G6&$.]!28B*"U%Q?:+B^EHQ0L3<\43,V0C:&(MSWL&@C64C&-'OD\I%)ZMQ MY=G<&CL>9%44Q.,*,1EQU!!J+OCF6'!5,=\=5_B.89?E<47^#.*[/*[0H<'MGW8#DCY%E';*6_7Z M.<&7/^+=&=E^5T]N?Z:U/2A*"_VH_;?Z3G-:$T MM#KF=0RE8E[MPDP_^E_U[A@LH$(U8/M>9[-#P["V\32PQ;?;]ECQL/"VWELJ MQ+:9C&TK2;7G J'_VE%&__&/6W;9M=#4^IL=:EKK5'!^-4[1P5;FTB9L9[?T MF_1F>/FQW/Q:\ES$G<8:*$!D>+Z'"=YHI75/855A<:^;2[.H@9N! FN"(URG MY\H)1W@? >2=XP?WW@K=+3E@BPHR=:[GC6R!1CMWK+YQR@&0X=OY#M8X0^-'? M'JLJD1YM'(<6K/VZ>TV_OGOC^#S+:]JPS2?4>1"C#B\- ,,<7]IF,CC '"GNT"S3[G=H83> MTNP1+8X)E-_0*KT7FP5&I8EM,%"6<$AN;3O0:Q2'M+2?,<#6 [Q6(CKJ.$S M.SK&#T6]62H-])V9:QW%/4XW2ZLWKVWC#,AMZY-_Y3=436?W\?.DJDCV4%?, M8'6/;]&2%<(L'M=G,0B%'N,?OO#H(#[J.Z##>"YSK[PK.HUH&P'2R')Q?H87 M"UPTI)2OE^I9G.>;6,])D6Z5*SX"?4=T#X&W(<9[^1]]@ -;!4/NCIWBYC# MVJLV YUV/K7V27L?>3=+53*8XP41QEH#7&H?$.>Z'3H-,;1! #IL/N$0"#_ X%L M1D6,-C!D^*@(EYR)7:U%YM9)184BY*(_S)@%PEQ@A+/O6O34!@Q$13B\-WL(M1\<1$:'%*FPN&,)]J#];#\V%1CA[= ('<6L=5AT'FG#R.0@HZ(A2.JQZ"-@LV M7!KU15C7:O^&PZTK<$A&W4TLR8?-!PM+P1V;;Y).&[J3QZZJF8+ M75YP0)2E=&=/JMZ^)#AH7CR " (K>@L0E;WYA_X]59*)_^3]02P,$% @ MBXIM65SC]G.!"0 "0H !H`A>71U,C R,S$R,S%?,3!Q:6UG,# Q+FIP M9YW5>3C4^QX'|-

Q!1;C$Y;1.>PU:WH/+!,)TX MW"M>!=.:=^+7AVB*NNXA|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f+MCE:CIYYOU8]/E4H0R M3/XJ*S>\/B!^0AG7Q_S*,%;?PZ81\(?6D!06&VTy>9@Q)K^QO!Y4N.-;(-P19;U[EX%*3S/B6(Z M5,6X0J $8B1Q])&%-RQC5:Z-M%K]F+MULZ+R1JT%;1V,:.GUD0K[1Z1RE M]M)^YO)9V0;Z3(]"V?J1]N<X=+U8XZ$//W1'_>-6M5TX0#=>.&!:KF/$_<^& MNF(++K7,;IWM^W4>U#V4$[!3@K1_P59XMZ].VZ_3(S?-VXU4YD[A;FE]3=00 MWGP^!A]LMHQWHE96!$ST1#TI"@]+%LMP+-* 48U5P10_M;OVB=BD&Y]GV0RO M$O.R&TJ/)BD(Y]>%WO7L;Q67(@__F0PG#TZ0![P=9>?WRQCY@0R;[NB MDXQ.Q?:ZR; M+NE= [D.UUK'CS"I49\O>2KS1'5@V,]3!T:TIVTBG M0-7&>]O!IXHT0])CB ?!8:W0$X^_^TIU7M SO#A@/@@NN+>DLH5* ((Z8&$5 M>"B68DEO3\|)\;,9.)SP#5B$^[CL(Z,OTW'TFB$CO;G1;W82S?#UQZBIG\4T*H"9NT?F+5.J[V] MWC#%G7-KACT9NXK* Z(&$UY2L %=?W[1? QD99&KRZ[UEZDQR-7P/'[MXJIH# MC$IP@._ZU9$W)2\I'*>[0H-I'(HRT>W)13,TK0TBR=A%2J3*H8R$DQCXI=S MLCM1]O=W> <*3>J, ^MR;]6BS2$D7;Y0!G-J.YH3W0S[>K6YV15P(4G14:N4-> MBTR#L-(^'44A[0BVS[PFHM=RWA+R,5DQ O?*W@8[WDX[UFYGO>H+IB!6,"'4 M:18SJ29KPC9+K[WQ<>W?4OOK1;?)6\Z['G21':')&K^(S:V^((C_N4V616"_ MN%!VEY#S!79"V9*K@4|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|||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

~~A33MBSD/HF6Y0%_YEF$>^UQ@6< MQ X>U5="B^:ZJ++#HKK8>X;7;[U^Z_5;K]JZ_=;KMV]!O[5^= Y0%>Z>=0$G M!4,-@1[YO$NCPH>J66&Q#)(LXG]-GDFP2,/,U*8 ';Z)24%+%F]1\!8%!9/F MG_0SR0L2W_/_94G$_^NAX!_NPRQD)!]%?'4U52NT,51/NNL%G8OLOFH+$Z5Q MKBFKI.6;&XGOPJ7XZ$;B5Q=,FTY%VX&]A<1;2+R%Q%M(O(7$6TC>@H7$ MSGDY0+-(>|(^0+.'1)?K>U V71J"/P?=08# .)9$.X,30T_!T;]KQ MIAV8JBFVM1E-^7:47U6FPR]\? 7U;KZTQNT^,F,TJN>|-"3-0A*"?4&2R')&>1,.*"G)! MXB0MA;_JOA1!5($25R]160+E<\UW":$,E\5:1[Y:+[\[LM*K-8H/6GY03_-U M*)<(&{E6?PIH)%8TZEE-)I7.+S"X14.KW!XA<,K'&]!X6AQ2 [0?=4U8W*H M@;W[F>]&N?@[DDQ40A<7/%?"&OHMP..YT,4TA?$*F5?(8.5^DGQ!\S#]Q&BY MR&\R|;7SS_IR;ZV-MTN-_TSG9+OS[U\3R#?(41Q7:SU,16^^LY6,Z-0/,7&*S9O0;'IZ8!UJ0$$>3F?AVP9T$F0)],LF211R'|-HXB6 M N,T6- TB40I^)@489)R^LS%+L/MDH$J!Q8>Y41OL"8G3*4XGKCJNN4KCI$N M"7^>A4BVH]D%(WP)'9S7D*8Z[$)/F#\X/,JNR2';T>J#0^'!)8U7OPY(Z_YN M>KL."T%[J\=]EK5P&\PU#EM[:N37!<329$A%>3U4G]&+[<\XW_8G62|UU] M=Y1+<.D/X/[:C2\T$YGR%67;2ZO?YT-U%V\ NGGEW[RS70UD# 1P+5WX ' MIVGKG8_H=#? >SF\10&|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|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}.K^0;G@I)H$2:+X: M;;/4KD8=(,,"U9?5G=6D?)U MUWS=M1.LNV80AX#.# 6#:C62%YV-JL4V0=U[=[6.0DI/OFJO_ M%SR%J3@I@GQ&2!$DV82R>56R;ELI; <&WH*R8D2*)PG2+'U@!SM+37%2)LRHJ MK)*<+]!Q2@4Z?%*-OP859\2NMQR_!$S+F>T(H;EJX%4_>.O8>2<9)Z,U\P>AS M)?,H3>EWP6,.]FP;0]FH!*F4@)Z3NS");[(H+>/-SZLRRB+BB'!9:HODV1L5 M!WW")8TG1'7=A)#_V7+I[CP8%H1 MT09^8PB)T+18K_^B?"3_>-HMM5*VUT=X:NUHM,8AGS,*(B&< Z"6S,RCB M>= QPEL<&?&,6/TL!O1%-/@3VPV&'+?*M]AR-.S(7[&5F-A0?V%R-QJL$[> M"^6J4%M%RWNAO!?*>Z&Z-&%89Y@#=4?95#L&ZI2R0#\&ZIJR0C@'ZJ"RH64, MU$UE0{$79&3^ER;3Z(/)/C.:' M2]I=QR&?5S2>#?#@5+. ^9JKFN[7 MQ9';8BR-ZC;$> ^\+NR@9(_(;GG+WB3^O,J73$A^3Q;;6D9WFYWM)H-F$=D8 M$^\L-.:=M!H,.6YY!DJ+H;!BUDI&L31L;W/QA681>,LZ;NR-XMXH+C6|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||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

Copyright © 2026 Ancestry.com Operations Inc

*C%6=$*R!VK7LGLT#-8"U8&8#M8N9 M4&V7)I=WP21,6/ LKA+F<,.\9"LK>9"7\WG(EI7Q0626!^^#;":,Z*;11%:> MY<008T]0;Y/Q-AE5V2B^S*I;O, ^7V__\]X0PO@/,EK=B@:EJT&EU[@?73;8H MB[P2YKVR9!&@1S\(/N\^_V]),?N:T2<1Q"O(YTK4>|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`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|=7MJ\ MLKKRJ.1/WJU[*#A*$B1JKFC\3C>G>K>G6I=S@-[Y"KJ5MS$LSM_\F8/O.$H&) >":?: M%XS&\.YQ[_KSKC_O^CN I&ON&*CSKR,U>& .02O$-:+4VV4-C8258#.-,P MNB/C8H6"D'C^TY6([UBEYtF1L.P__O#FV]=_(#1;L#C)'O[C#Y]O3^:WIQ<7?R!% M&65QE+*,_L532F-P_D[O5-HMI_H&M*?G? M[V\NR0EY_=,O;W^Z_D@^WYV2MZ_?_NGDS9N3-^].3O[(OZ=)]O=?X/_NHX(2 MCD16B!__XP^KLMS\|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}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|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|Y,V ?S9=O!NRO9UIF)K6)IZJ/_]7>(8*]7*-5D*J3P M8D"ZOT'4.!VG^U1H3:X*JM'&,9N[$>0-6/VEU_Y[KJ=7VU/,DZ4+['^_KZ^* M;ZQ&+ZD6C469K$)&(K8^ML&*L, M'9^WV\!TF79YG\8<$X-]OQ7WP(:2"ACM[*KFMQC\#$MOG 45\CG&%:H!QS M^PW=\+|*;W>YHH2VZQ3]:[@]BTBQ(T_<)4_4(/ZM?^\X1BJ9Z2Y,WU]>>ZK. MGFB^2 K0J0?U+.J_T&NNB*W77<)!]^TMU\/2M;+MH#$CK'EN/2H90VNW0U=1PD$ 7XXDHBKS!CRQV")T65(EH\6D=GC$08<*(R1;O$0+PDUZ_QB<\%:!GW3] M/K%^N>^WH[OJYO0V2:|-?DYW2JDH*I6WCLYI TP"G=,(C%T+= >E_WKGM D' M63RGC=GBQ9S3\I7ZN.EK0@]TIBMB.?FP.+WE>(V*?Y>I+B<|;\N"YH_ MP@7_(MML2_YGOF])F@@R7";1/?]W^?PK-^@O65&TV2Y7RXMLP=:T?LGCGU\F MA2S>RR]PI);P@Z1SW=#VZ)R1%K<9:==$Q*)FI+LL(M9%]APP$?:_/[+;LGD++NNZS3Z,$$WGGF/A64H;_KD5\;B MKTF:SK/X(N,&TP/@,R|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|W72|%BNUTGJ6%Z 2F@KK,%T:3NMH.#[K M.BDP)B>$TL0N#XI!! *<%]NF;&F^*UM:G1,0"W[TRZVH9?HBCA"UK=8]233V M[^7<3^=QG, G45HO>5NN6[\DUKOKZ,.,=0M58[9B[FHRI<0Y*YJDZ*AKZN[MM;0WUW8UP=6B#ZFT>6=590R?O3(64;&Z$&=BDCWPNT+=6BU[N"CI6M8X#_] NOB%&AP/K3!. !.2-*@(LV'9($.BJMIW0HM?0G6^T-P19DSFZ=3E7SM^AW<-+S>,B=PKT.L0__?GROJL-/=@Q7;+('QK MNQY4)]_H>G#VJN.LT"R,>A/_(37N4S'=;(N0#6TVNL<^'V_8FMY%3[2XCI+XM$Y5Y0N0#\8\K!Q-Z21S8<%@B)"6I]JDF5@$"H-P\919DZF4P?N?.D^%]1?I]D M4=KV3QIXY!X?CGKDED_K_)&;@R8-[%V|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{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|Y)>5KY89/LH77$#K1:5_S0J-O'$ #7;'WT7$^ W^BI_W&\|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|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|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|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

MF?:+E#15UA1!N%-49 M[?M2QB!/P$RAJ)E-X)]BKAQK0@\=XZ570(2O&2^&-K8",^%Q\R\QJ!^S\QI MQ&W06"C&/'EXJ -REX)F??Z8E^N.4=8=:CX9O2WV9L+O]QBZH_E:8L/+!R*-M^.,)?5GQQY Q9KP-_&WT^@+(2E5*'=GR XS!U*EEU1-Y]L0MFNR!QN"O/JZ)<"*?+] MYO9S\0U>:-VO'2>SMZLHIYVFL 74K/ZZ2A8K: /))>B1YF52=ZDK!$&X_$:9 M* (OY&*5P@]^9O(NH6,U(M.0',XE(L:&+9)E0D7X/%;3!F$W6%&;XNJ+9_@!1 M%QN*$'.@<5(J1@)N:QK"N$7+!,.RX8::X6l;%DE,ZRJ?&40))H_T.AWJW:7Z M#4;RQ^9V+>DU_+:*;8,! 13P0FU_6>8'+ZN7"K?&IG1MN]Q-&/35ES)K,11A More:Z(WB]G: 5.4R_(\AB1:+L\1(%9[V"57\6OD/? D=E=2U8-7AR=T1X"06Y3 MJK1F2):Z?GS3DLOJWZ#[PO9T[\T? I5J:;M;Y%:F@E&,[=$QRZ4-)@HG>, M]S /V'ID9T:T]%B;N^H_71|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|*&@I"WDRFPR=JH4!ZB^+"X,=+L'+,1U,5CQC9T_\M|\^T])(2*00%W56DHB MJ=AI3*MO*X)S7ANEK6E=68L!^1B}$WUEKU'D=>26_E G/53.SBIJZ)S_[O @ M4AJ+ <$Q+YW3-7 W@QC5=@28"MG?/]#AEF1:Y BFZ@9NU?* 59>7CKGVHCh!= M7@=H*54WEJZSN@H%7D_4U,G12+5++ 5+ MDUB$J*H% [JM\@@YED4_M/I2E WMR ?A*1&<82GJ,;F2Y*%(\=E(]!Z+C&P|G M=-[= R">E%!%.O"!-4!,IDXA_Z\$=_"Z.*:1D:;OB#LS^H\61O 0IY$49(O M G1PK3-&WS[' 1#1'-LJUTT,K"2X9W" <@^-04+Z1FF)E,FT30|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|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|HO>31-*==AK,+JQ6NQ(5&QJ,5&=|^;%OLMRH5&G6?Q#5S=NU53H!B& M1"6I? H;4+V/3^U(68WA@)-_^VA 638.$>-"JT.@6_9F)HE/DU5]HE(<19&4& M8UC*>G24IFGUT/8QRO].X<)W5KFII;I1L0_0[E#9Q.X]H *R8+=U SN0FW.4 MN$R?8D%#K"]I%M.\M]6; [F<6 Z:[TSM/UY<% 5=(A.D9ITW[D8!>.4'}-=W8 M63B@93^Q+-KJ}H[_JX#0$&[@#+[](&?!MN70@^::54]9RC]@X/A[I'L.!-"- MW9^K8)QR%65D_Z.@W(S=/&9I1T*_UU>1!9_H5_$GJ?=2ZV,782 (!%5+AOBID6C]>A<^,<(RJ$1.X#NNQH6I;6\H="[;:!$HNJ'Z#])8P!O,E5';&=+77IQ_-/VG.3&CM"K*Y9RHA9G_]@. M52!1^PS-3\/3^\MD'<8#E[!J>VWX4)!.SU:P[XL,,O_Z+S^]??/COQ&JL%!G M8J7(9 Q+7?!VP7F2)<6*QK\R%NL9!>-?FEH%<@BNY:V!3!X =%B[0('.?8:! M*O'\LJQO+/_[17:=LP4M]%AN_$M3EI-#<,UR !$B+ \IT#H/IY3I9XW MGOO #>-'X09JX\7J3M;@!$-JR4\L_$EDN<4(+CFN1T*[=`[/"/K'1:<(3D: M07A19P.8 57]|:)ZQ9JJ>R_DGFUS2,>7|:CYC%C>Q4/VDJY=@:I;.<-3!RI5 MVQ5G6]@VYF O#%,,CCL=M!&[I}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

*?1\R%)!N#7LK0G>!+EE3 M0SA*R6W)64ZAV*@[M\4H]S $;T)S'YC!.A3,OP>/SH>*2S2>7V)BA0!C*#8 M6(U)3-Q!,Y.-"Y\@4C+.-$R;=OY377J$5VJSCW]BFMS2,[5K46EADQWP|%XZ M)6+W);B,4C"8P0T,OX!PK03Z1&6QML$]/H$E@UL.*(#!W2!#&FPF:&\K[,R MO:U*;G_F0W\=[]$@+.7OL.;$V/S>S(HQ1%#FA?W5H:SQ]N7PE\-R]H'L#&6N M8FAB^GL&7*QHO$WIU;(]L4XKA.Y$./G8PZ#FY]BG0D4PSA\:SP@(J;%9$9J M7+B5(OKBAK95M#>%F5)Z.B=!>U._6K;7]VM6)/#\]?O94<@L_X*

^9KI7<[8O5>;BT:/8'OLH$70DF[%%Z(D[I+-,XESSV%J3\L"LO MUIN@U.KA'@N"RK=?]3W*O0ULLIQK5Y MZM*O>>K'J7GZ$KQ]AX0>/T![J3<1)G/E- 4%/[X1Q7X:_Y/3WY"S!,X"R0$W> M3;*/OFB<=+7\7%"1_J,D3Y)OK C)P=S^.+\R/'(?*6)UO^@TIFF)ZI'KC2?.SWASYZ@DF[5.%XB(49S8;$M1<:.^*M0]3- =^(09E5>@VAFCY8\MR:$J"%RY1]K>MJ+NNC)*!+0(WJDH-DA)33.% :W#YL M*72HO>,P9:'ZZ'E<'"1]\%RS*J?L3]/3DH.45]60X^3TJ1V3DF/V2..+K.3T MATMJ54'#:^\\3/X951=^$<0_7_+3"U ^YQ_(=:?IC'C-BH7LFIGO5OS4CP#B MC"RWT#|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{)IN5LT8GT,Y_0I0MF6G%]TW71*$?LV:+Z%.SHFV:'NH;/-.:H?=<)FQ)8FABW"0RB|:% M25%L18KL G +PLO:>\),">V_FD]]^RQ&.K^-CC>MXG,XK[*/K6)'J@]YCAA M^XK:#%/+&Q=5+:?NHJ=KEB:+Y_%63\/#D3PDF]9]BR> 2SC@&:E DR_U?T-[M? 4&G2U>\S8G%1%%L:7^?)@E[37/QNZ"5Q:+S)8V+?O%Z?W_H0 M0+\DVED-QBX1T$D%GM^4 0'",2#B#^15DI&8I6F4%V3#?UO ;\/XKL>YZ?"M M<9RH_OS/!X$ (PZ]L>%8_)D6M=R|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`_:3679[AO)=V')%6?(IV OA#U^T=| 2Z=>J-*,'KG,7;17F5W]+\,5G0 M^5-R:!J/#4.HP+[I7+- V#5,XF&NPY L J]\"!ZG)5$GD@R\@?+Q&H.CML*IT M%L\AQW,&89-0]^IQRC(M*Y: @5 MM_*+K*2QO)L=%(0UAW:&:9 [M$-,IQ$N.? V"%!7U&31YQXD0")Q5(+>6I"81/[A1L$G^B,@^$9!2ZBN[>;,Z? M4>%P%,% 2ZY\DAIXH&*Y 71DBL3QP7& 8G7QYV'%U.!8O)XYGM.#BIEPS-@P MF9D6[3SR$;P)EL_7G- EOT1"W9<-6'+JQ7XP4Z"Y3AV4!W^!P&5&!#:"%UM\ MR ZA\$6!4!O$;%]/!NCF=;F0I! IT"FOD2>A];.15'94T,.#'M)4ZX6JJ-X^+% MI$]H,J7T-)E8$D5;.JVJ,7=)'VGZKC\_OG=:|$Y\)NJ7'WU-OMA"Q5L MJZ;/E:/BMRC/(ZY+SYYHODB*(Y^;P0R:G(6 Y-S5T/139DNRZ&2L5[%)M$8# M_OJU1@WKH_.R>&R#O+H/#:F0(A56C>]N1AK,2(O:I*D0L\46S(>>3G!#(?,K M2K(MR"9L]WXD$+S&E_SO+1,TG!%_ZU4/F<@JLT!]-WI*J$@3-34\@44MU0]H M>DK*EDC:6B]> (BO?%PBD6'%"H]E<3*B.,*/(Y*H0G3_%NG[Y^/+F#!H>L+= M<1^;VJF#0,+>S/U'S2.WH,]XU:"K-[;\1$L[I>7Q$R'951^@EZ##WM(H6N] M&VP.LT=Q;TS=Z/QY%M] [F]QM8L^E["ORB=(1AV:VE<.[A .F))$>|GX&!>9ED](+_4V:1R 1X0A^I>74R M'L D FBH'HM2:C)UODK+<016J+&[J@R2,$ ^\'1,-P74>$3;%&W@:F==X*I M84,/F!KX#+K A"G.ID)CAB&##2Z(U'O MK,Y9J04K$E=.DHPL*LB!V@,-TY9I$LSC$7;8;!IO=)R1.U#MN?"U6]#V$$6TS?J%I[+'>=T*= M3S".TI&I77-,#9Z\)QR!DW.!P>ZY0NVMT,>J< [0&[KA? ZWZM?%%#B[6O_-3 ME:L8AJ@>FW)$\06I0S0AORE]I%).37IY,ZK@(@$U:K39+C[AB*!#\N3*5(M M?*+?^^<[CL/ LXS&E[93_780G"LTECV<7":/_(B\X[]/(+/5)@+^1JC0WF5 MY#X9.4U-S!6%7]ZN:+H">V&HFM|:3UMNH404)>&C#G7H;U2JK2$ MH/[RCE%XMJR2R/%F,95&.#<=Z M"R73^GHBEL"/_;6PLF$) <#AT"W)A$2$)AFZN,H)S%=DOH/9]L5;"G&"J,H M?6,:O-8WM|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|+87^H]H7?V9\8(VM6$' MDO8PU99;W_3YN:)/ M1A^@0. <=XE6OPD(0GB5]=O0MONE90J*2G[SWVU)4W>?W MMKA>)'F 51B%T!/VE4:S-V6&VK=4W[5 MY.R0_R>-TG+U(7GDIM,V[V\:KOX!1DL.3NP\7J4&3BKHI 6/MT8LK\?P4H).X- _0GL%B?I >3+K:".$<8EX'*]V.N\: %7 M(T3NG\FK+=3;2[)OZE:I^X59IE2798@?Q^NQC!+=GTN3G[0U_=;4]Y.MT7) MN#YIF[F>;M=;4)2/]#0]%ZO/FWG\- SY&Q(^R&_I(^=%*EP#%]E9429K;CA> M+>$R5,"NL4R$0"N)/T>I98%9!13KPV] M+R^RHLRW55^R?,TU/H ZIQ 6N@"+]:'?+:/Q) MD8@L:%Y&$/;- QC"KZ$G=7L[TODCB)\N=.\L- .O;H M>&QFCFQ>YV5\NIDL(=.MQRG+M,D5(KWK4[3>-|X&4U+5/S1/^9(\,QA(9-0 M-:C=GQ:E1$) ,4OV2UQ X)F$S09&8HN3', HRQ?0 QIS=[>R H3C\+(-=]Q% M.(:IK3+ %$R#3E:OFO,UR\ODGX(L55C/^"53_HWYJ?)X[@ 7RV,D#*]:-E9E MXS+9Q:/N9$->_85&N7ZC&OL+Q-\BXVTEU^ "^[I*%JO=)?)KDJ8DJK +?U$< MD)S^*^(874._T_44BM=[IQN8P'D3@<#O=#T867RGL()>DW>Z^FNMV7"E%[F MAC@0U2G!X6E]G=--] S_J>TBB4:/ZX'/C(_KWLF#W@]V!A>*!969>-(WN' M2.7^G<[J\.? U9KUD/\.'Y8CQ+=;_7;YD%:+I6R8285;CO3>?,@ M'\C_^ M\'Y;7F57^7OQ+MO^^B=YR#/F>XR!J@/'>0<0P*5*7GKS=@8)3#]4$?LL@Z?L M^E&[^_>?|*'2;A=N)8U+\M[? _752D$B?:@&L1Q0_,^.J\G9&_9]SHN!'Z#*1 MI9;WC$">3)V9?!U'*9"8\@(8\11)."!U3:*KZ/SIV^SF0(]#$^=:'K'X7G[& MC(_&G"CR69UW!1 *[_V>P@-J]SW^E+*Y&*0+8%_; [REUX;BO(UB[Z_6OWA58 MB6F2U&,HU5%>+7]E+(; GUN:/R8+6MRR]/!U3_T#="";7;&+W<5Q%E6@9I8$L M=@6B,GU*F3%1D9<=!N(_[9B' |"1V&;<,-E$>? D,P1<]H5ECPS0913:=>_;8 MP20 -$0PUB@MF2]!G'(%-^(Y%5=10>>- S;11PJ1WHBOSFS,N=L^_Y4G)C>:O MLJP4^4#DL70\H6LY;2&2KP#R).8P,6YU&Y@CPJYVZ/^FB+ZC8V^ %9@ZE8+% M,0C;8(VF.H*/C:2RL Z%L!>AP4B#GB$/N'R&/-ZZ_KH),KY:[.E!9+&XR M%T6QY;^A\'@@;6FMJS52+A2A^!(4170PDN-L10A1JG&!6_[YK@):%M?9OPU" M1&&QCD1.E N8(:%]"V51^Q0T)''P$S/QZYW:L\SUXF @:);6A)>N8I=.KR-0 M3A>U7WP9K30*L:JD6=4BM)H8%HUCW:! QF!WH5W#3=T+T<"7EFY%/1#\7XUV M2(3OJZJS!0.7I%&Z^CN> ?KPQQ>-1I5[8OVX&(Y:2K$]"S1E;I79S*&IZS3H)C;!6|P)1)Y(W!;RC4LZ7Q M691##_;^/KUJ@Y&LWC^I:WYOH)(&K&+XAB.>&:$LTR.71^X155/C)[MJGLDS0NNP@L:WT5/4M9"SX3F.VV(^DSY2/-[IJO(:LPPFM?+HO0D#4H_Y"HK M,YB%BGK]E981J6(F6^N'I(,FL%QF-M@WWS^;H)A4F>&B--3<_C M.($8O2B]CI+X(CN--DD9I8- GO=(W2-4[.+?ST,X6. 'H)TE&:OAA30 U@C,4 M%;T6|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|+J6E^A> ; MA=F=9^H*%,@>#C,BL(!WD1H3 JAXYRH=XC,D10.Y@T^C/'^&TCQK0$S)U]O_ MB15'[O[4KEE.O"&D4!EODR?\!-SP(S 2D"?@;)106>1)'"*=-][ZE68TC])Y M%L_C=9(E'#G.^H_TK JU&$R4T?H6R6U*,%RS78V$\!"OHT%]/,(FSNAM!#.B MKK\R3POA7.<"))).[+RZ4PN9*?#)HW%5WQZ]V99U MM>JS*,\@&XD;LK=PN1FL=65U;FR)&!LX.$_UZB!)BEU?F]"M:^QN(.Z*]XD MYK?:53*O/"5-VYT/L!P;"_R*\<:KR%F04J)S7UU?P&W]3J=-%ZG!5NO6IL:MS"O[[^Q48[H *N87"DD% [LL@C0H-ZH-I?'Y?*(;Z73KB;WH M#]HVJQ[>S.O55*G+UN^=`^3+[W-Y?I=R[UH"9&OSKWACT)4=| MO?MK#A3U14]_9QK P7"",_NKOKX5&N5;)7?*'*??DB@LP]T9W5&K\SJC=-*

*K5K M8)2)MJNYRT*A6(.?IMSZM:5Z@ZCY1ZC"TF[@F3/1?"UW^2]EIRWCP&?;K>2W?V%1%O<)_HBJE8K-4Q|Y.=$6?:-\S=?_QC^?KL#>!_+RXL@8#W<4^ M.2U30_D"K ZZ16?*
0*^PDE$6MY.@7IFX CFV/@919W)MZJ?U@/[LHUO]-#8^-?S7N8)RUP!0H:)9;T)BJ M#RBL-X(/H(!N[V] &)VA. K)'0YAR9A*J\[P 8VIO!*=5A@-+^*T/+=OV:#Q
MM$U'42WF81CX[YHCJ:Q$G4,8235=FMPZCK?1* IE -6:?9\CA3;M^X/GXJ(! M3:$]#6".4-\41GN=_$:Z?=_[Y#>VUAJHRRQ3&/':V%IEB#:@+?1%;"AIB=A2
M<4,9V]A"6P@UCBUTQPA<:8&<%V$FNK86RA-U(F M1#7?K)?RM7)CS1%LH3UV0C8-AE&K%W.S"\3R>(%8GH'6HS<[H':OQZ#N5W9K MJM: =>C[$\A=?VWDP:
>AN%.8S2\0FD]U7BV'JO7UQ]8PEKOUGR%=9YEC_YC MZRZ[MM[,]/^UU;M?Q>[/UQQ)ZW0]87$>=BJ83//ECE$>FTJOMOGB.;C+' 4'>A9%AS=%&D N?'%T+!%XT+9L(CG67!(WB]
()RCM3[>0?=?^A-HRGO8>M>=0ELU]*#H@'2H>Y2X\Y0[RQJMEYLQ@GZG0VZS/YY9YD&D+M+K,'UZSKXG8_K^&9 2V8AL_)8LM$+-3 '+?]/@1 ,/SNG2I%F%;*
<4_8A=N M3<>U^39H?%8Z,%:,VKG+RB:[N-OV M' ^(IKK=&EBV]__%L>OO.D\-HKY@$/4L!K'R]#?2GOXYF^AAAVZH;O.5YQ-R MA W"X0MU=.>':74=9K]2D'VWYM'#.J%R9,%)@?
&5ZN:=Y3@Q*>I;5_-%9Z-4 M:BP1G=*IEI8_X,Y?G;/UI*@I(#W83_I+WZ?G M_WHF0V$4O'(Z\%^USUJ!6/D.^@1$"(Z93U D6J9?<./Y$7K)9B1-DI4Z'F.J+YRW$YJO/,?%
MHOZBJV5JN'>'!YW:Y#0N7;0EM0%< C]JZ'&EYQN0U#"8]F74IFI_LNRF<[7! MRB'=>9F_M,#$09*%*07"#4LLAH6^$-0WDR#^4,SE6OJ%D[3"Y>%7T;C(H]TQ T7
M|&388FB5.%Q\=_K4?!CR[9"O?*9O(U-K]\<&C6HQ:0M1\E&V?%15E+3XJ%I. M.D997R4<+YVWGXMM*%VN;D+I#18B3-4NGCR#*<5N50%IU=*L(8A)W[,JUJ-Z M?
7)I-.%IE;IO%?;JWC)7ZEBCMN>.Q7O5L0>FF]2I>K:S-;=?FU&Q9UFN:;D, M?4|O0"6^0*-F(73XZI7K2K'6J+."UJC20J5'M4*WUZL56+E<*M75F6FQTBPS12]. ^,]#7NV4C)[
MM5ZUHI:J!<:T6J%2U&BA6ZX7"ZI6;-94M=@K:M7V>V MJCN,6#VBU&MXH(@?\54@ZD^' MDCBXL';XYA)*AKCPPNK_[A\EDR&SB8.R=(/A*O52HUDO5@I=H$&A @,LT%H=
MI%JO7H6QTI+2I;G+#@S Y#(8VWT+9]X:BR="'7SUS(!>;ER,8]TJN2)[@!0 M!]!K' &4*><;)26O*-7D$;]%N2_[3*&[[G TDC/M@<: MX\'Z4#W#_TD@!-X8JG-
DX%=FTQ=&;#:@NHFD1!F.!H<'8LO0>XSH)D$5OLFX MF[U*HU9584RE1K=0:;!*H5DJ5PLEM=J15AO=1D]M^OB*1CN6+6 Z8'^PNV[? M9HR N>+VH02?
GB3&YE)KKKA+E'&;BC+^+>Y.S_VF&"S!'/B.%X N''[=!70A MX5>S+OK\EAMN31?"RPMG[PZLC?S7>/'AUYRC#X8&XU<)IBOEWQW+L_VO_,K: M1:!Q^73/T[B705G&7=_#;[!NA.^
;!@@I0EWD^[NOUMTF5_^L>7X:/)VH=| MW1=^ SEAN^AC?CGN8?B[\;NHFUJL:).[H$^^',^'C9Q/S$4T-VC7\XGQ[?JP M_H&_U7<9-,_]%,{PG?
A=ZPB<:Z#74U%@9$(,,''G2KWDQA) M8ZR)..;:YF.,@R+R9 Q;T?17Z-=EK.B]?[?/LC?$S\SO|>$U,ZT!'G?/5KNJ MD)BHXGRR]\O@.\^#)WLJ3\CM\NIRN[R5W)X'^Y_1B:&__8A[EI;)
[ZO@UD;, M^2S8S=CQ! ;SP%ZP2_Y7#1I[1ZFI!SX"1-,'>*AIF;%=UT7#R%TF.-/Y=7T^ M3VPBFL>H)_ODWPV)U=(T[BY#C4>]:[=FL% ^"L(M'-LQ$?&)N;!H8%J;VKAT
M<(Z"\LF#$IYL\|Z4I,Q,C6[9K&*V[)*4M2=,?"FC#Y3[!\4UZ=2VF< MA>6[?R)*J2H8V*H_G1APH3!L1]\Y-ZD:$4L)P_]E/R 1O\$ZEQ?\E$<=8 MVEJ,D8,@O\D?
5C_IGS>$C^'OU_8:+4/??GZA!N8D>.XSYMY9JG\/-HI+,(|# M$PO.([:RFS>@L9Y;-K+=;?R7TT%\@C8HBP'^+;1!?&YVX"SP:%N:I[H/]C.S M7W65!;9X7\.L"#W+T*W@GGED+(41DYY]
<@>&WWOP54PF<&SW(FFD.9XZXB)A MO'/!OKYUF31A0<-3T[:SE7IV_BD)&S,2SV E>5V2:3C&HQBE! M;|&XCPN"XDL]"
<$CAZ#X4C!XV#*UX"E?!APW\L?)=>:/_;AP*+XHE#@\!1P* M0\/&E4B4EPR[JT\9,/I3=X0!#5%:XKG>D,_.:!P*EII>#\.58+"0 MJ(#85%YA7
&M%XUN=_NS.PA9(&F9$2U3OA6\,E\^J'I@V$1O;CS;U&'H#(K' MK)W#I^IJXSP^7I7TW0]]L^)?GOND;QG:[6!H6Z_<*!'\R',EHH:%%XSO^)A5 M$O- .),/Y&H<@0^#
[,;$[?.0JNS6_,+LMY'YR$S3&1FOU-2IV+2<-ZH)$;MD M;,(SY;Q=!S^W2;2PFW0N"3--!4F"Q";C@I'OH2AW0:6Q"2U$>W'[$)5U]9 MCOO0>Z:&Z#YB*U%Y9C22ER6!CYR#^?
W[SR#2/ T M]._V7/OB]_"G&X4*_GFC0S%VI[\R[=8$N_|%YSI?1=_I?R^:)5'S7 M':;V3;$AM,9 QY!::<3"+\LV)O@U>V6&-63:>![|'#A'2.HE M8ST8(M5#('D(?1E&2T8ZM.
[]1NZN;U&B]V(R) MZY2!9$L:0^B&/G\D(JR6=A0[=O^5U]LYMS]_XBG;0R^0 ;0P+#F3=AY$$$7 M&2MW(<[$F]PO)O9YX'0UR!"!<]KI"EZ0]()Y<0_++H 8B$![64$H_[W034'IE
M,TUW;ZC*LUER K950Q\Z+/02#P),W1GJG47-*LZT8N03QS M-=/PF=@TGS<' ;.N,Q/;J_*DJ1R#;V9.=[G$5DHJG".-@D\";P53) X]):8
M((&B:9D@$IH2FGO1P.5"J;)7M(VOL#VKS*308=]8,Q_L+ZQGV>Q_J>E1>U2J
MX;Z'1.C>$;JT0=Q_2B1BZ.FZB)2[8PQ$\A$R1JL'/YV8R"^>.SN]%=>;M,LMUP)RP'NDL]S094HE2C=]EPX M_>@:-0E-"=&S8>F6FQ\))A1D5&RNS(P@-KN1Q M[(@^P82F95F%]-
F(5#__#;8G[1KL"012$-8-)@Z_G0@M5VYQ>J;BT> FIFQG M&F<*.(LTSE31;35.""SNH_K0^P_%8W?WP>;>]+/X"MX+?A8]=5!)2)HDFJ7:K>-X>#@O-M7F#B:):I-#VAW5<)K3
MIIKDM<.BFE(LE*J2:KNF&I]F(6PG4:F6I9DKB+T2;C%*8@IW.#]OGTV2ZCAV MIM8DYE$?;^UOD7HH1THI7URHC(^4:E*(I'T(4UG]$*:6]O:V4DHB9K"=B^'G
M#IB4B:/8Y6;P3CV-5R73[%9CL'"^\,IL$U<6-[H)BW7=?,$2SU9/\!"T*=%W MY?;F;T"N.)6P!+EB

MR"3?@ MUSEJ'CEH-O;#RS<;@J0JS1R/6;=_TOS02$&3I\ /Y7RQ+$C !)GL2-8OZS^F M^H4_#LIN9^MAR&R"8@(>Q\RTV&.3!"0;?V?(T?8A#L9AS.,0Z_@0P'H/5% M6%,_|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|"=.E^/72(M:):H4ZGL3?A5G|K=[G95L;;3@^ J"VO<")Q__U))?WC):!@H].=VJ195%9VZOW&>D;;5O\)P!+R\|?*03?H,ONOAQ\LZ M#V.H<&A%MD=Q9=OC]OZ&)UV1-?)%)9OTH(<)N1"(X0O+97;)8(SE:/'GKHHO5,/[FJ;%6V*GJK)VZX9[>]-NLQ.&2V M;ZZ/+?2+1)/!^%$I6Y6M'G]K\N#B !,I^H<>A7E7HO;LI;3EU!V8;VB&3ALI M]7_A0CGI0LPR7Z=`9BYAT0#?L+]74UR2DY'7V]>_#'#58EFXQNJ>AMN;#>S\)::N[#DUX+A5>2 M=_F>-'<*RP[4W=GD !,5?)EW0#3T+];=28[->]+=*6\W';+V/O95]V$Z%YBS M(5"D8X$\IMS0L:";Y(&_J:71IK8)/7'"]UO=6BN>E3*U(4X,Y@?74/GR\4V M4%+#QDUMH#09,WZF4+EH!Q^YEY'A[=,),RF"EX'V#=HU1WB_-.D.ESBAI8) MI#1=$*<%4D#^-!9<@B1Z,;KDXX<-WC2=\78%WLSTZ;*TY.=NU]\&^(UV#79) M_D9 ,&OZ[\I47E.=>33N$W>Y(1Z"+1##"|]P|1TGP)U,0GTX8)6%\W"5D]I M,;V[%?0P=[GL,|]G5 5-/Z3F"-W;|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|X8#4J2V@=";1: Y!@KH26A%;] MT+JB0WUO&R&26R>%K6O6TU5=RBV)K?2QU?[3T|V1,- 2/]MJZ%55*?XC*X=Y M?@70H*:*M?RO9S)2!MRAX_41>LHO::HI5AJ;^M1]93WPAZ\5RL6?SZ'3IL|S M5]9@:)GH9-9ZUYV"OW7,=P2^,TQ;LRS738K=)KU4KY6%L;E6!1P9>4T+QIH MRSL!=4)2|?A^F%_?)IG%R[E+F5I,0CD1RI6-H3QV6,'SG%LS6/#M%=;E2CU? M:T@Y?;K@7GBWJ5[=&-U/S*6ZR;3P1M,^83V^]U16FF"+E$7!]PG?VQ--;M?FM(WM/LK=4S]>5;.)0'GK"1S$NEG,D%+K4X=?O!D-F.CSF$V'O^)G)Q7/63+Y: M1/G4U!%8]-9Q/"9=>S8HOT<8CA4DBPV#9##M*@:9C5?:M6P"V9R([;8"W'>X M-SS+24O\IQLEI93L0"TQ<"HB;[7 W#M>FLX*OW]3PV-+9-^:.S+BF/6B8%&* M/BGZ3E?T-3:);"S%UX$=E^X[-BIB 4]&,8:#ZE_&3CP<>]9"8X.0Z(VDF-"[6R;2D>LM7B/^)T!2.T#7IO&?0,C4L6B M4&G)Q$9GYAT0D3U6B^.;SL'M(N;@2G@^;TSIWY[^SK3"7\RVIE5O9"U*KCB0 M#HC(%4E!=/>QT$Z/0Y98[)5:-A;J02(T\PZ(R"*KA75-\2!9:@_9@<-@C:2@ ML:ON54@-!MG>#LL0U$RCV2>,?-D[1,&4DR4L9'QZDP4C,I M\?=.-S36XJ!E)\[Y2ET0;\',09QU^'Z?,1&FX:9P>/\A407-$\WR,-G#00FL^?U>*+'FW,'?R=V!M.[@U_)*I9F'C@HJX?:- MX*S;WP*;PERI2XF=YMS^3W\#Y]AN_V<.XJS;ETP4,=&1SD0PIP+!--2D:6C'P$C"P338HL)62B29EH4DK(;/$B$TU**#"9:%+"02::M/!Q@R11'F3&%3#0IH;4C]2L334IH]09:,M&DQ-:3"4334LI0[,M'DFF.0 M.-%D6>;*R#92ZRM--%ENYLO5NBC0E(DFEZ^39:+) UL\)R6:+(JCVI0//M&D4LX7 M:W)MDBWB=[@]+!.N'0@&1))Z27$EUY9ZPN>;K.0NF^5LU4;,L>"Q)[XV%NDTY+R/*:Z MB2%#PTOF.63FD8+[!+ G9D3UA:>GI:1$BVM+[DSR$E1B9ZB-/(Q:%&^CV-5 MR4E93%)[VI>^*>65FB!> M]+O,'?#/]3[^&-9U(/C!KN86_RC4,,=4=ZNDE-5:<&#"*0W Z!]36A %"H^,6&5T-J MN\3]03VZ,RYW)MP,S*93"..F/7[I\EMR3H19[5/N.3@CW)!4H:)^NY_2%\8 MZF*-Q M34P0#P>8@[?G-GH_30O2CW=AZL[W?#0!',<9%,-$UWA@8=X0DEIF@M= T0@I.@X/V(M6B"?*>);_ 7F9F|#K6S K.DA9'4'G4PM+3#^.|#GY.)7-6YZW [GL"O4 ML.'GQ2?P8$%%P.A: MOW=^D"^W#X_?6D_?6WF,_[AO_;B^[;2OR=7#_?/# MW>UU"[!\=^#/]_9]YYD\W)"KUO,W0TW-^9A%)TXD M>PW9319I@<^13BT2^B%%A5H4[Q^$*R/?X6G?(6T J)99H//Y<6LE-QTI-QUA M*+9%,7'C)IYIY+=U(K;)X-$KL(N,7)@:NV#>2V&X0&+H4#%4%@9#PM_D"C=< MZIG&OKRB3I_T#.O-(3W;&A!KR&$JHM&'F\IFO8*DQY^*XDFK(^F7]VZ^2O+7& M1+D@JG.'8_(1+XI^/,IX0/-.-)52!N$!%AU5)D7%]2*2N!"OE+&\ZU=R-'C M+%^1@7$SQ*1(\14KQ>1[#8]\UQ+ERB\&2N&OFEI__45@>FQT/(HI6 .Q\D-GPU.VY:IM6*$WJQ*+@GBU2<0 MB$X8KW.BH*QE*>|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|M&E*;AXET^[HS+G2/TSPA L)_BC' MJYNJ[_['IZC"A,Z0B4;21QM.U#1"P;;>PC<3KSH/5W>Z^0>!(BHSC&2B;;HS-"A, MG6X:NLD*7<-2_Y@$!>]'U +Y3$G?1E'ZBVNIN0F\O@6SHH.TU1%T/K6PQ/3# M")^3CU-1G1V4;,AE5Z@:^$52&DW0& ,3>|B+OB5")]3G?KG*?D]P:;&7OJA% M1T'*E2<79CGBZBZVG&GP+2 KE8*Y:OW=^D"^W#X_?6D_?6WD|HPXZW;V\O:\Z MB_PX]MO_ ^X=. ^YET'DCG6YO\N&_?N=2

*M;GZDD>M)01^D5$M7GL%!$*QY6]H;WF_=U>]5/O[UR,SG2#WN:)O=!=D'ZG M;2'20L1["C<+|+QS;VIK^(\5F,O?F8HS]F:S>=]8#_=ONP,,XHE_O?NH4-T' M:%62%^Y-!U0W?(6V+6]FRV))!(ZVE_%AV8B12_IBEO91PON%S&GC'2FE($7M[+-FR*E8#;Y]SL46=1\ J35!4HKH]8G_Z?ANYK M3O="F+;YIL)CJV>%0E1T%'"%X?_?O13V"-W.>^0,1=Q1P6UNV&4'=NDVI%(6 MNWA!XCIP04-#QT1#O=K04"-)CT'QJ!UYO^65VZX-EKK|IE#*>VVKFDQ:,& MO5SQJ-^%6_/*NF76HSYE!-::=[|WKS;@LTB:%]5^-OWBYEG\-0W/ M+VSR.]U\(CG>XF*R8-~"3GW7MY?!0=V\,6=(O("S7E4W>3+8XX;5\<=W1;@^&@CMS1&+)ERX!/.]KFMW*M)UO%^_Z0VLFA'+/.U56C7:XR<6'$T,3GQ+=+'+.PZHS](:D.SA.'?O^KYLFX MC/F\^L,+Y,EN3?Q:VP1^&D,^I%-X_YSQ-%O341?!JH.#Z1J]/YM6^B/_3[&Z;SF&YXFD^W.$ZF M&[7&M=7@-XF>*POO17KV>|HL#U211$ C7BW>P97L!H7U,G:H5I'P"? UIFL3 M5HE)^ >,,+_@4TMW" A AK(TE[#QHU5_L[4A3/WP=&H/2-"Z@20G]KIFS00M#:00=[OVFR6(LO[02GP@!P%/9S.&Z+99 !H"*,_09I]KI?"2\/6_D*V]DK/Y M]U+[;,=6/=VOE:\,V!*MYOI4D2W\FDJGS ;D7@%_D |U09LKBVDFM0!GJ2 5_M5#JO&\$:*3W4N)+#$X.B:'S30(1^A"5\85"XWKAYO1#N#ER%3]S&^RHIR M2)"%^<0O P2^1'Q!SBPPG3^I? SA %E+ K38@?:2A,JAYKMU8,6MG$\B&.>] M"LL-@UM($ ["E%FUMD3[R]$R';FK4O45)V@2OVM0\QPW&S85,6\MTT$P0/= M");=%CV&8,T$F;DV]B[$?F90V& 5FE3+U>"/L A.1@&06S2MOQ?DP^O2QA< M#[*-OLW3J'?!Y0F\70)^&GB+A^A/3"420)HH.@,_#,)&"0 M-XQ"J"";ARO5![[#,;4('[HH@B7I]W*4KWV"'S/0A9\(0S(`#,=:)UWA46,F0!+M>$\IH+;6+TM\:$+3?0R4A;PG^3_:US:HNK@3F8C2EX*8%F%]48MRQ&S%-T MTDS/Z\[G'Z[\]JCV:@U4]O7 2VK7";M^4MF4)9O:,%"ZT;((IT>(_T]4J3+6H8M:W\A%2E#+'KM5)I[F;W30F4>@<:) 1-T,>T5;Y#8>(N/&#IM4Z% MWICFSAA%W!GZ]CX,.) ?\CQ^,@=!H6QF/3*]2/2Q_^;3"",N!4./A?:GY$-_MC50TB]>BX8&H"-/EA\/#4=%^TM=R4&*UHOC?8?]^S85Q&4FNY7/.>&?YBZ?P MS;CF9U &Z_1:O6'Q.JP7*8+K23MG.TO=TFEGT!IUBU6RK;=G6\5X-2B.>"= MUJAWMD<&[1WK_?'ZZ+*W\W6RUUV6YW^9M+38>FRIA4(K[<-3;=I0].TH3E4 M&Y!#I-E?6UC?XJRO%["7$T.[^)^KK|"R+"/M'D>]4|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|F|IIR?]\QS^P,%A,5'2%3/NE:0C) NN&FPC6M:*>A[R] MD|&>^'Y17>\SLZ;8L HV7A7+ID=@$_BO%&>]$NVR3+#4+5MV_,*6C1:3_;*H M<=%*I3+G$^5<[#;(B#;VB<+Z86Q.)=8]*A*8W,JUIG.](9Z+9S7OQ@SU%8H]P,^PHA4((62"BX!GTE3^<2?!;4PY7B369 -MD,9W M< *|/,|:)+MO!J?7(+6F9;&0_GDE*8C>$%SA#[['WQ|UWQE"0(US5CXJO/R MS:=.KW5ZNHFY..A&E=$:HA(CD|1NFHQOT;%W- M?MD,^[H7-S$WHQ%*T(26:MI"WO?9^Y.6U[^__=E44,K1MK9;T'83M68$>B"_CNB)V5L>"121[BV8!S'EO6A8AO"C$<:@RI9U7"M)|>>=U M#89W], PPX"Q\+%]$<+Q!F;NG5R[F_OH" DPQF_R6P,2=# EF(XE0\P7/.-@^+(W!],(=SHK7&I6|MSWLCN(:V|!%V7.'&9BU#36F[_^93:UB|Y^M>:/ME&%\10RO9XOPO,Y%;9?NY MM$=BQ=1#;,C%SE9M2KE|T9I!Q4AGI0O,T6&4 2('3*+;51DX*1][M-$%7APUMCP|S_9=&S=WBMS&;|9OPFTU$9(=<8TB2#=E9<6 MKHE.OVXMQJAA@5N5"7@Y6^D4*C(+$D:7LS_9EI[3^99485 M/2JE[GZLM|;74/<^J;N[N^VR7^K.-~")%BCK;FX90=9>'S/?7HN=#A4FGJ6*ZC.@I=D7:PKT4E-.2 L7/CUSS M.#@I'_K]KYJ5R@C65L]*66K.$7+2*U-]O%M;>'&;$&|N7;TS'0^*9Y\1VU*@ M=RL5>16!\AYHSJER.E^,.%WP|AP9Z]0D-'9PRCST^QO.\#DC7[RY6L|7G8722 MX;!BSBCO:MR^%KEVT-KP:09,N2)$73'V6IV/77R[N;U(^H !"*1%D)C3"? MM2WSR?LJ^AWBK2C77W_^^I%==I6(L!+9DX_^V|*PH#]9-*;F=U'/E+Z,]S M3U&[GGR|:'^^N9C\LSVYO+NX^;"HBR=U;4OV1JW&8*$-^JC.&0J7#TH7J%,1 M^MU?3NE_\+I-U4]\]>9]I-'_4O\T5 Y82D'HNGV;J&<N<1<7 MNL':]PCD$UO+Z!^JLPME#Y_<B'GJ88_K@4'B9@ M', 1.(L06;R"L;D45Q+XA'@HRE>2WC6?]!DUUZZY6"P^^3%U0TH0|9PQ!U?B= MH!,N(&|$)M%$;<+HS(U758D VP&8_'8Z9Y]+L/%T%WY>?^8KO\6%?_/7'0M> MQ5'+^[&HY8L_R869O#]7CL5,G&Q$R!\HS,2>VAR>_^F_>YO5(*%>U*RNC' MLF565;O%(*%U*RHQFU+_E9??/I4&_I2=R2AA XJV7V=JR"AL#@14EB+,[X&J&K'FJ8$6?2KQ M<-KFK.T&9.\A\NFVN]_"5G?@;JFL8WPM7U..3*CS"E_6:U[N>177A/.\Y[7I MQS#Z=[!*];&"ZS;%^@]8_TT*Z&3##3CDV ML-=S4QQ.00NF/RY>0OTB3>#:T4M"'_EM#=Z2Z&74*0Z,VUB\?ILOC& _)+]LV MF];UY_9C$:UI>#7H],3G,^UY&]@.'?9J6K_GL79G$]/7R'_IM[|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|(1YM4$WJAD87YMZ7!P*W61I3XU,ORED5(9+>^<+D5*&Z$:G]F%E=Y\VDIGV M,K'1@YD2G%!D :["8JFE4*#"F3. ^L'-SN5*-M:+I6MH@ANGPMNYSJ9$I^._M+"I\LYPHV3,*Q6(5+R#64J+3(HDV^@A7F.NX%E.6\,:ENXPX;)4G=GBX@AV: M97]GMLU\@) ?*JP5_IO2&WM4H|[86W2)KU>BT$|M[77WY(M=]?9Q,O+N T(QWS2H[:>XZ.N2[K2SQ"OBT@E>5;G<5)<48^SL M]+0H("'7XA) WZ0EQHLLX2*]FEW]:3)!ZLG"V+#GQ7'AB]Y1_?O==N)$PXH M!(8OD-_SE!15])EN2H\,%B_<$B07BW]QV4\8^NZ)+1X9SX$OR."[L ^* CX=G M\,/=^ =E\%'#X =G\(0>+N4Q.-[:=T|F4;[> =[!\'S|2B_N<SQ\(@Y^Y7>V&<-9Q^F6|36[@V*9[8>GK%?YY7=M.VT8^^",G0#L43)CZX^%;NP^YC@4SS8^/&,7:@WT]5?!UD +W6#?'+9L/W8? MVQC,PMVJQF*18N\3HKK(9W(7GX-"X#DL?$+9%65%M*G3@L74F<.L M?0E:0+_TU3/I[E<^/X\ ;637_\TG?|P MY|QOE2@$;DG ^*OERYB*2FBW*11@[L0PZ\343$ M"6UL=U0)?AD29IAI%|\@%|B3)?ZMH+TUZ-;&WGI?P>W?F%IA4RLD/$HTN[@4 M_M4[R@IVH.V4X8OU2_U^'%S3|L/P:O;,ICJ3A6";_BBEW_77R[N;U%*)0+&7K^C3"?M2WSR?LJ^AW6 ME"G77W_^^I%=D)&H_$7VY*/_MK1*P@XO'/0F|AYFYJT@\)?0G^?>[7(]^7K1 M_GQS,?EG>W)Y=W'S =3')W5M2QY#86FPT 9]5..;*Q==!/=Q*?WEE/X'O]NX MK\17;|[''LW?O\0?#1)@.0=S=W7^73?^\-X"UMQJH;YQ%_%>;]|C<6%8A-'+M@P>@*G,+I<%?"/(Z)D323V(S=! 8.MXJ)3QB>B'W44_KB4*X2*%*[]!Q% M&ODEU:VH@M@WQ$-!I1+|%GDFCN?Q"#[1Z/Q' #GYGN*%HE+Z?C5-[4E2+*:& M]LUP5.-!AY5/[']D)-CM8F+9K)12-CF.+1DM#NXQB6_XT'9;&NR-B7;Y+;<5? MC#(1K5A$&=.K+NY6;'<)/UTC;3MSID3KHC4V0W9BH*,^T :KHHL6 M8V-K^-QUY>(WH$6O&-SACVRQ;BFZS3?X*$NS),.L4>] G9-JR M^Z,KOCZ;7-[:Z> ^M5WI.'XBW*<.42LH"-T=5D/\E- KP9=O&OTIOY!Y;()Y(M*G6L%3\@'^5#P2 ^Y=CP7;P7F>&2P|E\MT|:5<|6RUEBRS,,^E5',MF?94$^]MJ6R:(1L)UMU:^ MZS-6#SI[5+B\IA 8JY;Y)/YR"/JO?UN8TG9|/T=Z$"FV_U-<,]7:[PD>/(TQ M2X+LR\N*&NC_7-T"]7-EF9H[=12'3><&;,+#FH=I2PMR5QK6SI?-5E6 .M_; MTT+-O91:A=]3?*J?US_4_YK6.5Z.DV?=;M]YQ_=9M3>?_T%>FTR8W*37D;5; M.+.FU=VA]\G.VU\AK;TR0D[-\NJEY-K7B)(#EG?0\"Z:H=%KG8T/2-OO&K*N M6#ZG)([7B*]_L[(YY|U]SNN).W\94OGBO-[MZ+PD-%ZAH:VJX3;:<;8X41-?=F0'5/6|UA)5 # MA>[7H465$/]U4GQPA'"E=@[@TZK>[HO>^?%R_#<%%(IVR:3F+,,FVH,DE&: M0=(Y.=N/0?*R.!6"3;;Y;C?UF+4(_S7UF^'H'G.SS+PIQ:PU"S7U+$TI9D.] M=:*>IA2S(:"F%+.AG;84LRG%;$HQFU+,&DBQIA3S|83:FU+,NI3Z#!)B*L-Z ME?HTI9@-(6>$P0<)I9@UH^322S$[XWY3BGG49)U*U0FEF#6CZAVRAL>MTT-2 M\+%*YQH$PG,%N*LBU I"YH.,4LQ14XI94QNB*<6L969,H0J984(IYM:"I"G% M;&ID7<2WD)H|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|K?K_0B'S?!\?7#^3NEL53L 8USDE7+X*[W!SQH/SB'|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|@%"$&T1>@'83,E-#4HM#HI&||D./0E"8VE]L'KZE-XD5X+@.B],#HH"K(4<>TR%^2&,!H@;']S LYV$ M+H5T%IBEB[5!Z-BPO=][5I?O&YR:%@L882"MI]#^K$RTO4">@3"]9PCR0: Y M(MXDS4-A,))TY7H23@L%M_+$%@M/K,4YU=%!\XE\#YPX^7/2"U&|W)YC8DRG MELNT||IZKRI@7LR.+YWOQL.5\&4) I_PJZFZ;'C@-795L0BE, J7K"HW$)8 MB'U9^/N"!&(#NT@:1^ MLF C*G% EX,3<36+H>)D%(A>*@H$=^)Z !!% "&V MP'J(LDK-$!TVIIK0[I8V_;-#"#]5=T>VZ;O1'.D+.=+7*TV&E9+>?FF]"&3- MEENWG|SV(]T6]OTB;*_Y(=SP/-Z M\ZU@_>E+-=1=A6RK5\/MZ6'_]6|7ENR_!.W5MF"CCT7H9 MW9*9_#/6B.%"#+4U#F*0H<|%D4P,3=2G"-ZZA,,X=RT+K,+'=YJ$KHJ](EW|ZQXL5NC%6\GG#&-W%PSAEE66-I*266-0"[3X41["[$ M$6R]-[LR4K=3'':VD<1|HYR45O.'H9Q^:WA:O$]BHQ_G$\$WS'$M U/.F/6X M':1 PSF<<[;&'",=AF_\#=_W73FEVRG>&([1L7NCE*VIBI=/*>/>6_C5Z+6 M7O&&?IM)C#47KR4!/E7$6Z7 .IT5AG6B0|W,U|R-'IO CU7Z (O ,S64>1C* M+-RFO"+*[%;] *D0..RH5?)8$+ CO$J] /+:$_L6@^LZVSHD*?FW:-;M]5JC M;166T5'Q;'(B?/UH$C@%_Z[?\OIZH>TD=X@:H5 M\B;DZG%%;F6<'1A8!) %3%.870?\9BP2$.Q&?WIN'"*Q,M^& 9H@0Q,/V'0:RUTLH_$6-LJ'IC[KF4B&NCQZ@/CQ8[$V),!1|E\@,RDIH*C^+VW5T"Z^$LL MFB1-,GAB|14P#>2?1*D:-I!_#>3?H2#_]EG4'W)F!+3,+W!]+TS;M1**HOOU M]N_"|7W\VMDN^K^72=9=^61|TD9E?UE[U3IM)M2RS]H:OF;6OX:E=HUM?PO M^@R;6OZFEO]5%'XW1_KBCO3U2I.FEK^IY4_/-+K4G[DCD_NK+4LU'CBHZ='% MA^M5F3T^[6[=?HF2]>A$KOF!3 +G43!,-FKU=VBZ]")3.X^ =!)2 3+R/$LF MG7&KURO>4[3]|@PR-K(MB%;6&W:,.Z0CH M):$*.4\GTTAT2\"9_)1HP13UK+E9??/L'0, 7T2.RJ9;($MKO3NJ4:6% MJ$TYT_&08T)5=$,YRIM+(\718,W\I#2IX;!&3&4W\]2?F=44_5*J&$/*>4WQWK ML--MC3L-M-814$I"I7-._5R"Z,VU^F>=1OW>HZ#]SFS[@S+EA5G<RK2(*LS9MT%Z(@O4UET*T#C$D,NELEW]@UWJ^5G)#S\:XAQX.2XJ9!RVK(<=PZ&^X5 MHB:=^%^#NNZIZ++#C[9=P>]RRNFY@W]T#ITG, ^],TICM"3)UU]]3Z&O"!HR72 MK8.Q%1+IH->)>*0<#'SC.ZC'919RG,XH4*&422F=!5TW$\]Y?/)6=!@K%S7OX MFFB#>,>-E)]R'Z/P,YHTUMG3+<$"O(K$+?C:"/L%'ZM]3M57ZIM:P7$9K>ET"8'&XJ3XC5U\>9GKCY8C$A#>=*=N7)GZ40-|-!2-Q!9 '^\IT*>(M2-$*=OINP=0-=P92T;7P^/#@;'>U6JP#8VH$UI VU9_F(Z];@\D"68S%E"56 M!4SESOT3 294Y?^[4=[B;&1+=_GY=SXI92)?*QN!GRC7KF6[L-\>Z(=<%W63 M5ZFI>MKL0F5MBE?7$&Y$/U=M#P5"56SE. N^>JD,K_$U?TV!|4Y3(+E__ZPN M5&/*;N>,.=_-*4U^]XQA"$5N/A^T(Q_OUNOL'FTS_ST&SS@?ZK6/6S' MPMLP_HOTZ_766U>*%3?.?\$.WGP:G&S& 3GG 7\M.&Z'L"NDP1$L"38- ?-B MD"%+|'+/|TJQ<-:0?I<02J"=;C/FHVP0&,U=!0&(M<01|!&DD2= M&-H7N21,-$3X&@=_<0W3,+4W85G2#3%AVV;3#YIKK9EJXDXVRRU^OXHQ& J!1V: 0""M"$E(Z$E\BV.(&\8V:>M M@-@*W%'ZTEW2HH.81;0@0G\B5" ;Y)T-1(R"*0A"A4?*11O6B D%+4T,3=P' M8$&E(_4%RW0?YMF"]]<1US5>HVEDD1*0W ,M^+_GVTIG# _3P'V0)20*GN2G@ MV_+-Y]&IZW3T\T0)TT-T;4,CM648RMA*P9<^H=X4$===?1MBVM!>!%%.'*I M_L':A /F]?]9>D9*.*$LA2''.0B6_ $+^+?.7QASOQ#:+7A&(4&' KOH:?5B M3HH Q51@(V(R#BN'[)JZ?RGXG2^+D-NT*YR./7$4E40%R#M)_L40,SPX55+,*W M_[%BFFZ*2|$OQ7ADR-3K"@V?I;MPI-6"[:\?F![Z$0P6[C&0JNTAUKDK%&NI MQ]D22G?_[^D*NZ\A=5Y%"'((Y.8N21/%3O2I^ZL+GP'M!LT_0*;HRF(OU9 MMA,%%(3S_'7Y@7P!6>S5Z5:OU6UW))>X).] A#0$K>Z&[U&A$[V"6Y+7SK%HT0=)/*]7-S('1"/FJ5[<3CIV3S=K5D.!_X4< MDQHYO79Q)V1Y(8_5.I>.=:]*U:MH4|Y%E2KWJ^>:WK'NPG8^BG0N3#-WTKG0 M#UIM,.(.I8C;<54OQBVGA!CJXN9<0MGR#SS&"B8')EK!U=K!!\8;KTI8UK8M#P0U/S+*$:C%("@2%Q4P> 0"@Q#E_>8=.Y M82[,AS581*IAPT\)P]OO@)\]N|@8]*[*4_>UM_:L]U#9;P?=,%SB2@.S[< M0+HWD.ZY(-U'#:1[^G^F8#=;^>FY=PQ:_F%W3OQ<-C#>]&X8X$;UTUNV*.Y MP 8WPEY6+KD*M&ZN:[RNT_W/A#K4F_=?4*:#;5M ^]3(CY8RCY^FL.%2GAGP)X))2!?3A:["W*/2WB&2E^C! M=U)I69B8JD6I#&!=8T;1-CE65U/'|%.LSL0F8|82SAK=7.OR-JDC$ONRI_5# MM4 /POG TQS_ ?%&MM=(=MH)9*]%]M&`33$LLUBW MXJ;IG9[TDQ!_>;'E\G=/D!8W*2BM#?D9+61U:<*%9(H]Q>YKJ4VGG">3#\5% MC6?XPS;O2"CZ/$ITX;6M?(=OO=,AH8OQ*G$KXN=K8A3-CS!GZ?,,4@LE>AT?P?=F%W-N#XBU1%R,XOW M2*81//-[,<5%1B(YO^,6.5(I6Z\8C7"+=Q#3\+,\B:-Q.Q$AU<^F95$7%Y@% M?!/ <-HR#M2/2ZH1K8.(4_A[)" MP_0'FVL9|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}5/]3GIRR/SU9K6\'O M50,.) ,E]!WN"M8WQ..X# #-")'GU(QJGCPI:-M);>5M+67<%Z$N5AM.+.9CHR'ILS4!)90R3=I8*I$Z#.>< 1(.4O :QJ;]>["(8,* @P20/,S+<3[M60$0@O XJ+-9^M2O7VC%NE4%E8E"E@-R)]I*+E; MW("6(%+@S*0#Q]X%N|+W7>66"V/_]?L7DCJ:KOU"AZ==-S> MKRD:#%88IEX@]@3:9;-X_D'*LT.B(! ZB)]H(Z$I?@CN8<[1.!7I">|.W-8)U>-R+6*N11:1G#8$P^2;A&T(B7T+;I) M9^7/BZ=0**8_*6/IXAJB("O)$SX?(2GY7S1+?3+2*55Y@E/A3Z<2W*B&_M", M4%M!\]NJ?]#(P62"0TCS]3NU^*^^SOG&4AE]03I*2,[F1V$!E!:V[.?Z%$/%YRLLA\CEQ&|/3.4S62.RC<]R(7Y'QAVBANOX#=YV>@M)9Y!K.F{B>6D" GGOH7?('6|M4*XV0HMS!OIA),+.7;MY;R_>3ZA-ZY MS>.VES67,BV>"&<'**8A/2 KB670&:8 62-028"V4@V7XN-I*#6.,X[!"=]MJV](~*'BA[99LT,?:ZVY,U*"5G4@VCLM@DNLOM!6_ M!|.YZ,%K/ W\6QWRO$8QNC=NE(!\)(MVL:8HOF7Y$'>A(+]D,X]$MQ#U@T!L MQ*M)|\K/DP0T&9P*:>.,^:1:HHX]X,KC,_)2;AOLV^B-',1T3=OJ39=E,!I% M/N@ LN=B[:$-DQ'MOD= 3(<[ZNW4;*6K*Y.6]$=GP=(CPDCP$HE0B"%7TI!P@DJB$]X5CE+[I M'8Y3-8)AA *'&P4ZQEC.7&?YC^@+G"CW:W3D,8D$EW=*N?D:WT_81O,;$A_K1! M:P23&U@K;:1N,.$27,LG9GD_:"P06CFX,'ZI%='CIB*ZJ8@^5$5T_2@G?P2 MW^1|%W9_J#9'U=_(!4:$DXBG49B2BR*_PH5W*L-+S1*PW;$_EF8UY@>YUG1. M\$ESX>))^Y@.92+"!A"N*.-ASP@R:9-I. VDRJ:;U&=IQN$Y^$"NXQ@5X7]KB6[M3%,BUVS_IQECA*[A| M:4?3W"=RFU,^&AH \$#D4/IVH'5&*

[&4S3\I! \/ZY:F:#|\;81#]4RX%F" M;BQ!3M)/,ZY9PFLYS=QZL0@!7N_1'CG21H,JH9RQ<^^\ZM&^(.F3$6,GIVH M,H&UW'.?*
30+KBA08+A'\U(XD^MJ<&$@FS!:"#73F&_E;Z<1*5!C,OA&(P)-L M,%GL>87)6V8^@2KTV)&P_B=(_U.VVJQ+4SEPFZC&35LNJOUP_);^R)V=0F0&*
MVH<(YYB_SYY4S7!:&*8P4D5S'2,%O'-Y?(8EF! M.'@&TJ7-36?^04;A;,O-EO%*!%X6^,IR:6C<*"[MT8:8DAPT79BRN<'FO9$L;)"GG[S(C+)"2'/P?NH)M71BC:NPZ&)>_,GH]UOI
MW5\C!/O5[!:?OS#LFDM&VN67H0_L;R4JZ5/P'"!$0Y&Y.X1@6>7D"XQLY:,77&8$F,*UD?"[%X%&:Q9\\E]RB,.^3K6W&'1_2V HE2 M6K/-#!0?/$&*@S)>AM*<@4H8F):H _> 5(3J:EKZ
\&KAV%,9,<4QH?_,\5VSBDK)$GS]F7VB0WU (@.%K@(G$-47=YCMG!TI:XUX6T3?] MV#HMF^:"%>I.BMSS]$BAFU-2M_%?U^'BQ\OJ3MC6;,,
[+E^KV^Z^">'4IE!!R5GP822%)I*:XM\P=BL%V6S)F;FN H M|K,G(\-[4F)?I9Y96C.MG3.IJ!((/,JUE_U2!DY19QCCHOD-3B.UD"DBHQ:1 M*J;(,09]FJAN*;N"I',:!_35\].H>[ML<,4%1QE-
=O+DR^RQUD@\G5Y&U-P+ M%4#U)+$MRKR9NUB<*+_(+T-P QOY M=;'\GI8OAF^,~@"UI/*_6N=@;9(R:P:(,RP9R%K"+NU%1MHG.: %5RX%V. M=F-*V<3B6=8DB+LIS>E"
(F>>N_U@N1,(:<[4&I=D.QE$,Y+NDH_N;2ZK5VO MO)A-OT1GQ6Z--|,B/9|/B]ZCB!?YP?-MHH*A(7CI(@Y>Q%ZR(%P>*FD@K6&X? M=#* [6D]2'72ZWT']>X!_87F9S%'X!+R"
<;"LK1B9D@?2W\]PC2PMCF;24@T M2U:Y>8@NFOIP4@FX"-4:(O0@* S.;DIM,/E-L3!MV@N@)/BA]!MS*=;Q16$X
M%W\';GZ63;\)!>=]OPAN6*;V]A7A3[[#G)E]95R$YGPU*Z[+*39<^/"G#.J. M@/'XI))R>\KC2LN9-M'YL%.'M=>AL'D-&;.*4U.5MYVBFL]P"!0@;U/4%8J> M'!C9W<=
[B$%GQUV(KA:V8<]C# L'T8$/.Q= >_F'/2SEL$BO9NV!Q)!+R*!)0C'[F'PV'QF:.90J7U@/#2R842G[%NP-/Y4W)T-U.M MPVFI6=']$[EF^@/EA"?*3-?-P"07T=V*
<%.Q!W>QR+ ^ZW\S2&1R15DJL%#-7.%(M1X\/YN M(V2Z_#M72.$2)C7-4R!#6O5VUD'X/$]!$W_SZ6_.O:FMX3]6X(U_9ZI D>#O MW-3/K8?[M)T!%M^*?[W[J#S"58KP?9(\
IDT']"9\A19+KAO3V]10Y6DZ6HFC MP!(PCHO^MDS+*_=;!,.TT0J0>4[EY7$%YB>F%P6 3Q%;(:DEY)7(LBIY9YOS M*7(^$M"HNJ-Y[UB?_I^&Q4LG(2'/VWP;X+'5LV*;"UVCS0.5 ?
__KCZ4YC4\ M*XG*%'&!!3>@=*72]2O5YH,7]"%)8<4Y9@RUIOZOVVDFGBM,^$$1O7"%5 M)!E,V8>4)YW13J+9;R3UQNZH5.!_VY9BDJA!AP'_FC16||>PJ6>AP!H,$D!S
M2O1&R9ENVO2N6M09Q%,E>[N7W-%"Z6FO0V\QT+&WSXS:G|/-]Z00S3N[% MMU^'H73WUFD,%-W>"":GM%W^#JY6VOXR?"2)+*?H5O)W.^_9-IIO.6_;JYBF
MSR$/GVXWK^(]-M4WDX!ZMB&MP/T\D50RK7%EKJ[G!C4\E#*6)XCQ?QD1>^+ M;O^L,._ONN'QO/BNH?RCI/Q^0L+_MK?:WBA_6%Q-JI3R7X/IX?U$QFT1P@'2 MJ+-
GS6V/W;FU=`VRGU]D'WG! NP@+4MD03Q3;7:EQ^F_R7#N.8:#C4"I5G$C MI3O>!#!ZY49*"2DKL8]AOI0UZFW&VAMKI]@>T2.?V>V_4&9\L,.EF5M++=KK
MKMP55Z)>BKJ7@OM4AF@0$]&H'&B-!\4OF,:P:6@_E?83D+/*NA9?+.W7WK0I M'S7(-VU:U/$4.U:$[\<]WHN]?3L]X(6*9KJ81!9AL)U<\B5+@>19IDJ!PG&? M?
%*@"/OWL2:LU>\5=^B7S?_5DUQ#Y%42>>%8575$WB,B'X_J<\EMDAR_Z=Z+ M--7WE$<;J#[RDWM?=P;VI4N5/'X&@M?O/;VB&*M+5-F\W3[J_&S?YW$U"_(_MY4_'9VN?-=G;1Y-
|U>3]!/?]+]IL%X2P=9ND@%?!#TVR8*54(4D:=CEP%4; MVNW0!9PNL]/N>|K-'2AO?=#H,U%I]I-C&]E(M3 MT90!:J5&$#.A2W_"^'=/;/(?I
$/4:';G,=GG9'+^KFVT>>09'K+R'7H&2> MQ/ON[LD\""L>T957S_7KF"MN\WN?6!PR*/29%"[/P6ON^6-E[#NN/L)"*Z!_M.IO+VH?S>Z>=KVW\=K^K2Y5."1"?
54@GA/@H*)I&K7YW7PG=VY)^372'0^5& M\4#P+,GAW22^%E#C4SKXI;0ERQ>9^FJ9]@YIB >MP]N]6;R/-$2WJI*K5\1] MJ6E0@\(I@,=7ZU1H]_:.I53$SH\H4-NJ64V:<9-
J67&JY2"E26E^O?NU)U2^ MF(N^2:A\P;EF@U(2*C^;QK0XNQ]# N5VN66QGR$6-N4,\7'Y_?LIDM5 MM_ZE+ER&^MS"M,'DC0>>Q)AG3"I3%9UD*6,@LZ%"5W;,Q"4HM
;$&;=U(&]N M%S:]7C^^370T!C'2&8<6'N&&_=(&T>-A"4:-Q1=0%7MP"74DH&^6.@MP4/)\'3#N MF>CA9_JK#<[NMD<7(6R?|A>0?1FAMP63!9+Y-:=@9IQBK$:T#C(V/H5]5N&-G
MP]'9QUBU(&92^U-FDF")D5!3I=0'3M'? G1LL=D"H>5=0|5P**!6G!AO=S=E MA NN\@Z/,(4_F/P=9=).X0%;1SH""I^L'1?O2P6Q(&ES)*>:5I!1@QN:TZ[_T!>SB!
$5_+[\9$7Y]IC\SS6M2 M3>,\4%L?T0!+N,5$!97TPQT,?HE>5]P":"FQ1KT<2NEE%TRE[#C<']4T1;6OB MMBS4&&S'7?-G'+-[V-O),I_UI6A*"49YP#+'EE"\!R=\1!.7?;[AIR>*" PH
MB;M!EZ#%0U!VH.F(D/!+,YQCQ7DCQO%(4GAG$/Z@=ZKRXHZF$>B52*_]4HMX MX@=0-5- ,.4U^\Y7GR&SZP==*)[F^>'= ^NTR,-5\!HDFZ>S3STW-
MWU7+ZVH4Z..;V1 VYC>XS5.8S(-ITX9]X- X,;3WH'AA@S=T]\6,+?8, MX&G@#_BKC+|1+3>M93I'*4"=0G3K;F[Q.ZI;")-5>[AFOOOIOPY/*=LQ98_*UH5KN\34[.QK1LVP6-;9EO7
M#76S^!V$BD%.;^[.WFT='=PWV$_00NX,.+|_,!5=|"+/|)[Z!3Y= M#GKM_L5IM_WY8M)M=WN?!YU!9WC9&_6/]7#_L D&TK#K]7[;:_%/@%;W79<3 MK-@&FY7_N;-
QTN7E<$>2PF(\$IG5_2ZS 2@8%;K;IH*]_V\(ZQY8 M*'[GA,I=/)%*&

*M#CSKL5$ (YJPO5G@CB9@O\!;+N/O7^&;HK'P8_SD[_#)0?ADU''X%:@0M%C7 M1VQ$U#;] -&!$!T+BCDNZ"8PE1<@GX UO$Y,X#O))8HF!TA^@+WX 98$,SUC M:S% W2OS;5AQXC*R:RA0TM&OWDQT<@-=,P=7>.V4((8RJO):+$PKV&6XUV M6K(P(@YU3_O@I2)Y:33>L0KPB'[R-B^6VVNWU.[ULGM7B=]J19U:X&SG3*0"+ M?(CO 8X(R%4XA@#^C^/7=9;5/6#XO(9/AE"V3!90YRJ>&(XTPJ?"4L@H@AD=# MXO]A+*81*AP=#2QB3&L(EU#N0#('Y"6+X>"CX([1+8L9'^>+RN.F)[5N-50 M? =$Y+9V)^9:$,ITC<$003K&0$ASF(H5X:QNV-8"QF'-50TDX"T$U5Z[74:VTY M7C@7U,A?KLR7'&A_W #:G6V@_?&&P/|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|CJH:-SW37 M#U\>0# ; VG$+BP'T,UE,ZZ;)KP+H;\|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}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|'5F"(?2B_&>:+,K)T M#\|C^^=/3S_>%!6@"L':?.:SR1@R0&F$RKKG.:_33XF\C9EG*?_??OI:.$LV M1$)@+H#Q? 3R;\AN;)N'_JV+;$SAT!$3S^K=W:!HO[!XL+-I!XH_4YTEDR7P?_2C:ZK??QO-_AG;?#IZ>['KXINO>IS+S2=\9QLE@+0>V5"ENRO2A.-.Z$_ ;U! M_P? O+>E&XJ#:+N;@WEZN/EBVG|&LQBF-[/T.4+1,FU6&UK. MZ,\T[M'DR0/0E8F+_.-OOC-ZDZ*%5P$,$UB,B0C-3QF?6/PRPOWTUSL1&$|(MPWC!>X/\T,9+6WTMK"#*3]%0DJA">EMZ)F(,*3K>@N49@%/$P9O6Y;S"EO; M(1X&X/$]Y-+^!#Z&,;B*/]%]P-/ ,I0A.KAMSP349H8'AV'6#'%)KM(-N ^$ MQ6 $IH (X+L6&S9X.7- X(&F (\B-M7WIXK(=AH#79EF&O?=KS-R.!^,,-@O| M@&]VF:-R>F-:R#Z.)LP(+/8P'@#LC:5]Z3L!:RRG?.-,9X%/T'@8+TKG)YCX MQ0+N&ZX1-'O7VC6V<6$@KF?(2]R A13\&|<.SM) (DB-C$+Z]Z&]OIH^BOSD+ M&9LV$=:;13E-?+"8GZ!\SBG0-^B6ZSJNEKQ[TJD.9VUG|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|<9 2^((=%E2F6G1PV*)6)SSES!@_#=@C/H9(I_4Q(N:IK0>&B9-C_3N\ M7;*5C $X-JS* N*&+PC>|&(!EI",'H !5+15/ L;<)&T.4/V87ZH*;?)93Y$ M0^-3;^L7SL50U@NJSL20S5B(X@6@5,%/Q03N\6^7>$>",2(B"FZ!9+/ 03EF M"Q1+(5;$3EX:GX@#P9@3_067P0HU&=OA(C"37#/ !>:F@%==N>4KQ(45S.!C MW3, ^R=2AXF<,BY^5-"E;#=*QVGG*=|2W"X;[>Z/.4G\%%H) M,8:GFT8,^,1KK6(%LMSP\,+137T)X3 MYAMZQ$R#4:GO% QAXV U,00:Q^1G,B!%Q6]N!LYXIU0/O6CANLY]0^&*&M#]NUYIR[<6N$ MD[B#[L8WW[L.@3LPW0,]F-YR!K0>36V2+]&.R<) #T/!$0Z L6Y:X2^"]OS MF1S9<[P("1,-;"]NY2-<9&39 '&4^7 VL\3JL6CY=<:I8; Y4M8)-L M2I1>]DR&ND7E,O Z]$K1K"M|[:$=*) A:3PO/#(.->[/"4WE'.:$,,_-/UIQ MW,XY1N/T&X +!N-N+C[-$#U'0(%_D8H&P%3CI@9IB6.8A99I9- >)A>OYRQ8^ M/)^&!TYM>R+ "('*90',YP5##\@<7P<&.F(,T/L5[-U2BQARAQA8D'_!/I%K M6,6@%'Y$+P$-%9?(+YQFCFG[*6C02J(I ',$(>M,F7*%/K>WA4XW*0]V$@5_ MLCEQ8##_A,\(29CEP9_R>89JP:$UU;UN5I'_UUFPKY1HD0,?2C;?6]M=U := MWL=:Y^9C^U/SKC.XZ[9DSY"+*80O>X;(GB$2IV4!>]DS1))+ ;G(?@^R9XC$ MH2KA4_5[ADA.6F'%HW+H?44A_T[X67(VV,IRU4MAU.-/C??&$;IO# [8.>8 M0]IY.W >*E;9ME>Q>LX'/Z>-|+:\6E;T(]Z;XU=0M72O!6$NE+WY_O"T,+BB> MZP='Q2@SME4Z,];6>O.AI_6J4>#B3%/'3YF:2G:PD=0445-;;?9/N7K]Y=6& M>?,!TV;P?HAB/,Y0H%>N*L6;#U>%;*=D'YJS8CN4N_4P_NPXAO?H6,:&_*?5 MJ4C)N3PGEB_1+0\,Q9RH1]MJ(;4],V/1\QX^4XGQXY*MI>I M+C0:P+P0&$D+3^+C=FRI,OY"*>&/2U(E>\Q(DBHFJ?:;#]U>9;K'2_-]E9P? M3#&UZ:^H8(]I^[K];%*.$N6$7:BXK]!-8+MD'YBS8DVWB4)2N/H$FN:Q):HU M5?N+N*H/OERSX2W9HN73J6G7W59V:=VG F+B=/5^9)O'2GC\N_5QB^-RV M] /&NR9M]PW346#=*3F;$N[+36%VD&K^YL./N/\&7KF-0S>*703"P;M M?7.MG$45,JZ3#\|;IZHQ1N.,"(MODDB\J2]@'<8ZWX[]/ZV>D[GK+C2>.BI) ,;AI7<*1FEV5;5Q_"/7%&1'S0 MZ\"==)OG'S(XOYI^-1N#'?7AOX20QU^&WZX+UVX4AD2*H6E+GW])_-R"T(MU^Z.?7_4>;* MYU3_,/RJ'S9R-6P+W>F(IM14E]9"0[#8WE\X=1#3#S(&BZ> MQH]- @'.*B#P>D<6]1+>=5>SCF-3V-IY>ND%R]8;[2 4(&[1)+|@E&%#G%':Y M/"HPM+OQF(U]AB^_/NF?H^*I&X?G72.(?]%D^XYQ73NCG2K>40(+4@PGP%R8!>936$3NJ! <^^6M>Y5,YFX#3$I:= M!R3R,-["<=+/2F4_DBF70TB'IJ9(>CXX/1?[:\XF G;_!%U1)TT^92IY;MZ) M)D/OJ#|2HIGO0E_>PJC4$ILHGVKK MNY#1]5N_[+TKAQ(K$A5L4Y- <7.5Z=12PAY ['*(=3=X)GF(3&HGZZP72GBB% M'+UX&4SDDTT,[_=,#>LEM>R!1DHNX-'4LW]!.8V5*@&PQBN$'.S*.*0R+A@. M)//DNX-'4LW]!.8V5*@&PQBN$'.S*.*0R+A@. M)//CW=/C\<3L7N>]M"%>A"[;ID|| M&KZN3)'S'?*LRY#>"SSKWGXI-'=<\R(;D(6/D\%0Q)G:E*90K2;"TURT^HG MUY4IR"B5I^T8T7>7S733*$LT\@LU7K5QE+(V9%["6L'-!V=Q.PEN[G8NA1,* MO(>%4V&[>'X=ERQT^I7@RMN$.0L=;8B5]GU>2""X^O6 ELL<,*]+,D;.X2NLHW75S*WZHJ5KS. 9KYKV@5!YW5M^[- N4?NC+]$-?F'[32E2 M)#&,MG8L6 ,;&+[9ZY!;.HS.D[-.JD*[$\56+"';",# M^5V8?;2//+&C<\F"/+$B-GE]TFOR W-IYQFX%DI8.=VVW=^=H$T0:04 M7AT^^>5^\/^R_W3_9V,H90QE-7CR\>.H2R7-"@=6%)ZG"\YY 52SO0Y!]I= MA(%6)<.KV*#J-4 ;H-H@@/(IQ\,MKZ&J4C;PM.VHBC H%^5S0G;+L*0+\+CW M+BET'#'\2XS@6T9]MBH2,K[_F*3+4-F6W.[E]B+4.4NU!?>,^T(]@2[.V!\ M4J>358ZMRE[WW%>LR:) !Z])=*'UV)JR'INLQW:L>FQ9Y1?Q"#[0Z/PE_EPX M3S9#6,3]==D!EH+1211-#?V-XIL^SD"?Q:G!,P"0^Z>[KT]SKGP=? /$_WKW M[8G*@O?>/R]W]X|WOS\^WC|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|P &=DNMQ_LJ3J5$7!9H$P\,68CR M/6*].!1^_9T!]_%=X(/1;UPA2S_/MYB<*]I2I'*'+N:'U(UO]_$]^>L#XR|F MST'_!4UO HE%; 1F(8-51FT99T7+)]P;H&(Y,]A_P,R=T/WT+M M#'!H9@E)?35E_F1NP?@V*6QO492M-S3??P9@8EC'X(>]E-WAZ 4"F9Z-:(_ MG9^T/:!!F!"0+G,%@DFBA9"SSK$)>GLD',F0\$U >0Z\O/NAKX&SZ^0*@& ! M!XE^'7Y(BHT$ZH" R PX!&CA)3BHO^[8\UK_V/6EGH&H OGEPS_%LE/.-L M <\;Y64*^<=6X+B@P->&.A))0H$/D1-=!%YJR3#'69|#%%8Z%T CJR1W,A(FX#-Y208P>YAO+O M &@0> $.- \P;$&#HLE'A4KFX)K9!6$PI%O-6: M"QN5>X1HIA7&RG9F1%+*B!8;IR/N6GC.?+ET>4,*&3>HR?_MH1HS_|H@[$DA19N0H^RHA MM7@-3]C#6XV0@R;Y'E+%O>? JH)I'3!V8#NS//O@H@\"?/K[\H"6XW-[PBO M=[W5+P%8$"H9[D///":]J$A(^6\X06)'F;CG0Z4WEBSE%(N X%^MV#Y_^T:W M=4,G ^C5M"RQNK3D2;T(HX;PO>_Y5)SF'/+9,M! [!4<1+HF(@0$5$N,2C&1Y M'#ULV@*,<89B W54W!$H0.1_M9P1>72?D8LY ",RT5Y EZ91N%5"N@@_P+1 2 MO&[H)RS|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

XG#&1<;+K,BWPFH)1Y(CI&X1'7UURCX G4#$.W/H .!L 5# M">]#Z/X"13R(UXD)N V"SG!@XSY? #KY2$HG[E]A^A]X9ZSC|[__B68&7W+\ M+M?*
L<44T2KB$O.'HAMHT#)C_#NP953%]NF1U/&Z4D+S$AP"48\N$D='E(Z2F MK_);(6T?#)CF"J"3W0#K D/K5A|/,:E>'B%)71+<:42&XDF0R4+:0&P)T;T M?7Q%+)[&D4-
S2W_132OAP>"P%891!"%8YT@/T$LF/+YYITCJ30@V'G"3@1E> MTJA=Q@2^[^A>B^[MJ+^R.08M&& ;1Z#395VG$$,XVXX\?2 YM?\44Q0/2(&AEPL\BI&1JR
M8KL3'5%]BMB&9)O^37H?:E\ )F^,%U93.C7AI)UAOPNZFAI'RYHSW5VE2$G[MK, ^>QCY3LHUPYN*K(E@P!'8ROILHMS_CW*#=YV(=61C?'. VS#E" -19]X2 M@26I;Z/H$K*5/H-
>""O^)ZRXP!/[NU1/1HA?"Q\6:68,>XP11KRR:S'NU7 M$T[$L-#0O$+V("R@T*H?,G2[$/X NINQB:1;:!R1S]S2P G+=-+Q*]P&J> MF?+1N]=XKWVX'$>(6+$^XH[U%:
(]2T$;7^7,$!.%: M%6O'BUDD9K";3$/E=(T!/"/&&\, !;V#=9 I@C\.24:A8QCV.9P++APY1Q). M7A4O]9'A(9,/XX[R]T*\!5<30Y-;JZ&[.P6\F!.U.XH!:C-'$!*^F1 .EH8W M7?'#2I'WZ (T6;
(163IKUX 2*(_(U#C4^'7$,:S.XRBXD1!PYONG&F3WAS> MN +N$L0\XZT$-_P@6"&\[4:8>P2!5Y OX5&'2QIZ I'$X>G]5IBU,-I9
M.BX=771NPN6&80KZ@KF=:HJ[H\X$NTAD35V\3HN?)NH(JS6.U$RY [J.]0*:PO75:A8L21DFZ'HHNR9RN)9; $'1%3=%/!Y:SF]B:%:G/ M6R'B*
[W\MMKI7Q^31*MRWA59QL6@7:\GT:XZR[@0M+O2KAL5O+K-E92CNP6J MT4C@,T4)\R1MJ:^<,P5KFGK=[U20AJ7D.&^\:ZF-5E_B7666<2%X=Z6IC1T\@+YBI8DC#O0U2C$#-
&;8\EV\2>(V:<]#3+ MO9+/8%/G-8T\HLI/DW=$)Z?*5]'1^,@L*RQQ&O69._OXI*K:UF\ ^=-1NYZBW M2Y4]C(LX_J[:N-;D\5=BQF.$';6QE]I!AU=]A6V>))'Q;EY\5W=F)JV2442
MJ5N2E*1'DZI:\Z@W;4C(LX_J[:O);'7XT9CQ/,J.&CQSXG=.59"K/YC' M=!=+'E.CE;@0M92J1ZK=K,KF6HE9CR6Z2B4E:D5F/(U$[1!9227MU"WEZ6"*
MJ!M+7[6Z/9YD65(;E_QM^.$+EC[A_;J7&ST=Y8Q3,#@B0UM_'0*%DU]=:'#B1\6[ECN(R#U]1FOT)QA-4XB(LX^N9Q&R*%)Q3+UH6F9Q@E3/NNFK5Q9CH>-WV0\:=6OQ#:/L&IJ
M_7X5"_W+P+ZS1KNCGK=.&KWLQ+%FB7*G1/*]=5>OXH8MZ4.:"K_:'\%PIAU@A&A|S:\,V=AQF;@"4'S]9^PRD $)^2K@S/7U/9UOQ]7 M<2=U8E59QQ$O<7MJNU>1>UP9
7!BR--7KWM:14,NCU*7Q@LKW_IWCA?I?^] M?=*X=6EERE19F2I[YH@G.=V&G$XZ-LH|-KXQ/W16K\1N2!?&]=D2FMJXKH@= M>E(G5I5U2!>&=&&
<(/+TU4ZW6]$3.S$7QGYK:.Q2F MB?3GAO1@^3;[5<>R$W5455|7S7)L'==[);"B=:Z\!S:F&$Z =?87*/'OY\AW M\K?+ X=Z[:.9O]7#M$HN2]+_OM#_JI]JS>.5SLE'M:/Z$24%7
X%7*N=ZY,0 M D%%#X.'6-.\/G'7;&/Z\=0+51R!3' -,V&#[1ZJ;2[F9\)8;YHHPLW?/^ M\\WWSQ_ ^681G(W&+UD7QN*;Z+!H2.GQ_OT]",.;(F-(X:YW^^5Q"2ACIT<
M8#*NNO,L"3]NLT&.9[<+@#\]W'PQ[3^C.0S3FUDZ0-*T=L/ZM'M:'EC/Y,\QZ:.AI4^4U7)BX;_^>;O_G.Z$V*$%X%($S;]$W$9GYX_^3BE\B MI;0^]_>28#C$Q(]^M%OX"=
(^^W=_]'LMB0^)1-Y?^QL*K_*!FOD1?A)!=HNC# M\|;BR;^99/+^8" ,#EBX#O=#9!8>+XYGF?S7024RP&E#.?* MS"]L6.9#DSB*OY$0,\'TF#*%.:=>
J#$0SEDK|>^X1(`@]^^))O&F[49#]"Y$9_>S-] M%/W-6='8M(E"LV75KAP>Z4,43A8B]5BFGFT0P*D @MG_^49KK%8B]E0'X7#@$]K9$D]_(E;RE;.2 M.V0EJYQ|>SRD16?
NZ9&:)*^CDE?INXV*46%*>A^* #=-9I4V91$N191 MHNY=-5J4B',:B-.2B",19VW$N9GH]O/*,A=2_DOY?U):>>7H[,JT%7_B!)YN M&ZNC6@YH\%8\DOYX=#2X_<>M\CUTHIY|[>
L&CKV'7#&DK2.VNP>N91P14N\ M7B0R: >-%Y7(4&%D:'4KA@DG%BA\/%'[G1FF[KOFZ(+D;47B^[,(26U>'[EB
M>T4/XR*.OZEVND>M%5+9P[B(X\>&#;U#=KQ9T;!!V]LEA2AUL3M[L7E:V7,: MNXFU(R1_IKRRE\F7+P;IFD?H@B?QZV+PZTJK?/\&:9V742RB?]>TAB?'URT] M B,BC<]?X5A)!-7-
H=IBZ5I7[?2.*2-:ERLC+A3C>FK]%OQ+@+PSAT=;2/ MZNG,Q,%<-->7(R9Z53X"Z#5PL?5LV7:FM)A49Q6 CE^D>/]#F<*W 7ZDV^6]B4
M93JV]CBNTOME.3'*TZ=,F<&!.P9_(2\YJLY_?IK$4RFONJ?,7!.V"Z!3#%@% MC*K'OYMV:HE4F@\GS;@P40S7A*LY$/BYVYS!NYY@QK_,$&0;G5GUE=^8,I%,X"3Y@V+ Q>=7R35P)4
M7DU_DN%*0U'# VC!)9/3RLZWRV\&XQH6 &NL(TDK#)P.46-&; 2YQ4!"C^+ MX89S_OK?6_66$IW Z\0<3;)F2<(+1V&)%,=GR',0M(?P9I-0!0Q5/31R UT
MB|!-9^", ,]%#MPW8HLLLG<^78W)EB8YGL;A/>]DQ0 MG1%4T\RMOP,V]CDQ.O\&7L;H-^ 2]%PG;CZA'"<3H%Z3=U*[AH^]G5 M!\J8P:& R
.Y,W/PU5^2@!]V0R&XBO+.JR3!9V:#)F1 ?&U+1+SW=)]Y)4 MM:FT2H!43X%TF;3R%73MN@19K9 A:=(RDY2E"^43=;NX//;(\7PE5G39&.26
M]|%.S"E0T4NRA#9L$1XP1R:SX9^W@FY.%%%".OG|/+ [0&='6-P"I["5]% @91X"-W].Q'M @%,S3R(ALIEC0 4S0\'20;3BQBO(41ICK8GO"/FMK "/ 7"&"P6\%^ MP_=A#V!,
MV1"?:CIC4T'(/YYTU:@RF U?R+F/[CNX!2/:SB=)\@+OW)(UM M2&-Z$K(A70&$S1C"A%^@N["?(RLP2!F<.H'MHYZ$WW#G!,D%>-'3+51T0%MB M2=HDCX3GJ/=39A3BHYL"-E?
+0B|IU!.WY+NS" M?O:HO9_L;3,$9+8/K5%O+2O0FJT<'QK_LC3"BT$6KE=CG@\IA,Y5tC_EKB/AJ!0!?2T:+^KK42+!V-+',&FWW"E[_MR_PA^ 5,.Z;,11?')=T+1Q?
4;L2P'<,R_(GR[T!WX0%%YY8NXZ3=AJL\ZV,-77WA#E\N[X"US?.AU'NNFJ[SH M5D!F@1'#[%7 U$K U/040,I1P/6JP*-;*)/D&6+Q1PLLNMKC:.)8\+###SN
M&+'6+="!P2Q%7*]B)4ZFW.BNY2B>.<4!X5G!&.A!-A$&'VBD|-C;/% $V!;3O \"5O\P (S8ZHKG]:[*W[%84?.LTU^ M1. /@4T])_[UC-B&X1?-^G4(CXR?FG8ZC>IK2Z\1\HOFM"BZ+UR
SPXX]=(BZ|V<[V).0, !3,K MO"AA/\%$05@AD8LP-RS#KH-MON>]3SBRHJ:|S\,!!0^=9H2M 5^!41]U_R8Z'],="5,;$=-*X.V|GM*97CP M=HR?K+|OYK|#T\"
(;CRZ&WUF^L15/#@VD#QGZ[>)HBOY/A'!(E!<@,J#-/^ M@RD3':2=,X1?!+DL7"20;T=_!@F,]@CP"E@ST+YC,TQCH.^(EBRP.FPO$3*B MB@!,.OKCX57%#$YB@E%;%/!
(%LZ91EBM=09CTR:U .&=T%%"8UQ'< WAF3"6 MA (60L:+H(2ON?&'(!>^"#B H>,Z#G#N9P\,4H/Q"!^\GJ7X.) ^3]!CIWD3$_"$RT'?QTL[SS'*&,6'6&!CDLPAQA U+?D&X^F G-.|F
M-^'K&9MHY^B*1[!5@*1O *<0^RS07P8ZV5-.X,-K+(1CVKW\)$>]R[PO<> M1KZ#,V]=T$E#|E[A7)0EY<4*C -C(P_"%EA>$&GA2$HX6Q#I:((9)7DAUP.V
M]RR,@+]KC4;"A9U!?"I>NL(DN!/QA<&&ON*Q$7 _= FJ"=]DD!D>5Q?8)GRZ MPE6B+M-LO,=-|O40+M*WVONWN& .$KCZ1&'NAEA@6K]10[\|KCKM<7(9ANR)
M_>HOH/F0KYUS"!QX878!;?$DSPU#Z ?#?|%IA?=L<%2DB/7>>^$NACH UDML M(&%RHYWM,3*G?'0WTE'?V_S]&'^_KW^L=Y,OB'E"!#HT"Y(!4GD!4ET9("4# MI&2 U
JE(KSS'(2JM%OIA&M9^;_ %A<9D3I!-U3,1<5%$8A:<;D==##TPX&!]MYH6WVXD$:!00$; !R :1 M^%>&S>3_/D'>W&1%Y3=^,R)NO2.0IRG?(B+'>"RD72\ +!'Y@R3 ME_Y_>U?
6G$:RI=_G5U0XNB-D!R! N^WV!%KWZ$]<#;GK(*$'.9**:LFJ%4Y/?Z\FM- M5DETD\C!7/(D)WFQ'4L1\GQW'V?]]'1&D7YG"=7BSG%KEF7MSK0D;ZE(\= D@K:T_?; @-)U&H'3P"1E
M7W@M-*GQS#FE,MG3A|R|/8%>.AAW:%$2N$"BKTGB]S"GINNV(C7L".WE\BG; MS"9RZF?D0ZI$N?N(MTPPX=(B:(,&5KRXW>!!CA?07 [T>079@-2&X<4VWQ648?MSA"X?
|X%9[L2=:|=6D.V#!NDJT;JG=-[P M&4E/0KE@M@\ES!OAJ,L+P'BU[QW)=-"%[8"1^8A$D.3C0)S2-*FCG*.<9H|2 M9]0 .G7V-R*4LX(H]PD&K+XBMV9&%=|GI"A].UL=ETGEI-
MLYC9DY>>P=[>[U-0W&>_9IYD %:FD0|&H0N,;G-1!4)48.J;\L3+8+8_]>0L M_=YU=1#<;N"M4JYT5'R.);/|F>9_2F72MGN;.SN'!TQQ:-%,.3W(7Z'I*$=%EVS.7:L!2.Q M.
(K;"PVA\%)Y4K.9NO(!+(BBF[5R4AM19/2J<,_\N7@WQFZ?B!(Y#+;/-6L) M R/3>])(&#@3 W(1IP#U]?L2HR5C(1PP"$A4FM$G58YY#RL.L ;ID\(0X\)2 MR5B1Q0$,Q?Q)?
<#^3E3:I[GLD^:>H2_&GYU^$'G$L+0J5X0^U>!MC9Y*\QM] M1N9GX1DGPR#T,+?S[U$W6RN,D+PDN%$K>D%V0[(TI(/Y)N.))L8VM3" MCL,?
+,KDTPXQ'MZ-.;L>PXV!RQOQ#*]LD,79*96_??PCXI9W;J)#O5,@F- MIAU.!"Q:MTN'"!?T4"LU]6]?H;)Y9M|;>\1[W'+_@F3C5<;^L'ZG49AFX&7R M_9I'9QFO90HGT-;Z0<]#F*B%$?
_>|*E;3D1|U='53$3-+:+&A;3I@EUQ&.ER M42C.W)"E1;(*+01]HVQ4C(7ZGLT0O,Ds9T*)L9YH4=||%F7RSPX9#[?6W9KT M\[F_TN:C8W1_U\@R12#E/]AV-P
M]30&)H5@2CLJ!L/TG;'-WA<%LXDAQ%Y?^ -<#MZ6CQ264N*+!(PD2@_X=/V! MP=Y850-?:3BM2,$=&-!,SV_C-B#-,E]O>?"3GV* IDR9N"L%9B)X^^K)_Q.^ MF7/.'
(L&G*3@7*4AI G1?H:78(4"!=*U;X(6'@=:OZLQ372,4B @5]QE MW\,5,*.0X6||PTVH9#0:OZ'JO. #DU2BZ>A]%O IPTDQFH*TB#HNFO7I=RJ@ M#78Y]#(=O& CD3? U#=]
('VS&Y#X5) -1L R)HM"H>R'!/\ANU\0!$/H-4W? M6;+H3UP*?^<0^;E 26|)"%@NEHY8+$<(FR,?!O0E+A&PB!() M"<#!26(XV M3@0SK2OIDV2YT'1"@5N='R)L4!S&8 >I@S71_] '@-
#R2X6#U"%3D.+#@?^E M3E?&S(. ;;M)M$P^4J->C+[LC%+Z-YBBYD@A)]V71$RH F< MFE1O:(7M0P<'?M7#$6$<)/.=2WVGT6^BQQZ"L-NB<]H#"=T8Q7R1D#+[!Q:D
M3'HF;"RI\651 R:.\D$2&Y[7).8%KC**K==9!U\T.QY01]I? M!AELC$'(S'#[^L%]X!Q[0;\C@-%X]^1^]9=FOX@"+1>5FA)4%"G;M]MDD'1D M58 @-T""]R 8-'+0Q Z23]0-IZ>-C>(G$
XL])HCOT MC#!F;FH\3WH@,3] M%O3O$-[FQO<0A!6M"$61[]]N##EH^HM/?9Z9IZ&O8%2BG &8!WL+8=P,.6SS
M0YY('J_+Z;4X0XQ+_FW71@Z3[%V*1[G=W0.0O.!|I#E&,)I_*UL3 MQ%;4(I(X0]*F 3,G"K1:DTGF/L*;2;,,&24,!]*K FD[A2(A)&&$-)0M(W1< M5!Y4;5.!D4@@212
*^;*Q2*6/A$2&4N529RE0/GFX[#1W2@X_X.S&"N*I&*# M!!$SS6*&YW&Z' ML?3-*IC:0(H. ^-)!2-R.4PD]5R&!PY] U8^(G\(M/[OIA$\Q=D+?T-
1)F@/A<2V&V**!M@V]$9R&@6H=Y5KD M'J;.F:@?H!H0+31[1!^Y!IL7H3[@UD0FJR-$*S.HKE9)DC R"]+DI"-<#Z]'XW^ MG8YF=^*X_W%[^^'AH1"YS<)M<+_M/?
YW*VC^L5T)08'=N]&VV|H5X3:X1F*[MM',X=U@ZW :U5]K=.3C8/2KO%G>*Q?WRMAC$"7IVQ?V=XM^EXEVA$_=TG#P/ M+\^#B,#@WT?
WL0.Z&,67P4M7\.L_&C]2V0$28%SI80(%; MZM?$31:<$;VC3VI.+CD?^[TR+TUI4#JC8U0=J@/9GRI;I-RWJ'L4R0_X] M5"V)V-@<C(-P&!S6\%I$(15"(DX$%94+DIQ#^?]\VGU
M^N3\|OJF=G;M5(XO;^K.STKMQUG=[56O?V2&()Y:/&_"B> E7=!(IK5N4[EM M"&@,AX9KBVI)%Y%6&WG=U>_LD0\7JEVV)+6NMAQ9B?YLI5BT>8%]+1%RR|I?
M;$]IPF%6J["5*KR54H451!.D>](D>="-M(8R?YBNI'8+SLGE1;UV>7Y-"N]] M=GER=HHZZ_,\0ME=*MI6$&5ILU"?=> H7?9"D:WCQ,3|[64"M8QOPQ>4'X+1.2]VU5M MG,'O
:=&U:**.&6(V89:PU4S9$(E$;>MT"I4G6^Y-Q[Z.5'2Z'GQ!"9SMKSW MW'R7\[TY7F,4X?]&='T+3DA+ALUP -E77%;YQ)[I1NU$?;?IM3W3:M?NSA;2 M$:!.C[H&8G;|GAXT6PFO82C?
MXN|7?C M3P:\|3 ^D 8F'F$$"?Z+DZ+;RQZ(#H%NJ]^4OB3V,>@#6>]U&.)#=QF+06CM MX-X=%AW)']:W(J19Z=TRG*1R^A0_A6 MB081G/<<#(?
G%CN4=T#4/*[S@X]*+YX8Q8MBNBE[:M3WM*HFAQ-6S2BH)MP M2Q:E>;2H":@7#,;]E29.3X5"!3TWYOR.U/R8"? 'Z@F9/*'E>RKKX?EDIG"N M2>5O[;"]R3-0^-#K!-R=2@4,
[SD9)9O+((FQ'16&+8:7@5.1$R-R1TD3;^IP MN@KSR+C[V.R4A&G+N0U$5Z44(BS.=]M>'*4(2N]-QR,I?X7^,4W6&P,=W19Q731Q*62XR527L'-1)IWE^5I#
MYV6N2S)26X"N&RCRPX\:|)*[5O#@TQ.!V"0A/*=)"]8!5AK1 :8(:2.2@I[+L> M9= Z20\-=9(B/IIWS'X,'52+!T1237.)P"?]%W,+YJP(=VX56(.H M9=_3F^4MYJQ\E3
6./MJN7E26*,_85DUI^2S6/FFQ,J/LEAY%BM_A;%R')ZF MQW^29TY/ERHFEHX63?P0Z%"Z_IR*I%]5:O54)+U:+3B7]6]G-:=Z\?6RJK-2 MKUY>K%M7VO/NNK>BJV"F$5BA?
F05/Z,BSH$+G1,>XG5,<7>E2PS25@:$|G M\!GMU%3P.%(10YX\B,XD9*-,/5|P?@:1 KN*7'L$SF3/4N!*?ZL7YL87F02A M-2OR/D)7(9Z #?
Y@7LLKE:@0!"0E(Z^A*T496N!!J&_'S67!L/E@>;TI:TH/ M;M48:]KI+ ^TY>;CE.BA|A1YY-><4T67BD4:9LT$%;4ZZEDT7\YG;6M*M,HO%
MHAZ$(OO>#I3"X^ZQSKJI'U1_O.RMU:58SI*\A*_.FVI(WC'QB.'W+;QSH>N\QE08IRJYQA9M45&6"C-O1'W5ZI02R,$[K9/X MPQB55"E0T9/SM7)2OZQE^HACNEIGM
6&DNRZ7:0DG^+$ET%&+M4^D1%'KX<' M0U!JI(EU>U1|/*PBAKAW2%7@85*9D['\/+'FGK\:! GV0<;"PB:<(VP]/]#Q M/#S-/:5H='4F"7R,(NDI*D=:9L-
PX7DLF0ZB%R3I%,07K,$_"94*D\W=(UI MON8SBF=PCTQ7M%SU::4_ TU__YN_&#VYGT&X6W/|R %+6OT>K-/M?9ENZI
M;>G# _:QI,"I"G$*64K&Q1X3)3WN(25DRDZICR!:)QS/F/SR=1)]A[S':\%D_G8+)6+1^7#@X-#V-LY MGCO[+BZ\XNAP0P6V?9U!F1Z0X:R=< M/MNCU@Z093QEE-
WB(8\#&USC"Z#H'"%SG?UA(N6EUL6#49'4J1"H]4W1H_C"J M-/8+SMF_OU6/J_67L/2H984,9O[QKOC.P:B@;*BJ/\/):JK/BQ..@Y04&K4# MSR*)@T^IN#/]106>35\-_!#J>)U!\C%?
&^4)[9AT//1H2M_5%7#$&>^\. ^N=P*(.7 M/R0R]0*10]KY85IRYZZP\'6;E7>B/OXIT&YO+!?G,>)0(>.O+Y8US=,*N:! M2_?O!B ZQA6A8T@(GIZ%6W4MH5V5VBOJ2S+4(&P+|O?
SE8]<=+4'4D?%,N%LL% M%-E/8]=T"]'7Q*[EC%W3[%IZ$KN.5B%OK(KN^5NE:!NF:\6N:7\LK%]^]7&T5 M_Q4W'^%XC>U"|OO,7I9I4+UXOIE.78"'_W!N'8.&|<%?,YIT$RHJC8O2POE
MWUOJ[I[5O3[K@A54HJJ!03?CS@5L0!^Z,JZ|@Z+'6F<6,@\!88F6|WT)8,J M%23P@VJ\PDN*-MRVZY-O'S9LQVPZU<5CX >|@7/=[+B(#^;Y=UB8JS=R>0*N MX"PA
4|JYZ^"@">BVU0QAQ52<45L>'KVl550\13C/=ZJB;@B5CRO'+|*(IZ+ MAMN--I +KVIGKX*
5WQ5:>6'^95Z=Z7B[B|N+)|0]>Z5N)UDJ6SQ%4P*V&N8<*]CMYC=Z\CN=;S">QVK,O2M@>19 MFE"5$'FW1B*!/Z2]$:ZK?UY4ZF\:[&C^TBJ[NPW?+"8L#Z[L5K%]MYF$?-TX
MA:8"7Y>.=G85^NXMM=#O8[|4V\(6+Q3V;*5* 1G0!8M:&=T&8Z(-MR.Z;;X4 M(#%^Y0-H&R8(V4FO X.Y$Q!"RW/;BJ^O>@2D,U:* ?&N_&Z"@XK^*0];/ICL MW"
[TGMW"_C0_=Y@&R]5;5OZW?N,<5R^OOE5J/RL2_J5Z<3+-#5T7=6;]ME0X M7/[']Y?*$7Z]T86LJ@3D5L?M1>GL7P3U7899V5!7FW&8$5JN:;['@X_39I4N
M.N)Z(ZP\4H:1S$UO!U$N'4"@AIUP'3Z;T>A'5D)7\9XDW(<+_! ME7|VOFQ=:3BTD16_YX;C;V9ZU43, ^3Y4NLEF;MP+)W7Z\Q7!LH2LC80OO,= MFWUVP83TW^#FO_T53JC
>8,K3U:VW(:-Q)|MK\"JY0=N8IWV;&7 MI%A%68KCW:6MR,K#/FUA9GHX6&. ,8#A9;]^NX'A1;S(4AS'8HHIQS2!!KJ! M.0=|@ 'IF3OKER=2O^!UW6;A6NQWO!RG,A9UWVI'.I7>]:Y
>YBP M*YUS%0I[K.!)(M2HRUI"L5:C+52/Q:6QVG09+YWND<_BAJ.JW[4.>\L@? S^ MZY@;P97K*AJ?[#F8NC]78J2Z1HPRU\NY&0G517LV_ |5ML7)B087TTQ$PK&3 M=]/=;T:#?
K,8/-X1RX]KP?QXEVB6SM'4AQ79HG>;CZ\;XP/$\Q-GSC(X;^O M?V-G;S|<_C*\>C>LL;?O7S> ^--AO$LAK,$ZD(N8$/X+XZTO RBZF$)=.C(%] M2+$6S'<)[A(!66(+YC3[&!A"
<53/+]JL\LF\R>*N^R=.A>.1!!9I@TOFZ5$+%S>0LEIX%M]MP>/Y]RJDB4A< M1G/1>E(-5."J2U/1*J:T,#UZ_ B7;C.W\)X8B[G\^%TX:W(^%GKM//2Q^DK M%W.P8!2/2S>=Z-
&@W_-20\Z9+=H0X7WYWA_A':;0+12SC MR'P#8P$33'PN$Y;]6G*#'}4S=@4%ICZ&R\7/B #LJ?XK<6TX,8MX@^1EL_8)Z4G$I(1U (@38!A MHM&;TLXK)XYBAJL9*Y4S)6#$*-QR?
%Z$3XX+*)8H&9+.:4'PW0N?&[Q=AL& M"F*PEIL9F>3\$_A$L^C38EF"P:!+2:)FGHEB8>(R1S.%S9G7BVR2B3ACMJ2_ MENTG8*#]A :0"RM1XR$$V42X# =H"TQZY)WZ+3 TG>
P$61!C:Y,PX%H#Y5H M)_M--&'N4 AE8L42NC5D&9ICM5FI%RKL9TA)"A7+,L$ ^D1XK.*TAM00ED0+1 M3<0DPDJY9%X%>KOF&LF=".JX1A:E1 .DFRYH:X:EUL<36/506?5|+UAU?
0."3WIXU6F_[-F*-Y4JI^5> MASV6!^=;Q@UX&B"L!3UWA"L#2Q@0-B-S,LLQU5&ZH^^)L+'4ML1VE 2-EH$/ MA=$Q)%ALV3'"/P'D4|#XQ33.N\|?WR==E1(MVB?9P[6?)]
MB6HLK_]^ M: 7*]T.[^67>7.V\!B3W!*R4XPIQ1%"M/L, .(B!#3*W8'I]#**MUWID9|R-0[YZH- MPMX]RI\V9M\CUL4B(CMQJY'(+5*9-HK$46Z2.:60P8]'O#HW(RF[5ZVM'IZ%
MGF"!^#=,5S::7D%,JP$5I2F0W]9+[SA&)O@ _)9SY%]V2.0YUD!BIA,<#L= MN(RJ7A28N |LWG\.\|0'N3(G3(6NWF?,U6'MXCAY*6U7%<&B+"BL;F6(?5E$ M!?LY615QC 3S'|\-
T9JS*14#/0C@9MPMY30G14Q\2KQ3\ M1%19?,:D^ 2R.B5>LZ]|]=QL"08FH= ^]O;$W783&RT0X;>Q"XOH"[#+/A7/@.;NE6:110%-=(C VW\$Q4A63
MK*4DCI^T0YXO+/"Y%!BZ7T1*Y:\6V&>'XZ1]3ZO[<9PTE+@]PS)_\0812(>D ML0#D"+I S"Y.=2; /Y'4#+LU+S;]/M,_O)R__+2@7\:JSFG#&O"6#|00;6E@D ML)TDK7:GV
39ADBM!;UK;3+*'&<39\$$N%(,6U\3';3L7X%T^W$R-$3)FAK, MJ7D /CTARSR+]XKNM6"\!-JK.482/TI/JKN#Y@J8T)>2#T#K)UD,I1/?H/+ M2+X_1/ON^ZIQ^7
@!!/H!!'G1#;I8BI"ORUT>X"0X%IZTA;8U:DG=-YU7OG MI-%YLH&_K[S!N'Y?\1R!U&7O\9'F$3[5]DF-T;7@O0W$'0RY+>YVX1636U> M6P?=;IQLMJZ I"MG\/>%HBI:[44"6L74_9#
MR__7N\LT?KO@F[:Y>9%VQX*\A_C[IHO@EGG;7/[V=^]HSOQM5^3W?GQB<'P9 M7O2@'-D8)$H]L3[*/UN2)&+,8LFM/3WZU_#C=?UR^.:B?G9U,?PG_6AEI?;R
MS<_75VME65I'3&X6DHG8AEV >__9NZ0TMZ)GPO^@Z/]02P,$ M% @ BXIM68WQE9TX" D#4 T !E>%\W,C(V-C$N:'1M[5MM?6] MW<3:H_U0B+5 ;S38!U!@N(.$16-VD94J ?
-,Y\#.M'% M=P\/NR]?L;-/K-'H'^7@.(LS;BRXXUKITL:;6E6]> [*M52:G+M& @YB)[2] ML5@K!PJM'4@H,JW@6.E;_^G1?G#Y*-
+)F%DWEKZY<@TK_@M=UFX5KL=\0ZS@22+499>UA&*M9ENH'HM+8[7I,EXZ MW:,QBVL#5?TN=-B;,>%|\%^'W BN7%?1_&3/P95K<"DN5=>(R|SUJB
M/9O_P;;8G"B_NE5)B+AV$&IV3G:C_I'^T7_Z1I??EYPYN=-O)D-C@,_^5Y$M M>C>-<;_YOKB88*Z/B9,6_,.OB=W;R|\45|% ?']}L1;_7^+<&0*RQ!;,:?B5I.(3\]-8LZA^T.DRG MS&7
OG(3<06V\>5*PI@-8D9^Q[[3VEQ M# MA$^.FR8"F/)8RBDE&*9SX?,)MULR4!"#M=R,R23GW\ GEVF?%LL2= :'E"1D M)MDG%B8N!7J[,#22.Q'4<9TL2HD&2#==
MT'$,2ZWW)^8V8ZG4(SOAHH%+89TAVQW.51Z<'QDWX&F L!:T[@A7!I8P(&Q&YF26 M8ZJC=$??$V%CJ6V)[2@)&BT#'PJC8TBPV+(]A\"\"R*> |=.K../J$OS9Z+R4 M:-$^X-[!3]]]N
+:EYBGAL+Z[(=6H'P_=(:?YIS MO*+ZTI*2]#N2]:+39T!M 8=QF"'1L8(3Z$K)*6^CK[[GF2#%'D'>$]MR_%<$ M9(BI%=M#LDNEV|A: N9NG&N6B+LYEEN8]XBUXY
M22;40@8+'@DIW)BD[*IA:??P+/0$"\2_9CIWT/0*XJ]:4%&: OEMO?2.8V2" M=\ ?.2_] PZ)/,<:*$@1DPD>IP.74=6+ A/WCLW;SN9X*]A\.N2R] _<",J0
MIG3Q/T20VA5'O*F^WB#9AJ^K3WV>O-@0#[VG"TC7;KU'FPB!_C4&NC@G-Y^ MH\.BR9'<[T<0(H'^]*CS'?^VG')5O#O78#V,D7HDK4ZS?F:E3R\0PXE+:OC MN#1$A#F-
N:+77%N'Y?28$/NRB KV/3R;8'MKFJ3(;.QN$[/*XQ@)YB^&Z(2G?0VTMGTZEKO$RS[T9.);XOP"[S7#@' MGK,KFD4:!335)0)|\QWL(54QR5I*XOA))^3)Q@+?2X&N^TVD5/YU
OMB=VYT M[6EU.ZZ3!A*/9UCF7[9!!-(E:2P .8)#(&:GMSHXC]{:H;3FA>; ISI'UY. M'G[M12,,L=H8A0\@RO% MH(/QT4[+_@BDVXZ;H0%*UM1@+/JDC!\"G/V21?
!>T:T>A)|00RV'0.IA\((8LEM ;X]L!UXO&V>##:>/D_'3P#_]USUSMV8?W%^<+95G;.']T7$A: MD)U]^/S[|]EH:$$_65KQ@5[LTT^8,"3^EUA_ %!+ P04 " "+BFU9Y=QN MQ1 %_"$(0
#0 &5X7SM'8] M?8S5#F04=ML!)7YVSTE;AG2+EW^:=]RIO>M*G+;M8*(W%]T'8XHIPF1U(?Y M"F9!QGX:'(J(PE@DDH2@@VG6\,\RK%UX;>_MV[L-&+|'7>^V(RH(> %)4BH[
M6B87>D,KJ9Q$M*,M1!(1]?M44D\RP37P!)>4XV!)0QH'@M,.%UIWIUTK3&[/ MA; ^"5*["?#N7>LK^HC:81BQ;D!,6)&+ARH;GGS,A6S,6T12&] PF(B*\(+8@ M)K[/^(D-!N-
@5$W&6^!E22H2&T@F14OIC+]05,J[(K!U841N0WYI2A)&N+2Y M\B|L2;J4.@G9";<3=A+(5D22$\9M7_K;P/W(CCSKKL)V0Q]*M5LUV;=]NU
MN+MS@RTOKACSXENLN5"."I_S>1]WQJ;CW_GKX<.DR9.YD-^H.>.QN, MAC#J0^_-P.V#^']'M'<\&O[E(0]X[6=X6/+Z@Z$S[V<<=VO>/X%S*X:/CR?3 M8V7HF?4]HW(GQCA3<
Y'XYE|"">-RQ],IK&O MPFGVQH6I,SEPANY4'WU\Y_X.3F^F.)9A6/?A6'T|/5V?V=8:H50)4|(EUP" M"3YEJ62+%5HRJ,!:D089@4D5+EDZ3]19J3R:*'X%8LQY&O%RG(OO)D0&%*DCGA-
'W^M&$9S=9H&=(5.)Y4? 5\!5<1 M65&[HQ7\R<592/T36LDW?]A(@H\V7,&$QEA< &7WT5%$H)3W0:HK(Q M]27M&NE68)&%Z(DGHCAD^(3/F QR"Q/Z.6)C3",4^7.!=0OR2M -

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end XML 101 aytu20240930_10q_htm.xml IDEA: XBRL DOCUMENT 0001385818 2024-07-012024-09-30 0001385818 2024-11-01 0001385818 2024-09-30 0001385818 2024-06-30 0001385818 2023-07-012023-09-30 0001385818 us-gaap:CommonStockMember 2024-06-30 0001385818 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001385818 us-gaap:RetainedEarningsMember 2024-06-30 0001385818 us-gaap:CommonStockMember 2024-07-012024-09-30 0001385818 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001385818 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001385818 us-gaap:CommonStockMember 2024-09-30 0001385818 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001385818 us-gaap:RetainedEarningsMember 2024-09-30 0001385818 us-gaap:CommonStockMember 2023-06-30 0001385818 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001385818 us-gaap:RetainedEarningsMember 2023-06-30 0001385818 2023-06-30 0001385818 us-gaap:CommonStockMember 2023-07-012023-09-30 0001385818 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001385818 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001385818 us-gaap:CommonStockMember 2023-09-30 0001385818 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001385818 us-gaap:RetainedEarningsMember 2023-09-30 0001385818 2023-09-30 0001385818 2024-01-012024-03-31 0001385818 2023-01-012023-09-30 0001385818 2023-12-31 0001385818 2022-12-31 0001385818 us-gaap:OtherNoncurrentLiabilitiesMember 2024-03-31 0001385818 2024-01-012024-03-31 0001385818 aytu:AdhdPortfolioMemberaytu:RxSegmentMember 2024-07-012024-09-30 0001385818 aytu:AdhdPortfolioMemberaytu:RxSegmentMember 2023-07-012023-09-30 0001385818 aytu:ThePediatricPortfolioMemberaytu:RxSegmentMember 2024-07-012024-09-30 0001385818 aytu:ThePediatricPortfolioMemberaytu:RxSegmentMember 2023-07-012023-09-30 0001385818 us-gaap:ProductAndServiceOtherMemberaytu:RxSegmentMember 2024-07-012024-09-30 0001385818 us-gaap:ProductAndServiceOtherMemberaytu:RxSegmentMember 2023-07-012023-09-30 0001385818 aytu:RxSegmentMember 2024-07-012024-09-30 0001385818 aytu:RxSegmentMember 2023-07-012023-09-30 0001385818 aytu:ManufacturingEquipmentMember 2024-09-30 0001385818 aytu:ManufacturingEquipmentMember 2024-06-30 0001385818 aytu:OfficeEquipmentFurnitureAndOtherMember 2024-09-30 0001385818 aytu:OfficeEquipmentFurnitureAndOtherMember 2024-06-30 0001385818 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001385818 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001385818 aytu:OfficeSpaceInBerwynPennsylvaniaMember 2024-09-30 0001385818 us-gaap:OperatingExpenseMember 2024-07-012024-09-30 0001385818 us-gaap:OperatingExpenseMember 2023-07-012023-09-30 0001385818 us-gaap:CostOfSalesMember 2024-07-012024-09-30 0001385818 us-gaap:CostOfSalesMember 2023-07-012023-09-30 0001385818 us-gaap:OtherExpenseMember 2024-07-012024-09-30 0001385818 us-gaap:OtherExpenseMember 2023-07-012023-09-30 0001385818 us-gaap:TechnologyBasedIntangibleAssetsMember 2024-09-30 0001385818 us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0001385818 us-gaap:TechnologyBasedIntangibleAssetsMember 2024-06-30 0001385818 us-gaap:DevelopedTechnologyRightsMember 2024-06-30 0001385818 srt:MinimumMember 2024-07-012024-09-30 0001385818 srt:MaximumMember 2024-07-012024-09-30 0001385818 aytu:TrisKarbinalAgreementMember 2023-07-012024-09-30 0001385818 us-gaap:OtherCurrentLiabilitiesMemberaytu:TrisKarbinalAgreementMember 2024-09-30 0001385818 aytu:TrisKarbinalAgreementMember 2024-07-012024-09-30 0001385818 aytu:TrisKarbinalAgreementMember 2024-09-30 0001385818 us-gaap:OtherNoncurrentLiabilitiesMember 2024-09-30 0001385818 aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember 2024-06-12 0001385818 aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember 2024-06-122024-06-12 0001385818 aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember 2024-09-30 0001385818 aytu:OnOrBeforeJanuary262023Memberaytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember 2024-03-24 0001385818 aytu:AfterJanuary262023ButBeforeJanuary262024Memberaytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember 2024-03-24 0001385818 aytu:AfterJanuary262024ButBeforeJanuary262025Memberaytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember 2024-03-24 0001385818 aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember 2024-07-012024-09-30 0001385818 aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember 2023-07-012023-09-30 0001385818 aytu:EclipseBusinessCapitalLlcLoanAgreementMemberus-gaap:SecuredDebtMember 2024-06-30 0001385818 aytu:AvenueCapitalLoanMember 2022-01-26 0001385818 aytu:AvenueCapitalLoanMemberus-gaap:PrimeRateMember 2022-01-262022-01-26 0001385818 aytu:AvenueCapitalWarrantsMember 2022-01-26 0001385818 aytu:AvenueCapitalIssuanceMember 2022-03-07 0001385818 aytu:AvenueCapitalWarrantsMember 2022-03-07 0001385818 aytu:AvenueCapitalWarrantsMember 2022-10-25 0001385818 aytu:AvenueCapitalLoanMember 2022-01-262022-01-26 0001385818 aytu:AvenueCapitalLoanMember 2024-09-30 0001385818 aytu:AvenueCapitalLoanMember 2023-07-012023-09-30 0001385818 aytu:AfterJanuary262024ButBeforeJanuary262025Memberaytu:AvenueCapitalLoanMember 2024-09-30 0001385818 aytu:AvenueCapitalLoanMember 2024-04-012024-06-30 0001385818 aytu:EclipseTermLoanMember 2024-06-12 0001385818 aytu:EclipseTermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrMember 2024-06-122024-06-12 0001385818 aytu:EclipseTermLoanMember 2024-06-122024-06-12 0001385818 aytu:EclipseTermLoanMember 2024-09-30 0001385818 aytu:OnOrBeforeJune122025Memberaytu:EclipseTermLoanMember 2024-06-12 0001385818 aytu:AfterJune122025ButOnOrBeforeJune122026Memberaytu:EclipseTermLoanMember 2024-06-12 0001385818 aytu:AfterJune122026ButOnOrBeforeJune122027Memberaytu:EclipseTermLoanMember 2024-06-12 0001385818 aytu:AfterJune122026ButOnOrBeforeJune122028Memberaytu:EclipseTermLoanMember 2024-06-12 0001385818 aytu:EclipseTermLoanMember 2024-07-012024-09-30 0001385818 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001385818 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001385818 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001385818 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001385818 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001385818 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001385818 us-gaap:FairValueInputsLevel3Member 2024-07-012024-09-30 0001385818 aytu:TrancheBPrefundedWarrantsMember 2024-09-30 0001385818 aytu:June2023WarrantsTrancheAMemberus-gaap:MeasurementInputSharePriceMember 2024-09-30 0001385818 aytu:OtherWarrantsMemberus-gaap:MeasurementInputSharePriceMember 2024-09-30 0001385818 aytu:June2023WarrantsTrancheAMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001385818 srt:MinimumMemberaytu:OtherWarrantsMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001385818 srt:MaximumMemberaytu:OtherWarrantsMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001385818 aytu:June2023WarrantsTrancheAMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001385818 srt:MinimumMemberaytu:OtherWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001385818 srt:MaximumMemberaytu:OtherWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001385818 aytu:June2023WarrantsTrancheAMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001385818 aytu:June2023WarrantsTrancheAMemberus-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0001385818 aytu:OtherWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0001385818 srt:MaximumMemberaytu:TrisKarbinalAgreementMember 2024-09-30 0001385818 us-gaap:RestrictedStockMember 2024-09-30 0001385818 aytu:The2020ShelfMember 2020-06-17 0001385818 aytu:TheAugust2022OfferingMember 2022-08-112022-08-11 0001385818 aytu:August2022PrefundedWarrantsMember 2022-08-11 0001385818 aytu:August2022CommonWarrantsMember 2022-08-11 0001385818 aytu:August2022CommonAndPrefundedWarrantsMember 2022-08-11 0001385818 aytu:TheAugust2022OfferingMember 2022-08-11 0001385818 aytu:PrefundedWarrantsMember 2022-08-11 0001385818 aytu:SecuritiesPurchaseAgreementMember 2023-06-082023-06-08 0001385818 aytu:PrefundedWarrantsMember 2023-06-08 0001385818 aytu:TrancheACommonWarrantsMember 2023-06-08 0001385818 aytu:TrancheBCommonWarrantsMember 2023-06-08 0001385818 aytu:CommonWarrantsMember 2023-06-08 0001385818 aytu:CommonWarrantsExchangedForPrefundedWarrantsMember 2023-06-08 0001385818 aytu:SecuritiesPurchaseAgreementWarrantsMember 2023-06-08 0001385818 aytu:SecuritiesPurchaseAgreementWarrantsMember 2023-06-082023-06-08 0001385818 aytu:TrancheBCommonWarrantsMember 2024-06-142024-06-14 0001385818 aytu:TrancheBPrefundedWarrantsMember 2024-06-142024-06-14 0001385818 aytu:TrancheBPrefundedWarrantsMember 2024-06-14 0001385818 aytu:The2024ShelfMember 2024-09-26 0001385818 aytu:The2023EquityIncentivePlanMember 2023-05-182023-05-18 0001385818 aytu:The2023EquityIncentivePlanMember 2023-05-18 0001385818 us-gaap:EmployeeStockOptionMemberaytu:The2023EquityIncentivePlanMember 2023-05-182023-05-18 0001385818 srt:MinimumMemberus-gaap:EmployeeStockOptionMemberaytu:The2023EquityIncentivePlanMember 2023-05-182023-05-18 0001385818 srt:MaximumMemberus-gaap:EmployeeStockOptionMemberaytu:The2023EquityIncentivePlanMember 2023-05-182023-05-18 0001385818 srt:MinimumMemberaytu:RestrictedStockAndRestrictedStockUnitsRsusMemberaytu:The2023EquityIncentivePlanMember 2023-05-182023-05-18 0001385818 srt:MaximumMemberaytu:RestrictedStockAndRestrictedStockUnitsRsusMemberaytu:The2023EquityIncentivePlanMember 2023-05-182023-05-18 0001385818 aytu:The2023EquityIncentivePlanMember 2024-09-30 0001385818 aytu:The2015PlanMember 2020-02-13 0001385818 us-gaap:EmployeeStockOptionMemberaytu:The2015PlanMember 2015-06-012015-06-01 0001385818 srt:MinimumMemberus-gaap:EmployeeStockOptionMemberaytu:The2015PlanMember 2015-06-012015-06-01 0001385818 srt:MaximumMemberus-gaap:EmployeeStockOptionMemberaytu:The2015PlanMember 2015-06-012015-06-01 0001385818 srt:MinimumMemberus-gaap:RestrictedStockMemberaytu:The2015PlanMember 2015-06-012015-06-01 0001385818 srt:MaximumMemberus-gaap:RestrictedStockMemberaytu:The2015PlanMember 2015-06-012015-06-01 0001385818 us-gaap:RestrictedStockUnitsRSUMemberaytu:The2015PlanMember 2015-06-012015-06-01 0001385818 aytu:Neos2015PlanMember 2021-04-19 0001385818 us-gaap:RestrictedStockUnitsRSUMemberaytu:Neos2015PlanMember 2021-04-19 0001385818 us-gaap:EmployeeStockOptionMemberaytu:Neos2015PlanMember 2021-04-192021-04-19 0001385818 srt:MinimumMemberus-gaap:EmployeeStockOptionMemberaytu:Neos2015PlanMember 2021-04-192021-04-19 0001385818 srt:MaximumMemberus-gaap:EmployeeStockOptionMemberaytu:Neos2015PlanMember 2021-04-192021-04-19 0001385818 2023-07-012024-06-30 0001385818 us-gaap:EmployeeStockOptionMember 2024-09-30 0001385818 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0001385818 us-gaap:RestrictedStockMember 2024-06-30 0001385818 us-gaap:RestrictedStockMember 2024-07-012024-09-30 0001385818 us-gaap:RestrictedStockMemberaytu:The2015PlanMember 2024-07-012024-09-30 0001385818 us-gaap:RestrictedStockMemberaytu:The2015PlanMember 2024-09-30 0001385818 us-gaap:RestrictedStockMemberaytu:OutsideEquityIncentivePlanMember 2024-07-012024-09-30 0001385818 us-gaap:RestrictedStockMemberaytu:OutsideEquityIncentivePlanMember 2024-09-30 0001385818 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001385818 us-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0001385818 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001385818 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001385818 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001385818 us-gaap:SellingAndMarketingExpenseMember 2024-07-012024-09-30 0001385818 us-gaap:SellingAndMarketingExpenseMember 2023-07-012023-09-30 0001385818 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001385818 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001385818 aytu:NetLossFromDiscontinuedOperationsMember 2024-07-012024-09-30 0001385818 aytu:NetLossFromDiscontinuedOperationsMember 2023-07-012023-09-30 0001385818 aytu:SecuritiesPurchaseAgreementWarrantsMember 2023-06-08 0001385818 aytu:SecuritiesPurchaseAgreementWarrantsMember 2023-06-082023-06-08 0001385818 srt:MinimumMemberaytu:August2022CommonWarrantsMember 2022-08-11 0001385818 srt:MaximumMemberaytu:August2022CommonWarrantsMember 2022-08-11 0001385818 aytu:August2022CommonWarrantsMember 2022-12-31 0001385818 aytu:ReverseStockSplitMember 2023-01-062023-01-06 0001385818 aytu:August2022CommonWarrantsMember 2023-06-30 0001385818 srt:WeightedAverageMember 2024-06-30 0001385818 srt:WeightedAverageMember 2024-07-012024-09-30 0001385818 srt:WeightedAverageMember 2024-09-30 0001385818 aytu:LiabilityWarrantsMember 2024-06-30 0001385818 aytu:LiabilityPrefundedWarrantsMember 2024-06-30 0001385818 aytu:TrancheBCommonWarrantsMember 2024-06-30 0001385818 aytu:EquityWarrantsMember 2024-06-30 0001385818 aytu:TrancheBCommonWarrantsMember 2024-07-012024-09-30 0001385818 aytu:LiabilityWarrantsMember 2024-09-30 0001385818 aytu:LiabilityPrefundedWarrantsMember 2024-09-30 0001385818 aytu:TrancheBCommonWarrantsMember 2024-09-30 0001385818 aytu:EquityWarrantsMember 2024-09-30 0001385818 aytu:LiabilityWarrantsMember 2024-07-012024-09-30 0001385818 aytu:LiabilityWarrantsMember 2023-07-012023-09-30 0001385818 aytu:EquityBasedWarrantsMember 2024-07-012024-09-30 0001385818 aytu:EquityBasedWarrantsMember 2023-07-012023-09-30 0001385818 us-gaap:RestrictedStockMember 2024-07-012024-09-30 0001385818 us-gaap:RestrictedStockMember 2023-07-012023-09-30 0001385818 us-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0001385818 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012023-09-30 0001385818 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0001385818 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0001385818 aytu:ConsumerHealthDivestureMember 2024-07-012024-09-30 0001385818 aytu:ConsumerHealthDivestureMember 2023-07-012023-09-30 0001385818 aytu:ConsumerHealthDivestureMember 2024-06-30 shares thunderdome:item iso4217:USD iso4217:USD shares pure utr:Y0001385818AYTU_BIOPHARMA, INCfalse--06-30Q12025 0.00010.0001500000005000000000000.00010.0001200000000020000000061492026149202597263859726380100000http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent0100000P4YP7YP4Yhttp://fasb.org/us-gaap/2024#DerivativeGainLossOnDerivativeNet2,352,351P5Y1P5Y01P5Y1P5Yfalsefalsefalsefalse10-Qtrue2024-09-30false001-38247DE47-08831447900 East Union Avenue, Suite 920DenverCO802377204437-6580Common Stock, par value $0.0001 per shareAYTUNASDAQYesYesNon-accelerated

Filertruefalsefalse6149369201080002000600023159000235260001173900012141000573200050970000112100060738000618910006920006930001225000829000512050005218499000-319973000298260002771600011583100011809500016574000178170004589000477900011985000130380005659000609100051250006295000426000595000921000924000781930000-867000542000584000994000128300028800005907000149800037400000-747300040500001093000-747300038100006470001474000-812000060680195482037909960154820370.18-1.36-0.2-1.360.06-0.120.04-0.120.24-1.48-0.15-1.485972638100034768800031997300027716000564173000173000176000046300004630000014740001474000614920210003483240003184990002982600055171741000343485000304129000393570001306193000093000008120000-81200005530235100034415000-312249000321670001474000-81200001427000184300017300072500028800005907000270001480006800051000468000600015700059200047800016840003340001121000119000467000314300094600049690004827000101000374400060000112400011900002110005170000136000-0-076000381000760001875000348000500000220400001600000464000220009110002734000102000302100020006000229850002010800019964000366000135900044600024600048300000 Note 1 - Nature of Business   Aytu BioPharma, Inc. (“Aytu,” the “Company,” “we,” “us,” or “our”), is a pharmaceutical company focused on commercializing novel therapeutics. The Company was originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and was re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (“Neos”) in March 2021 (the “Neos Acquisition”), the Company changed its name to Aytu BioPharma, Inc.   The Company’s strategy is to become a leading pharmaceutical company that improves the lives of patients. The Company uses a focused approach of in-licensing, acquiring, developing, and commercializing novel prescription therapeutics in order to continue building its portfolio of revenue-generating products and leveraging its commercial team’s expertise to build leading brands within large therapeutic markets. The Company’s primary focus is on commercializing innovative prescription products that address conditions frequently developed or diagnosed in childhood.   The Company’s business from continuing operations is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of attention deficit hyperactivity disorder (“ADHD”): Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (“Adzenys”) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets (“Cotempla” and Adzenys together with Cotempla the “ADHD Portfolio”). The second consists primarily of Karbinal® ER (carbinoxamine maleate extended-release oral suspension) (“Karbinal”), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency (the “Pediatric Portfolio”).   Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (“CODM”). After the previously announced successful wind down and divestiture of the Consumer Health business that occurred during the first quarter of fiscal 2025, the Company determined that its continuing operations now operate in a single operating and reportable segment. The Company’s CODM is its Chief Executive Officer who manages operations and regularly reviews the financial information of the Company’s continuing operations as a single operating segment for the purposes of allocating resources and evaluating its financial performance, and for which discrete financial information is available. The results of the Consumer Health business have been reported as discontinued operations (see Note 20 – Discontinued Operations).   In July 2023, the Company entered into an exclusive collaboration, distribution and supply agreement with Medomie Pharma Ltd (“Medomie”), a privately owned pharmaceutical company, for Medomie to sell Adzenys and Cotempla in Israel and the Palestinian Authority. In September 2024, the Company entered into an exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada Ltd (“Lupin”), a subsidiary of global pharmaceutical company Lupin Limited, for Lupin to sell Adzenys and Cotempla in Canada. The Company will supply Adzenys and Cotempla to Medomie and Lupin based on forecasts and provide product training. Medomie and Lupin are responsible for seeking local regulatory approvals and marketing authorizations for both Adzenys and Cotempla, which is expected to occur over the next 18 to 24 months. The agreement with Medomie and the agreement with Lupin represent the Company’s first and second international commercial agreements for Adzenys and Cotempla, respectively. Note 2 - Summary of Significant Accounting Policies   Principals of Consolidation   The Company’s unaudited consolidated financial statements and notes thereto include the accounts of its wholly owned subsidiaries Aytu Therapeutics, LLC and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries, as well as Innovus Pharmaceuticals, Inc. and its wholly owned subsidiaries prior to the divestiture of Innovus Pharmaceuticals, Inc. on July 31, 2024. All significant inter-company balances and transactions have been eliminated in consolidation.   Basis of Presentation   The unaudited consolidated financial statements and notes thereto contained in this Form 10-Q represent the financial statements of the Company and its wholly owned subsidiaries and have been prepared pursuant to the rules and regulations of the SEC regarding interim financial reporting. Accordingly, certain information and disclosures normally included in the complete financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been omitted pursuant to such rules and regulations. The unaudited consolidated financial statements and notes thereto should be read in conjunction with the Company’s 2024 Form 10-K, which included all disclosures required by U.S. GAAP. In the opinion of management, these unaudited consolidated financial statements and notes thereto contain all adjustments necessary for the fair statement of the financial position of the Company and the results of operations and cash flows for the interim periods presented. The consolidated balance sheet as of June 30, 2024, was derived from the audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. The results of operations for the period ended September 30, 2024, are not necessarily indicative of expected operating results for the full year or any future period.   Use of Estimates   The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results may differ from estimates. In the accompanying unaudited consolidated financial statements and notes thereto, estimates are used for, but not limited to, stock-based compensation; revenue recognition, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for credit losses; inventory impairment; determination of right-of-use (“ROU”) assets and lease liabilities; valuation of financial instruments, warrants and derivative warrant liabilities, intangible assets, and long-lived assets; purchase price allocations and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. The Company periodically evaluates estimates used in the preparation of the financial statements for reasonableness.   Prior Period Reclassification   Certain prior year amounts in the Company’s unaudited consolidated financial statements and the notes thereto have been reclassified to conform to the current year presentation. These reclassifications did not impact operating results or cash flows for the three months ended September 30, 2024, and 2023, or the Company’s financial position as of September 30, 2024, or June 30, 2024.   Warrants   The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC Topic 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option pricing model or Monte Carlo simulation model at issuance and for each reporting period when applicable.   Income Taxes   The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three months ended September 30, 2024. The effective tax rate was 27.0% and zero percent for the three months ended September 30, 2024, and 2023, respectively, primarily driven by the limitations on losses as a result of Section 382 of the Internal Revenue Code changes in ownership coupled with existing valuation allowances.   <p style="font-family: "Times New Roman"; font-size: 10pt; font-

variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">An ownership change has limited the Company's ability to offset, post-change, United States federal taxable income. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past five years have caused a significant limitation on the Company's ability to use the change in control net operating loss carryovers. The ownership changes result in increased future tax liability and are a driver of the change from a zero percent effective tax rate.   The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized.   The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense in the unaudited consolidated statements of operations.   Employee Retention Credit   On March 27, 2020, the United States government enacted the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") to provide certain relief as a result of the COVID-19 pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit ("ERC"), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to 70% of the qualified wages paid to employees after December 31, 2020, through September 30, 2021. The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-19 pandemic.   As there is no authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company accounted for the ERC by analogy to International Accounting Standard ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance ("IAS 20"). In accordance with IAS 20, the Company recorded a $3.8 million ERC accrual in other non-current liabilities, which represents the proceeds the Company received from the ERC program during the first quarter of fiscal 2024. Further in accordance with IAS 20, when management determines it has reasonable assurance that the Company has substantially met all eligibility requirements of the ERC and following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Code of 1986, as amended (the "IRC"), the ERC accrual shall be recognized as a benefit in other income in the unaudited consolidated statement of operations. The associated vendor fee of $0.4 million was expensed as incurred in the first quarter of fiscal 2024.   Recently Adopted Accounting Pronouncements   Debt - Debt with Conversion and Other Option   In August 2020, the FASB issued Accounting Standards Update ("ASU") No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company adopted the guidance on July 1, 2024, and the adoption of the standard did not have a material impact on the Company's consolidated financial statements.   Recent Accounting Pronouncements Not Yet Adopted   Segment Reporting - Improvements to Reportable Segment Disclosures   In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company's consolidated financial statements and disclosures.   Disaggregation of Income Statement Expenses   In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). The amendments in ASU 2024-03 require public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation, amortization and depletion expenses for each caption on the income statement where such expenses are included. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company's consolidated financial statements and disclosures.   For a complete set of the Company's significant accounting policies, refer to the Company's 2024 Form 10-K. There have been no significant changes to the Company's significant accounting policies and there is no other accounting guidance has been issued and not yet adopted that is applicable to the Company and that would have a material effect on the Company's unaudited consolidated financial statements and related disclosures as of September 30, 2024, and through the filing of this Form 10-Q. Principals of Consolidation   The Company's unaudited consolidated financial statements and notes thereto include the accounts of its wholly owned subsidiaries Aytu Therapeutics, LLC and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries, as well as Innovus Pharmaceuticals, Inc. and its wholly owned subsidiaries prior to the divestiture of Innovus Pharmaceuticals, Inc. on July 31, 2024. All significant inter-company balances and transactions have been eliminated in consolidation. Basis of Presentation   The unaudited consolidated financial statements and notes thereto contained in this Form 10-Q represent the financial statements of the Company and its wholly owned subsidiaries and have been prepared pursuant to the rules and regulations of the SEC regarding interim financial reporting. Accordingly, certain information and disclosures normally included in the complete financial statements prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") have been omitted pursuant to such rules and regulations. The unaudited consolidated financial statements and notes thereto should be read in conjunction with the Company's 2024 Form 10-K, which included all disclosures required by U.S. GAAP. In the opinion of management, these unaudited consolidated financial statements and notes thereto contain all adjustments necessary for the fair statement of the financial position of the Company and the results of operations and cash flows for the interim periods presented. The consolidated balance sheet as of June 30, 2024, was derived from the audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. The results of operations for the period ended September 30, 2024, are not necessarily indicative of expected operating results for the full year or any future period. Use of Estimates   The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results may differ from estimates. In the accompanying unaudited consolidated financial statements and notes thereto, estimates are used for, but not limited to, stock-based compensation; revenue recognition, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for credit losses; inventory impairment; determination of right-of-use ("ROU") assets and lease liabilities; valuation of financial instruments, warrants and derivative warrant liabilities, intangible assets, and long-lived assets; purchase price allocations and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. The Company periodically evaluates estimates used in the preparation of the financial statements for reasonableness. Prior Period Reclassification

*   Certain prior year amounts in the Company's unaudited consolidated financial statements and the notes thereto have been reclassified to conform to the current year presentation. These reclassifications did not impact operating results or cash flows for the three months ended September 30, 2024, and 2023, or the Company's financial position as of September 30, 2024, or June 30, 2024. Warrants   The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 480, Distinguishing Liabilities from Equity ("ASC 480") and ASC Topic 815, Derivatives and Hedging ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own common shares and whether the warrant holders could potentially require "net cash settlement" in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option pricing model or Monte Carlo simulation model at issuance and for each reporting period when applicable. Income Taxes   The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three months ended September 30, 2024. The effective tax rate was 27.0% and zero percent for the three months ended September 30, 2024, and 2023, respectively, primarily driven by the limitations on losses as a result of Section 382 of the Internal Revenue Code changes in ownership coupled with existing valuation allowances.   An ownership change has limited the Company's ability to offset, post-change, United States federal taxable income. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Previous acquisitions, financing transactions, and equity ownership changes in the past five years have caused a significant limitation on the Company's ability to use the change in control net operating loss carryovers. The ownership changes result in increased future tax liability and are a driver of the change from a zero percent effective tax rate.   The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized.   The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained upon an examination. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense in the unaudited consolidated statements of operations. 0.27 Employee Retention Credit   On March 27, 2020, the United States government enacted the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") to provide certain relief as a result of the COVID-19 pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit ("ERC"), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to 70% of the qualified wages paid to employees after December 31, 2020, through September 30, 2021. The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-19 pandemic.   As there is no authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company accounted for the ERC by analogy to International Accounting Standard ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance ("IAS 20"). In accordance with IAS 20, the Company recorded a $3.8 million ERC accrual in other non-current liabilities, which represents the proceeds the Company received from the ERC program during the first quarter of fiscal 2024. Further in accordance with IAS 20, when management determines it has reasonable assurance that the Company has substantially met all eligibility requirements of the ERC and following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Code of 1986, as amended (the "IRC"), the ERC accrual shall be recognized as a benefit in other income in the unaudited consolidated statement of operations. The associated vendor fee of $0.4 million was expensed as incurred in the first quarter of fiscal 2024. 3800000400000 Recently Adopted Accounting Pronouncements   Debt - Debt with Conversion and Other Option   In August 2020, the FASB issued Accounting Standards Update ("ASU") No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the SEC, for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company adopted the guidance on July 1, 2024, and the adoption of the standard did not have a material impact on the Company's consolidated financial statements.   Recent Accounting Pronouncements Not Yet Adopted   Segment Reporting - Improvements to Reportable Segment Disclosures   In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 was issued to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance should be applied retrospectively unless it is impracticable to do so. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted, including in an interim period. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company's consolidated financial statements and disclosures.   Disaggregation of Income Statement Expenses   In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). The amendments in ASU 2024-03 require public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation, amortization and depletion expenses for each caption on the income statement where such expenses are included. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company's consolidated financial statements and disclosures.   For a complete set of the Company's significant accounting policies, refer to the Company's 2024 Form 10-K. There have been no significant changes to the Company's significant accounting policies and there is no other accounting guidance has been issued and not yet adopted that is applicable to the Company and that would have a material effect on the Company's unaudited consolidated financial statements and related disclosures as of September 30, 2024, and through the filing of this Form 10-Q. Note 3 - Revenue   Net revenue from continuing operations consists of sales of prescription pharmaceutical products from the Company's ADHD Portfolio and Pediatric Portfolio, principally to a limited number of wholesale distributors and pharmacies in the United States. Net revenue is recognized at the point in time that control of the product transfers to the customer, which typically aligns with shipping terms (i.e., upon delivery), generally "free-on-board" destination when shipped domestically within the United States, consistent with contractual terms.   Savings offers, rebates, and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. The Company's periodic adjustments of its estimates are subject to time delays between the initial product sale, and the ultimate*

*reporting and settlement of deductions. The Company entered into negotiations with a vendor related to certain variable interest accruals that reduce revenue for the Company's ADHD Portfolio. As a result of these negotiations, the Company and the vendor agreed to a reduction to the liability purportedly owed by the Company of $3.3 million, which resulted in a decrease in the estimated variable consideration accrual as of September 30, 2024, and a related increase in net revenue of $3.3 million for the <em style="font: inherit;">three months ended <em style="font: inherit;"> September 30, 2024.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Revenue </i><i>by Product Portfolio</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net revenue disaggregated by significant product portfolio for the <em style="font: inherit;">three months ended <em style="font: inherit;"> September 30, 2024, and <em style="font: inherit;">2023, were as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Three Months Ended</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ADHD Portfolio</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,264</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,128</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pediatric Portfolio</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,293</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,565</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">124</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total net revenue</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,574</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,817</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Other includes net revenue from various discontinued deprioritized products. The Consumer Health business was divested in the <em style="font: inherit;">first quarter of fiscal <em style="font: inherit;">2025 and is reported within discontinued operations (see <i>Note <em style="font: inherit;">20 – Discontinued Operations</i>).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Revenue by Geographic Location</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company's net revenue is predominately within the United States, with insignificant international sales.</p> 33000003300000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ADHD Portfolio</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,264</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15,128</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Pediatric Portfolio </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,293</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,565</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-

left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">124</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total net revenue </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,574</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,817</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table>
1526400015128000129300025650001700012400016574000178170000 Note 4 - Inventories   Inventories consist of raw materials, work in process and finished goods, and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of its inventories to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are no alternate uses for the inventory, the Company will record a charge to reduce the value of the inventory to net realizable value in the period first recognized. The Company incurred inventory write-downs of $0.1 million for both the <em style="font: inherit;">three months ended <em style="font: inherit;"> September 30, 2024, and <em style="font: inherit;">2023, primarily as a result of unsalable and slow-moving products.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Inventories consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 30,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">720</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">266</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Work in process</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,363</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,725</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,656</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,150</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Inventories</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,739</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 100000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 30,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">720</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">266</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Work in process</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,363</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,725</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,656</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,150</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Inventories</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,739</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>
7200002660003363000572500076560006150000117390001214100 Note 5 - Property and Equipment   Properties and equipment are recorded at cost and depreciated on a straight-line basis over the assets' estimated economic life. Leasehold improvements are amortized over the shorter of the estimated

economic life or remaining lease term.   Property and equipment, net, consist of the following: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> June 30, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Manufacturing and lab equipment </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,443</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,838</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Office equipment, furniture and other </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">956</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">945</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Leasehold improvements </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">158</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Property and equipment, gross </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,557</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: accumulated depreciation and amortization </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,865</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Property and equipment, net </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">692</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">693</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table>   Depreciation and amortization expense from property and equipment was $0.1 million and $0.3 million for the <em style="font: inherit;">three months ended <em style="font: inherit;"> September 30, 2024, and <em style="font: inherit;">2023, respectively.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 30,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Manufacturing and lab equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,443</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,838</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Office equipment, furniture and other </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">956</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">945</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Leasehold improvements </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">158</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Property and equipment, gross </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,557</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: accumulated depreciation and amortization </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,865</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-

bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Property and equipment, net </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">692</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">693</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 1443000183800095600094500015800035000255700028180001865000212500069200069300010000030000 Note 6 - Leases   The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment, and finance lease agreements for certain equipment. These leases have original lease periods expiring between calendar year 2024 and calendar year 2030. Most leases include one or more options to renew, and the exercise of a lease renewal option typically occurs at the discretion of both parties. Certain non-real estate leases also include options to purchase the leased property. The Company's lease agreements generally do not contain any material residual value guarantees or material restrictive covenants. The Company had no remaining finance leases recorded as of June 30, 2024.   In June 2024, the Company entered into a forward-starting operating lease agreement to lease office space in Berwyn, Pennsylvania from the owner of the office space that the Company is currently renting under a sublease arrangement. The Company determined that it is an operating lease, and that lease commencement occurred in July 2024. The initial lease termination date is July 31, 2030, and under the lease agreement the Company has one five-year renewal option to extend the lease through July 2035. Undiscounted minimum monthly rent payments average approximately $13,000 over the initial term of the lease. The Company has elected to utilize the practical expedient to not separate lease and non-lease components upon recognition and variable lease payments will be expensed as incurred. The Company recorded an operating lease ROU asset of $0.5 million and a lease liability of $0.5 million at lease commencement in <em style="font: inherit;"> July 2024. The ROU asset and lease liability will be recorded at present value using an incremental borrowing rate of 12.3%.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The components of lease costs are as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Three Months Ended</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 34.9%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><em style="font: inherit;">Statement of Operations Classification</p> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 35.1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease cost:</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease cost</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">122</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">360</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Operating expenses</p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Short-term lease cost</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">91</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Operating expenses</p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease cost:</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Amortization of leased assets</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Cost of sales</p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Interest on lease liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Interest expense</p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease cost</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">213</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td

style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">398</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> </tbody></table>   Supplemental balance sheet information related to leases is as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%;"> September 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%;"> June 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 34%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 36%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding: 0px 0px 1px; margin: 0px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2024</td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding: 0px 0px 1px; margin: 0px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2024</td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding: 0px 0px 1px; margin: 0px;"> </td><td style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; width: 34%; padding-top: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> Balance Sheet Classification </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 16%;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> Assets: </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> Operating lease assets </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,225</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">829</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> Operating lease right-of-use assets </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> Liabilities: </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> Current: operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">484</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">712</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> Other current liabilities </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> Non-current: operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">577</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> Other non-current liabilities </td></tr> <tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> Total lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,628</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,289</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> </tbody></table>   The remaining weighted-average lease term and discount rate used are as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> June 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Weighted-average remaining lease term (years): </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating lease assets </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Weighted-average discount rate: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating lease assets </td><td style="width: 1%; font-family:

Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table>   Supplemental cash flow information related to leases is as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Three Months Ended </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Cash flow classification of lease payments: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating cash flows from operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">168</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">360</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating cash flows from finance leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Financing cash flows from finance leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   As of June 30, 2024, the Company did not have any remaining finance leases. As of September 30, 2024, the Company's future minimum lease payments were as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Operating </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> (in thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> 2025 (remaining 9 months) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">792</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2026 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">399</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2027 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">377</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2028 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">386</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2029 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">358</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2030 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">230</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Thereafter </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">19</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total lease payments </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,561</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: imputed interest </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(520</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Less: tenant improvement allowance </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(413</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td></tr> <tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-

html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Lease liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,628</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0130005000005000000.123 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 34.9%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><em style="font: inherit;">Statement of Operations Classification</p> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 35.1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease cost:</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease cost</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">122</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">360</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Operating expenses</p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Short-term lease cost</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">91</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Operating expenses</p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Finance lease cost:</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Amortization of leased assets</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Cost of sales</p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Interest on lease liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Interest expense</p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease cost</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">213</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">398</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> June 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Weighted-average remaining lease term (years): </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family:

Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating lease assets </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Weighted-average discount rate: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating lease assets </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Three Months Ended </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Cash flow classification of lease payments: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating cash flows from operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">168</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">360</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating cash flows from finance leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Financing cash flows from finance leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 122000360000910002300001400001000213000398000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%;"> September 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%;"> June 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 34%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 36%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding: 0px 0px 1px; margin: 0px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2024</td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding: 0px 0px 1px; margin: 0px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding: 0px 0px 1px; margin: 0px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2024</td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding: 0px 0px 1px; margin: 0px;"> </td><td style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; width: 34%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> Balance Sheet Classification </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 16%;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> Assets: </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> Operating lease assets </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,225</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">829</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> Operating lease right-of-use assets </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 34%; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> Liabilities: </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> Current: operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">484</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">712</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;

margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> Other current liabilities </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> Non-current: operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">577</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 34%;"> Other non-current liabilities </td></tr> <tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> Total lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,628</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,289</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 34%;"> </td></tr> </tbody></table> 122500082900048400071200011440005770001628000128900OP4Y2M12DP2Y8M12D0.1110.10168000360000010000230000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Operating </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> (in thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> 2025 (remaining 9 months) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">792</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">399</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">377</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">386</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2029</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">358</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2030</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">230</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Thereafter</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">19</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total lease payments</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,561</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less: imputed interest</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(520</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Less: tenant improvement allowance</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(413</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td></tr> <tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,628</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 792000399000377000386000358000230000190002561000520000413000162800 Note 7 - Intangible Assets   A summary of the Company's definite-lived intangible assets as of September 30, 2024, and June 30, 2024, respectively, is as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"> September 30, 2024 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Gross Carrying Amount </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Accumulated Amortization </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Net Carrying Amount </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted-Average Remaining Life

</td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="10" rowspan="1" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%;"> (in thousands) </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%;"> (in years) </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> Acquired product technology rights </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">41,268</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(13,988</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">27,280</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">10.5</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired technology rights</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,200</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,275</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,925</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13.5</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total intangible assets</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">71,468</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(20,263</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">51,205</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11.9</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr></tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"> June 30, 2024 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Gross Carrying Amount </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Accumulated Amortization </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Net Carrying Amount </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted-Average Remaining Life </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="10" rowspan="1" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%;"> (in thousands) </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%;"> (in years) </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> Acquired product technology rights </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">41,268</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(13,184</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">28,084</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">10.7</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired technology rights</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,200</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,831</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,369</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13.8</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total intangible assets</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">71,468</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(19,015</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0,

0);">52,453</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12.0</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table>   Carrying amounts are net of any impairment charges from prior periods. An intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period. Certain of the Company's amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $1.2 million and $1.5 million for the <em style="font: inherit;">three months ended <em style="font: inherit;"> September 30, 2024, and <em style="font: inherit;">2023, respectively.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table summarizes the estimated future amortization expense to be recognized over the next <em style="font: inherit;">five fiscal years and periods thereafter:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 0pt; margin-left: 0pt; width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Estimated Future Amortization Expense</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025 (remaining 9 months)</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,742</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2026 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2027 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2028 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2029 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> 2030 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2,847</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Thereafter </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,660</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total future amortization expense </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">51,205</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   Acquired Product Technology Rights   The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of the Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021.   ADHD Portfolio   As part of the Neos Acquisition, the Company acquired developed product technology for the production and sale of Adzenys and Cotempla. The formulations for the ADHD products are protected by patented technology. The estimated remaining economic life of these proprietary technologies is 14 years.   Karbinal   The Company acquired and assumed all rights and obligations pursuant to the supply and distribution agreement, as amended, with Tris Pharma, Inc. ("Tris") for the exclusive rights to commercialize Karbinal in the United States (the "Tris Karbinal Agreement"). The Tris Karbinal Agreement's initial term terminates in August of 2033, with an optional initial 20-year extension.   Poly-Vi-Flor and Tri-Vi-Flor   The Company acquired and assumed all rights and obligations pursuant to a supply and license agreement and various assignment and release agreements, including a previously agreed to settlement and license agreements (the "Poly-Tri Agreements") for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States.   Acquired Technology Rights   TRRP Technology   As part of the Neos Acquisition, the Company acquired time release resin particle ("TRRP") proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlines each of the ADHD Portfolio core products and can potentially be used in future product development initiatives as well. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"> September 30, 2024 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Gross Carrying Amount </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Accumulated Amortization </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Net Carrying Amount </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted-Average Remaining Life </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="10" rowspan="1" style="text-align: center; font-family:

"Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%;"> (in thousands) </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%;"> (in years) </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> Acquired product technology rights </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">41,268</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(13,988</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">27,280</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired technology rights</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,200</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,275</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">) </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,925</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13.5</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total intangible assets</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">71,468</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(20,263</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">51,205</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11.9</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"> June 30, 2024 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Gross Carrying Amount </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Accumulated Amortization </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Net Carrying Amount </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted-Average Remaining Life </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="10" rowspan="1" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%;"> (in thousands) </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 1%;"> (in years) </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> Acquired product technology rights </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">41,268</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(13,184</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">28,084</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">10.7</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired technology rights</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,200</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,831</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">) </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,369</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13.8</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 40%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total intangible assets</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">71,468</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(19,015</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">52,453</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-

bottom: 3px double rgb(0, 0, 0);">12.0</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table>
4126800013988000272800000P10Y6M30200000627500023925000P13Y6M7146800020263000512050000P11Y10M24D41268000131840002808400OP10Y8M12D30200000583100
<table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 0pt; margin-left: 0pt; width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Estimated Future Amortization Expense </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> (in thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> 2025 (remaining 9 months) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,742</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2029</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,989</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">2030</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2,847</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,660</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total future amortization expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">51,205</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>
37420004989000498900049890004989000284700024660000512050000P20Y Note 8 - Accrued Liabilities   Accrued liabilities consist of the following: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> June 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Accrued savings offers </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,929</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,054</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Accrued program liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,990</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,964</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Accrued customer and product related fees </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,540</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,395</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Accrued employee compensation </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,212</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,603</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Return reserve </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,218</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,832</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other accrued liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,295</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total accrued liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">33,723</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left:

0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,143</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Accrued savings offers represent programs for the Company's patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Accrued program liabilities include government and commercial rebates. Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. The return reserve represents the Company's accrual for estimated product returns. Accrued employee compensation includes sales commissions, paid time off earned, accrued payroll and accrued bonus. Other accrued liabilities consist of various other accruals, <em style="font: inherit;">none of which individually or in the aggregate represent greater than <em style="font: inherit;">five percent of total liabilities.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;" /> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">September 30, </p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 30,</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued savings offers</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,929</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,054</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued program liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,990</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,964</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued customer and product related fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,540</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,395</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued employee compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,212</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,603</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Return reserve</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,218</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,832</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other accrued liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,295</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total accrued liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">33,723</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,143</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 992900011054000599000099640005540000539500052120004603000421800048320002834000229500033723000381430000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note <em style="font: inherit;">9 - Other Liabilities</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Other liabilities consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 30,</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Fixed payment arrangements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,405</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,337</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Employee retention credit </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">3,759</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,628</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,289</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;

border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">106</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total other liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,810</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,491</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: current portion of other liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,889</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,962</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total non-current portion of other liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,921</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,529</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   Fixed Payment Arrangements   Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in 2019, including fixed and variable payments.   In May 2022, the Company entered into an agreement with Tris to terminate the license, development, manufacturing and supply agreement dated November 2, 2018, related to Tuzistra XR (the "Tuzistra License Agreement"). Pursuant to such termination, as of September 30, 2024, the Company has accrued a settlement liability of $5.8 million in other current liabilities on the consolidated balance sheet payable to Tris, with a provision that allows the Company to pay interest on any principal amounts due but remaining unpaid past July 2024.   The Tris Karbinal Agreement grants the Company the exclusive right to distribute and sell Karbinal in the United States. The initial term of the agreement was 20 years. The Company pays Tris a royalty equal to 23.5% of net revenue from the product. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make-whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net revenue from the product, the first of which is triggered at $40.0 million. As of September 30, 2024, the Tris Karbinal Agreement accrued fixed payment arrangement balance was $1.7 million recorded in other current liabilities on the consolidated balance sheet.   Employee Retention Credit   The $3.8 million ERC accrual in other non-current liabilities as of <em style="font: inherit;"> September 30, 2024, represents the proceeds the Company received from the ERC program during the <em style="font: inherit;">first quarter of fiscal <em style="font: inherit;">2024. Please see <i>Note <em style="font: inherit;">2 - Significant Accounting Policies </i>for further detail.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Operating Lease Liabilities</i> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment. Please refer to <i>Note <em style="font: inherit;">6 - Leases</i> for further detail.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Other</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Other consists of taxes payable, deferred cost related to the Company's technology transfer, and various other accruals, none of which individually or in the aggregate represent greater than <em style="font: inherit;">five percent of total liabilities.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 30,</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Fixed payment arrangements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,405</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,337</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Employee retention credit </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">3,759</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,628</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,289</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">106</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total other liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,810</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,491</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: current portion of other liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,889</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%;

text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,962</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total non-current portion of other liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,921</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,529</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>
7405000833700037590003759000162800012890001800010600012810000134910007889000896200049210004529000580000P20Y0.235700003070000210000030000004000
Note 10 - Revolving Credit Facility
  On June 12, 2024, the Company and certain of its subsidiaries entered into consent, joinder and amendment No. 5 (the “Eclipse Amendment No. 5”) to the loan and security agreement dated October 2, 2019, as amended by amendment No. 1, dated March 19, 2021, amendment No. 2, dated January 26, 2022, amendment No. 3, dated June 1, 2022, amendment No. 4 dated March 24, 2023, and the Eclipse Amendment No. 5 (together the “Eclipse Agreement”) with Eclipse Business Capital LLC (“Eclipse”), as agent, and the lenders party thereto (agent and such lenders, collectively, the “Eclipse Lender”). Under the Eclipse Amendment No. 5, which provided for among other things, two loan agreements, a term loan (the “Eclipse Term Loan”) and a revolving credit facility (the “Eclipse Revolving Loan”). The Eclipse Term Loan is described further in Note 11 - Long-Term Debt. The Eclipse Revolving Loan provides for a maximum amount available under the revolving credit facility provided under the Eclipse Agreement of $14.5 million at an interest rate of the secured overnight financing rate as administered by the SOFR Administrator (“SOFR”) plus 4.5%. In addition, the Company is required to pay an unused line fee of 0.5% of the average unused portion of the maximum Eclipse Revolving Loan amount during the immediately preceding month. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Agreement remains subject to a borrowing base and reserve, and availability blockage requirements. The Eclipse Revolving Loan maturity date, as amended, is June 12, 2028, and the effective interest rate was 9.8% as of September 30, 2024.   In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 2.0% of the Eclipse Revolving Loan commitment if such event occurs on or before June 12, 2025, (ii) 1.0% of the Eclipse Revolving Loan commitment if such event occurs after June 12, 2025, but on or before June 12, 2026, and (iii) 0.5% of the Eclipse Revolving Loan commitment if such event occurs after June 12, 2026, but on or before June 12, 2028. The Company may also be required to pay an early termination fee related to the Eclipse Term Loan as further described in Note 11 - Long-Term Debt. The Company may permanently terminate the Eclipse Agreement upon written notice to Eclipse.   The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company’s obligations under the Eclipse Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of September 30, 2024, the Company was in compliance with the covenants under the Eclipse Agreement. The Company’s obligations under the Eclipse Agreement are secured by substantially all of the Company’s assets, as defined further in the Eclipse Agreement.   Total interest expense on the Eclipse Revolving Loan, including amortization of deferred financing costs, was less than $0.1 million for both the three months ended September 30, 2024, and 2023, respectively. The amounts drawn on the Eclipse Revolving Loan were $4.3 million and $2.4 million as of September 30, 2024, and June 30, 2024, respectively. The unused revolving credit facility amount as of September 30, 2024, was $2.5 million. 145000000.0450.0050.0980.020.010.00510000043000002400000025000000 Note 11 - Long-Term Debt   Avenue Capital Loan   On January 26, 2022 (“Closing Date”), the Company entered into a loan and security agreement (the “Avenue Capital Agreement”) with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. as lenders (the “Avenue Capital Lenders”), and Avenue Capital Management II, L.P. as administrative agent (the “Avenue Capital Agent”), collectively (“Avenue Capital”), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $15.0 million loan. The interest rate on the loan was the greater of the prime rate or 3.25%, plus 7.4%, payable monthly in arrears. The maturity date of the loan was January 26, 2025. The proceeds from the Avenue Capital Agreement were used towards the repayment of the term loans.   Pursuant to the Avenue Capital Agreement, the Company was required to make interest only payments for the first 18 months following the Closing Date (the “Interest-only Period”). The Interest-only Period could be extended automatically without any action by any party for six months provided as of the last day of the Interest-only Period then in effect, the Company received, prior to June 15, 2023, a specified amount of net proceeds from the sale and issuance of its equity securities (“Interest-only Milestone 1”). The Interest-only Period was able to be further extended automatically without any action by any party for an additional six months provided, the Company had achieved, prior to December 31, 2023, (i) Interest-only Milestone 1 and (ii) a specified amount of trailing 12 months revenue as of the date of determination.   On January 26, 2022 (“Issuance Date”), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the “Avenue Capital Warrants”). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was not fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately $0.6 million.   On March 7, 2022, the Company closed on an equity offering of shares of common stock and warrants at an offering price of $25.00 per share. As this offering precluded the Company from pursuing any equity financing prior to July 7, 2022, and the effective price of the March 7, 2022, offering was more than the exercise price of the Avenue Capital Warrants, the shares of common stock issuable upon exercise of the Avenue Capital Warrants were set at an exercise price of $24.20.   On October 25, 2022, the Company entered into an agreement with Avenue Venture Opportunities Fund, L.P (“Avenue”) to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in January 2022, extended the interest-only period to January 2024. In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $8.60, corresponding to the warrant exercise price associated with the Company’s August 2022 equity financing.   On June 13, 2023, in conjunction with the Securities Purchase Agreement described in Note 16 - Warrants, the interest-only period of the Avenue Capital Agreement was extended further upon the achievement of both the revenue-based milestone and equity raise-based milestone stipulated in the Avenue Capital Agreement. As a result, the interest-only period was extended to January 26, 2025.   In addition to the debt discount discussed above, the Company also incurred $0.4 million loan origination, legal and other fees. The debt discount and issuance costs were being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 16.6%. Total interest expense on the Avenue Capital loan, including debt discount amortization, was $0.7 million for the three months ended September 30, 2023.   On June 12, 2024, the Company used proceeds from the Eclipse Term Loan and a portion of the proceeds from the exercise of warrants to repay the Avenue Capital loan in full. Upon early repayment of the Avenue Capital loan, the Company was required to pay Avenue Capital a fee equal to 1.0% of the loan or $0.2 million. In addition, upon the payment in full of the obligations, the Company was required to pay Avenue Capital a fee in the amount of $0.6 million (“Final Payment”). At inception, the Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount. At retirement, the early termination fee, the Final Payment fee, and the write-off of all remaining related debt discount and deferred financing costs were included in the calculation of loss on extinguishment of debt. The Company recorded a loss on extinguishment of debt of $0.6 million related to the retirement of the Avenue Capital loan in the fourth quarter of fiscal 2024.   Eclipse Term Loan   On June 12, 2024, the Company and certain of its subsidiaries entered into Eclipse Amendment No. 5, which provided for among other things, the Eclipse Term Loan and the Eclipse Revolving Loan described further in Note 10 - Revolving Credit Facility. The Eclipse Term Loan consists of a principal amount of $13.0 million, at an interest rate of SOFR plus 7.0%, with a four-year term maturing on June 12, 2028, and a straight-line loan amortization period of seven years, which would provide for a loan balance at the end of the four-year term of $5.6 million to be repaid on June 12, 2028, the maturity date. The Company used the

proceeds of the Eclipse Term Loan and a portion of the proceeds from warrant exercises described below to repay in full the Avenue Capital loan. The effective interest rate on the Eclipse Term Loan was 12.3% as of September 30, 2024.   In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 3.0% of the Eclipse Term Loan if such event occurs on or before June 12, 2025, (ii) 2.0% of the Eclipse Term Loan if such event occurs after June 12, 2025, but on or before June 12, 2026, (iii) 1.0% of the Eclipse Term Loan if such event occurs after June 12, 2026, but on or before June 12, 2027, and (iv) 0.5% of the Eclipse Term Loan if such event occurs after June 12, 2026, but on or before June 12, 2028. The Company may also be required to pay an early termination fee related to the Eclipse Revolving Loan as further described in Note 10 - Revolving Credit Facility. The Company may permanently terminate the Eclipse Agreement upon written notice to Eclipse. The Company's obligations under the Eclipse Agreement are secured by substantially all of the Company's assets, as further defined in the Eclipse Agreement.   The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company's ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make certain asset sales without the prior written consent of the Eclipse Lender. A failure to comply with these covenants could permit the Eclipse Lender to declare the Company's obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of September 30, 2024, the Company was in compliance with the covenants under the Eclipse Agreement. The Company incurred interest expense on the Eclipse Term Loan, including debt discount and issuance costs amortization, of $0.4 million for the <em style="font: inherit;">three months ended <em style="font: inherit;"> September 30, 2024.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Long-term debt consists of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 30,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Term loan principal amount</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,536</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unamortized debt discount and issuance costs</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(249</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(266</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,287</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less: current portion of debt</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,857</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,857</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Total debt, net of current portion</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,430</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,877</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Future principal payments of the Eclipse Term Loan are as follows: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Future Principal Payments</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman";">2025 (remaining 9 months)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,393</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> 2026 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,857</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> 2027 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,857</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> 2028 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">7,429</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total future principal payments </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,536</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: unamortized debt discount and issuance costs </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(249</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; margin: 0px; padding-top: 0px; padding-right: 0px; padding-left:

0px;"> Less: current portion of debt </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,857</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total debt, net of current portion </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,430</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 150000000.03250.07424.224.26000002524.28.64000000.1667000000.01200000600000-6000001300000000.0756000000.1230.030.020.010.005400000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 30,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Term loan principal amount</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,536</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unamortized debt discount and issuance costs</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(249</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(266</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,287</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less: current portion of debt</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,857</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,857</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Total debt, net of current portion</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,430</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,877</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 125360001300000024900026600012287000127340001857000185700010430000010877000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Future Principal Payments</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman"">2025 (remaining 9 months)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,393</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> 2026 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,857</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> 2027 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,857</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> 2028 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">7,429</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total future principal payments </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,536</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: unamortized debt discount and issuance costs </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(249</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; margin: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px;"> Less: current portion of debt </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,857</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total debt, net of current portion </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,430</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 139300018570001857000742900012536000249000185700010430000 Note 12 - Fair Value Considerations   The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to determine fair value as follows: <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-

family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="vertical-align:top;width:18pt;"> ● </td><td style="vertical-align:top;"> Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="vertical-align:top;width:18pt;"> ● </td><td style="vertical-align:top;"> Level 2: Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="vertical-align:top;width:18pt;"> ● </td><td style="vertical-align:top;"> Level 3: Unobservable inputs that are supported by little or no market activity. </td></tr> </tbody></table>   The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities, contingent consideration liabilities, fixed payment arrangements, and current and non-current debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Current and non-current debt are reported at their amortized costs on the Company's consolidated balance sheets. The remaining financial instruments are reported on the Company's consolidated balance sheets at amounts that approximate current fair values. The Company's carrying value of its consolidated amounts of cash and cash equivalents approximate their fair value as of September 30, 2024, and June 30, 2024, and are categorized within level 1 of the U.S. GAAP fair value hierarchy. The Company's policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.   Recurring Fair Value Measurements   The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2024, and June 30, 2024, by level within the fair value hierarchy as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%; padding: 0; margin: 0">   </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" rowspan="1" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; text-align: center;">Fair Value at September 30,</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td colspan="10" rowspan="1" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">Fair Value Measurements at September 30, 2024</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> (Level 1) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> (Level 2) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> (Level 3) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 54%;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> Liabilities: </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> Derivative warrant liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 22%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,402</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,402</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> Total </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 22%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,402</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,402</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%; padding: 0; margin: 0">   </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 22%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; text-align: center;">Fair Value at June 30,</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td colspan="10" rowspan="1" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">Fair Value Measurements at June 30, 2024</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> (Level 1) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> (Level 2) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> (Level 3) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 54%;"> <p style="font-family:Times New Roman;font-size:10pt;font-

variant:normal;text-align:center;margin:0pt;">(in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> Liabilities: </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> Derivative warrant liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 22%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> Total </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 22%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Summary of Level <em style="font: inherit;">3 Input Changes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A summary of changes to those fair value measures using Level <em style="font: inherit;">3 inputs for the <em style="font: inherit;">three months ended <em style="font: inherit;"> September 30, 2024, is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Derivative</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Warrant Liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 79%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of June 30, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,745</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Settlements ⁽¹⁾ </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Included in earnings </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,880</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Balance as of September 30, 2024 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,402</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:4%;"> ⁽¹⁾ </td><td style="vertical-align:top;width:auto;"> Relates to the exercise of 176,000 of the Tranche B Pre-Funded Warrants, which were liability classified and exercised at a price of $0.0001 per share.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Significant Assumptions</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The valuation methodologies and key assumptions used for the mark to market fair value measurements of derivative warrant liabilities as of <em style="font: inherit;"> September 30, 2024, are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 2023 Warrants</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Warrants</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Tranche A</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Other ⁽¹⁾</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><i><em style="font: inherit;">Monte Carlo &</i></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt; width: 13%;"> <em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"><i> </i></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><i><em style="font: inherit;">Black-Scholes</i></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 13%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><i><em style="font: inherit;">Black-Scholes</i></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman";">Aytu closing stock price</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; text-align: right; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman";"><span style="-sec-ix-hidden:c120928246">$ 2.35 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;

padding: 0; margin: 0"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; text-align: right; padding: 0; margin: 0"> $ 2.35 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> Equivalent term (years) </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">3.7</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">2.3-2.9</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> Expected volatility </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"> 79.9% </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"> 79.9%-82.7% </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> Risk-free rate </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"> 3.6% </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"> 3.6% </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"> 0.0% </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"> 0.0% </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:4%;"> ⁽¹⁾ </td><td style="vertical-align:top;width:auto;"> Includes August 2022 Warrants, March 2022 Warrants, Avenue Capital Warrants and Tranche B Pre-Funded Warrants. See Note 16 - Warrants for definitions of these terms and further information. </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%; padding: 0; margin: 0">   </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" rowspan="1" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; text-align: center;">Fair Value at September 30,</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td colspan="10" rowspan="1" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">Fair Value Measurements at September 30, 2024</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> (Level 1) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> (Level 2) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> (Level 3) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 54%;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> Liabilities: </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> Derivative warrant liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 22%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,402</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,402</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> Total </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 22%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,402</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,402</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%; padding: 0; margin: 0">   </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; text-align: center;">Fair Value at June 30,</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td colspan="10" rowspan="1" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">Fair Value Measurements at June 30, 2024</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> (Level 1) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New

Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Level 2) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> (Level 3) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 54%;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> Liabilities: </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> Derivative warrant liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 22%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 33%;"> Total </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 22%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,745</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 940200000940200094020000094020001274500000127450001274500000127450000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Derivative </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Warrant Liabilities </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 79%;"> Balance as of June 30, 2024 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,745</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: "Times New Roman";">Settlements ⁽¹⁾</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Included in earnings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,880</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of September 30, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 18%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,402</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 12745000-463000-288000094020001760000.0001 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 13%;"> June 2023 Warrants </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 13%;"> Warrants </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> Tranche A </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> Other ⁽¹⁾ </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 13%;"> Monte Carlo & </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 13%;"> Black-Scholes </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 13%;"> Black-Scholes </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%; padding: 0; margin: 0"> Aytu closing stock price </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; text-align: right; padding: 0; margin: 0"> $ 2.35 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; text-align: right; padding: 0; margin: 0"> $ 2.35 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> Equivalent term (years) </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">3.7</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times

New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">2.3-2.9</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> Expected volatility </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"> 79.9% </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"> 79.9%-82.7% </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> Risk-free rate </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"> 3.6% </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"> 3.6% </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"> 0.0% </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"> 0.0% </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>
3.72.32.90.7990.7990.8270.03600 Note 13 - Commitments and Contingencies   Pediatric Portfolio Fixed Payments and Product Milestone   The Tris Karbinal Agreement grants the Company the exclusive right to distribute and sell Karbinal in the United States. The initial term of the agreement was 20 years. The Company pays Tris a royalty equal to 23.5% of net revenue from the product.   The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make-whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net revenue from the product, the first of which is triggered at $40.0 million.   Legal Matters   Witmer Class-Action Securities Litigation   A stockholder derivative suit was filed on September12, 2022, in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armistice's Chief Investment Officer and Managing Partner, and a former director of Aytu), and certain other current and former directors of Aytu, Joshua R. Disbrow, Gary Cantrell, John Donofrio, Jr., Michael Macaluso, Carl Dockery and Ketan B. Mehta. Plaintiff amended the complaint on April 5, 2023. The Amended Complaint dropped Mr. Macaluso as a defendant and alleges that (i) Armistice facilitated the sale of assets of Cerecor in 2019 and Innovus in 2020 to Aytu in exchange for convertible securities which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enriched and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in insider trading: and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants' breaches of fiduciary duties, in connection with these acquisitions. The Amended Complaint sought unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys' fees. While the Company believes that this lawsuit is without merit and have vigorously defended against it, the Company agreed to settle the matter for various corporate governance modifications and the payment of plaintiff's attorneys' fees. That settlement is subject to court approval, the hearing on which has not yet been scheduled.   P20Y0.235700003021003000000040000000 Note 14 - Stockholders' Equity   The Company has 200 million shares of common stock authorized with a par value of $0.0001 per share and 50 million shares of preferred stock authorized with a par value of $0.0001 per share. As of September 30, 2024, included in common stock outstanding are 19,019 shares of unvested restricted stock issued to executives, directors and employees.   On September 28, 2021, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 7, 2021. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the "2021 Shelf"). The 2021 Shelf expired in October 2024.   On August 11, 2022, the Company closed on an underwritten public offering (the "August 2022 Offering") utilizing the 2021 Shelf, pursuant to which it sold an aggregate of (i) 1,075,290 shares of its common stock; (ii) in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock; and (iii) accompanying warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was $8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant was $8.58, which equated to the public offering price per share of the common stock and accompanying common warrant, less the $0.02 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in August 2022. The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The Company raised $10.0 million in gross proceeds through the August 2022 Offering before underwriting fees and other expenses of $0.9 million. The pre-funded and common warrants had a combined fair value of approximately $6.0 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders' equity in the Company's consolidated financial statements (see Note 16 - Warrants).   On June 8, 2023, using a placement agent, the Company entered into a securities purchase agreement (the "Securities Purchase Agreement") with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Company's common stock; (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the "June 2023 Pre-Funded Warrants"); (iii) accompanying tranche A warrants to purchase 2,173,912 shares of common stock (the "Tranche A Warrants"); and (iv) accompanying tranche B warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the "Tranche B Warrants" and the Tranche A Warrants together with the Tranche B Warrants, the "Common Warrants"). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the June 2023 Pre-Funded Warrants (the "Exchange Warrants"). Each pre-funded warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. The Common Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance or (ii) 30 days following the closing price of the Company's common stock equaling 200% of the exercise price ($3.18 per share) for at least 40 consecutive trading days. The Tranche B Warrants were exercised in June 2024 as further described below. The Company raised $4.0 million in gross proceeds and net proceeds were $3.4 million after deducting offering expenses. The June 2023 Pre-Funded Warrants do not have an expiration date. The warrants had a combined fair value of approximately $5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in derivative warrant liabilities (loss) gain along with the issuance costs of $0.6 million in the unaudited consolidated financial statement of operations (see Note 16 - Warrants).   On June 14, 2024, the Tranche B Warrants were exercised, generating proceeds of $3.5 million. The Tranche B Warrants were converted into 367,478 shares of common stock and 1,806,434 pre-funded warrants to purchase shares of common stock with an exercise price of $0.0001 per share (the "Tranche B Pre-Funded Warrants"). The Tranche B Pre-Funded Warrants had a fair value of approximately $5.1 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders' equity in the Company's consolidated financial statements. The Company used a portion of the proceeds from the Tranche B Warrants exercise as part of the Avenue Capital loan repayment described further in Note 11 - Long-Term Debt.   On September 26, 2024, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 15, 2024. This shelf registration statement covers the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the "2024 Shelf"). Through the filing date of this Form 10-Q, $100.0 million remains available under the 2024 Shelf. This availability is subject to the SEC's "baby shelf" limitation as set forth in SEC Instruction I.B.6 limitation to the Form S-3.
2000000000.0001500000000.000119019100000000107529087500126555478.68.580.028.610000000900000060000001743695430217217391221739120.00010.00011.591.58993.
Note 15 - Equity Incentive Plans   2023 Equity Incentive Plan   <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;

text-indent: 36pt; text-align: justify;">On May 18, 2023, the Company's stockholders approved the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the "2023 Equity Incentive Plan"). Prior to the Company's adoption of the 2023 Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. 2015 Stock Option and Incentive Plan (the "Aytu 2015 Plan") and the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan (the "Neos 2015 Plan", and collectively with the Aytu 2015 Plan, the "2015 Plans"). For the 2023 Equity Incentive Plan, the stockholders approved (i) 200,000 new shares; (ii) 87,129 shares available for grant under the 2015 Plans be "rolled over" to the 2023 Equity Incentive Plan; and (iii) any shares that are returned to the Company under the 2015 Plans be added to the 2023 Equity Incentive Plan. With the approval of the 2023 Equity Incentive Plan, no additional awards will be granted under the 2015 Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. Stock options granted under the 2023 Equity Incentive Plan have contractual terms of 10 years or less from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards and restricted stock units have a vesting period of 3 to 4 years. As of September 30, 2024, the Company had 187,422 shares that are available for grant under the 2023 Equity Incentive Plan.   Aytu 2015 Plan   On June 1, 2015, the Company's stockholders approved the Aytu 2015 Plan, which, as amended in July 2017, provides for the award of stock options, stock appreciation rights, restricted stock, and other equity awards. On February 13, 2020, the Company's stockholders approved an increase to 250,000 total shares of common stock in the Aytu 2015 Plan. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu 2015 Plan will be added back to the shares of common stock available for issuance under the 2023 Equity Incentive Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, and the restricted stock units have a vesting period of 4 years.   Neos 2015 Plan   Pursuant to the Neos Acquisition, the Company assumed 3,486 stock options and 1,786 restricted stock units previously granted under the Neos 2015 Plan. Accordingly, on April 19, 2021, the Company registered 5,272 shares of its common stock under the Neos 2015 Plan with the SEC. The terms and conditions of the assumed equity securities remained the same as they were previously under the Neos 2015 Plan. The Company allocated costs of the replacement awards attributable to pre-combination and post-combination service periods. The pre-combination service costs were included in the consideration transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years.   Stock Options   Stock option activity is as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Weighted </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Average </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Remaining </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Number of </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Average </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Contractual </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Options </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Exercise Price </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Life in Years </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> Outstanding at June 30, 2024 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">146,539</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: "Times New Roman";">Forfeited/cancelled</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(5,100</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">4.18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Outstanding at September 30, 2024 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">141,439</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at September 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">63,059</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left:

0pt;">11.32</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   During the three months ended September 30, 2024, no stock options were granted. As of September 30, 2024, there was $0.1 million total unrecognized compensation costs related to non-vested stock options granted under the Company's equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.7 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Restricted Stock</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Restricted stock activity is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Average Grant</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Number of</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Date Fair</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested at June 30, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100.34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Vested </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,924</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16.84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested at September 30, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,181</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">127.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   During the three months ended September 30, 2024, no restricted stock was granted under the Company's equity incentive plan. As of September 30, 2024, there was $0.9 million total unrecognized compensation costs related to non-vested restricted stock granted under the Company's equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.5 years.   During the three months ended September 30, 2024, no restricted stock was granted outside of the Company's equity incentive plan. As of September 30, 2024, there was $0.2 million total unrecognized compensation costs related to non-vested restricted stock issued outside of the Company's equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 0.3 years. As of <em style="font: inherit;"> September 30, 2024, 838 shares of restricted stock remain unvested that were granted outside of the Company's equity incentive plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Restricted Stock Units</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Restricted stock units ("RSU" or "RSUs") activity is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Number of</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Date Fair</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Value</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested at June 30, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,775</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24.14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Vested </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(564</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24.29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested at September 30, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,211</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24.07</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   <p

style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the three months ended September 30, 2024, no RSUs were granted. As of September 30, 2024, there was less than $0.1 million of unrecognized compensation costs related to non-vested RSUs granted under the Company's equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 0.4 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Stock-based compensation expense related to the fair value of stock options, restricted stock, and RSUs was included in the consolidated statements of operations as set forth in the below table:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of sales</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling and marketing</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">32</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">138</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">724</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Net income (loss) from discontinued operations, net of tax</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">205</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">173</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">930</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table>   20000087129P10YP3YP4YP3YP4Y1874222250000P10YP3YP4YP4YP10YP4Y3486178652272P10YP1YP4Y <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Weighted </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Average </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Weighted </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Remaining </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Number of </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Average </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Contractual </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center;

font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Options </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Exercise Price </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Life in Years </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> Outstanding at June 30, 2024 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">146,539</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: "Times New Roman";">Forfeited/cancelled</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(5,100</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">4.18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Outstanding at September 30, 2024 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">141,439</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at September 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">63,059</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.32</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>
1465396.18P8Y9M18D51004.181414396.25P8Y7M6D6305911.32P8Y4M24D0100000P1Y8M12D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Weighted </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Average Grant </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Number of </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Date Fair </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Shares </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Value </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> Unvested at June 30, 2024 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100.34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Vested</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,924</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16.84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Unvested at September 30, 2024 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,181</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">127.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>
24105100.34592416.84181811127.540900000P2Y6M200000P0Y3M18D838 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Weighted </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Average Grant </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Number of </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Date Fair </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Shares </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-

align:center;margin:0pt;">Value </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> Unvested at June 30, 2024 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,775</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24.14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Vested</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(564</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24.29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Unvested at September 30, 2024 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,211</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24.07</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 177524.1456424.29121124.070100000P0Y4M24D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">September 30, </p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of sales</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling and marketing</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">32</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">138</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">724</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Net income (loss) from discontinued operations, net of tax</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">205</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">173</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">930</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 10000200010003200001380007240000205000173000930000 Note 16 - Warrants   Liability Classified Warrants   The Company accounts for liability classified warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of liability classified derivative financial instruments was calculated using either the Black-Scholes option pricing model or the Monte Carlo simulation model and is revalued every quarter. Changes in the fair value of liability classified derivative financial instruments in subsequent periods are recorded as unrealized derivative gain or loss in the consolidated statements of operations (see Note 12 – Fair Value Considerations).   On June 8, 2023, using a placement agent, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Company’s common stock; (ii) June 2023 Pre-Funded Warrants in lieu of shares to purchase 430,217 shares of common stock; (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock; and (iv) accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche A Warrants together with the Tranche B Warrants, the “Common Warrants”). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the June 2023 Pre-Funded Warrants (the “Exchange Warrants”). Each pre-funded warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. The Common Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance or (ii) 30 days

following the closing price of the Company's common stock equaling 200% of the exercise price ($3.18 per share) for at least 40 consecutive trading days. The Tranche B Warrants were exercised in June 2024 as further described below. The Company raised $4.0 million in gross proceeds and net proceeds were $3.4 million after deducting offering expenses. The June 2023 Pre-Funded Warrants do not have an expiration date. The warrants had a combined fair value of approximately $5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in derivative warrant liabilities gain (loss) along with the issuance costs of $0.6 million in the unaudited consolidated financial statement of operations (see Note 14 - Stockholders' Equity).   On June 14, 2024, the Tranche B Warrants were exercised, generating proceeds of $3.5 million. The Tranche B Warrants were converted into 367,478 shares of common stock and 1,806,434 Tranche B Pre-Funded Warrants to purchase shares of common stock with an exercise price of $0.0001 per share. The Tranche B Pre-Funded Warrants, which do not have an expiration date, had a fair value of approximately $5.1 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders' equity in the Company's consolidated financial statements. The Company used a portion of the proceeds from the Tranche B Warrants exercise as part of the Avenue Capital loan repayment described further in Note 11 - Long-Term Debt.   On August 11, 2022, the Company closed an offering (the "August 2022 Offering"), pursuant to which, the Company issued pre-funded warrants to purchase 87,500 shares of its common stock and common warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, which one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant was sold. The pre-funded warrants had an exercise price of $0.02 per share of common stock and were exercised in full in August 2022. The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The common warrants provide that if there occurs any stock split, stock dividend stock recapitalization, or similar event (a "Stock Combination Event"), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing the sum of the VWAP of the common stock for each of the five lowest trading days during the 20 consecutive trading day period ending immediately preceding the 16th trading day after such Stock Combination Event, divided by five; or $2.32, and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of 2,325,581 shares. The common warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to the second anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or $2.32 (see Note 14 - Capital Structure).   In November 2022 and throughout the quarter ended December 31, 2022, the Company sold shares through its ATM Sales Agreement. Per the warrant agreement in the August 2022 Offering, these sales qualified as an equity offering, and the sales price was less than the current exercise price of $8.60. As a result, the common warrants exercise price was adjusted to $3.30. On January 6, 2023, the Company consummated a 20 to 1 reverse stock split. Pursuant to the warrant agreement described above, the Company triggered a Stock Combination Event, and the warrant exercise price and number to be issued was adjusted based on the average of each of the lowest five trading days during the twenty-day consecutive trading day period beginning on December 30, 2022. Subsequently, as a result of the Securities Purchase Agreement in June 2023, the common warrants from the August 2022 Offering had an adjusted exercise price of $2.32.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A summary of warrants is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Average</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Number of</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Average</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Contractual</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Warrants</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Exercise Price</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Life in Years ⁽⁴⁾</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding June 30, 2024 ⁽¹⁾</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,075,880</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.71</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%; padding: 0; margin: 0"> Warrants exercised ⁽²⁾ </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(176,000</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">0.0001</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding September 30, 2024 ⁽³⁾</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,899,880</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.22</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody> </table> <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/> <table border="0"

cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:4%;"> ⁽¹⁾ </td><td style="vertical-align: top; width: auto; text-align: justify;">The number of warrants outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,806,434 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants.</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:4%;"> ⁽²⁾ </td><td style="vertical-align:top;width:auto;"> The warrants exercised during the three months ended September 30, 2024, were 176,000 of the Tranche B Warrants, which were exercised at a price of $0.0001 per share. </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:4%;"> ⁽³⁾ </td><td style="vertical-align:top;width:auto;"> The number of warrants outstanding as of September 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,630,424 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:4%;"> ⁽⁴⁾ </td><td style="vertical-align:top;width:auto;"> As pre-funded warrants do not have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years. </td></tr> </tbody></table>
17436954302172173912217391 20.00010.00011.591.58993.184000000340000050000006000003500000367478180643 40.000151000008750012655470.028.62.3223255812.328
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> Weighted </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> Average </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> Weighted </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> Remaining </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> Number of </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> Average </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> Contractual </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Warrants </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Exercise Price </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Life in Years ⁽⁴⁾ </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> Outstanding June 30, 2024 ⁽¹⁾ </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,075,880</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.71</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: "Times New Roman";">Warrants exercised ⁽²⁾</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(176,000</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">0.0001</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> Outstanding September 30, 2024 ⁽³⁾ </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,899,880</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.22</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 60758803.71P3Y7M6D1760000.0001589988 03.22P3Y3M18D382111543021718064341811417600 00.000138211154302171630424181 14 Note 17 - Earnings Per Share   Basic net income (loss) per share is calculated by dividing the net income (loss) available to the common stockholders by the weighted average number of common shares outstanding during that period. Diluted net income (loss) per share reflects the potential of securities that could share in the net income (loss) of the Company. For the three months ended September 30, 2023, the Company incurred a net loss from continuing operations and discontinued operations and thus did not include common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive.   Basic net income or loss per common share is calculated by dividing net income or loss available to common stockholders by the basic weighted-average number of common shares outstanding for the respective period. Diluted net income or loss per common share is calculated by dividing adjusted net income or loss by the diluted weighted-average number of common shares outstanding, which includes the effect of potentially dilutive securities. Potentially dilutive securities for this calculation consist of warrants to purchase common stock that are either liability classified or equity classified (see Note 16 - Warrants); employee stock options (see Note 15 - Equity Incentive Plans); employee unvested restricted stock (see Note 15 - Equity Incentive Plans); and employee unvested restricted stock units (see Note 15 - Equity Incentive Plans). For the three months ended September 30, 2024, and 2023, if the Company incurred a net loss from continuing operations; a net loss from discontinued operations, net of tax; or a net loss then the Company did not include common equivalent shares in the computation of diluted net loss from continuing operations per share; diluted net loss from

discontinued operations, net of tax; or diluted net loss per share because the effect would have been anti-dilutive.   The following is a reconciliation of the numerator and the denominator used in the basic per share calculations: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 17%;"> Three Months Ended </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"> September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 17%;"> (in thousands, except share and per share data) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> BASIC </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerators: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) from continuing operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,093</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(7,473</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) from discontinued operations, net of tax </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">381</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(647</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,474</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(8,120</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Denominator: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Basic weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,068,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Per share calculations: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) per share from continuing operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.18</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1.36</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) per share from discontinued operations, net of tax </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.06</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) per share </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.24</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1.48</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;

text-indent: 36pt; text-align: justify;"> The following is a reconciliation of the numerator and the denominator used in the diluted per share calculations: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 17%;"> Three Months Ended </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"> September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 17%;"> (in thousands, except share and per share data) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> DILUTED: CONTINUING OPERATIONS </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Numerator: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) from continuing operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,093</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(7,473</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Adjustment for change in fair value of warrant liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,880</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Adjusted numerator - net loss from continuing operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,787</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,473</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Denominator: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Basic weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,068,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Dilutive effect of warrants to purchase common stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,028,862</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Dilutive effect of unvested restricted stock and restricted stock units </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,720</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Diluted weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,099,601</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Per share calculation: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) from continuing operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,093</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(7,473</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Adjustment for change in fair value of warrant liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,880</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Diluted weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,099,601</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Per share calculation: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) from continuing operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,093</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(7,473</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Adjustment for change in fair value of warrant liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,880</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Diluted weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,099,601</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Per share calculation: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman",

Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net loss per share from continuing operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1.36</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> DILUTED: DISCONTINUED OPERATIONS </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Numerator: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) from discontinued operations, net of tax </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">381</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(647</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Denominator: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Basic weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,068,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Dilutive effect of warrants to purchase common stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,028,862</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Dilutive effect of unvested restricted stock and restricted stock units </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,720</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Diluted weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,099,601</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Per share calculation: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) per share from discontinued operations, net of tax </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.04</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> DILUTED: NET INCOME (LOSS) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Numerator: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family:

"Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,474</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(8,120</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Adjustment for change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,880</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Adjusted numerator - net loss</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,406</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(8,120</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Denominator:</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Basic weighted-average common shares outstanding</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,068,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Dilutive effect of warrants to purchase common stock</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,028,862</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Dilutive effect of unvested restricted stock and restricted stock units</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,720</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Diluted weighted-average common shares outstanding</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,099,601</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Per share calculation:</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Net loss per share</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.15</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1.48</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"> </p> <p style="margin: 0pt; font-family: "Times New Roman"; font-size: 10pt; text-align: justify; text-indent: 36pt;">The following table sets forth securities that could be considered anti-dilutive, and therefore are excluded from the calculation of diluted weighted-average common shares outstanding and related per share calculations:</p> <p style="margin: 0pt; font-family: "Times New Roman"; font-size: 10pt; text-align: justify; text-indent: 36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024 </p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants to purchase common stock - liability classified (note 16)</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">455,392</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,498,980</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants to purchase common stock - equity classified (note 16)</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;

text-align: right;">18,114</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">39,072</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Employee unvested restricted stock (note 15) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">10,644</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">46,656</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Employee unvested restricted stock units (note 15) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,211</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,463</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Employee stock options (note 15) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">141,439</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">162,683</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total anti-dilutive securities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">626,800</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,750,854</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 17%;"> Three Months Ended </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"> September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 17%;"> (in thousands, except share and per share data) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> BASIC </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Numerators: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) from continuing operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,093</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(7,473</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) from discontinued operations, net of tax </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">381</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(647</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,474</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(8,120</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Denominator: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Basic weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,068,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:

"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Per share calculations: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) per share from continuing operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.18</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1.36</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) per share from discontinued operations, net of tax </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.06</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) per share </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.24</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1.48</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 17%;"> Three Months Ended </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"> September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 17%;"> (in thousands, except share and per share data) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> DILUTED: CONTINUING OPERATIONS </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Numerator: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) from continuing operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,093</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(7,473</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Adjustment for change in fair value of warrant liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,880</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Adjusted numerator - net loss from continuing operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,787</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,473</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Denominator: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Basic weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,068,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Dilutive effect of warrants to

purchase common stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,028,862</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Dilutive effect of unvested restricted stock and restricted stock units </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,720</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Diluted weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,099,601</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Per share calculation: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net loss per share from continuing operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1.36</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> DILUTED: DISCONTINUED OPERATIONS </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Numerator: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) from discontinued operations, net of tax </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">381</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(647</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Denominator: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Basic weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,068,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Dilutive effect of warrants to purchase common stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,028,862</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Dilutive effect of unvested restricted stock and restricted stock units </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,720</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Diluted weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,099,601</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Per share calculation: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net loss per share from continuing operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1.36</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) from discontinued operations, net of tax </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">381</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(647</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Denominator: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Basic weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,068,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Dilutive effect of warrants to purchase common stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,028,862</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Diluted weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,099,601</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Per share calculation: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;

width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) per share from discontinued operations, net of tax </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.04</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> DILUTED: NET INCOME (LOSS) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Numerator: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net income (loss) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,474</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(8,120</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Adjustment for change in fair value of warrant liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,880</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Adjusted numerator - net loss </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,406</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(8,120</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Denominator: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Basic weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,068,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Dilutive effect of warrants to purchase common stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,028,862</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Dilutive effect of unvested restricted stock and restricted stock units </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,720</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Diluted weighted-average common shares outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,099,601</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,482,037</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Per share calculation: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Net loss per share </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.15</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1.48</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> 1093000-7473000381000-6470001474000-8120000606801954820370.18-1.360.06-0.120.24-1.481093000-7473000-28800000-1787000-7473000606801954820373028862027200909960154820370.2-1.36381000-6470006068019548203730288620272009099601548203700.4-0.121474000-8120000-28800000-1406000-8120000606801954820373028862027200909960154820370.15-1.48 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-

align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Three Months Ended </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Warrants to purchase common stock - liability classified (note 16) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">455,392</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,498,980</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants to purchase common stock - equity classified (note 16) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">18,114</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">39,072</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Employee unvested restricted stock (note 15) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">10,644</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">46,656</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Employee unvested restricted stock units (note 15) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,211</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,463</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Employee stock options (note 15) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">141,439</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">162,683</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total anti-dilutive securities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">626,800</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,750,854</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 455392649898018114390721064446656121134631414391626836268006750854 Note 18 - License Agreements   Actavis   On October 17, 2017, the Company entered into an agreement granting Actavis Laboratories FL, Inc. (“Actavis”) (acquired by Teva Pharmaceutical Industries) a non-exclusive license to certain patents owned by the Company by which Actavis has the right to manufacture and market its generic version of Adzenys under its ANDA beginning on September 1, 2025, or earlier under certain circumstances. The ANDA was approved by the FDA on June 22, 2023.   Teva   On December 21, 2018, the Company and Teva Pharmaceuticals USA, Inc. (“Teva”) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla under an abbreviated new drug application (“ANDA”) filed by Teva beginning on July 1, 2026, or earlier under certain circumstances. The ANDA was approved by the FDA on June 19, 2020.   Note 19 - Restructuring Costs   As part of the Company’s previously announced restructuring activities related to the wind down and divestiture of the Consumer Health business and the closure of the Grand Prairie, Texas manufacturing site, the Company has incurred expenses that qualify as exit and disposal costs under U.S. GAAP. These include severance and employee benefit costs as well as other direct separation benefit costs, right of use asset impairment charges, fixed asset and other asset impairment charges, accelerated depreciation of fixed assets, contract termination costs, and inventory write-downs. Severance and employee benefit costs primarily relate to cash severance. Restructuring costs associated with the Consumer Health business are recorded within the net loss from discontinued operations, net of tax in the unaudited consolidated financial statement of operations (see Note 20 - Discontinued Operations).   The expense associated with the closure of the Grand Prairie, Texas manufacturing site such as severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations. There have been no inventory write-downs associated with this closure. During the three months ended September 30, 2024, the Company incurred $0.8 million of costs associated with exit and disposal activities related to its manufacturing facility in Grand Prairie, Texas. The Company does not expect to incur additional significant restructuring costs.   Note 20 - Discontinued Operations   On July 31, 2024, after the wind down of operations, the Company entered into a definitive agreement to divest its Consumer Health business to a private, e-commerce focused company. The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, external workforce and contracts, and provides for the Company to receive contingent consideration payments on certain future sales of former Consumer Health business products.   The accounting requirements for reporting the Consumer Health business as discontinued operation were met when the wind down and divestiture was completed on July 31, 2024. Accordingly, the accompanying unaudited consolidated financial statements for all periods presented reflect this business as a discontinued operation and certain assets and liabilities of discontinued operations have been reclassified to the current assets of discontinued operations; non-current assets of discontinued operations; and current liabilities of discontinued operations financial statement line items on the accompanying unaudited consolidated balance sheet as of June 30, 2024. The Company elected to record the contingent consideration portion of the arrangement when the consideration is determined to be realizable and, therefore, the Company did not record a contingent consideration asset at the transaction date and any subsequent proceeds will not be recognized until the contingent consideration asset is realizable, at which point the Company will recognize it to income (loss) from discontinued operations.   The key components of net income (loss) from discontinued operations, net of tax for the three months ended September 30, 2024, and 2023, were as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New

Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Three Months Ended </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> (in thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Net revenue </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">717</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,282</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cost of sales </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(359</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,536</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Selling and marketing </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(155</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1,331</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> General and administrative </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(670</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Amortization of intangible assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(382</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-operating other expense, net </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Recognized contingent consideration </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">412</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Loss on divestiture </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(254</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Income (loss) from discontinued operations before income taxes </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">355</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(647</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Income tax benefit </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">26</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net income (loss) from discontinued operations, net of tax </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">381</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(647</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table>   The key components of assets and liabilities of discontinued operations as of June 30, 2024, were as follows: <table cellpadding="0" cellspacing="0" class="finTable" style="width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"><tbody><tr class="finHeading" style="background-color:

rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> June 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding: 0; margin: 0">(in thousands)</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding: 0; margin: 0"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> ASSETS </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> Current assets of discontinued operations: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> Accounts receivable, net </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">91</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Inventories</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">492</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">538</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current assets of discontinued operations</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,121</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-current assets of discontinued operations:</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other non-current assets</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total current and non-current assets of discontinued operations</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,165</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> LIABILITIES </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> Current liabilities of discontinued operations: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> Accounts payable </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">126</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">431</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total current liabilities of discontinued operations</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">557</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Three Months Ended </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> (in thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Net revenue </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">717</td><td

style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,282</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of sales</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(359</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,536</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling and marketing</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(155</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1,331</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(670</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Amortization of intangible assets</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(382</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-operating other expense, net</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Recognized contingent consideration</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">412</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss on divestiture</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(254</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income (loss) from discontinued operations before income taxes</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">355</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(647</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax benefit</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">26</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net income (loss) from discontinued operations, net of tax</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">381</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(647</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">June 30,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding: 0; margin: 0">(in thousands)</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding: 0; margin: 0"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">ASSETS</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current assets of discontinued operations:</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts receivable, net</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">91</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin:

0pt 0pt 0pt 9pt;">Inventories </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">492</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> Prepaid expenses and other current assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">538</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> Total current assets of discontinued operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,121</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> Non-current assets of discontinued operations: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> Other non-current assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> Total current and non-current assets of discontinued operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,165</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">LIABILITIES</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current liabilities of discontinued operations:</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">126</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> Accrued liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">431</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> Total current liabilities of discontinued operations </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">557</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>
717000428200035900025360001550001331000200067000-038200040001000041200002540000355000-647000260000381000-647000910004920005380001121000440001165000126000431000557000
Includes August 2022 Warrants, March 2022 Warrants and Avenue Capital Warrants. Relates to the exercise of 176,000 of the Tranche B Pre-Funded Warrants, which were liability classified and exercised at a price of $0.0001 per share. The number of warrants outstanding as of September 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,630,424 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. The number of warrants outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,806,434 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants. As pre-funded warrants do not have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years. The warrants exercised during the three months ended September 30, 2024, were 176,000 of the Tranche B Warrants, which were exercised at a price of $0.0001 per share.